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With the advances from genome-sequencing projects, the functional annotation 
and characterization of newly discovered proteins have become increasingly 
important. As key regulators of virtually every biological process, even minor 
imbalances in the activity of certain enzymes might lead to severe pathological 
conditions. Deeply understandings of how an enzyme works at its molecular and 
cellular level will have direct relevance to drug discovery. To reach the goal of large 
scale studies of a significant number of enzymes present in any particular organism, 
development of high-throughput amenable chemistry and enzyme-screening tools are 
becoming very urgent. This thesis examines and addresses these challenges by 
combination of various synthetic approaches and introducing high throughput 
screening platforms. Chapter 2 describes a solution-cum-solid phase strategy for rapid 
assembly of diol-containing small molecules as potential HIV-1 inhibitors. Chapter 3 
presents a high throughput synthetic strategy for rapid assembly of 475-member 
aspartic protease inhibitors library using “click” reaction. With this platform, new 
inhibitors against malaria were discovered. Chapter 4 and 5 present a small molecule 
microarray-facilated platform for proteome profiling of aspartic proteases in cellular 
lysates. Chapter 6 and 7 describes the cell permeable, photo-affinity drug-like probes 
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1.1  Summary 
In the last decade, much attention has been turned towards proteomic research 
after the successful completion of the human genome project.
1
 Proteins is very crucial 
for cellular and metabolic functions. They play crucial roles in cell division, cell 
migration, cell-cell communication, signal transduction, cell death etc.
2 
Dysregulation 
of certain protein activities has been implicated in many diseases including cancer, 
AIDS, malaria, Alzheimer‟s, diabetes, and so on. To date, it has been estimated that 
enzymes account for more than 20% of all drug targets. However, the physiological 
role, substrate specificity and downstream targets of many enzymes are poorly 
understood thus far. Therefore, it is very significant to develop chemical tools 
capables of studing enzyme activities in a high-throughput manner.
3
 
High-throughput amenable reactions are mainly characterized by near-perfect, 
modular and robust and biocompatible nature and offer an efficient and rapid analysis 
of proteomes on a global scale.
 
To date, many high-throughput methods have been 
applied to drug synthesis and proteome analysis, especially in the field of 
high-throughput enzymology.
4 
This chapter will provide a brief overview of 
applications of high-throughput technologies in chemical proteomics. Much attention 
will be focused on studies of high-throughput strategies for proteomic profiling of 
aspartic proteases as well as protein kinases. 
                                                                         2 
1.2  Aspartic Proteases as Therapeutic Targets 
Proteases belong to one of the largest enzyme family encoded by the human 
genome with more than 500 known members. They catalyze the hydrolysis of peptide 
bonds in the proteins, which is related to many physiological and pathological 
processes such as cell proliferation, tissue remodelling, embryonic development, 
blood coagulation, blood pressure control, protein activation and maturation, protein 
catabolism, protein transport, inflammation, infection, and cancer. The importance of 
peptide bond cleavage in biological systems is also reflected by the finding that nature 
has separately invented the necessary catalytic machinery multiple times with 
different solutions. This provides the basis for the categorization of proteases into five 








Figure 1.1 Classification of protease family. 
In fact, aspartic protease is the smallest class with only 15 members in the human 
genome. However, they have received considerable attention as potential targets for 
pharmaceutical intervention since many have been shown to play important roles in 
physiological and pathological processes, which includes renin in hypertension,
6 
cathepsin D in breast cancer,
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malaria
9 




Table 1.1 Some representative aspartic proteases and their functions in diseases. 
Name Source Function Disease 
Pepsin Animal stomach Digestion of dietary proteins 
Digestion 
disease 
Chymosin Animal stomach Digestion of dietary proteins 
Digestion 
disease 
Cathepsin D,E Spleen, liver Lysosomal digestion of proteins Breast cancer 
Renin Kidney Regulation of blood pressure Hypertension 
HIV-1 AIDS virus Processing of AIDS virus proteins AIDS 
Plasmepsins Food vacuole Degrade hemoglobin Malaria 
β, γ-Secretase Brain Leading to production of amyloid-β 
Alzheimer‟s 
disease 
1.2.1 Catalytic Mechanism of Aspartic Proteases 
Proteases are known to play essential roles in many biological processes. They 
catalyze the hydrolysis of peptide bonds with high sequence selectivity and catalytic 
efficiency. These enzymes carry out their catalysis by different mechanisms. Aspartic 
proteases are characterized by two catalytic aspartic acid residues located in their 
active site. Although the catalytic mechanism of aspartic proteases is poorly 
understood, it has been generally accepted that peptide bond cleavage occurs by a 
general acid-base catalytic mechanism (Figure 1.2). One of the two catalytic aspartic 
residues is protonated in the enzyme substrate complex. The other aspartic residue 
acts as a general base activating a water molecule which then attacks the carbonyl 
carbon of the scissile amide bond resulting in the formation of a tetrahedral diol 
                                                                         4 
intermediate. Subsequent deprotonation of the hydroxyl group by one of the catalytic 
aspartates and simultaneous activation of the leaving amine by the other protonated 














































Transition state  
Figure 1.2 Catalytic mechanism of aspartic proteases. 
1.2.2 Inhibitor Development for Aspartic Proteases 
Aspartic proteases generally bind 6-10 amino acid regions of their peptide 
substrates which are typically cleaved with the aid of two catalytic aspartic acid 
residues in the active site.
12 
Thus far, most of aspartic protease inhibitors are transition 
state analogues which mimic the transition state without becoming hydrolyzed. It has 
been proved that transition state analogue inhibitors are typically more efficient than 
substrate analogue inhibitors since the transition state is bound with a much higher 
affinity. In the last decade, many inhibitor scaffolds have been developed based on the 
tetrahedral intermediate of hydrolysis of aspartic protease substrates (Figure. 1.3). In 
this study, inhibitors with hydroxyethylamine and dihydroxylethelene have been 
mainly emphasized. 





















































































Figure 1.3 Some well-known transition state scaffolds for aspartic protease inhibitors. 
Pepstatin A, a natural product first isolated in 1970, was first found to be a potent 
inhibitor of pepsin (Ki = 56 pM).
13 
It was subsequently shown that pepstatin A is a 
generic aspartic protease inhibitor.
14 
While these hydroxyethylene-based inhibitors in 
general lead to potent enzymatic inhibition, their use as therapeutic agents is, however, 
often hampered by their unfavorable biopharmaceutical properties due to their 
peptidic character. The protease of the human immunodeficiency virus (HIV-1 
protease) has proved to be an attractive drug target due to its essential role in the 
replicative cycle of HIV. So far, nine HIV protease inhibitor drugs have been 
approved by FDA and are clinically available: Saquinavir, Nelfinavir, Ritonavir, 
Lopinavir, Indinavir, Amprenavir, Fosamprenavir, Atazanavir, and Tipranavir. 
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Among them, Amprenavir, a hyrdroxyethylamine transition state analogure, is one of 
the most potent HIV-1 inhibitors with an IC50 value of 0.6 nM.
15 
In addition, some 
potent inhibitors for other aspartic proteases (Renin, cathepsin D, β, ɤ-secretase .etc) 






































































Figure 1.4 Some representative aspartic protease inhibitors. 
1.3  Protein Kinases as Therapeutic Targets 
Protein kinases (PKs) play a key role in signal transduction pathways, which 
regulate a varity of cellular processes including growth, division, differentiation and 
metabolism. Dysregulation of cellular kinase activities has been implicated in many 
diseases (including cancer, HIV, malaria, and so on). Thus, protein kinases have 
emerged as a major class of drug targets in recent years.
16,17 
To date, approximately 
30 distinct kinase targets have been developed to the level of a phase I clinical trial, 
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and around 518 protein kinases are encoded in human genome. Most of them share a 
catalytic domain conserved in sequence and structure but are notably different in how 
their catalysis is regulated.
18 
The majority of kinase targets are being investigated for 
the treatment of cancer. However, dysregulation of kinase function has also been 
implicated in other disorders, including immunological, neurological, metabolic and 
infectious diseases.
18 
1.3.1 Catalytic Mechanism and Classification of Protein Kinases 
Protein kinases are ATP-dependent phospho-transferases that modified other 
proteins by chemically adding phosphate groups to them. They require an essential 
divalent metal ion, usually Mg
2+
, to facilitate the phosphoryl transfer reaction and 
assist in ATP binding. Classical protein kinases have a catalytic domain (~250 amino 
acids), which is constituted by a small N-terminal lobe of β-sheets and a larger 
C-terminal lobe of α-helices. ATP first binds in a cleft between the two lobes so that 
the adenosine moiety is buried in a hydrophobic pocket with the phosphate backbone 
orientated outwards towards the solution. Subsequently, the protein substrate binds 
along the cleft and a set of conserved residues within the kinase catalytic domain 
catalyse the transfer of the terminal γ-phosphate of ATP to the hydroxyl oxygen of the 
Ser, Thr or Tyr residue of the substrate (Figure 1.5). Although all protein kinases 
share a common mechanism, some of them are different because of the charge and 
hydrophobicity of surface residues. Certainly, the order of the steps also differs for 
different kinases. For example, some kinases bind to their protein substrates before 
binding ATP and others release ADP before releasing the protein substrate.
19
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Figure 1.5 A common mechanism for protein kinases. 
In human genome about 518 human protein kinases have been identified 
(constituting about 1.7% of human genes).
17, 20
 Within this large protein kinase family, 
at least 90 tyrosine kinase genes have been identified [58 receptor tyrosine kinases 
(RTKs) and 32 nonreceptor tyrosine kinases (NRTKs)]. Thus far, a large number of 
tyrosine kinases (both receptor and non-receptor types) are associated with cancer. 
Clinical studies suggest that overexpression/deregulation of tyrosine kinases may 
cause great effects on patients. 
1.3.2 Development of Protein Kinase Inhibitors 
Small molecule inhibitors of protein kinases are widely used in signal 
transduction research and constitute a novel class of drugs for therapeutic intervention 
in a variety of human diseases.
21
 To date, approximately 80 inhibitors have been 
advanced to some stages of clinical evaluation. Most currently known kinase 
inhibitors discovered are ATP competitive and present one to three hydrogen bonds to 
the amino acids located in the hinge region of the target kinases, thereby mimicking 
the hydrogen bonds that are normally formed by the adenine ring of ATP. Generally, 
N 
C 
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the kinase inhibitors are classified into several types based on different interactions 
between inhibitors and protein kinases.
22 
The most popular type is ATP-competitive 
inhibitors which only recognize the active conformation (DFG-In) of kinases. 
Dasatinib (BMS-354825) was identified as a highly potent, ATP-competitive inhibitor 
of Src and Abl kinases.
23 
Dasatinib was also found to inhibit a wide variety of other 
kinases. Studies have shown the activity of dasatinib against Bcr-Abl-positive 
leukemic cell lines as well as epithelial tumor cell lines including human prostate and 
breast cancer cells.
23b,24 
As a result, this compound has become a promising 
therapeutic agent for preventing cancer cell growth. By contrast, the type II inhibitors 
recognize the inactive conformation (DFG-Out). For example, the 
phenylaminopyrimidine compound imatinib mesylate (Gleevec, STI571) was the first 
tyrosine kinase inhibitor approved by FDA, and this drug has been successfully used 
in the treatment of chronic myeloid leukemia (CML), whereas resistance formation 
and subsequent therapy failure was observed in patients with advanced CML.
25 
The 
third class of inhibitors binds outside the ATP-binding site at an allosteric site. The 
most well characterized allosteric kinase inhibitor is CI-1040, which inhibits MeK1 
and MeK2 by occupying a pocket adjacent to the ATP binding site.
26 
The fourth class 
of kinase inhibitors is capable of forming an irreversible, covalent bond to the kinase 
active site, most frequently by reacting with a nucleophilic cysteine residue.
27 
Clinically, the classical irreversible kinase inhibitors of epidermal growth factor 
receptor (EGFR) is HKI-272 and CL-387785.
28 
Thus far, most small molecule 
inhibitors are primarily developed from a combination of methods, including 
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high-throughput screening using biochemical or cellular assays, analogue synthesis, 







































Figure 1.6 Several representative kinase inhibitors. 
1.4  High-throughput Amenable Chemistry 
The term “Catalomics” is used to define an emerging “-omics” field in which 
high-throughput studies of enzymes and other biocatalysts are carried out by using 
advanced chemical biology/proteomics approaches (Figure 1.7).
29 
The progress in 
catalomics has made a very important effect on drug discovery, and it heavily relies 
on both powerful assay technologies such as microarrays and recent developments in 
some of the most reliable and robust chemical reactions. Thus far, one of the main 
challenges in the field of Catalomics is the development of high-throughput (HT) 
amenable chemical reactions that allow rapid synthesis of diverse chemical libraries 
for the interrogation of different classes of enzymes. Herein, we have rapidly and 
efficiently synthesized the enzyme inhibitor libraries by using high-throughput 
amenable reactions (Click chemistry and solid-phase) due to their near-perfect, 
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modular, robust and biocompatible nature. 
Microplate Microarray
High-Throughput Amenable 
             Technologies
High-throughput Amenable
Chemistry









Figure 1.7 Overview of “Catalomics”. 
1.4.1 Solid-phase Chemistry 
    Combinatorial chemistry has emerged as a powerful new technology for 
chemists to synthesize a large number of compounds for biological evaluation. One of 
the techniques used in combinatorial chemistry is solid-phase organic synthesis. The 
first landmark paper on solid-phase synthesis of tetrapeptide was published by 
Merrifield in 1963,
30 
and Ellman was the first to report the solid-phase combinatorial 
synthesis of non-peptide based small molecules, benzodiazepines.
31 
Solid-phase 
synthesis has several advantages over solution-phase synthesis, which are listed 
below: 
(1)  Can be automated easily and amenable to high-throughput synthesis 
(2)  Isolation of the compound is very simple, usually by simple filtration 
(3)  High product purity 
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(4)  Easier to generate a large library of compounds in a shorter time 
(5)  In some cases, the reaction can be forced to completion by using excess of  
reagent 
(6)  In some cases (especially peptide synthesis), solubility problems are minimized 
However, the main limitations of solid-phase synthesis are difficulty in monitoring the 
reaction, usage of excess reagents and solvents, difficulty in multistep stereo-selective 
synthesis. 
 
Figure 1.8 General principle of solid-phase synthesis. 
    We have adopted a traceless solid-phase methodology to synthesize an alkyne 
sub-library for assembly of aspartic protease inhibitors in our study. Traceless 
synthesis can be defined as a synthetic route which yields compounds composed of 
inherent atoms only from the particular target molecules.
32 
Synthesis using 
solid-phase traceless resins leaves no residues on the final compound after the 
cleavage from the solid support. We have explored the solid-phase amide bond 
formation reaction using an aldehyde traceless resin (PL-FMP),
33 
and a 19-member 
alkyne building block library was efficiently generated. 













Figure 1.9 Traceless synthesis of alkyne building blocks. 
1.4.2 Click Chemistry 
    A set of chemical reactions, known as bioorthogonal reactions, that are 
orthogonal to most functional groups in biological systems have so far shown 
promising use in biological research. Similarly, click chemistry, defined by 
Sharpless,
34 
has been identified to have minimum synthetic demands, a wide range of 
solvent compatibilities and high yields. Of the different click reactions, the Cu (I) 
catalyzed version of Huisgen 1, 3-dipolar cycloaddition reaction between azides and 




 has emerged 
as a powerful tool in chemical biology and proteomic applications. This reaction is 
characterized by its high chemo-selectivity, modularity, near-perfect yield and 
biocompatibility in the aqueous conditions. As a result, click chemistry has become an 
attractive tool in many research fields ranging from materials sciences, biology to 
medicinal chemistry/chemical biology. It also has emerged as an integral part of the 
drug discovery pipeline by providing a high-throughput amenable chemical reaction 







Figure 1.10 Cu (I) catalyzed azide-alkyne ligation. 
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    In addition, “Click” reaction has some other features: (1) highly exothermic 
reaction (ΔH = -45 to -55 Kcal/mol); (2) high kinetic barrier–due to the high energy 
content of the azide and alkyne (25 kcal/mol); (3) in the presence of Cu (I) the 
reaction is not significantly affected by the steric and electronic properties of the 
groups attached to the azide and alkyne reactive centers; (4) the reaction is unaffected 
by water and other functional group, the rate of Cu (I) catalyzed is 10
7
 times faster 
than the uncatalyzed one; (5) triazole ring is very stable, inert to oxidation, hydrolysis, 
and reduction conditions even at high temperature; (6) strong dipole moment, 
aromatic, good H-bonding acceptor.
 37
 
    Development of enzyme inhibitors is one of most important areas where click 
chemistry plays an active role. It has been identified as a convenient strategy towards 
fragment-based inhibitor assembly, where large libraries of potential bidentate 
inhibitors are generated with minimum synthetic efforts. This approach is powerful 
especially against protein targets which possess multiple binding pockets in their 
active sites (e.g., Proteases, Phosphatases, and Kinases, etc). Currently, three methods 
have mainly been used to assist the assembly of compounds: (1) the tethering method 
developed by Wells et al
38 
(2) the NMR-based SAR strategy
39 
and (3) the in situ 
screening approach developed by Wong and co-workers
40 
which was largely based on 
the “click” chemistry pioneered by Sharpless et al. Among them, the click chemistry 
approach is highly versatile due to its several advantages: (1) water compatible or 
non-toxic solvent should be used for the reaction; (2) reactions are usually carried out 
at microscale level; (3) products no need to be isolated or purified; (4) reactions have 
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very high yields; (5) no protection group required. 
N3 N3 N3
`Click` assembly library In situ screening by enzymes
Enzyme Enzyme
HIT
Figure 1.11 “Click” assembly and in situ screening. 
Thus far, many groups including ours have utilized this powerful tool for the 















47 α-1,3-fucosyltransferase,48 acetylcholinesterase49 and sulfotransferase50 
(Figure 1.12) 
G16
EC50 = 1.04 mM  (Plasmepsins)
                  AB2
Ki = 1.7 nM (HIV1 protease)
G6
Ki    = 1.4 mM  (MMP-7)
IC50 = 6.5 mM  (MMP-7)
Ald-SC2
IC50 = 4.67 mM  (Caspase-3)

















































































Ki    = 62 nM  (a-1,3-FucT VI)
IC50 = 0.15 mM (a-1,3-FucT VI)
W1-SA20
IC50 = 700 nM (Abl)
Figure 1.12 “Click” inhibitors targeting various enzyme classes. 
    Amide-bond formation reaction between an acid and an amine is also a very 
useful reaction and can be amenable to high-throughput synthesis and in situ 
screening except for “Click” chemistry40 (Figure 1.13a). The most common coupling 
reagents used in this reaction is DCC/ EDC, HATU, HBTU, PyBop, etc. This efficient 
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reaction has recently been applied successfully in the rapid discovery of inhibitors 




α-fucosidases,53 SARS-3CL protease54 and β-aryl sulfotransferase55 (Figure 1.13b). 
This high-throughput amenable reaction has some key features, in that quantitative 
product formation can be achieved using powerful acylating/coupling reagents. 
Therefore, in situ biological screening may be carried out directly without product 
purification. However, the method is severely limited by the presence of excessive 
coupling reagents, byproduct and excessive starting materials in the reaction, which 












































Ki = 400 nM (HIV-1)

















Ki = 5 nM (Arylsulfotransferases-IV)
 
Figure 1.13 Traditional amide-bond formation reaction and representative inhibitors. 
(a) Amide-bond formation reaction. (b) Representative inhibitors assembled by 
amide-bond formation reaction. 
1.4.3 Small Molecule Microarray 
Over the last decade, microarray technology has become one of most popular 
high-throughput screening platforms for wide application from expression profiling, 
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mapping interaction networks to molecular fingerprinting and ligand discovery. 
Microarray technology was originally reported as peptide microarray by Fodor et al. 
in 1991
57 
and later adopted by Affymetrix and the Brown group to create DNA 
microarray.
58 
Subsequently, MacBeath et al developed small-molecule and protein 
microarrays for the first time.
59 
Thus far, four key microarray-based platforms have 
been successfully developed for high-throughput study of enzymes. Those are 
protein-, peptide-, small molecule- and cell-based microarrays, respectively. Among 
them, small molecules and protein microarrays have witnessed great growth in recent 
years with significant technical and conceptual improvements. 
    Small molecule microarrays (SMMs) provide a valuable platform for the 
large-scale, quantitative determination of protein-ligand interactions in 
high-throughput. It offers a cheap and convenient method for the screening of 
thousands of compounds rapidly and has been successfully used in ligand 
identification, and in protein profiling. Furthermore, microarray-based technologies 
have also been used in the discovery of biosensors and biomarkers for disease 
diagnostics. The first small-molecule microarray (SMM) was developed in 1999 by 
MacBeath and Schreiber who showed that thousands of binding assays could be 
performed in parallel from molecules synthesized on individual beads.
59
 Besides, it 
was shown that the SMM can also be used to study the weak binding pairs, such as 
FKBP12 and its ligand (Kd values in the μM range). Our group identified four novel 
ligands for human IgG from a library of 2,688 triazine compounds using SMM. The 
best hits showed the Kd values of 2.02 µM. In fact, immobilization strategies have 
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become critical for SMM.
60 
In the last decade, great effort has been put on 
development of immobilization chemistry. For example, MacBeath and coworkers 
reported the Michael reaction in 1999.
59a 
Schreiber group developed the reactions 
between a primary alcohol and silyl chloride, a phenolic derivative and 
diazobenzylidene in 2000 and 2003, respectively.
59b 
Recently, Waldmann et al. and 
Raines et al. have independently developed methods based on the staudinger reaction 




1.5  Activity-based Protein Profiling (ABPP) 
Activity-based protein profiling (ABPP), developed by Cravatt and coworkers,
62
 
is a novel technique that is designed to address the proteome at the level of discrete 





probes typically used in 
ABPP possess three general elements: (i) a binding group that promotes interactions 
with the active sites of specific classes of enzymes, (ii) a reactive group that 
covalently labels these active sites, and (iii) a reporter group (e.g., fluorophore or 
biotin) for the visualization and affinity purification of probe-labeled enzymes. ABPP 
has recently been shown to be a powerful tool in proteomic studies, which takes 
advantage of mechanism-based probes to record variations in the activity of enzymes 
in whole proteomes. To date, many ABPP probes have been developed for relevant 







 Notably, these probes have been shown to selectively label active 
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enzymes but not their inactive precursor or inhibitor-bound forms. Therefore, the 
current activity-based profiling strategies are limited in that they are applicable only 
to a few classes of enzymes which possess covalent intermediates in their catalytic 
mechanism. 
       
Figure 1.14 Structures of activity-based probes. 
1.6  Affinity-based Protein Profiling (AfBP) 
Affinity-based protein profiling (AfBP) of enzymes is a complementary strategy 
for activity-based proteomic profiling without the need of mechanism-based suicide 
inhibitors. The affinity unit comprises a known reversible inhibitor that binds tightly 
in a non-covalent manner to the active site of the target enzyme (or a specific class of 
target enzymes). Because the enzyme-probe interaction is mainly based on affinity, in 
order to promote selective binding and modification of proteins‟s active sites, an 
additional moiety, the photo-labile group, is used to covalently link the probe to the 
enzymes. The incorporation of a fluorescent tag eventually results in a trifunctional 
affinity-based probe for potential large-scale protein profiling experiments. Two 
photolabile groups, namely diazirine and benzophenone, have usually been used to 
covalently modify molecules in a variety of biological experiments. These 
photoactive labels operate by generating reactive intermediates such as carbenes, 
nitrenes, and ketyl biradicals and inserting them into the target molecule to form a 
enzyme 
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permanent linkage. The selected wavelength for UV irradiation is usually greater than 
300 nm, thus preventing potential photochemically induced damages to the enzyme.
70
 
Our group recently reported some affinity-based probes which targeted other class of 






Figure 1.15 Proteome Profiling with activity-based probes (ABPs) (a) and 
affinity-based probes (AfBPs) (b). 
1.7  Research Objectives 
    The aim of this thesis is to develop high-throughput amenable strategies for 
chemically profiling of aspartic proteases as well as protein kinases. The 
high-throughput synthetic and in situ screening strategy we developed may offer a 
useful method for drug discovery of diseases. It may also provide guidelines for rapid 
synthesis and validation of drugs in future. Additionally, our small molecule 
microarray (SMM)-facilitated strategy for the discovery of new AfBPs should 
provides a useful tool for high-throughput developments of novel small molecule 
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Chapter 2 
 
Expedient Solid-phase Synthesis of Both Symmetric and 
Asymmetric Diol Libraries Targeting Aspartic Proteases 
 
2.1  Summary 
    C2-symmetric diols have been shown to be highly potent against HIV-1 protease 
(PR). However, gaining access to these compounds has been hampered by the need of 
multistep solution-phase reactions which are often tedious and inefficient. In this 
chapter we describe a solid-phase amide-forming approach for rapid assembly of both 
symmetric and asymmetric diol-containing small molecules as potential aspartic 
protease inhibitors. One potent and selective inhibitor of HIV-1 PR, SYM-5 (Ki = 400 
nM), was discovered which should possess better bioavailability properties (fewer 
amide bonds, lower MW) than its parental compounds. The clear advantage in our 
strategy lies in its feasibility for solid phase synthesis of asymmetric diols. When 
compared with other potent HIV-1 protease inhibitors, our compound pales in terms 
of its inhibitory activity. 
2.2  Introduction 
    A key challenge in current drug discovery is the development of high-throughput 
(HT) amenable chemical reactions that allow rapid synthesis of diverse chemical 
libraries of enzyme inhibitors. In recent years, one reaction that has received much 
attention is the amide-bond formation between an amine and a carboxylic acid using 
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suitable activating/coupling reagents.
56
 The reaction is highly efficient in that it often 
generates desired products in nearly quantitative yields, thus allowing direct in situ 
biological screening to be carried out. This strategy has been successfully adopted, in 
both solution- and solid-phase, by several groups for the rapid discovery of small 
molecule inhibitors.
51-55,71 
The solution phase amide-forming strategy is 
comparatively easier to implement but has the following problems: (1) undesired 
chemicals (starting materials, reagents, by-products, etc) are present during the 
biological screening and therefore often cause false results; (2) multi-step reactions 
can not be carried out without proper purification of the intermediates; and (3) 
excessive starting materials/reagents normally cannot be used to drive an 
otherwise-difficult coupling to completion. Solid-phase synthesis could potentially 
solve many of these problems, and has been widely adopted in the synthesis of 
biopolymers (e.g., oligonucleotides and peptides) as well as small molecules (e.g., in 
combinatorial chemistry). In most cases, however, low-quality products are generated 
and need to be laboriously purified before screening. We have recently become 
interested in developing highly efficient solid-phase strategies that enable large-scale 
synthesis of high-quality compound collections which are suitable for direct in situ 
biological screening.
72 
With these new chemical tools, we have successfully 
developed small molecule inhibitors targeting different classes of proteases, including 
cysteine and metallo-proteases. Herein, by making use of the amide-forming reaction, 
we report the solid-phase synthesis of both symmetric and asymmetric diols as 
putative inhibitors of aspartic proteases. The key advantages of this method include (i) 
                                                                         23 
chemical modification of the library building blocks (i.e., diol core & acids) is 
unnecessary; (ii) it is solid-phase, enabling a large library to be constructed efficiently; 
(iii) it is robust, giving high-quality products. 
Many aspartic proteases are known therapeutic targets.
72,73 
For example, HIV-1 
protease is one of the main targets of AIDS.
72 
Renin is currently being used to treat 
hypertension.
73a 
Cathepsin D is involved in breast cancer metastasis.
73b
 β-Secretase is 
related to Alzheimer disease.
73c 
Plasmepsins, key aspartic proteases from malaria 
involved in the hemoglobin degrading pathway in parasite-infected macrophages, are 
being pursued to treat malaria.
73d
 
HIV-1 protease (PR) is one of the best known aspartic proteases, and an 
attractive target for the treatment of AIDS. The enzyme consists of two identical, 
non-covalently associated subunits of 99 amino acid residues formed in an 
C2-symmetric fashion. The highly symmetrical active site is formed at the dimer 
interface. Over the years, many HIV-1 protease inhibitors (PI) have been 
developed.
72a
 Two of the most effective PI are shown in Figure 2.1 (top two): they 
contain a C2-symmetric, diol-containing moiety which mimics the transition state of 
amide hydrolysis. Wong‟s peptidic inhibitor developed in 1998,72b for example, has a 
Ki of 1.5 nM against HIV-1 PR. Its poor bioavailability (e.g., peptide-based, large 
MW) however makes it ineffective in cell-based assay. Abbott‟s Ritonavir,72c an 
FDA-approved drug and improved version of Wong‟s inhibitor, is nearly 
C2-symmetric, and much more effective against AIDS due to its smaller size (MW = 
820) and fewer amide bonds. The rapid emergence of drug-resistant HIV-1 PR, 
                                                                         24 



















































SYM-5 (this study; Ki = 400 nM)
 
Figure 2.1 Structures of two known diol-containing HIV-1 protease inhibitors (top 
two) and the inhibitor identified from this study (bottom). 
Thus, there is an urgent need to develop chemistry that permits rapid and 
efficient synthesis of new PI. Another paradigm shift in HIV PI research is the 
introduction of asymmetric PI which could be more effective against some of the 
drug-resistant HIV strains.
72d 
In the current study, we have developed a solid-phase 
strategy for rapid synthesis of potential symmetric and asymmetric PI (Schemes 2.1 
and 2.2). As a proof of concept, the strategy was successfully used to synthesize 75 
diol-containing compounds, which, upon direct in situ screening, revealed a small 




































Scheme 2.1 Traceless synthesis of symmetric and asymmetric inhibitors targeting 
aspartic proteases.  
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2.3  Results and Discussion 
2.3.1 Solution-phase Synthesis of Diamino Diols 
    In our strategy, we adopted a solution-cum-solid phase strategy, in which the 
most important component of the inhibitors-the diamino diol core group, was 
synthesized in solution (Scheme 2.2) and purified to homogeneity before being 
installed onto the commercially available 4-formyl-3-methoxyphenoxy (FMP) resin,
74 
followed by diversification with a variety of acids (Scheme 2.3). As shown in Scheme 
2.2, following previously published procedures,
72c 
three different C2-symmetric 
diaminodiols, 6a-c, were made from commercially available Cbz-protected amino 
acids 1. Upon reduction, the corresponding amino alcohols 2 was oxidized to the 
aldehydes 3 using Dess-Martin reagent. Subsequently, pinacol homocoupling reaction 
between two equivalents of 3 in the presence of VCl3 afforded diastereomeric diols 4 
in a single-step transformation (~20% yield). Subsequent protection of the dihydroxyl 
group with 2, 2-dimethoxypropane, flash chromatography to remove minor 
diastereomeric impurities, and deprotection of the Cbz groups using H2 (in Pd/C) gave 










































Scheme 2.2 Solution-phase synthesis of the diol warheads. (a) Isochloroformate, 
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NMM, DCE, -15 
o
C. (b) NaBH4, THF, 0 
o
C, 70-77%. (c) Dess-Martin, DCM, r.t., 
60-70%. (d) VCl3, 1,3-dimethylimidazole, Zn, dry THF, reflux, 10-20%. (e) 2, 
2-dimethoxypropane, p-TsOH, acetone, r.t., 60-70%. (f) H2, Pd/C, MeOH/EA, r.t., 
60-70%. 
2.3.2 Traceless Synthesis of Symmetric and Asymmetric Inhibitor Library 
    To start the library assembly on solid phase, the aldehyde-containing FMP resin 
was used for capturing of 6 by reductive amination, followed by amide bond-forming 
reaction with acids. First, the three diaminodiols, 6a-c, were treated with FMP resin in 
the presence of Na(OAc)3BH/2% glacial acetic acid in DCE to give the resin-bound 
amines 7, which contain an 1°and 2°amine each. Initially, simultaneous acylation 
of both the 1°and 2°amines with the same acid building blocks was met with some 
difficulties under most coupling conditions (e.g., DIC/HBTU/TBTU/HATU); in most 
cases, only the monoacylated product (at 1°amine position) was generated. This was 
clearly due to the chemical and steric difference of the two amines in 7. We therefore 
took advantage of this to make both symmetric and asymmetric diols (Scheme 2.3). 
An exhaustive testing of (7 + acid) coupling under a variety of different coupling 
conditions finally gave rise to the following two sets of optimized conditions: (I) to 
make symmetric diols, Route I was used in which PyBrOP/ DIEA coupling with the 
acid (10 equiv) was carried out to gave 8; (II) to make asymmetric diols, Route II was 
used in which PyBOP/HOAt coupling with the first acid (5 equiv) was performed, 
giving 9, followed by PyBrOP/DIEA coupling with the second acid (5 equiv) to give 
10. Finally, cleavage of the products from the resin using an optimized TFA cocktail 
(5:4:1 TFA/DCM/water) gave a total of 44 C2-symmetric and 31 asymmetric diol 
inhibitors (representative compounds are shown in Scheme 2.3). To ensure the crude 
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products generated from our strategy were sufficiently pure for direct in situ screening, 
the compounds were further characterized by LCMS and NMR; in most cases the 
desired products were obtained with good purity (>90% and 60–95% for symmetric 






























































































































































Scheme 2.3 Solid-phase synthesis of both symmetric and asymmetric diols. (a) 
Na(OAc)3BH, 2% AcOH in DCE, r.t. (b) acid (10 eq), PyBrOP/DIEA in DMF, r.t. (c) 
acid 1 (5 eq), PyBOP/HOAt/DIEA in DMF, r.t. (d) acid 2 (5 eq), PyBrOP/DIEA in 
DMF, r.t. (e) TFA/DCM/H2O (5/4/1), r.t. 
2.3.3 Inhibitor Fingerprinting 
    Next, the inhibitory activity of these 75 diol-based inhibitors was determined 
against HIV-1 PR, plasmepsin I (PM I) and plasmepsin II (PM II) using a standard 
fluorescence microplate assay method. The activity of the aspartic proteases was 
determined by measuring the rate of hydrolysis from the commercial available 
fluorogenic substrates (AnaSpec, USA). The inhibition of all proteins were screened 
using black polypropylene flat-bottom 384-well microtiter plates (Greiner, Germany) 
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in a total reaction volume of 20 μl/well, monitored with a Tecan Infinite F200 
microplate reader at excitation of 390 nm and emission of 492 nm prior to the 
addition of substrate. The results were shown in the heat maps below Figure 2.2. 
Eventually, an inhibitor fingerprint of the library against the aspartic proteases was 
obtained, from which six potential hits (SYM-5, -21, -35, -43 and ASM-16, -29) were 
identified. 
2.3.4 IC50 Measurements of Selected Inhibitors 
    Besides, we also determined some representative compounds‟ IC50 values for 
HIV-1, plasmepsin I/II and pepsin based on Figure 2.2. As shown in Figure 2.5, 
compounds SYM-05, SYM-35 were identified to be relatively potent against HIV-1 
PR and not against plasmepsin I, plasmepsin II and pepsin. Compound SYM-21 were 
identified to be relatively potent against both plasmepsin I and II but not against 
HIV-1 PR and pepsin. However, SYM-24, SYM-43 were found to specifically inhibit 
plasmepsin I but not plasmepsin II. Interestingly, ASM-16 and ASM-29 were against 
plasmepsin II but not against plasmepsin I. Detailed inhibition studies were then 
carried out to obtain the corresponding IC50 of these compounds, and the results are 
summarized in Table 2.1. The best inhibitor against HIV-1 PR was found to be 
SYM-5, with IC50 value of 395.4 nM. Significantly, it showed a very poor inhibition 
against PM I and PM II (>25 μM), indicating that this inhibitor is highly specific only 
towards HIV-1 PR. None of the asymmetric compounds was able to inhibit 50% of 
the HIV-1 PR activity at a concentration of 25 μM, which is expected since the assay 
was done with the C2-symmetric wild type HIV-1 PR. However, two of these 






HIV-1 PR Plasmepsin I Plasmepsin II Pepsin
  
 
Figure 2.2 Inhibition profiles of the 75-member library against four aspartic proteases. 
Inhibitor concentration is kept constant (25 μM) with different enzymes.  
compounds exhibited moderate activity against PM II (IC50 = 12.6 and 11.7 μM for 
ASM-16 and -29, respectively), which may be developed into potent inhibitors in 
future. SYM-21 and SYM-43 were identified to be moderate and selective inhibitors 
of PM II and PM I, respectively. These results thus validate our strategy as a feasible 
method for future discovery of other aspartic protease inhibitors. 
0% inhibition                 100%
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Figure 2.3 IC50 graphs for various inhibitors against (a) HIV-1 PR, (b) Plasmepsin I, 
and (c) Plasmepsin II. 
2.3.5 Ki Measurements 
    To further investigate the potency of the strongest inhibitor SYM-05 identified 
against HIV-1, a detailed kinetic evaluation was performed. Dose-dependent reactions 
were carried out by varying both the concentration of substrate and inhibitor while 
keeping the enzyme concentration constant. Briefly, a dilution series from 
Table 2.1. Inhibition of the six selected inhibitors. 
 IC50 (Ki) in nM 
Enzyme SYM-5 SYM-21 SYM-35 SYM-43 ASM-16 ASM-29 
HIV-1 PR 395.4 (400) >25000 1313 >25000 >25000 >25000 
PM I >25000 4391 >25000 2642 >25000 >25000 
PM II >25000 3908 >25000 >25000 12657 11773 
Sym-05
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approximately 10000 nM to 100 nM (final concentration) was prepared for SYM-05. 
The enzymatic mix was incubated for 15 min before initiating the reaction with varied 
amounts of substrate (2.5 μM to 10 μM). The enzymatic reactions were immediately 
monitored at λex = 340 nm and λem = 490 nm for a period of 10 min. The kinetic data 
obtained were analyzed using the Dixon Plot (1/initial velocity plotted against 
inhibitor concentration); affording four different linear graphs (corresponding to the 
different substrate concentration) that converged on the left of Y-axis to give a value 
that corresponds to Ki (Figure 2.4). Finally, it was found that Ki of SYM-05 was 400 
nM, which was quite consistent with its IC50 value. 
 
Figure 2.4 Characterization of inhibitor hit. Structure of SYM-5 (a) IC50 (b) and 
Ki of SYM-5 (c) against HIV-1 protease. 
 
2.4  Conclusion 
In summary, we have developed a solid-phase amide-forming approach for rapid 
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potential aspartic protease inhibitors. One potent and selective inhibitor of HIV-1 PR 
was discovered which should possess better bioavailability properties (fewer amide 
bonds, lower MW) than its parental compounds. The clear advantage in our strategy 
lies in its feasibility for solid-phase synthesis of asymmetric diols. When compared 
with other potent HIV-1 protease inhibitors, our compound pales in terms of its 
inhibitory activity. Nevertheless, we believe the chemical strategy discolsed herein 
may be readily expanded in future for the construction of much bigger compound 















                                                                         33 
Chapter 3 
 
High-throughput Synthesis of Aspartic Protease Inhibitors and 
Probes for Proteome Profiling of Plasmapsins in Malaria 
Parasites 
 
3.1  Summary 
    In this chapter we describe a high-throughput strategy to synthesize the 
475-member inhibitor library against aspartic proteases using “click” chemistry. The 
strategy is robust, giving high-quality products which are spectroscopically pure 
enough to be used for biological screening without any further purification. 
Additionally, we have also developed the first affinity-based probes for functional 
profiling of all four plasmapsins (PMs) in intraerythrocytic malaria parasites. 
Subsequent in situ screening of parasites with these probes has led to the 
identification of a compound, G16, which showed good inhibition against all four 
PMs and parasite growth in infected RBCs. Molecular modelling indicates this 
inhibitor binds to the active site of the plasmepsins tested, as originally designed. Our 
finding indicates that feasibility of using AfBP approaches for identification of 
inhibitors against less-characterized enzymes (i.e. HAP) and those against multiple 
targets. We anticipate that these new chemical tools should facilitate discovery of new 
parasite biology and new anti-malaria drugs. In the current study, we were unable to 
detect previously predicted but unidentified aspartic proteases from the malaria 
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proteome. Thus, G16 might have further targets, other than the four plasmepsins, in 
the malaria proteome. 
3.2  Introduction 
3.2.1 High-throughput Amenable Chemical Reactions in Inhibitor Discovery 
    High-throughput enzymology occupies a crucial role in modern drug discovery 
programs. The main challenge in this field is the development of high-throughput (HT) 
amenable chemical reactions that enable rapid generation of enzyme inhibitor libraries 
as well as probes. One such reaction is the Cu (I)-catalyzed, 1, 3-dipolar cycloaddition 
between an azide and an alkyne fragment, also known as “click” chemistry, which 
was pioneered by Sharpless and Meldal
35, 36
 (Figure 3.1a). The major features of this 
reaction include its high efficiency, chemo-selectivity, modularity and 
biocompatibility, which allow direct in situ screening of the products formed without 
the need of further purification. To date, many research groups have successfully 
adopted this platform for the high-throughput screening and discovery of inhibitors 













and others. Another class of reactions possessing similar qualities is the amide bond 
forming reaction between an amine and a carboxylic acid using suitable 
activating/coupling reagents. Some research groups have recently used this reaction 
for solution-phase, rapid assembly of small molecule inhibitors against a variety of 




and so on. This reaction are 
highly efficient, often generating the desired products in nearly quantitative yields, 
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thus allowing in situ biological screening to be carried out directly in some cases, 
even in the presence of excessive starting materials, reagents, or byproduct (Figure 
3.1b). The effectiveness of this method, however, had recently been challenged, as it 
was discovered that unexpected byproduct may give rise to false results. Wong et al. 
recently reported that an intermediate benzotriazole ester of the amide bond-forming 
reaction was found to be responsible for the inhibitory activity toward SARS-3CL 
protease.
56 
To avoid such limitation, we aim to develop a combinational synthetic 

























Figure 3.1 High-throughput amenable chemical reactions. (a) “Click” chemistry 
pioneered by Sharpless and Meldal. (b) Wong‟s solution-phase and in situ screening 
approach. 
3.2.2 Functional Profiling Identification and Inhibition of Plasmepsins in 
Intraerythrocytic Malaria Parasites 
    Malaria is a global disease, affecting 300-500 million people annually and killing 
1-2 million. The most deadly form of the disease is caused by the pathogen 
Plasmodium falciparum. Currently, quinolines and antifolates are the most common 
antimalaria drugs.
75 
The cost of the drugs, as well as the emergence of multidrug 
                                                                         36 
resistance, has however become a major problem, highlighting the need for newer and 
ideally cheaper drugs against this devastating disease.
76 
Proteases, including cysteine 
(i.e. falcipains) and aspartic proteases (i.e. plasmepsins, or PMs), are required for 
parasite growth through the digestion of human hemoglobin and delivery of necessary 
nutrients. They have long been considered promising anti-malaria targets.
77
 Genomic 
datas obtained for P. falciparum predict at least ten genes encoding aspartic proteases, 
four of which (PM-I, -II, -IV and the histo-aspartic protease or HAP) have been found 
so far, mostly in the food vacuole (FV) of the parasite. The other hypothetical aspartic 
proteases, however, have not been experimentally confirmed. In the last few years, 
drug discovery efforts on potential plasmepsin inhibitors have somewhat waned after 
gene knock-out experiments showed that parasites could still survive, albeit with a 
reduced growth rate, without most of the four functionally redundant FV 
plasmepsins.
78 
it is now believed that the only effective way to kill the parasite with 
PM drugs is to look for potential inhibitors that can simultaneously target as many 
plasmepsins as possible.
79 
At present, most inhibitors developed are only effective 
against selected PMs.
73c 
This is due to difficulties associated with recombinant 
expression and insufficient biochemical characterizations of certain PMs (i.e. PM-I 
and HAP) in vitro,
80a,b 
and the lack of methods that allow simultaneous screening of 
PMs‟ activity in situ.80c Previously, activity-based probes (ABPs) was successfully 
used for in situ screening of malaria cysteine proteases.
81 
We report herein the first 
chemical proteomic approach for functional profiling of all four PMs in 
intraerythrocytic malaria parasites. This is made possible by the development of 
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affinity-based probes (AfBPs) against PMs (Figure 3.2).
82
 In situ screening of PMs 
with these probes against a focused library of 152 hydroxyethylamine-containing 
small molecules has led to the identification of G16 as an effective inhibitor against 

































AfBP assembly "Click" to BP-TER






A: R1 = Phe; R2 = I
B: R1 = Phe; R2 = II
C: R1 = Leu; R2 = I
D: R1 = Leu; R2 = II
E: R1 = Tyr; R2 = I
F: R1 = Tyr; R2 = II
G: R1 = Val; R2 = I
H: R1 = Val; R2 = II
Inhibitor assembly
"Click" to 19 alkynes




















Figure 3.2 Assembly of affinity-based probes (AfBPs) and the 152-membered library 
of potential inhibitors against all four FV plasmepsins in P. falciparum. Click 
chemistry and in situ screening of inhibitor discovery. 
3.3  Results and Discussion 
3.3.1 Solution-cum-solid Phase Synthesis of N, C-terminal Azides Warheads 
    Based on previous reported procedure with minor modification, we designed and 
synthesized a library of compounds which contained a hydroxyethylamine isosteres as 
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transition-state mimics, while diversifying the P2/P2‟ residues to generate new 
inhibitors. Starting from commercial available amino acids, two different azide cores 
were prepared as summarized in Scheme 3.1. In the 10-member N-terminal warheads 
sublibrary, R1 and R2 positions, corresponding to the P1 and P2 residues, respectively, 
upon binding to the aspartic proteases, were varied with aromatic/aliphatic moieties 
(R1 = Phe, Leu, Tyr, Lys, Val; R2 = two aromatic acids as shown in Scheme 3.1). In 
the 15-member C-terminal warheads sublibrary, R1‟ and R2‟ positions, corresponding 
to the P1 and P1/2‟ positions, respectively, were similarly varied. Briefly, L-amino 
acids first reacted with diazomethane prior to treatment with isobutyl choloroformate 
in order to activate acid group. Subsequently, bromination of acetone was carried out 
to afford compound 2 with good yield. Compound 2 was treated with NaN3 overnight 
under acidic condition to give compound 3 in moderate yield. Subsequent reduction 
of ketone using NaBH4 followed by coupling of the hydroxyl group with 
4-dihydro-2H-pyran (DHP) resin under acid-catalyzed conditions gave resin 5. 
Deprotection of the Fmoc group followed by standard acylation with two aromatic 
acids and finally cleavage by TFA to afford the 10-member N-terminal warhead 
sublibrary 6(a-j). Similarly, starting from azido amino acids prepared following 
previous reported procedure, compound 10 was prepared following above the same 
four step reactions. Subsequently, it was attached to DHP resin followed by alkylation 
reaction with i-butylamine, acylation with five commercially available sulfonyl 
chlorides then TFA cleavage to afford C-terminal warhead sublibrary 12(a-o). 
Eventually, the resulting 25 warheads were analyzed by LC-MS, which confirmed 
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most of them were sufficient purity (>90%) and were subsequently used for direct 




























































































Scheme 3.1 Solution-cum-solid phase synthetic approach for synthesis of the N, 
C-terminal warheads (WH). 
3.3.2 Traceless Synthesis of Alkyne Building Blocks. 
    To start the synthesis of alkyne building blocks on solid support, propargylamine 
was treated with FMP resin in the presence of Na(OAc)3BH/2% glacial acetic acid in 
DCE to give the secondary amines 13 (Figure 3.2). Subsequent amide bond-forming 
reaction between the resin-bound secondary amines and the acid building blocks (A-J) 
was found to be highly challenging and required extensive optimizations. A variety of 
coupling reagents including HATU, PyBoP, HBTU, EDC and DIC were attempted, 
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only PyBop gave the desired products in satisfactory yield and purity. For sulfonyl 
amide bond-forming between sulfonyl chloride and the secondary amine was quite 
easy with excellent purity (> 90% in most cases). Finally, cleavage of the products 
from the resin using an optimized TFA cleavage cocktail (TFA:DCM:Water = 10:9:1) 
gave a total of 19 alkynes 15(A-S). Most crude products were characterized by 















































Scheme 3.2 Traceless synthesis of alkyne building blocks. 
3.3.3 “Click” Assembly of Aspartic Protease Inhibitor Library 
The Cu (I)-catalyzed “Click” reaction between azide warheads and alkyne 
building blocks was next carried out. After optimization for “click” condition, it was 
found that a mixed solvent system containing water and DMSO (1:1) enabled both the 
alkynes and the azides to be completely dissolved, and at the same time the 1, 
3-dipolar coupling could be completed with extremely high efficiency. More 
importantly, the products could be taken directly without further purifications. 25 
hydroxyethylamine warheads were clicked with 19 different alkynes to afford a 475 
member library containing N-terminal and C-terminal sublibrary (Scheme 3.3). 
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LC-MS analysis of all coupling reactions indicated the complete consumption of the 































































































Scheme 3.3 “Click” assembly of the N, C-terminal inhibitor library. 
3.3.4 Preliminary Screening Experiments with Aspartic Proteases 
    When the inhibitor library was in hand, their biological characterizations and 
utilities were further determined by my collaborators. The 475-member inhibitor 
library was firstly screened directly against several different aspartic proteases. 
Detailed procedure for the microplate based screening for HIV-1, pepsin, PM I and 
PM II was described below. The aspartic protease activities were determined by 
measuring the rate of hydrolysis of the commercial available fluorogenic substrates. 
The inhibition of proteins were measured using black polypropylene flat-bottom 
384-well microtiter plate (Greiner, Germany) in a total reaction volume of 25 μL/well, 
monitored by Tecan Infinite F200 microplate reader at excitation of 390 nm and 
emission of 492 nm prior to the addition of substrate. One concentration of inhibitors 
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(2.5 μM) was first used in the assay, where necessary. Negative controls were 
performed in the absence of enzyme, and positive controls were also carried out in the 
presence of enzyme but without inhibitor. Consequently, some hits were picked out 






From 0 to 100% inhibition  
Figure 3.3 Inhibition profiles of the 475-member library against five aspartic 
proteases. 
Table 3.1 Preliminary results of inhibition percentage for some hits. 
 
3.3.5 “Click” Synthesis of Affinity-based Probes 
    Unlike other previously known aspartic protease probes, which were based on 
specific inhibitors against their respective targets (e.g. presenilin and β-secretase),83 
we aimed to establish a general approach that could be applicable for a variety of 
aspartic proteases. As shown in Figure 3.4, 25 probes (A-G), each containing a 
hydroxyethylamine warhead (WH) with a varied P1 and P2 group (assuming the 
orientation of probe-enzyme was as drawn), were assembled from the corresponding 
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azide-containing warheads and the alkynes, which contains a benzophenone (BP) 
photo-crossing unit and a tertraethylrhodamine (TER) or biotin reporter,
35,84 
using 
above measured click chemistry. Hydroxyethylamine scaffolds are general transition 
state analogs of aspartic proteases. In all probes, aliphatic/aromatic groups were 
strategically chosen since they are preferred in some different aspartic proteases (for 


















































































Scheme 3.4 “Click” assembly of affinity-based probes (AfBPs). 
3.3.6 Labeling of Recombinant Aspartic Proteases 
    To demonstrate the suitability of the probes for the UV-initiated proteomic 
profiling of aspartic proteases, 15 probes which have good purities were characterized 
with various recombinant aspartic proteases, such as pepsin, renin, PM II and HAP, 
respectively. As shown in Figure 3.4, distinct labeling profiles of 15 probes against 
various aspartic proteases were observed. To further investigate the reactivities of our 
probes, 7 probes derivated from N-terminal warheads were characterized with 
previous several proteins. Because of the unknown catalytic mechanism of the 
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non-classic aspartic protease HAP, labeling reaction for HAP was carried out in both 
acidic and neutral pH. Each of the 7 probes was tested with each aspartic protease 
individually. Highly distinct labeling profiles against different aspartic proteases were 
observed. This result indicated that the variable R1 and R2 groups exerted a strong 
influence over specific enzyme/probe interactions. The labeling was abolished by 
treatment with pepstatin and mutations of key catalytic residues in the enzyme active 
site; thus, labeling was indeed dependent on enzyme activity. 
 
Figure 3.4 Profiling of P. falciparum aspartic proteases. (A) Structures of 7 
affinity-based probes. (B) Characterization of recombinant PMs with seven AfBPs 
A–G. labeling profile of recombinant PMs with the AfBPs. (C) Tree-view 
representation of labeled bands (on the basis of their intensity). 
























































































(B)                               (C) 
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Stages P. Falciparum 
    To profile the aspartic protease activities in blood stage plasmodium falciparum, 
the probes were subsequently used to label proteomes of highly synchronized 
parasites obtained at different stages of parasite development (ring, trophozoite, and 
schizont; Figure 3.6a). A 37 kDa protein band, which corresponds to the molecular 
weight of the four known PMs, was highly visible across probes A-G, although the 
labeling intensities varied. Probe G consistently gave the strongest labeling profile 
and thus was chosen for further studies. Analysis by two-dimensional gel 
electrophoresis/MS and western blotting confirmed unambiguously that the 37 kDa 
band corresponds to all four labeled PMs The probes could therefore be used to 
profile all four known PMs and their enzymatic activities directly from the parasite. 
The detection of neither zymogens of the four PMs nor other proteins indicated the 
specificity of the probes in targeting only active PMs. Since it would be highly 
desirable if the probes could also detect the activity of other previously unidentified 
aspartic proteases in the malaria proteome (i.e. those predicted by genomic data), a 
deliberate effort was made in the 2D-GE/MS experiments to look for new protein 
spots. However, these attempts were unsuccessful; either these hypothetical aspartic 
proteases were present in very low abundance or our probes were not suitably 
designed to detect/label them. Subsequently, we determined the enzymatic activity of 
the four plasmepsins by labeling both detergent-soluble and detergent-insoluble 
lysates from each development stage (Figure 3.6B). The results indicated that PM 
activity was highly regulated and peaked at the trophozoite stage for the insoluble  
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Figure 3.5 Profiling, identification and proteome characterization of P. falciparum 
aspartic proteases. (A) Parasite extracts at different stages were labeled with the seven 
AfBPs (the TER–BP–alkyne was used as a negative control). Top: in-gel fluorescence 
scanning showing the specific labeling of the 37 kDa band across different stages; 
bottom left: spectral counts of the labeled bands; bottom right: schizont-stage parasite 
extracts were labeled with probe G and then subjected to 2DGE/ MS analysis to 
identify the four PMs (spots 1-4 were identified as PM-II, PM-I, HAP, and PM-IV, 
respectively). pI = isoelectric point. (B) Characterization of plasmepsin activities from 
total lysates (left), NP-40-soluble fractions (middle), and insoluble fractions (right) 
across different intraerythrocytic stages of P. falciparum. R = ring stage, T = 
trophozoite stage, S = schizont stage. Top: spectral counts of the respective bands 
observed by in-gel fluorescence scanning. 
fraction. This observation is consistent with the role of these PMs in hemoglobin 
degradation, which occurs in the food vacuole. The distinct profile of soluble-fraction 
activities peaked at the schizont stage; this peak probably indicates a change in the 
sub-cellular localization of the PMs (PM-II was previously shown to be released from 
the FV in the late schizont stage). Western blotting with antibodies against the four 
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labeling profiles observed with probe G. Thus, the utility of our probes for the 
accurate reporting of the activities of PMs from crude malaria proteomes was further 
confirmed. One of the key advantages of these AfBPs is the ability to use them for the 
simultaneous detection of the activities of multiple PMs in their native environment. 
This so-called in situ screening method, originally described by Cravatt and 
coworkers for other enzymatic systems,
63 
enabled us to identify potential inhibitors 
against all four PMs directly from the malaria proteome without the recombinant 
production of every active PM. 
3.3.8 Inhibitor Library Screening for PMs 
    To identify the most potent inhibitors against all four PMs, we preincubated each 
compound of the 152-membered hydroxyethylamine-based library from N-terminal 
sub-library with the parasite lysate and then added probe G and subjected the samples 
to UV irradiation. We determined the relative potency of each inhibitor by measuring 
the decrease in fluorescence intensity in the 37 kDa labeled band. A total of eight 
candidate “hits” were identified. These eight compounds were re-synthesized and 
purified, and their G16, showed an IC50 value of 937.5 nm (Figure 3.7A). In contrast, 
G15, a“false positive” identified from standard enzymatic assays by using selected 
recombinant PMs, showed significantly weaker inhibition (IC50 = 21.6 µM). This 
result underscores the importance of our in situ screening assay for the future 
discovery of general PM inhibitors. The inhibitory effect of these candidate 
compounds was tested with parasite-infected RBC cultures. The distinct 
activity/solubility profiles of PMs prompted us to test the inhibitory effect of the 
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inhibitors against schizontstage PMs, which showed the highest activity in the 
detergent nonyl phenoxylpolyethoxylethanol (NP-40). RBCs were treated with the 
inhibitors 40 h after parasite invasion (i.e. in the late schizont stage). Upon cell 
rupture, we measured the percentage of parasites in the ring and schizont stages 
(Figure 3.7B, C). Compound G16, but not G15, caused a marked decrease in the 
number of newly formed ring-stage parasites, and at the same time an increase in free 
extracellular merozoites. Thus, as well as blocking parasite development at the 
trophozoite/schizont stage, as one might expect, the inhibition of PM activity also 
caused the blockage of either the escape of the parasites from RBCs, or their 
reinvasion of RBCs. This speculation is further supported by previous findings that 
PM-II was able to digest an RBC membrane-skeleton protein in the late schizont stage 
at neutral pH, and that the invasion of P. falciparum merozoites was affected by 
treatment with pepstatin (a general aspartic protease inhibitor).
85 
The inhibition of 
parasites by G16 was dose-dependent, whereby the estimated EC50 value of 1.04 μM 
was similar to that obtained from the in situ proteomic screening (IC50 = 937.5 nM). 
In contrast, G15 showed little or no inhibition towards infected RBCs, even at the 
highest concentration tested. Finally, G16 showed no apparent cytotoxicity against 
common mammalian cell lines. 
3.3.9 Identification of the 37-kDa Band (as PM-I, PM-II, HAP and PM-IV) by 
2DGE & MS, and Western Blotting 
    To positively confirm the 37-kDa fluorescent band in the schizont stage parasite 
extract corresponds to the four known plasmepsins (PM-I, PM-II, HAP and PM-IV), 
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Figure 3.6 Inhibition of P. falciparum aspartic proteases. a) In situ screening assay 
and determination of the IC50 values of G15 and G16 against all four PMs in the 
parasite proteome. consistent PMs level detected by specific antibodies across all 
lanes(bottom four gels) show that the difference in labeling intensities were due to 
competitive inhibition of the PM labeling by G16 rather than loading 
error.inh=inhibitor. (B) Representative images of parasite-infected RBCs treated with 
G16 (10 mm; with dimethyl sulfoxide (DMSO) and G15 as controls); arrows show 
the abnormal development of parasites. Scale bar: 600 mm. (C) Dosedependent- 
inhibition results from (B). 
2-dimensional gel electrophoresis followed by MS analysis of the fluorescent spots 
was carried out. 1.0 mg of total proteins from the schizont stage parasite extract was 
pre-incubated in the reaction buffer (100 mM sodium acetate, 10 % glycerol, pH 5.0) 
and 5 μM of probe G. After labeling as earlier described, the sample was desalted and 
concentrated by acetone precipitation overnight at -20 
o
C. Precipitates were collected 
by centrifugation at 13,000 rpm. Samples were resuspended in 1× re-swelling buffer 
(8 M urea, 2% CHAPS and 2% IPG buffer and 0.002% bromphenol blue), and briefly 
sonicated. Just prior to use, DTT was added (final concentration: 3 mg/mL). 
Rehydration buffer and stock DTT (62.5 mg/mL) were stored at -20 °C. Rehydrated 
IEF strips were isoelectrically focused at r.t. under low viscosity oil with a gradient 
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V for 1.5 h. After IEF separation, the gel strip was reduced and alkylated. The 
reduction step was performed for 15 min in 10 mL of equilibration buffer 1 (0.5% w/v 
DTT in 50 mM Tris-HCl pH 8.8, 6 M urea, 30% v/v glycerol, 2% w/v SDS, and 
0.002% w/v bromphenol blue). The alkylation step was performed for 15 min in 10 
ml of equilibration buffer 2 (4.5% w/v iodoacetamide in 50 mM Tris-HCl pH 8.8, 6 M 
urea, 30%v/v glycerol, 2% w/v SDS, and 0.002% w/v bromphenol blue). The IEF 
strip was equilibrated in equilibration buffer stock solution (50 mM Tris-HCl pH 8.8, 
6 M urea, 30% v/v glycerol, 2% w/v SDS, and 0.002% w/v bromphenol blue). Next, 
the equilibrated IEF strips were each placed on a preparative well and sealed using 
1% agarose plus 0.002% (w/v) bromphenol blue. After electrophoresis the 
two-dimensional gels were scanned with Typhoon fluorescence scanner. Fluorescence 
spots corresponding to each target (spots 1, 2, 3 and 4 for PM-II, PM-I, HAP and 
PM-IV, respectively, in Figure 3.6A) were excised directly from the gel trypsin 
digestion was performed with In-Gel Trypsin Digestion Kit from Pierce. After 
digestion, digested peptides were then extracted from the gel with 50% ACN and 1% 
formic acid. Tryptic peptide extracts were evaporated by speedvac and reconstituted 
with 10 μL of 0.1% TFA, a volume of 2 μL of the peptide extracts were manually 
spotted onto a Prespotted AnchorChip MALDI target plate for MALDI-TOF Mass 
Spectrometry (Bruker Daltonics) and incubated for 3 min, followed with washing step 
with 10 μL of 10 mM ammonium phosphate in 0.1% TFA, then dried. MALDI TOF 
mass spectra were recorded using Ultraflex III TOF/TOF mass spectrometer (Bruker 
Daltonics) with the compass 1.2 software package including flexControl 3.0 and 
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flexAnalysis 3.0, calibrated with PAC peptide calibration standards. MS/MS analysis 
for the major peaks in PMF spectra were carried out by auto LIFT on the 
MALDI-TOF/TOF instrument. MS and MS/MS Peak lists with intensity value were 
submitted to Matrix Science Mascot server (http://www.matrixscience.com/) through 
BioTools 3.0 (Bruker Daltonics) using database NCBInr with species of Plasmodium 
falciparum (malaria parasite), variable modifications of carbamidometyl on cysteine 
(C) and oxidation on methione (M), allowing maxium of 1 trypsin missed cleavage, 
peptide mass tolerance at 200 ppm; MS/MS mass tolerance of 0.7 Da. 
3.3.10  Molecule Modeling G16 Binding to Plasmepsins 
    Lastly, to gain insight into the binding mode of G16 with FV PMs, we carried 
out molecular-docking studies with three of the four PMs (Figure 3.8, the X-ray 
crystal structure of PM-I has not been reported). The results showed that the molecule 
bound well in the active site confined by the D34-D214 aspartic acid pair in the 
structure of PM-II and PM-IV, and by H32 and D214 in the structure of HAP (Figure 
3.8a-c). Detailed analysis of the top 100 docked models identified the preferred 
conformations of G16 in PM-II and PM-IV, as well as in nonclassical HAP (Figure 
3.8g-i). The results also showed that the hydroxy group of G16 interacted closely with 
D34 and D214 in PM-II and PM-IV, as originally designed (Figure 3.8d, f). In 
binding to HAP, G16 assumed a position in which its hydroxy group fitted between 
H32 and D214 in the enzyme active site (Figure 3.8e). A similar interaction was 
observed previously between the hydroxy group in pepstatin (a general aspartic 
protease inhibitor) and HAP.
86, 87 
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Figure 3.7 Molecular docking of G16 in the active site of PM-II, HAP, and PM-IV. 
G16 binds to the active-site binding pocket of a) PM-II, b) HAP, and c) PM-IV. The 
hydroxyl group of G16 interacts closely with d) D34 and D214 in PM-II, e) H32 and 
D214 in HAP, and f) D34 and D214 in PM-IV. g–i) Preferred conformation of G16 in 
the binding pocket of PM-II (g), HAP (h), and PM-IV (i). 
3.4  Conclusion 
    In summary, we have developed a high throughput strategy for synthesis of 
aspartic protease inhibitors and affinity-based probes for the functional profiling of all 
four PMs in intraerythrocytic malaria parasites. Subsequent in situ screening of 
parasites with these probes led to the identification of a compound, G16, which 
showed good inhibition against all four PMs and parasite growth in infected RBCs. 
Molecular modeling indicated that this inhibitor bound to the active site of the 
plasmepsins tested, as originally designed. Our results indicate the feasibility of using 
AfBP approaches for the identification of inhibitors of less-characterized enzymes 
(such as HAP) and inhibitors of multiple targets. We anticipate that these new 
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chemical tools should facilitate the discovery of unknown parasite biology and new 
anti-malarial drugs. In the current study, we were unable to detect previously 
predicted but unidentified aspartic proteases from the malaria proteome. Thus, G16 
might have further targets, other than the four plasmepsins, in the malaria proteome. 
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Chapter 4 
 
Small Molecule Microarray-facilitated Screening of 
Affinity-based Probe for -secretase 
 
4.1  Summary 
    The ability to rapidly screen a large library of compounds represents a major 
bottleneck in the discovery of biologically relevant molecules and drug leads. This 
chapter extends the previously discussed high-throughput approach (Chapter 3) 
towards the rapid screening and identification of potent inhibitors and probes of 
enzymes. A 198-member library of putative aspartic protease inhibitors was screened 
with aspartic proteases. By incubating fluorescently labeled cellular lysates which 
over-expressed -secretase on small molecule microarray (SMM), we obtained 
inhibitor fingerprint of -secretase. A number of the most potent inhibitors were 
discovered and converted to affinity-based probes (AfBPs) using convenient, 1-step 
“click” chemistry. Overall this strategy offers not only a rapid method for inhibitor 
discovery, but also a viable method for high-throughput discovery of AfBPs against 
γ-secretase. We envisage that this platform will become a useful tool for 
high-throughput studies of proteomic profiling. 
4.2  Introduction 
    The field of proteomics aims to develop methods for the comparative analysis of 
large numbers of proteins in complex biological samples. A chemical strategy referred 
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to as activity-based protein profiling (ABPP) utilizes active-site-directed probes to 
profile the functional state of enzymes in proteomes.
62 
To date, ABPP probes have 
been developed for a number of enzyme families,
 
and have been used to discover 
enzyme activities upregulated in aggressive cancer cells. 
Microarray technologies based on surface-bound small molecules and proteins 
provide a convenient way to probe biomolecular interactions with a minimum amount 
of sample and therefore have been widely used in screening of primarily immobilized 
nucleic acids and proteins/peptides. Small molecule microarrays (SMMs) are 
becoming increasingly important for the large-scale determination of protein-ligand 
interactions, high-throughput screening of enzyme substrates/inhibitors and the 
development of biosensors and biomarkers for disease analysis.
88 
Although purified 
proteins are usually used in binding assays on microarrays, this technology has been 
extended to the use of proteins from crude cell lysates. For example, Bradner et al. 
incubated small-molecule microarrays with cellular lysates containing over-expressed 
epitope-labeled proteins from mammalian cells.
99 
Detection of small-molecule-protein 
interactions was achieved by treatment of the microarrays with fluorescently labeled 
antibodies that interact with the epitope tag. 
Amyloid β-protein (Aβ), a central pathogenic feature of Alzheimer‟s disease 
(AD), is generated through proteolysis of amyloid precursor protein (APP) by 
membrane-associated aspartic proteases including β-and γ-secretases.90 β-secretase 
has been well characterized; the study on γ-secretase, however, has been much more 
challenging, because the enzyme is a multimeric membrane protein complex, 
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comprising presenilin (PS), nicastrin, anterior pharynx defective 1 (Aph-1) and 
presenilin enhancer 2 (Pen-2). The proteolytically active form of PS is made up of 
two subunits, termed the N-terminal fragment (NTF) and C-terminal fragment (CTF). 
Despite recent advances, much remains to be understood about what the γ-secretase 
complex interacts with and how it carries out the proteolytic process. Due to 
well-known difficulties associated with biochemical studies of membrane proteins, 
much work on γ-secretase has so far relied on the development of the so-called 
affinity-based probes (AfBPs), which are typically generated from known inhibitors 
of γ-secretase by attaching a photo-cross linking group (i.e. benzophenone (BP) or 
diazirine) and a fluorescent dye (i.e. tetraethylrhodamine (TER)) to the inhibitors.
91 
For example, AfBPs based on L685,458, a potent hydroxylethylene-based γ-secretase 
inhibitor, were first developed by Li et al.
91a 
Recently, probes based on DAPT and 
arylsulfonamide derivatives have also been reported.
91(b-d) 
The key advantage of all 
these probes is their ability to selectively bind the active subunits of γ-secretase 
complex (i.e. PS subunits) from the whole cell extract and, upon UV-photolysis and in 
gel-analysis, accurately report the active state of γ-secretase without the need of 
isolating the enzyme complex. As a result, these probes have provided invaluable 
tools for the studies of Alzheimer‟s disease, both in its pathology and potential 
therapeutics. Similar strategies are widely used for the development of AfBPs against 
other classes of enzymes in the field of activity-based protein profiling (ABPP) 
pioneered by Evans and Cravatt.  
To convert an inhibitor into an effective AfBP, the following two steps are taken: 
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(1) identification of a suitable inhibitor (or an inhibitor scaffold) against the target 
enzyme (or the class of enzymes). This typically limits the AfBP strategy only to 
proteins for which inhibitors are known a priori. (2) Introduction of a BP-fluorophore 
linker into the molecule, which in many cases may abolish its target-binding ability 
and, as a result, leads to inactive probes.
101b 
Consequently, a much larger number of 
potential probes (than the final probes obtained) are usually synthesized chemically 
and tested biologically. Clearly, there is an urgent need to develop new ways for rapid 
screening and identification of AfBPs against different protein targets, including both 
well-known and less-characterized ones. In our studies, we realized one of the key 
steps in most current SMM technologies requires the site-specific immobilization of 
small molecules onto the glass slide through the introduction of a suitable chemical 
“tag” (and the connecting linker) into the small molecules (e.g. biotin in Figure. 
4.1).
4b 
Upon SMM screening, the “hits” identified were in fact the “tagged” small 
molecules. We reasoned that the direct conversion of biotin into a linker containing 
both BP and a dye should retain the full protein binding ability of the “hit”, thus 
making them suitable AfBPs against the target protein. So by combining concepts in 
microarray technologies and activity-based protein profiling, new AfxBPs may be 
rapidly identified. Herein, we report the first small molecule microarray 
(SMM)-facilitated approach for high throughput identification of AfBPs, in which 
γ-secretase was first used as our model target. 
4.3 Results and Discussion 
4.3.1 Synthesis of N, C-terminal Hydroxyethylamine Warheads 
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Figure 4.1 Overall strategy of the small molecule microarray (SMM)-facilitated 
platform for high-throughput identification of AfBPs. 
    To apply our strategy to the screening of AfBPs against γ-secretase as well as 
other cancer cells, we developed a solid-phase method for combinatorial synthesis of 
hydroxyethylamine-based small molecule inhibitors. Hydroxyethylamine are 
well-known scaffolds as transition state analogs of aspartic proteases, and have been 
included in the inhibitor design of numerous aspartic proteases including γ-secretase. 
In the 123-member N-terminal sublibrary, R1 and R2 positions, corresponding to the 
P1 and P2 residues, respectively, upon binding to the aspartic protease, were varied 
with aromatic/aliphatic moieties (R1 = Phe, Leu, Ala; R2 = aromatic/aliphatic acids). 
In the 75-member C-terminal sublibrary, R1‟ and R2‟ positions, corresponding to the 
P1 and P1/2‟ positions, respectively, were similarly varied (R1‟ = Phe, Leu, Ala; R2‟ = 
Sulfonyl chloride). Starting from commercial available amino acids, two different 
azide cores were prepared as summarized in Scheme 4.1. In the both N, C-terminal 
warheads sublibrary, R1/R1‟ positions, corresponding to the P1 residues, respectively, 
upon binding to the aspartic proteases, were varied with aromatic/aliphatic moieties. 
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Briefly, Fmoc protective L-amino acids first reacted with diazomethane prior to 
treatment with isobutyl choloroformate in order to activate acid group. Subsequently, 
bromination of acetone was carried out to afford compound 3 with good yield. 
Compound 3 was treated with NaN3 overnight under acidic condition and 
subsequently reduced by NaBH4 to afford compound 4(a-c). Starting from the azido 














































Scheme 4.1 Synthesis of the N, C-terminal hydroxyethylamine transition state 
warheads 4(a-c) and 8(a-c). 
4.3.2 Solid-phase Synthesis of Inhibitor Library 
    In both sublibraries, a biotin tag (and a connecting linker) was introduced in each 
compound for subsequent immobilization onto SMM. Since most known aspartic 
proteases recognize the four key residues (P2, P1, P1‟and P2/3‟) flanking the scissile 
bond of the substrates, our 198-member combined library could potentially be used 
for screening of other aspartic proteases besides γ-secretase. As shown in Scheme 4.2, 
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the synthetic strategy was so chosen because (1) it‟s solid-phase and amenable to 
large-scale synthesis of hydroxyethylamine-containing compounds from readily 
available Fmoc-protected L-amino acids; (2) the diversity of the library can be easily 
introduced throughout the P2-P2‟ positions; (3) the key azido intermediates in the 
synthesis could be easily recovered and converted to the corresponding AfBPs using 
“click” chemistry. Briefly, 4(a-c) were first immobilized at the -OH group onto 
4-dihydro-2H-pyran (DHP) resin under acid-catalyzed conditions. Subsequently, 
deprotection of the Fmoc group followed by standard acylation with different acid 
building blocks and azide reduction, gave the corresponding amines. Finally, 
attachment of a biotin linker then TFA cleavage gave the 184-member N-terminal 
compounds. Similarly, 8(a-c), again from the corresponding three L-amino acids, 
were attached to DHP resin, followed by alkylation reaction with i-butylamine, 
acylation with commercially available sulfonyl chloride building blocks, reduction 
with SnCl2/PhSH, attachment of the biotin linker then TFA cleavage, gave the 
75-member C-terminal compounds. Finally, the resulting 198 compounds were 
analyzed by LC-MS, which confirmed most were of sufficient purity (>80%) and 
were subsequently used for direct immobilization onto avidin-functionalized slides to 
generate the corresponding small molecule microarrays. 
4.3.3 Inhibitor Fingerprinting of HAP and Its Mutants 
    To assess whether the SMM could be used to detect aspartic protease-small 
molecule interactions, we carried out the preliminary screening with the recombinant 
purified protein, histo-aspartic protease (HAP), which is one of the aspartic proteases 
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from the parasite Plasmodium falciparum.
80b
 HAP was fluorescently labeled with Cy3 
before being applied onto the SMM (selected 198 compounds). As negative controls, 
three inactive mutant proteins of HAP (E278K, H34A and S37A mutants), previously 
shown to have minimum enzymatic activity, were used. Subsequently, the slides were 
scanned using an ArrayWoRx microarray scanner installed with the relevant filters 
(Cy3: lex/em = 548/595 nm). Only HAP showed distinct binding profile against the 
SMM, while none of the three active-site mutants showed any significant binding 
(Figure 4.2B). This indicates that our SMM platform is able to sensitively report 
activity-based binding events of aspartic proteases towards their small molecule 
inhibitors. 
1) 20% Piperidine/DMF
       2) PyBrop/HOAt/DIEA/DMF




































































1) SnCl2, PhSH,TEA, THF
2) Biotin acid/PyBOP/HOAt/DIEA, DMF
3) TFA/H2O = 95:5
O
R1: Phe, Leu, Ala
8(a-c)
R1': Phe, Leu, Ala
Scheme 4.2 Solid-phase synthesis of the N- and C-terminal inhibitor libraries. 
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4.3.4 Inhibitors Fingerprinting of Cellular Lysates 
    Previous SMM strategies have mainly relied on incubation with a purified 
protein of interest. Recently, Koehler and coworkers have shown cell lysates 
expressing a target protein could be used directly for ligand identification in SMM as 
well.
99
 In our case, since it is notoriously difficult to isolate γ-secretase, we decided to 
carry out our SMM screening using the fluorescently labeled membrane fraction of 
mammalian cell lysates. The γ-30 cell line, which is a γ-secretase overexpressing 
CHOK1 mammalian cell line, was used to ensure a sufficient amount of active 
γ-secretase was present in the lysate. The cells were grown as previously described.92 
           
Figure 4.2 Microarray screening images. (A) Fluorescent gel images of the 
dye-labeled HAP and its mutants used in this study. Cy3-and Cy-5 labeled proteins 
were colored in green and red, respectively. (B) Small molecules microarray 
immobilized with the 198-member library was screened against fluorescently labeled 
HAP and its active-site mutants. Results indicated the ability of HAP binding to SMM 
was lost after mutation. 
Subsequently, the membrane fraction was isolated, solubilized and fluorescently 
labeled with Cy3 before being applied onto the SMM. As shown in Figure. 4.3, highly 
reproducible and distinct binding profile of the 198-member library against the 
HAP 
H34A             S37A 
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membrane fraction of γ-30 lysates could be obtained. Interestingly, none of the 
N-terminal sublibrary showed any significant fluorescent binding. Of the strong 
binders, most were identified as members of the C-terminal sublibrary containing an 
alanine residue at the P1 position. C-c-5 and C-c-24 showed the strongest relative 
fluorescence binding, and therefore were chosen for further studies. N-a-31, a 
non-binder, was also chosen as a negative control. 
 
Figure 4.3 Fingerprinting of the 198-member library screened against the 
fluorescently labeled membrane fraction of γ-30 cell lysate, with (left) microarray 
image showing selected binders and non-binder and (right) their chemical structures. 
All compounds were printed in duplicate (horizontally). 
4.3.5 “Click” Synthesis of TER/Biotin Probes 
    To make the corresponding AfBPs of above three compounds, their azido 
intermediates (shaded) were taken, and „„click‟‟ assembled with TER-BP alkyne (for 
in gel activity-based profiling) and Biotin-BP alkyne (for pull-down experiments), as 
shown in Scheme 4.3. Previously, the modularity of „„click” chemistry had been 
successfully explored to facilitate the synthesis of other classes of activity-based 
probes.
4d 
Consequently, the final probes were purified by prep-HPLC and 
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Scheme 4.3 “Click” assembly of affinity-based probes (AfBPs) against ɤ-secretase. 
4.3.6 In-gel Fluorescence Scanning of Cellular Lysate with Probe and 
       Validation 
    To demonstrate the ability of our SMM-derived AfBPs for UV-initiated, 
activity-based profiling of γ-secretase in cellular lysates, we carried out in-gel 
fluorescence labeling and pull-down experiments. As shown in Figure 4.4a, the two 
positive probes identified from SMM, F5 and F24 (corresponding to C-c-5 and C-c-24 
in SMM, respectively) strongly labeled a 26-kDa protein in the total lysate of γ-30 
mammalian cell line with high specificity. This band was subsequently confirmed as 
the N-terminal fragment of PS (PS-NTF) by both western blotting with anti-PS 
antibody and pull-down experiments (Figure. 4.4b). On the contrary, the total lysate 
of γ-30 treated with the negative control A31 (corresponding to N-a-31 in SMM) 
failed to give any noticeable labeled band. From our results, it is interesting to note 
only PS-NTF was labeled by our probes. Previous work on the γ-secretase complex 
had identified that both NTF and CTF are needed to form the catalytic core of PS.
90,91
 
A quick survey of other known AfBPs of γ-secretase revealed that most also labeled 
only PS-NTF. This thus unambiguously confirms our SMM-facilitated screening 
approach as a valuable tool for rapid discovery of AfBPs. 
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Figure 4.4 Validation of γ-secretase. (a) In-gel fluorescence profiling of γ -30 lysate 
using different AfBPs. The arrowed band was identified as PS-NTF. (b) After 
pull-down, western blotting showed the biotinylated protein in γ-30 cell lysate labeled 
by biotin-F24 as PS-NTF. 
4.4  Conclusion 
    In summary, a small molecule microarray-facilitated screening strategy has been 
developed for high-throughput identification of affinity-based probes. This approach 
does not require known inhibitors of a protein target and minimizes risks involved in 
the loss of protein-binding property of these inhibitors due to linker introduction. We 
further demonstrated the utility of this method by successfully identifying highly 
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Chapter 5 
 
Applying Small Molecule Microarrays and Resulting Affinity 
Probe Cocktails for Proteome Profiling of Mammalian Cell 
Lysates 
 
5.1  Summary 
    Small molecule microarrays (SMMs) are proving to be increasingly important 
tools for assessing protein-ligand interactions, as well as in screening for enzyme 
substrates and inhibitors in a high-throughput manner. We previously described a 
SMM-facilitated screening strategy for the rapid identification of probes against 
ɤ-secretase, an aspartic protease. In this study, we extended upon this work with an 
expanded library of hydroxylethylamine-derivated inhibitors which non-exclusively 
target aspartic proteases. Our library was diversified across P2, P1, P1‟ and P2‟ positions. 
Accordingly, 86 new inhibitors were synthesized using a combinatorial, solid-phase 
synthetic approach, bringing the total library size to 284-biotinylated compounds, 
which were arrayed onto avidin slides. In order to elucidate enzymatic activity and 
profiles within complex biological samples, screens were performed using 
fluorescently-labeled mammalian cell lysates. This yielded reproducible profiles or 
binding fingerprints that corresponded with interactions from aspartic proteases 
present in the sample, or accessory proteins, as well as other interacting targets. The 
brightest microarray hits were converted to affinity-based probes (AfBPs) using 
convenient, 1-step “click” chemistry with benzophenone from the relevant building 
                                                                         67 
blocks. Pull-down/mass spectrometric analysis with these probe cocktails yielded 
target lists that included well-known aspartic proteases such as cathepsin D, which 
was a clear marker for breast cancer cell lines, T47D. Many other hits were also 
identified, which may be secondary or tertiary interactors of aspartic proteases, or yet 
unreported off-targets of the hydroxyethylamine pharmacophore. This provides a 
candidate list of biomarkers for further investigation. Taken together, this 
SMM-Cocktail AfBP strategy should potentially be useful for high-throughput 
development of novel probes and the identification of new aspartic proteases as well 
as related biomarkers in future. 
5.2  Introduction 
    Approaches in functional proteomics have classically included two-dimensional 
gel electrophoresis (2DE),
93 





These methods have been applied to the large-scale 
characterization of cellular, subcellular or circulating proteins and biomarkers.
106 
However, most such technologies are geared towards detecting changes in protein 
abundance, rather than actual functional activity.
4a,97 
To address this gap, 
activity-based protein profiling (ABPP) has emerged as a powerful chemical 
proteomic alternative for assessing the differing functional states of enzymes and 
other protein sub-classes within a complex proteome.
62a,62b,98 
To date, small molecule 
probes (the so-called activity-based probes, or ABPs) needed for ABPP studies have 
been successfully developed for a wide range of mechanistically distinct enzymes, 
such as serine hydrolases, cysteine proteases, aspartic proteases, metalloproteases, 
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phosphatases, kinases and others.
27a,41,45,65a,68,82,83b,99-104 
Gel-based separation of 
complex samples labeled with ABPs however limits its utility in that only a few 
probes, or a narrow pool of samples, may be screened at any given time. Small 
molecule microarrays (SMMs), on the other hand, offer high-scalability in the 
assessment of ligand-protein interactions.
4c,88a,105 
We and others previously described 
SMM-facilitated screenings, using combinatorial small molecule libraries, for the 
screening of purified enzymes and proteins.
106 
This included a recent example for the 
high-throughput identification of affinity-based probes (AfBPs) against  
ɤ-secretase,100 an aspartic protease implicated in the progression of Alzheimer‟s 
disease.
8a 
More recently, we have successfully demonstrated the first example of 
SMMs for large-scale functional profiling of cysteine proteases present in native 
biological samples, including lysates from mammalian cells and parasite-infected red 
blood cells (RBCs).
107 
Herein, we extend this SMM approach to the screening of a 
variety of mammalian cellular lysates from numerous tumor cell lines using small 
molecule probes derived from hydroxyethylamine-based pharmacophores. With the 
type of throughput provided by SMMs in the initial screening, we were able to 
quickly identify selected AfBPs suitable for the large-scale profiling of aspartic 
proteases and other potential biomarkers in mammalian proteomes. Additionally, 
unknown cellular targets identified from screening such probes may provide 
opportunities for future applications of hydroxyethylamine-based inhibitors in novel 
therapeutics (Figure 5.1). 
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Figure 5.1 Overall strategy for small molecule microarray (SMM)-facilitated 
development of AfBPs for proteome profiling of aspartic proteases in mammalian 
cell lysates. 
    Aspartic proteases are the smallest of all protease classes in the human genome, 
with only 15 members documented thus far.
108 
These enzymes, however, have 
received considerable attention as potential therapeutic targets since many have been 
shown to play important roles in the physiological and pathological processes.
6,7,9,10 
For example, HIV-1 protease is an important target in the fight against AIDS.
10 
Renin 
is a target in the treatment of hypertension.
6 
Cathepsin D is implicated in breast cancer 
metastasis.
7 
Plasmepsins are key mediator in malaria pathogenesis.
9 
Aspartic proteases 
are characterized by two catalytic aspartic acid residues located in their active sites 
and in most cases, by the conserved Asp-Thr-Gly (DTG) sequence in the primary 
structure. Although the catalytic mechanism of aspartic proteases is poorly understood, 
it has been generally accepted that the aspartic residues in the enzyme active site bind 
a molecule of water through extensive H-bonding. Of the numerous known aspartic 
protease inhibitors, hydroxyethylamine-containing compounds are amongst the most 
potent and successful, some of which are already FDA-approved drugs.
15,109 
For 
example, Amprenavir™ and Nelfinavir™ are just two examples of 
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hydroxyethylamine-based drugs currently used for treatments of AIDs (Figure 5.2A).  
By mimicing the transition state formed during the proteolytic reaction of aspartic 
proteases, the hydroxyl group on the hydroxyethylamine isostere binds tightly to the 
enzyme active site through H-bonding with the catalytic aspartic residues, thereby 
replacing the active site-bound water molecule. We previously showed that this 
pharmacophore could be strategically and conveniently diversified to generate 















Figure 5.2 Hydroxyethylamine-derivated inhibitors targeting aspartic proteases. 
(A) Representative structures of two commercially available drugs against HIV 
protease, an aspartic protease. (B) The 184-member library against aspartic 
proteases based on the hydroxyethylamine pharmacophore.
100 
In both N- and 
C-terminal sublibraries, the P1/1‟ positions were diversified by building blocks 
derived from three amino acid residues (Phe, Leu and Ala; in red). The P2/2‟ 
positions (highlighted in green boxes), were diversified by various carboxylic 
acids and sulfonyl chloride building blocks. 
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hydroxyethylamine-interacting proteins in various mammalian proteomes, and to 
discovery new cancer biomarkers, we conceived a multi-step approach, as depicted in 
Figure 5.1; in the first stage, an SMM platform was established, on which structurally 
diverse library of hydroxyethylamine inhibitors, with each containing a biotin tag (and 
a connecting linker) for SMM immobilization, would be used to probe the binding 
profiles of endogenous aspartic proteases and other proteins from complex proteome 
samples. We had recently shown this is feasible with fluorescently labeled crude 
proteome lysates.
107 
Subsequently, positive hits (e.g. bright spots) obtained from the 
SMM screening were identified, and the corresponding compounds were conveniently 
converted to affinity-based probes (AfBPs) via the Cu(I)-catalyzed 1,3-dipolar 
cycloaddition (Click chemistry or CuAAC).
4b, 110 
This step was made possible due to 
the modular design of our compound libraries and the introduction of a Benzophenone 
(Bp) and a reporter tag to the vicinity of these hydroxyethylamine pharmacophores 
would enable the covalent capturing of any potential interacting proteins. In the next 
step, the resulting AfBPs, either as individual probes or a mixture (or “cocktail”) of 
probes, would be used for gel-based proteome profiling against mammalian cell 
lysates. Finally, large-scale pull-down experiments followed by mass spectrometric 
analysis with selected probes would allow positive identification of 
hydroxyethylamine-binding protein targets which might be further developed into 
potential cancer biomarkers. 
5.3  Results and Discussion 
5.3.1 Design and Synthesis of Hydroxyethylamine-containing Inhibitor  
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      Library 
    Hydroxyethylamine isosteres are transition-state mimics that were introduced as 
the backbone replacement of the amide bond located between the P1/P1‟ position. We 
previously developed a solid-phase synthetic strategy capable of diversifying all four 
positions around the hydroxyethylamine core, i.e. P1/P1‟ and P2/P2‟ residues.
9
 From 
that study, two sublibraries (N-terminal and C-terminal as shown in Figure 5.2B), 
with a total of 184 different compounds were already available. To furtehr expand the 
coverage of our library compouds to be spotted on the SMM, an additional eighty-six 
new compounds, were prepared in the current sutdy (Scheme 5.1). In the N-terminal 
sublibrary, the R1 position, corresponding to the P1 residue upon binding to aspartic 
proteases, was varied with three amino acids (Tyr, Lys and Val). The R2 position, 
corresponding to the P2 residue, was diversified with 24 aromatic/aliphatic moieties. 
In the C-terminal sublibrary, the P1‟ residue (denoted as R1
‟
 in the inhibitor library) 
was fixed with Tyr for its general importance at this position amongst many known 
aspartic protease substrates/inhibitors. The P2‟ residue (denoted as R2
‟
) were simiarly 
varied with a variety of commercially available sulfonyl chlorides. As shown in 
Scheme 5.1, the synthesis of these compounds followed our previously reported 
solid-phase approaches on different pre-loaded 3,4-dihydro-2H-pyran (DHP) resins.
110 
Starting from scaffolds 4d-f and 8d, which were synthesized from the corresponding 
commercial available L-amino acids following previous reported procedure with some 
modifications,
51a,111 
compounds 4d-f and 8d were immobilized at their –OH groups 
onto the DHP resin under acidic conditions, giving preloaded resins for N- and 
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C-terminal sublibraries, respectively. Next, for the N-terminal sublibrary, Fmoc 
deprotection of the resin was carried out, followed by standard acylation with 24 
different acid building blocks. Subsequent azide reduction, which yielded the 
corresponding amines, attachment of a biotin linker and TFA cleavage yielded the 
61-member N-terminal compounds. For the synthesis of C-terminal compounds, the 
corresponding preloaded DHP resin was first alkylated with i-butylamine, then 
acylated with commercially available sulfonyl chloride building blocks. Subsequent 
azide reduction SnCl2/PhSH provided the corresponding amines, which upon coupling 
with the biotin linker and TFA cleavage, afforded the 25-member C-terminal 
compounds. The resulting 86 compounds were analyzed by LCMS and shown to be of 











Scheme 5.1 Solid-phase synthesis of the N- and C-terminal libraries using 
preloaded DHP resins. A total of 86 new hydroxyethylamine-derived compounds 
were syntheisized. 
1) 20% Piperidine/DMF
       2) PyBrop/HOAt/DIEA/DMF
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5.3.2 Profiling of Mammalian Cell Lysates on SMMs 
    Above 86 compounds were combined with the 198 previously reported 
compounds, giving a total of 284 hydroxyethylamines. They were robotically spotted 
onto avidin-functionalized slides in duplicate to generate the corresponding small 
molecule microarray. Eight different human cell lines, seven of which are derived 
from tumor cells (e.g. human normal kidney cell line HEK293T, Ovary cancer cells  
 
Figure 5.3 SMM profiles obtained by screening with eight different mammalian cell 
lysates. (A) The binding profiles of Cy3-labeled mammalian cell lysates obtained 
from screening against the 284-member hydroethylamine SMM. All 284 compounds 
were spotted in duplicate. Positions of 11 brightest inhibitor spots were highlighted on 
the SMM. (B) Color heat maps displaying binding of the 284-member compound 
library against eight Cy3-laleled mammalian cell lysates. The zoomed heat map 
shows inhibitor potencies of the C-terminal sublibraries presenting Ala and Tyr at the 
P1„ position. The scale bar represents the relative potency ratio. 
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OVCAR-3, erythromyeloblastoid leukemia cells K562, colon cancer cells HCT116, 
hepatocellular liver carcinoma cells HepG2, and three breast cancer cell lines 
MDA-MB-435, MCF7 & T47D), were selected for SMM screening. Briefly, cellular 
proteome lysates from these cell lines were minimally labeled by an amino-reactive 
Cy3 dye and directly applied onto the microarray, based on previously developed 
procedures.
107 
To ensure that all fluorescence signals were indeed attributable to 
activity-dependent interactions between the hydroxyethylamine inhibitors and their 
targeted proteins, the heat-denatured form of representative cellular lysates (i.e. T47D) 
was routinely applied to the same array as a negative conrol experiment (Figure 5.4). 
As shown in Figure 5.3A, all eight mammalian cell lysates produced highly 
distinctive and similar SMM binding profiles, with most of the brightest spots 
originated from selected members of the C-terminal sublibrary. We speculated that 
this is due to the presence of some commonly targeted proteins in both normal and 
cancer cells. Colored heat maps were generated from the corresponding SMM images 
in order to better visualize and compare different binding fingerprints obtained from 
the eight different cell lines (Figure 5.3B); each mammalian cell lines displayed 
characteristic patterns, and closer examination further revealed that spots which 
contained hydroxyethylamine compounds having Tyr and Ala at the P1‟ position 
provided the strongest binders. However, the effect of different substituent groups at 
the P2‟ position had a much less dramatic effect on the binding signals observed. 
Taken together, the SMM screening results provided a rapid screening tool to quickly 
delineate protein-ligand interaction and identify potential “hit” compounds for 
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subsequent follow-up studies. Additionally, the unique binding fingerprints obtained 
from these SMM experiments may also provide uesful clues for future design and 
diversification of hydroxyethylamine pharmacophores.
122 
Figure 5.4 Dose-dependent screening of T47D lysate on SMM. 
5.3.3 Click Assembly of Select AfBPs 
    To further examine the positive cellular protein targets that exhibited strong 
binding to members of our hydroxyethylamine library, the eleven brightest spots 
(boxed in Figure 5.3A) were chosen, and converted into the corresponding 
affinity-based probes (AfBPs). As earlier mentioned, this step was made possible 
due to the modular design of our compound libraries, and the implementation of 
Click chemistry into our design principle. The highly efficient and modular 
Cu(I)-catalyzed cycloaddition reaction between alkynes and azides (e.g. click 
chemistry) had previously been successfully exploited to facilitate the synthesis of 
other classes of activity-based probes.
4b,110 
As shown in Scheme 5.2, selected 
azide-containing WH, T(1-5) and A(3-8), which were actually key intermediates in 
the solid-phase synthesis of our hydroxyethylamine libraries (Scheme 5.1), were 
A           H 
Denatured T47D 
0.20            0.13           0.07          0.02             0 
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“click” assembled with one of the two alkyne-containg photo-crosslinkers, 
TER-Bp-≡ and Biotin-Bp-≡, giving 11 fluorescently labeled AfBPs (for subsequent 
in-gel fluorescence-based activity-based profiling) and 11 biotin-labeled AfBPs 
(for subsequent pull-down/target identification). The introduction of the 
photoreactive moiety benzophenone (Bp) enabled us to covalently capture 
potential protein binders from within the proteome and perform MS analysis for de 
novo target identification. A variety of „„click‟‟ conditions were investigated; 
eventually, conditions (0.1 eq CuSO4/0.4 eq NaAsc with DMSO/H2O as 
co-solvents) were found that afforded the desired 22 AfBPs with excellent yields 














































































































Scheme 5.2 Hit-to-probe conversion by click chemstry and structures of the 
twenty-two AfBPs. 
5.3.4 Activity-Based Profiling of the AfBPs Library with Recombinant 
       Cathepsin D 
    To demonstrate the ability of our SMM-derived AfBPs for UV-initiated, 
activity-based profiling of aspartic proteases, we first carried out in-gel 
fluorescence scanning of recombinant cathepsin D labeled with each of the eleven 
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tetraethylrhodamine (TER) AfBPs. Cathepsin D is a well-known lysosomal 
aspartic protease in mammalian cells and has been reported to play an important 
role in protein degradation and tumour progression. Following previously 
published protocols with some modifications,
100 
individual probes were incubated 
with cathepsin D for 30 min before being exposed to UV irradiation (at ~350 nm) 
for 25 min. This was followed by SDS-PAGE separation and in-gel fluorescence 
scanning. As shown in Figure 5.5A, one distinct labeled band, which corresponded 
to cathepsin D, was highly visible across all eleven probes, with varying labeling 
intensities. It thus indicated that all selected probes could positively label 
recombinant cathepsin D. The labeling intensity of each probe also indicated the 
relative binding preference of the enzyme to the corresponding hydroxyethylamine 
pharmacophore. In order to investigate the detection limit of the labeling reaction, 
varied amounts of recombinant cathepsin D were labeled by a cocktail of the 
eleven probes (that is, a mixture of equal amount of each probe; Figure 5.6A); 
results showed proportional increases in flureoscence intensity of the labeled 
cathepsin D with increased amounts of the enzyme. We estimated that using this 
method, as little as 1.5 pmol of cathepsin D could be readily detected. 
5.3.5 In vitro Proteome Profiling 
    To further investigate potential cellular binding targets of the probes within 
complex mammalian proteomes, we next carried out in vitro proteome profiling 
experiments. Four TER probes (T1, T3, A3 and A6) were used to label the eight 
aforementioned mammalian cell lysates. Briefly, each probe (1 µM final probe  
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Figure 5.5 In-gel fluorescence images of recombinantly purified Cathepsin D and 
mammalian cell lysates labeled with different AfBPs (individual probe or/and 
mixture cocktails). (A) Fluorescence labelling profiles of recombinant cathepsin D 
with 11 individual fluorescently labeled TER probes. (B) Fluorescence labelling 
profiles of eight mammalian cell lysates with four representative TER probes (T3, 
T1, A3 and A6; structures are shown in Scheme 5.2). The final concentration of 
each probe used in the labelling reaction was 1 µM. (C) In vitro proteome profiling of 
T47D cell lysates with 11 individual TER probes. The red asterisk indicates the 
protein band corresponding to cathepsin D, which was confirmed by 
pull-dwon/immunoblotting with anti-cathepsin D antibody (right gel). The red arrow 
indicates the distinct 90-kDa protein band that appeared only in selected cell lines. 
(D) In vitro proteome profiles of 8 different mammalian cell lysates with a mixture 
cocktail of 11 TER probes. The final concentration of each probe within the cocktail 
was 0.5 µM. Abbreviations: PD = positive pull-down assay; Ctrl = negative 
pull-down assay (avidin beads without probe). 
concentration; equal amount of lysates was used in each labeling reaction) was 
treated with each of the eight mammalian cellular lysates for 30 min followed by 
25-min UV irradiation. Subsequent SDS-PAGE separation and in-gel fluorescence 
scanning revealed the sub-proteome binding profiles of the mammalian lysates as a 
result of positive interactions between endogenous proteins and the 
hydroxyethylamine probe. As shown in Figure 5.5B, different human cell lines 
were each distinctly labeled desipte obvious similarities. For example, in T47D 
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and HepG2 cancer cell lines, many more positively labeled bands were observed, 
indicating significantly more positively interacting proteins that were present in 
the total cellular proteome of these cell lines. On the contrary, far fewer 
fluorescently labeled bands were observed for MDA-MB-435 and HCT116 cell 
lines (which was consistent with their earlier comparatively weaker fluorecense 
binding signals on the SMM; Figure 5.3). It is also interesting to note that, while 
the four TER probes did generate mostly similar proteome profiles within each 
mammalian cell line as expected, relative fluorescence intensities amongst the 
labeled bands varied from one probe to another. 
Figure 5.6 Proteome profiling of recombinant cathepsin D and T47D cell lysates 
by the probe cocktail. (A) Fluorescence labeling of recombinant cathepsin D was 
performed with the probes as a cocktail, and competitive experiments with 
pepstatine A. (B) T47D cell lysates was labeled by different amounts of the probe 
cocktails (0.1-5 µM) with (right) and without (left) the competition of pepstatine A 
(100 µM). 
    Next, all eleven probes were taken to label T47D cell lysates in order to 
obtain comprehensive proteome “fingerprinting” profiles as a result of 
hydroxyethylamine/protein binding interaction (Figure 5.5C); each probe again 
showed highly similar yet distinctive proteome labeling profiles,  indicating that 











+Pepstatine A (A) (B) 
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the both R1/R2‟ residues exerted a considerable influence over probe interactions 
with cellular protein targets. The experiments also revealed that each probe had 
different reactivity profiles. For example, a 90-kDa protein showed extremely 
strong labeling with probe T4, A3, A4 and A6, but no labeling was observed for 
other probes (labeled with an arrow in Figure 5.5C). However, a 55 kDa-protein 
was positively labeled by most of probes except probe A4 and A5. To validate 
whether this 55 kDa labeled band corresponded to endogenous cathepsin D, which 
is widely over-expressed in human breast cancer cells, we performed pull-down 
experiments using the biotinylated probe of T2 which had the best labeling 
performance for T47D cell lysates based on the labeling profile. Upon labeling 
with probe, T47D cell lysates was subjected to affinity enrichment and 
subsequently analyzed by immunoblotting with cathepsin D antibody (right gel in 
Figure 5.5C); results clearly showed that cathepsin D was successfully labeled and 
isolated by the biotinylated probe of T2. This experiment thus demonstrates the 
feasibility of our affinity-based probe for profiling of endogenous cathepsin D in 
cellular lysates. At this stage, attempts were not made to determine whether other 
fluorescence labeled bands in our proteome profiling experiments corresponded to 
other endogenous aspartic proteases.  
    While the detailed proteome profiling analysis of T47D cell lysates with the 
11 individual probes provided useful information about the interaction between 
cellular proteins and the hydroxyethylamine pharmacophore, the experiment itself 
was laborious, severely limiting its application in large-scale proteome profiling 
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against multiple mammalian cell proteomes. Previously, a cocktail-based 
approach, in which a mixture of several activity-based probes instead of individual 
probes, had been successfully applied in the profiling of metalloprotease activities 
in complex proteomes.
113 
We speculated that a simiar approach may be adopted 
herein to increase the throughput of our profiling experiments, therefore enabling 
much more comprehensive proteome profiles of multiple mammalian cell lysates 
to be obtained. We therefore applied an equal amount of all eleven AfBPs as a 
single mixture cocktail in our profiling experiments. By applying the same 
labeling protocol, the cocktail (comprising 0.5 µM of each probe, giving an final 
probe concentration of ~5 µM) was applied to each of the eight mammalian 
cellular lysates (Figure 5.5D); in general, cancer cell line K562 and three human 
breast cancer cell lines, namely MCF-7, MDA-MB-435 and T47D, showed similar 
proteome labeling profiles, with the exception of an 100-kDa band which appeared 
only in the T47D cell line. Similar proteome labeling profiles were also observed 
for ovary cancer cell line OVCAR-3 and colon cancer cell line HCT116. 
Comparatively weak proteome labeling profiles were seen for HEK293T and 
HepG2 cell lines. Collectively, the cocktail approach shown herein indicates it 
may be more widely adopted in future for large-scale proteome profiling 
experiments, and in some cases to differentiate different types of mammalian cell 
lysates. 
5.3.6 Pull-Down Experiments and Target Identification 
    Next, in order to identify the cellular targets of the known hydroxyethylamine 
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pharmacophore, we performed affinity pull-down experiments with the 
biotinylated version of the probe cocktail. The mixture of 11 biotinylated probes 
(0.5 µM of each probe) was incubated with T47D cell lysates for 30 min, followed 
by 25-min UV irradation to initiate covalent cross-linking of interacting 
protein-probe pairs. Upon precipitation with acetone and washing with methanol, 
the resulting biotinylated proteins were reconstituted with SDS buffer, then 
affinity-enriched with Neutravidin™ beads. Following SDS-PAGE gel separation 
and silver staining (Figure 5.7), the entire gel lane from the pull-down sample was 
then cut into slices and each slice was independently processed for in-gel trypsin 
digestion as described in the experimental section. As a negative pull-down 
control, the entire experiment was repeated with the same cell lysates treated with 
5% DMSO instead of the actual probe cocktail. Following LC-MS/MS analysis of 






Figure 5.7. Pull-down results using the biotinylated probe cocktail and target 
validation. (A) Silver-stained gel of the samples from pull-down experiment. 
Asterisks show the expected locations of Cathepsin D, HSP5A and β-tubulin. (B) 
Western blotting analysis of pulled-down fractions of T47D cell lysates treated 
with the biotinylated probe cocktail (or negative controls without the cocktail; 
right lanes) with their respective antibodies. Abbreviations: SS, Silver stain; PD, 
positive pull-down assay; Ctrl, Neutravidin™ beads without probes (5% DMSO 
instead). 
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MOWSE score of 40 as the cut-off threshhold. In addition, proteins that appeared 
in the negative control pull-down experiment (beads only) were excluded as 
potential false positives. In order to further minimize false positives in our protein 
list and obtain more reliable putative hits, we also performed competitive 
pull-down experiments in the presence of pepstatin A which is a well-known 
general aspartic protease inhibitor. Briefly, the entire positive pull-down/LCMS 
experiment was repeated, with the introduction of a pre-incubation step of T47D 
lysates with pepstatin A (100 µM) for 30 min, prior to the addition of the probe 
cocktail. By further substracting protein list obtained from the pepstatin 
A-competitive pull-down experiment from that of the positive pull-down 
experiment, a total of 39 proteins were finally identified as highly confident 
putative proteins hits (Table 5.1). It should be noted that all MS-based results 
obtained herein (including all the putative protein hits listed in Table 5.1) should 
only be used as preliminary data. In our current study, deliberate efforts were made 
to improve our pull-down/LCMS results. Nevertheless, due to the highly complex 
cellular environment, the intrinsic limitation of affinity pull-down assay and mass 
spectrometry,
114,115 
false positives/non-specific proteins binders could be 
minimized but not eliminated entirely from our results. Consequently, proper 
follow-up studies and validation experiments will be needed before any biological 
conclusion can be made to some of these protein hits. Of the 39 identified proteins, 
cathepsin D was one of them. This result is well expected as our previous 
immunoblotting results had independently verified this (Figure 5.5C). It is 
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interesting to note that missing from the list are other known mammalian aspartic 
proteases, which  might have been casued by their relatively lower expression 
level in the T47D cell line. Among other proteins identified, both HSP5A and 
β-tubulin are two of the well-known interactors of cathepsin D.116,117 Their positive 
interaction with our AfBPs were further confirmed by pull-down/western blotting 
with their respective antibodies (Figure 5.7B). Another two proteins known to be 
regulated by cathepsin D, namely superoxide dismutase (SOD) and eukaryotic 
translation elongation factor 1 delta isoform 4 (eEF1),
116 
were also identified. 
Notably, a known pepstatin A-binding protein, disulfide-isomerase (PDI),
118 
was 
also identified with a high MOWSE score. Additionally, a number of other 
targeted proteins were pulled down including one well-known serine protease (lon 
protease homolog or LONP1), several ribosomal proteins (60S ribosomal protein 
L5 or RPL5 and isoform 1 of plectin-1 or PLEC1), RNA recognition proteins 
(isoform 1 of heterogeneous nuclear ribonucleoprotein M or HNRNPM and 
Isoform 1 of heterogeneous nuclear ribonucleoprotein Q SYNCRIP), Leucyl-tRNA 
synthetase, cytoplasmic (or LARS) and DNA-directed RNA polymerase II subunit 
RPB2 (or POLR2B). At this stage, we do not have evidence to establish at whether 
these hits directly interacted with our probes and hydroxyethylamine 
pharmacophores in general, or were captured indirectly through interactions with 
other proteins. It might indicate that these hydroxyethylamines could potentially 
interact/target other protein classes besides aspartic proteases, and some of the hits 
identified herein may be considered potential off-targets of 
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hydroxyethylamine-derived drugs in cellular environments.
114c 
Collectively, it 
demonstrates that our SMM-facilitated, AfBP strategy should potentially be useful 
for applying inhibitor libraries for comparative proteomic profiling, with the 
potential for novel and disease-related biomarker identification. 
Table 5.1 Proteins identified by pull-down and mass spectrometry. 
# ID Protein Description MS Score 
Peptides 
matched 
1 IPI00011229 Cathepsin D 45.0 163 4 
2 IPI00023598 Tubulin beta-4 chain 50 1497 74 
3 IPI00786995 protein kinase, DNA-activated, catalytic polypeptide 47 801 38 
4 IPI00299402 Pyruvate carboxylase, mitochondrial 130.3 531 21 
5 IPI00646779 TUBB6 protein 50.5 531 23 
6 IPI00017454 Putative tubulin-like protein alpha-4B 27.8 510 18 
7 IPI00024993 Enoyl-CoA hydratase, mitochondrial 31.8 412 14 
8 IPI00171903 Isoform 1 of Heterogeneous nuclear ribonucleoprotein M 77.7 376 22 
9 IPI00020984 highly similar to Calnexin 71.9 289 13 
10 IPI00641706 TUBB6 46 kDa protein 46.3 259 22 
11 IPI00000494 60S ribosomal protein L5 34.6 244 10 
12 IPI00014898 Isoform 1 of Plectin-1 53.3 188 19 
13 IPI00037070 HSPA8 54 kDa protein 53.7 187 10 
14 IPI00010796 Protein disulfide-isomerase 57.5 181 6 
15 IPI00420014 
Isoform 1 of U5 small nuclear ribonucleoprotein 200 kDa 
helicase 
24.6 180 6 
16 IPI00292496 Tubulin beta-8 chain 50.3 177 17 
17 IPI00003362 HSPA5 protein 72.5 175 10 
18 IPI00003925 
Isoform 1 of Pyruvate dehydrogenase E1 component 
subunit beta, 
39.6 172 5 
19 IPI00022891 ADP/ATP translocase 1 33.3 167 9 
20 IPI00029737 Isoform Long of Long-chain-fatty-acid--CoA ligase 4 80.2 156 10 
21 IPI00005040 
Medium-chain specific acyl-CoA dehydrogenase, 
mitochondrial 
47 128 4 
22 IPI00219682 Erythrocyte band 7 integral membrane protein 31.9 125 5 
23 IPI00943207 Ribonucleoside-diphosphate reductase 81.7 125 9 
24 IPI00103994 Leucyl-tRNA synthetase, cytoplasmic 135.6 123 5 
25 IPI00003348 
Guanine nucleotide-binding protein G(I)/G(S)/G(T) 
subunit beta-2 
38.05 107 5 
26 IPI00027808 DNA-directed RNA polymerase II subunit RPB2 135.2 107 4 
27 IPI00022314 Superoxide dismutase [Mn], mitochondrial 24.9 99 6 
28 IPI00009634 Sulfide:quinone oxidoreductase, mitochondrial 50.2 94 3 
29 IPI00031517 DNA replication licensing factor MCM6 93.8 92 3 
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30 IPI00413641 Aldose reductase 36.2 89 10 
31 IPI00465233 
Eukaryotic translation initiation factor 3, subunit E 
interacting protein 
71.1 86 2 
32 IPI00005158 Lon protease homolog, mitochondrial 106.9 81 4 
33 IPI00021048 Isoform 1 of Myoferlin 23.6 81 2 
34 IPI00009253 Alpha-soluble NSF attachment protein 33.7 80 4 
35 IPI00018140 Isoform 1 of Heterogeneous nuclear ribonucleoprotein Q 69.8 80 3 
36 IPI00290462 Carbonyl reductase [NADPH] 3 31.2 80 4 
37 IPI00064086 Eukaryotic translation elongation factor 1 delta isoform 4 28.7 78 2 
38 IPI00169383 Phosphoglycerate kinase 1 44.9 73 4 
39 IPI00008986 Large neutral amino acids transporter small subunit 1 55.7 72 1 
5.4  Conclusion 
    We have synthesized a new 86-member library of hydroxyethylamine 
pharmacophore derivated inhibitors in this study. Combined with previous 
published compound library, we have, for the first time, developed a small 
molecule microarray(SMM)-facilitated strategy for large-scale profiling of 
multiple mammalian cell lysates against many potential inhibitors. Based on the 
valuable SMM fingerprints, a panel of affinity-based probes were rapidly 
synthesized by “click” chemistry, from the top inhibitor hits. Subsequent in vitro 
proteome activity profiling and large-scale affinity pull-down/LCMS 
identifications of putative protein hits enabled us to identify the direct as well as 
potentially indirect targets of the hydroxyethylamine pharmacophore in the 
samples. Our sub-proteomic SMM–Cocktail AfBP strategy thus provides a viable 
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Chapter 6 
Developing Photo-affinity Probes for Proteomic Profiling of 
Cellular Targets of Dasatinib
TM
 
6.1  Summary 
    In this chapter we have successfully developed a novel chemical proteomic 
approach for identification of the celluar targets of dasatinib
TM
 in native environment. 
Herein, we described the synthesis of two “clickable” dasatinib-like, affinity-based 
probes and further investigated their biological activities using c-Src as model protein. 
Our preliminary results demonstrated that these two probes exhibited comparative 
activities as dasatinib and positively labeled a wide of protein kinases in cellular 
lysates. More notably, we found that probe DA-2 had good cell permeability and 
enabled to label endogenous c-Src, c-Abl as well as some other kinases within live 
cells. To further comprehensively study dasatinib‟s cellular binding targets, we 
performed in vitro/situ labelings and pull-down experiments with this probe. 
Consequently, a total of 54 kinases were identified as potential binding targets of 
dasatinib in K562 and HepG2 cancer cells. Among them, in addition to some known 
dasatinib binding targets (SRC family kinases, c-Abl, BTK, EGFR, p38α, and so on), 
several serine/threonine kinases, for the first time, were identified as putative 
dasatinib binding proteins, and some of them were further validated by pull-downs 
and immunoblottings. Thus, we envisage that this cell permeable probe, combined 
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with the bio-orthogonal click chemistry, should be broadly useful for the large-scale 
profiling of kinases in functional proteomics analyses. 
6.2  Introduction 
    Protein kinases plays an important role in the development and progression of 
cancer by regulating cell growth, survival, invasion/metastasis and angiogenesis.
18
 As 
one important class of protein kinases, tyrosine kinases are involved in a variety of 
physiological and pathological processes in cancer, immunology and solid tumor.
16 
Thus, tyrosine kinases have become interest targets for biomarker discovery. As an 
example, Src family kinases (SFKs) have been reported to control a myriad of 
fundamental cellular processes, including cell proliferation, cell migration, cell 
invasion and survival.
119 
Clinical studies have shown that Src is correlated with 
malignant progression of human tumors, and it has become a promising therapeutic 
target in treatment of tumors.
120
 
    Kinase inhibitors are a new class of therapeutics to inhibit multiple targets.
121
 
Their biological functions as anticancer therapies are not thoroughly defined thus far. 
Identification of cellular targets of kinase inhibitors has become an important step 
toward understanding how inhibitors interact with the human kinome. In a clinical 
setting, the identification of potential off-targets of kinase inhibitors may help explain 
any adverse effects that are observed. Dasatinib, an ATP-competitive inhibitor of Src 
and Abl kinases, has been used for treatment of imatinib-resistant chronic 
myelogenous leukemia (CML),
23,122 
and recently it was also found to have activity to 
epithelial tumor cells including human prostate and breast cancer cells.
24 
Studies on 
                                                                         90 
off-targets of dasatinib, therefore, have become significant for therapy. The traditional 
method used for determining the binding targets of kinase inhibitors is the activity 
screening assays with purified kinases in vitro.
123 
Although this approach has been 
extensively used in the past and produced important insight in kinase inhibitor 
specificity, it is impractical for profiling the large size of human kinome. In order to 
overcome this limitation, some alternative and unbiased approaches have been 




and so on. 
While affinity matrix, namely a resin with immobilized kinase inhibitor, has become 
currently the most prominent approach for identification of drug binding proteins 
from cell or tissue extracts. Oliver and his co-workers recently found that Btk and Tec 
kinases were another two major cellular binding targets of dasatinib besides Abl and 
Src kinases by using the dasatinib immobilized beads.
126 
Additionally, a number of 
other dasatinib binding proteins have also been constantly identified by other groups 
using the similar approach.
127,128
 However, theses approaches are still greatly 
challenged in several aspects (Figure 6.1A): first, due to the non-covalent interactions 
between drugs and proteins, weak washing condition must be applied, which usually 
introduces many nonspecific proteins; second, the solid support may potentially limit 
the accessibility of the immobilized drugs for interactions with the target proteins. 
Some proteins that cannot interact with the attached small molecules because of steric 
hindrance can be missed easily; third, the in vitro activities of proteins don‟t always 
reflect their real behaviors in native environment. With the aim to overcome some of 
these shortcomings, more recently, Bantscheff group have developed an improved 
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approach in which the immobilized broad-selectivity inhibitors as kinase capturing 
tools have been used to analyze the interactions of competing “free” dasatinib with 
their protein targets in solution. A number of previous unknown binding targets of 
dasatinib were identified besides some known targets.
127b 
However, it still has become 
a great deal of interest in the development of new alternative approaches for proteome 
profiling of dasatinib binding targets. To address this gap, activity-based protein 
profiling (ABPP), pioneered by Cravatt, has emerged as a powerful chemical 
proteomic alternative for determining the bindings between small-molecule drugs and 
binding proteins under more physiological conditions.
62a 
To date, ABPP probes have 











as well as protein kinases.
27a,103 
Inspired by ABPP, we envision that 
the development of dasatinib-like probes which enable to extensively explore the 
on/off-targets of dasatinib in live cells may open up a new prospect for cancer 
treatment in future. To this end, we developed an alternative approach for proteome 
profiling of the binding targets of dasatinib in native environment. Herein, two 
dasatinib-like, affinity-based probes, for the first time, were synthesized and the 
abilities of profiling dasatinib cellular targets were further evaluated.  
6.3 Results and Discussion 
6.3.1 Design and Synthesis of Dasatinib-like Probes 
    Based on the well-known activity-based protein profiling (ABPP) approach, we 
have designed and synthesized two dasatinib-like probes. Our probes essentially have  
                                                                         92 
 
Figure 6.1 Activity-based proteome profiling. (A) In situ covalent capturing and the 
traditional affinity matrix method for identification of cellular targets of dasatinib. (B) 
Design of photoaffinity, dasatinib-like probes. The “Click”-based reporters used in the 




three structural components (Figure 6.1B): (1) a protein recognition group derived 
from dasatinib; (2) a photo-reactive group which enables us to covalently capture the 
potential binders within the proteome and perform MS analysis for de novo target 
identification. In order to study the steric effect of photo-reactive group to the binding 
between probe and the ATP binding site of kinases, two photo-reactive groups 
(benzophenone and diazirine) were adopted in this study, and (3) an alkyne handle 
incorporating to a fluorescent dye or biotin group via the copper catalyzed Huisgen 
1,3-dipolar cycloaddition.
34 
For the general design of our probes, we took advantage 
of several key points: (1) dasatinib is a potent Src/Abl inhibitor with very low 













































































(or cell lysates) 
                                                                         93 
nanomolar inhibition. Recent studies have showed that it is able to inhibit a wide of 
kinases;
127a,13b,130 
(2) previously reported crystal structure of the Abl kinase domain 
complexed with dasatinib indicated that the hydroxyl side chain on the piperazine ring 
of dasatinib was not involved in the critical H-bonding and it localized at the protein 
surface. Additionally, prior experiences showed that dasatinib pharmacophore shared 
much of the same binding characters in the kinase catalytic domain.
130
 We speculate 
replacement of piperazine part of dasatinib with photoreactive group should not 
disrupt the binding between inhibitor and the ATP binding site of kinase. Therefore, 
in order to maximally retain the activity of dasatinib, a minimal structure modification 
has been done in the synthesis of probes. The synthesis of the “clickable” dasatinib 
derivatives is shown in Scheme 6.1. Compound 10 was first synthesized following 
previously published method.
122
 Next, compound 10 was reacted with 1, 
2-diaminoethane in dioxane at reflux to afford 11, and then subjected to coupling 
reagents with commercial available Fmoc-protected benzophenone/Boc-protected 
diazirine (prepared in six steps from Glutamic acid) to give 12a/12b, respectively. 
Subsequent deprotections of amine protective groups with corresponding conditions, 
followed by couplings with hex-5-ynoic acid, gave the two probes, DA-1 and 2 in 
18% and 50% yield, respectively. 
6.3.2 Molecule Modelling and Determination of IC50 Values 
    To obtain insight into the binding mode of two probes with kinases, we 
performed molecular docking analysis with c-Src (PDB ID 2SRC27)
131
 and Abl (PDB 
ID 2GQG22)
132
 crystal structures using autodock vina method.
133 
The docking models  




















































































Scheme 6.1 Synthesis of probe DA-1 and DA-2. 
revealed that both probes bound well to the ATP binding sites of c-Src as well as 
c-Abl (Figure 6.2A), which is quite overlaid with dasatinib. In the binding modes of 
two probes with c-Src and c-Abl, a crucial pair of hydrogen bond was formed 
between the hydroxyl oxygen of Thr338 (or Thr315) and the carbonyl oxygen of 
thiazole amide, which is consistent with the reported crystal structure of Abl/dasatinib 
complex.
132 
As expected, the photo-cross linkers, localized at the surface of proteins, 
don‟t have apparent effect for the interactions between probes and kinases. 
    Dasatinib is known to inhibit Src and Abl kinases with very low nanomolar IC50. 
We compared the inhibitory potential of our two probes to dasatinib by measuring the 
kinase activities of the c-Src and Abl kinase domain in a drug 
concentration-dependent manner under optimized enzyme concentration of ~50 nM 
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Figure 6.2 Determination of biological activities of DA-1 and 2. (A) Molecular 
docking of DA-1 and 2 into the ATP binding pocket of c-Src and c-Abl. Dasatinib, 
DA-1 and 2 were showed in red, green and blue, respectively. (B) IC50 values of two 
probe (DA-1 and 2) and Dasatinib for c-Src and c-Abl determined by Kinase-Glo® 
Plus Luminescent Kinase. Data represent the average (s.d. for two trials). 
(Figure. 6.2B). Both probes maintained excellent potency versus c-Src and c-Abl, and 
were slightly less effective than dasatinib, which indicates the replacement of 
piperazine ring by photo-reactive group does not significantly alter the activities of 
probes. The observed IC50 values for c-Src inhibition by DA-1 (19.7 nM) and DA-2 
(14.7 nM) closely resembled dasatinib (3.6 nM).
134 
Similarily, the IC50 values for 
c-Abl inhibition by DA-1 (30.9 nM) and DA-2 (27.2 nM) were also close to dasatinib 
(8.8 nM).  
6.3.3 Effects on Cell Proliferation and Phosphorylation of c-Src 
    Next, two probes were evaluated against dasatinib (as a positive control) for 
 Dasatinib (IC50 = 8.8 ± 0.4 nM) (B) 
DA-1 (IC50 = 30.9 ± 0.3 nM) 
DA-2 (IC50 = 27.2 ± 0.1 nM) 
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potential biological activity. We carried out the cell proliferation assay using HepG2 
and K562 as model cell lines. The activities of three compounds (DA-1, DA-2 and 
dasatinib) against HepG2 and K562 cells were evaluated using XTT assay. Both 
probes showed inhibition of tumor cell proliferation with comparable potency, while 
they were slightly less potent than dasatinib (Figure 6.3B). The exact reason for the 
less cellular potency of the probes is not clear at the moment although we speculate 
that it could most likely be due either to the structure modification or poor cell 
permeability. In order to determine the cell permeability of two probes, we performed 
cell permeability assay together with dasatinib as positive control (Figure 6.3A). 
Results indicated that probe DA-2 had comparable cell permeability with dasatinib, 
whereas DA-1 was not cell permeable. Next, we performed comparative analysis of 
the compounds in their abilities to reduce the autophosphorylation of c-Src in 
Src-transduced CHOK1 cells. It is well known that dasatinib can inhibit the 
autophosphorylation of Y416 residue which is relative to the catalytic activity of c-Src. 
As shown in Figure 6.3A, CHOK1 cell treated with different amounts of dasatinib and 
DA-2 showed almost similarly reduced c-Src autophosphorylation. 
6.3.4 Cellular Imaging using DA-2 
    To further demonstrate our probes‟ cell permeability and utility for potential cellular imaging, 
we performed fluorescence microscopy to visualize the cells treated by probe DA-2 (Figure 6.3C). 
Live HepG2 cells were first treated with respective probes followed by irradiation under UV, and 
then fixed with paraformaldehyde, permeabilized with Triton X-100, conjugated to rhodamine 
azide by click chemistry, and imaged (colored in red). Immunofluorescence was also carried out  
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Figure 6.3 Biological activities of DA-1 and 2 in live cells. (A) Comparison between 
dasatinib and DA-2 on the inhibition of tyrosine phosphorylation in cells and the cell 
permeability assay. (B) Inhibition of HepG2 and K562 cells proliferation by 20 µM 
dasatinib, DA-1 and 2 using XTT assay. (C) Cellular imaging of HepG2 cells with 
probe DA-1 and 2. All images were acquired in the same way. Scale bar = 10 µm. 
on the same cells to visualize the localization of endogenous c-Src (colored in green). 
Results showed that minimal fluorescence was observed in cells treated with only 
DMSO as well as DA-1, again demonstrating that DA-1 has poor cell permeability 
and labeling performance in intact cells. On the contrary, higher fluorescence was 
observed for cells treated with DA-2 in which not only endogenous c-Src but also 
some other proteins were also labeled by DA-2, which is consistent with the multiple 
binding targets property of dasatinib. Taken together, probe DA-2 has good cell 
permeability than DA-1, and it can be potentially used for bioimaging in future. Thus, 
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Figure 6.4 Fluorescent Labelling of different recombinant proteins (15 pmol, lanes 1 
to 6 are Abl, c-Src, CSK, PKA, PAK6 and BSA, respectively) with DA-1 and 2 in 
parallel. 
6.3.5 In vitro Labeling of Purified Kinases  
    Next, to evaluate the labeling ability of the probe, dose-dependent experiments 
were carried out by varying the concentration of kinases in the reactions (Figure 6.5A). 
DA-2 was incubated with different amount of c-Src and c-Abl in parallel for 30 min 
followed by irradiation under UV lamp at ~350 nm. Subsequently, the reactions were 
subjected to click reaction with rhodamine azide (TER-N3) (structures shown in 
Figure 6.1B), after which the fluorescent labeled proteins were separated by 
SDS-PAGE and visualized in-gel with a fluorescence gel scanner. As expected, we 
observed increasing fluorescent intensity upon the addition of increasing 
concentration of kinases, indicating that the intensity of fluorescent bands observed is 
proportional to the amount of kinases used in the reactions. On the other hand, we 
could detect as little as 1 pmol c-Src or Abl by fluorescence scanning. 
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Figure 6.5 Fluorescent labeling of recombinantly purified protein kinases. (A) 
Labeling profiles of varied amount of c-Src, c-Abl and mutant SrcT338M by DA-2 as 
well as DA-1. (B) Fluorescent labeling of c-Src and its four mutants (Y416C, Y527C, 
Y416CY527C and T338M) by DA-2. (C) Dose-dependent reduction of labeling of 
c-Src (100 nM) in the presence of staurosporine (STS). IC50 of STS was determined to 
be 21.37 ± 0.8 nM. 
    Tyrosine residue Y416 and Y527 are two important determinants for the activity 
of c-Src. Phosphorylation of Tyr527 in the C-terminal tail is found to down-regulate 
the kinase activity. On the contrary, phosphorylation of Tyr416 in the activation loop 
is necessary for full kinase activity. In order to investigate whether the tyrosine 
residue mutations affect the binding between probe and ATP binding site, four 
tyrosine mutants (SrcY416C, SrcY527C, SrcY416CY527C and T338M) were created 
by QuikChange mutagenesis method, and labeled by DA-2. As shown in Figure 6.5B, 
T338M gatekeeper mutation of c-Src resulted in apparent resistance to the probe, 
which is consistent with previously reported.
135 
Other three tyrosine mutants were, 
however, almost equally labeled by DA-2, indicating that mutations of residue Y416 
Kinase (pmol) 
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and Y527 don‟t affect the interaction between probes and ATP-binding site. Indeedly, 
the previous modeling results also indicated that these two Tyr residues were not 
involved in the binding between probe and c-Src.
131 
Next, we performed labeling 
experiments in the presence of active-site competitive inhibitor-Staurosphorine. A 
dose-dependent reduction of fluorescence in c-Src labeling profile was observed 
(Figure. 6.5C), indicating the labeling is activity-based and points to the possible use 
of the probe for in situ screening of c-Src inhibitors. 
 
Figure 6.6 Labeling profiles of bacterial and mammalian proteomes. (A) Fluorescent 
labeling profiles of induced (ID) and un-induced (UI) bacteria expressing full length 
(FL)-Src, catalytic domain c-Src and its three mutants by DA-2. (B) Labeling profiles 
of CHOK1 lysates transfected with wide type c-Src and its three mutants together 
with competition experiment. The final concentration of DA-2 is 1 μΜ in all 
experiments. 
6.3.6 Labeling of c-Src in Bacterial and Mammalian Proteome 
    Next, to assess whether probe DA-2 can selectively label c-Src in the presence 
of competing cellular proteins, we expressed the wide type c-Src (including full 
length and catalytic domain c-Src) and its three mutants in E. coli following reported 
method, respectively.
136 
The corresponding bacterial lysates were then labeled by 
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DA-2 under previously optimized condition. As shown in Figure 6.6A, stronger 
labeling bands were seen for bacterial lysates treated with inducer, while almost no 
labeling was observed for un-induced lysates. These results indicated that DA-2 could 
be potentially used to label and detect the expression levels of c-Src in different 
biological samples.  
    Next, in order to further test the ability of the probe to selectively label 
endogenous c-Src, we examined the reactivity of DA-2 in CHOK1 cellular lysates 
which was transfected with the constructs encoding wild type full length c-Src and its 
three mutants (SrcY416F, Y527F and K295RY527F). The fluorescent profiles 
showed minimal background labeling of other proteins. We found that DA-2 
impartially labeled wide type c-Src and its three mutants, which were consistent with 
previously purified protein labeling results, and again indicating that dasatinib has 
activity against many mutants of c-Src. In addition, immunoblotting analysis with a 
monoclonal Src antibody identified comparable expression levels of wt c-Src and its 
mutants (Figure 6.6B). These datas collectively indicate again that Y416 and Y527 
mutations in Src family kinase do not fundamentally affect the intrinsic interaction 
between the ATP binding site of Src family kinases and our probe. Additionally, the 
labeling could be completely blocked by competing inhibitor if the cells were prior to 
treat with dasatinib, again indicating the labeling is activity-based. 
6.3.7 Labeling of Endogenous c-Src in Cancer Cell Lysates 
    To further test the ability of our probe to label endogenous c-Src, we carried out 
the labeling experiments for cell lysates (K562 and HepG2 cells) with DA-2 in 
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dose-dependent manner. Briefly, DA-2 was incubated with K562 and HepG2 lysates 
at a concentration range of 1-50 µM with or without excessive dasatinib for 0.5 h at r.t. 
The reactions were irradiated by UV followed by “click” with rhodamine azide, 
separated by SDS-PAGE gel, and analyzed by in gel fluorescence scanning. As shown 
in Figure 6.7A, in addition to the expected c-Src (60 kDa, marked with red asterisk) 
and c-Abl, confirmed by pull-down and immonoblotting with corresponding 
antibodies (Figure 6.7C), we also observed many other off-targets. Besides, those 
labeled bands could be competed away by treatment with excessive dasatinib, 
indicating that most labeled proteins are likely specific cellular targets of dasatinib. 
6.3.8 In situ Labelling in Cultured Cells 
    DA-2 has been demonstrated to label Src family kinases in cellular proteome at 
low micro-molar concentration. We wondered whether our probe could also label 
c-Src in intact cells. To this end, we studied in situ proteome reactivity profiles of 
DA-2 in both K562 and HepG2 live cells. DA-2 was directly added to K562 and 
HepG2 cultured cells at a concentration range of 1-50 µM with or without excessive 
dasatinib (notably, DMSO should never exceed 1% in the final solution). After 5 h of 
incubation at 37 °C/5% CO2, the cells were washed gently to remove the excessive 
probe followed by UV irradiation (~350 nm) for 20 min on ice. The cells were then 
homogenized, incubated with rhodamine-azide under “click” conditions, separated by 
SDS PAGE gel, and analyzed by in-gel fluorescence scanning. As shown in Figure 
6.7B, distinct labeling bands were observed. Comparing with in vitro labeling profile, 
apparent low background labeling profile was observed for in situ labeling.  
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Figure 6.7 In vitro (A) and in situ (B) labeling profiling of K562 and HepG2 cells 
using DA-2 (over a concentration range of 1-50 µM together with competitive 
experiments using dasatinib (100 µM). The red asterisks mark the position of 
endogenous c-Src. (C) Western blotting analysis of in vitro and situ pulled-down 
fractions of HepG2 and K562 cells treated with DA-2 (or DMSO as negative controls; 
right lanes) with their respective antibodies. Biotin-azide was used in the click 
chemistry with avidin-agarose beads for pull-down experiments. (D) Western blotting 
validation of pulled-down fractions of HepG2 cellular lysates treated with DA-2 (or 
DMSO as negative controls; right lanes) with several respective antibodies. 
experiments even at the highest concentration of probe. Additionally, in order to test 
the labeling ability of our probe for endogenous c-Src and c-Abl in intact cells, in situ 
pull-down experiments were performed followed by immunoblotting with 
corresponding antibodies. Results showed that DA-2 enabled to efficiently label 
endogenous c-Src and c-Abl in intact cells. Taken together, these data indicates that 
DA-2 is a cell permeable probe which can be potentially used to profile the cellular 
targets of dasatinib in cultured cells. 
* 
* * 
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6.3.9 Target Identification and Validation 
    In order to determine whether our probe can be used as an affinity reagent to 
isolate the binding proteins of dasatinib, the pull-down experiments were performed 
in vitro and situ with HepG2 and K562 cells using DA-2. In the meantime, imatinib 
probe (reported as a specific Abl probe)
45
 and dasatinib immobilized beads were used 
as negative and positive controls, respectively. In brief, the labeled protein extracts 
obtained from in vitro and in situ labelings were subjected to click reaction 
conjugation with biotin azide (structure shown in Figure 6.1B) followed by 
enrichment with avidin-agarose beads, separated by SDS-PAGE gel and visualized by 
silver staining. Visual analysis of the samples from the respective pull-down 
experiments on a silver-stained SDS-PAGE gel revealed similar patterns of protein 
compositions. The entire gel lanes for each pull-down samples were then cut into two 
slices and each one was individually processed for in-gel trypsin digestion as standard 
procedure. As negative control, a large-scale proteomic experiment was also carried 
out with cells treated by DMSO instead of DA-2. Peptides obtained from each gel 
slice were eluted and subjected to nano-LC-MS/MS analysis. The LC-MS/MS datas 
were subsequently searched against IPI human protein database using an in-house 
MASCOT server (Matrix Science, London, UK) for protein identification. 
    Consequently, a total of 54 kinases (49 kinases from in vitro pull-downs, 25 
kinases from in situ pull-downs) were identified as potential cellular targets of our 
probe. However, only 3 and 6 kinases were identified from imatinib probe and 
dasatinib matrix beads. Our experiments with DA-2 versus matrix beads showed that 
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only few kinases were found in the matrix beads experiments while many more were 
found when our photo-affinity based approach was applied. Out of those 54 kinases, 
21 proteins belong to protein kinases: 8 proteins are annotated as tyrosine kinases 
(SRC, LYN, YES, HCK, CSK, BTK, EGFR and PTK9), 13 proteins are 
serine/threonine kinases (p38α, DNA PKC, STK6, CDK2, and so on). The rests 
belong to other kinases, including STAT family, lipid kinases, pyruvate kinases, etc. 
Notably, in addition to several Src family kinases, CSK and BTK were consistently 
identified as the most prominent binding targets of dasatinib both in DA-2 pull-down 
experiments and positive control experiments (on bead pull-down experiments) with 
high unique peptide count (Table 6.1). More notably, 13 serine/thronine family 
kinases were identified in our system. Among them, 7 protein kinases have been 
reported as dasatinib binding targets before,
127b 
such as MAPKAPK2, p90-RSK-3,  










Src* Isoform 1 Proto-oncogene tyrosine-protein kinase Src IPI00641230 PNAS,(2007),104,13283
Src* Isoform 2 Proto-oncogene tyrosine-protein kinase Src IPI00328867
Proto-oncogene tyrosine-protein kinase Yes IPI00013981Yes*
Isoform Lyn A of tyrosine-protein kinase Lyn
Isoform 1 Proto-oncogene tyrosine-protein kinase Fyn
IPI00298625
IPI00219012
Isoform p59-HCK of Tyrosine-protein kinase HCK IPI00029769
Tyrosine-protein kinase CSK IPI00013212
Tyrosine-protein kinase BTK IPI00029132
Isoform 1 of Epidermal growth factor receptor
Twinfilin-1 (protein tyrosine kinase 9)
IPI00018274
IPI00183508
Isoform 2 of Serine/threonine-protein kinase PCTAIRE-3 IPI00394661
Isoform 1 of DNA-dependent protein kinase catalytic subunit IPI00296337
Isoform 1 of MAP kinase-activated protein kinase 2 IPI00026054
Isoform CSBP1 of Mitogen-activated protein kinase 14 IPI00221141
Serine/threonine-protein kinase 25 IPI00012093
Ribosomal protein S6 kinase alpha-3 IPI00020898
Interferon-induced, double-stranded RNA-activated protein kinase IPI00019463
Serine/threonine-protein kinase Pim-3 IPI00848067
Isoform 2 of cAMP-dependent protein kinase, alpha-catalytic subunit IPI00217960
Isoform Beta-II of Protein kinase C beta type IPI00219628
Serine/threonine-protein kinase 6 IPI00298940
Cell division protein kinase 2 IPI00031681

































































































































- : no datas;   * : sharing identical unique peptide
DA-2
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p38α, DNA-Pac, STK6, CDK2 and PKC-β. While the rest 6 kinases including PKN2, 
PCTAIRE-3, eIF-2α, Pim-3 and PKA, for the first time, were identified as previously 
unknown target proteins for dasatinib. In general, the majority of those 21 protein 
kinases identified by us are known to play important roles in signal transduction and 
cell cycle regulation. In addition to kinases, some non-kinase targets were also 




tyrosine phosphatases and 
serine/threonine-protein phosphatases, and so on. Most of them are likely to be 
interactors of dasatinib kinase targets. 
    In an effort to further validate our MS results, we performed in vitro inhibition 
assay for DA-2 with purified CSK and PKA (Table 6.2). Results showed that IC50 of 
DA-2 for CSK and PKA were 20 nM and 6 µM, respectively, which indicates that our 
probe is able to capture not only strong-affinity interactors but also weak-affinity ones. 
Additionally, we also performed pull-down and western blotting experiments with the 
respective antibodies (part D and E of Figure 5); results confirmed that, in addition to 
c-Src and Abl, PKA, Pim-3 and eIf2α could be indeedly labeled by DA-2 both in 
cellular lysates and live cells. While other several kinases including CDK2, PKN2, 
PCTAIRE-3 and YSK1 were positively labeled by DA-2 only in cellular lysates, 
which is quite consistent with our LCMS results. Taken together, our results further 
demonstrate that Abl, SRC family kinase, CSK and BTK are major binding targets of 
dasatinib. Likewise, Serine/Threonine kinases may be another important group of 
kinases directly interacting with dasatinib. 
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Table 6.2 IC50 values (nM) determined in biochemical enzyme assays. 
Enzymes 
IC50 (nM) 
Dasatinib DA-1 DA-2 Staurosphorine H-89 
c-Abl 8.8 ± 0.4 30.9 ± 0.3 27.2 ± 0.1 n.d. n.d. 
c-Src 3.6 ± 0.1 19.7 ± 1.1 14.7 ± 0.1 n.d. n.d. 
SrcT338M 319 ± 50 >5000 >5000 n.d. n.d. 
PKA 3620 ± 100 7041 ± 300 4759 ± 400 38.71 ± 0.3 81.73 ± 1.0 
CSK 7.06 ± 0.3 26.28 ± 0.2 20.66 ± 0.09 26.88 ± 0.5 n.d. 
n.d.: not determined. 
6.4  Conclusion 
    We have developed a novel chemical proteomic approach which can be used to 
identify the cellular targets of dasatinib in native environment. In addition to Src and 
Abl kinase, a broad range of putative targeted kinases have been identified using our 
probe. Most notably, some serine/threonine protein kinases, for the first time, were 
identified and validated as potential dasatinib binding targets in this study. We predict 
that our chemical proteomic approach should be broadly useful for off-target 
identification against a number of existing drugs, and it may provide a powerful tool 
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Chapter 7 
 
A “Clickable”, Cell-permeable Probe for Proteome Profiling of 
Potential Cellular Targets of Staurosphorine 
 
7.1  Summary 
    This chapter describes a photo affinity-based approach for investigating the 
cellular on/off targets of staurosphorine. As in the previous chapter, where a cell 
permeable probe derived from dasatinib
TM
 was developed for proteome profiling of 
cellular kinases, herein a staurosphorine-like, cell permeable probe was designed and 
synthesized. We further evaluated its biochemical characterization and utility for 
proteome profiling of cellular targets of staurosphorine. The preliminary results 
demonstrated that this probe exhibited comparative activity as staurosphorine and 
positively labeled a wide of kinases both in cellular lysates and live cells. In order to 
investigate the cellular targets of staurosphorine, we performed large-scale 
proteomic/mass spectrometric experiments in HepG2 cells. A total of 43 kinases were 
identified (35 kinases from in vitro pull-downs, and 21 from in situ pull-downs) 
including a number of previously well-known staurosphorine binding targets. More 
notably, by comparing the MS results between in vitro and situ pull-downs, eight 
kinases, for the first time, were found to be uniquely labeled in live cells by our probe. 
It may provide important implication for studing the therapeutic function of 
staurosphorine in future. 
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7.2  Introduction 
    Protein kinases (PKs) play a key role in signal transduction pathways, which 
regulate a varity of cellular processes including growth, division, differentiation 
and metabolism. Dysregulation of cellular kinase activities has been implicated in 
many diseases (including cancer, HIV, malaria, and so on).
18 
Kinase inhibitors are 
usually used to understand kinase function and as therapeutic compounds to treat 
cancer and other diseases.
138 
As an example, staurosporine is the most potent 
general inhibitor for protein kinases, and it has been reported to target hundreds of 
kinase.
130,139 
To date, staurosporine and many of its derivates have received 
considerable attention as potential anticancer drugs due to their significant 
biological effects.
140 
With the aim to elucidate the potential uitility of 
staurosphorine as a therapeutic agent, it is very significant to identify its potential 
cellular off-targets. Although affinity matrix method has become the most popular 
approach for identification of kinase inhibitor binding targets from cellular or 
tissue extracts,
128b,141 
this approach still limits in several aspects: first, the solid 
support may affect the accessibility of the immobilized drugs for interactions with 
the target proteins; second, due to the non-covalent interactions between drugs and 
proteins, it is hard to find a compromise condition between specific and 
nonspecific interactions; third, the false positive proteins could be easily identified 
due to the loss of cellular compartmentation in vitro. As an alternative approach, 
recently, Mathias and colleagues described a Capture Compound Mass 
Spectrometry (CCMS) method for comprehensive identification of 
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staurosphorine-binding kinases.
142 
They used a trifunctional 
staurosphorine-derived probe to profile the kinome of the human liver-derived cell 
line in solution. However, due to the steric hindrance of reporters for the binding 
between probe and the active site of kinases, the less potency and poor cell 
permeability of this probe limit its utility only in the profing of cell lysates in vitro. 
In an attempt to develop a staurosphorine-derivated probes which can be used to 
proteome profile the cellular targets of staurosphorine in live cells, we designed 
and synthesized a “clickable”, affinity-based probe (AfBP) based on the well 
known activity-based protein profiling (ABPP) approach which has been 
sucessfully applied for various classes of enzyme.
41,45,65a,68a,82,83b,101,102a 
Our probe 
essentially contains three structural components: (1) a protein recognition group 
derived from staurosphorine; (2) a photo-cross linker which was diazirine in this 
study, and (3) an alkyne handle incorporating to a fluorescent dye or biotin group 
via the copper catalyzed Huisgen 1,3-dipolar cycloaddition.
34 
Herein, we describe 
the design, synthesis and biochemical characterization of this probe, and further 
evaluate its utility for proteome profiling of cellular targets of staurosphorine. 
Figure.7 1 Overall strategy of affinity-based proteome profiling. 
Live cells 
or cell lysates UV (350 nm) “Click” 
Tryptic digest SDS-PAGE 
LC-MS/MS 
analysis 
2. Washing & elution 
Proteome labeling 
1. Affinity capture 
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7.3  Results and Discussion 
7.3.1 Design and Synthesis of Staurosphorine-like Probe 
    Towards developing affinity-based probes (AfBPs) against kinases, we chose 
staurosphorine core structure as the kinase recognition unit and diazirine as the 
photo-cross unit. An alkyne handle was used to incorporate to a fluorescent dye or 
biotin group for visualization/pull-downs. The general labeling strategy of the 
“clickable” staurosphorine-derived probe is shown in Figure. 7.1. To determine 
whether the introduction of the photo-cross linker affects the binding between 
probe and kinases, we carried out molecular docking study using PKA as model 
protein. The results showed that the staurosphorine warhead bound well to the 
ATP binding pocket (Figure. 7.2A), which is consistent with previously reported 
crystal structure of the PKA complexed with staurosphorine.
143 
Additionally, the 
photo-cross linker points to the surface of protein as expected, which has 
negligible effect on the binding between staurosphorine and the ATP binding site. 
The synthesis of the probe is shown in Scheme 7.1. In brief, the diazirine unnatural 
amino acid was synthesized as previously reported method.
144 
After protection of 
amine with Fmoc group, compound 2 was then coupled with propargylamine to 
give 3. The Foc group in 3 was subsequently removed by treatment with 20% 
piperidine in DMF to afford the compound 4 in 91% yields over two steps. 
Commercial available staurosphorine (STS) was coupled to succinic anhydride, 
yielding compound 5 in 92% yields. Compound 5 was finally coupled to 
compound 4 to give the desired probe STS-1 in 92% yield. 

































































































Scheme 7.1 Synthesis of the “clickable” staurosphorine-like probe STS-1. The 
“Click”-based reporters used are rhodamine azide and biotin azide which were 
prepared as previously described.
104c 
7.3.2 Biological Characterization of Probe STS-1 
    To characterize the potency of our probe for kinase, we compared the inhibitory 
potential of our probe to staurosphorine by measuring the kinase activities of PKA in 
a dose-dependent manner under optimized enzyme concentration of ~50 nM. As seen 
in Figure. 7.2B, IC50 of staurosphorine for PKA is 35.3 ± 0.5 nM, whereas IC50 of 
STS-1 is 62.2 ± 0.2 nM, which indicates the introduction of the photo-cross linker 
slightly affects staurosphorine activity, and probe STS-1 exhibits comparative activity 
as staurosphorine. 
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Figure 7.2 Biological activity of STS-1 in vitro and situ. (A) Molecular docking of 
STS-1 and staurosphorine in the ATP binding site of PKA. Protein, staurosphorine 
and STS-1 are shown in grey, red and green, respectively. (B) IC50 values of two 
compounds (STS-1 and staurosphorine) for PKA determined with ProFluor® PKA 
Assay. Data represent the average (s.d. for two trials). (C) Dose-dependent 
inhibition of HepG2 cells proliferation by STS and STS-1 using XTT assay. (D) 
Cellular imaging of HepG2 cells with probe STS-1. All images were acquired in 
the same way. Scale bar = 10 µm. 
    Next, in order to evaluate the potential biological activity of STS-1 against 
staurosphorine, we performed the cell proliferation assay using HepG2 cells. In the 
cell proliferation assay (Figure.7.2D), our probe showed a dose-dependent inhibition 
of tumor cell proliferation over a 72 h time period with comparable potency. On the 
other hand, this experiment also indicated that STS-1 was cell permeable. To 
determine the cell permeability of our probe, we performed cell permeability assay 
together with staurosphorine as positive control. Results indicated that probe STS-1 
had comparable cell permeability with staurosphorine. 
    To further demonstrate our probe‟s cell permeability and utility for potential 
cellular imaging, we performed fluorescence microscopy to visualize the cells treated 
by STS-1 (Figure 2D). Live HepG2 cells were first treated with STS-1 followed by 
STS (IC50 = 35.3 ± 0.5 nM) 
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irradiation under UV, and then fixed with paraformaldehyde, permeabilized with 
Triton X-100, conjugated to rhodamine azide by click chemistry, and imaged (colored 
in red). Competitive experiment was carried out in parallel. Results showed that 
minimal fluorescence was observed in cells treated with staurosphorine as competitor 
as well as DMSO. However, higher fluorescence was observed for cells treated with 
STS-1. Taken together, probe STS-1 has good cell permeability, and it can be 
potentially used for bioimaging in future. 
7.3.3 In vitro Labeling with Purified Kinase 
    Next, to evaluate STS-1 as an activity-based probe for kinases, the same 
amount (~30 pmol) of three protein kinases, namely c-Src, CSK and PKA, were 
labeled by STS-1, respectively. STS-1 was incubated with different kinases in 
parallel for 30 min followed by irradiation under UV lamp at ~350 nm. 
Subsequently, the reactions were subjected to click reaction with rhodamine azide 
(TER-N3) (structures shown in Figure 7.1), after which the fluorescent labeled 
proteins were separated by SDS-PAGE and visualized in-gel with a fluorescence 
gel scanner. As shown in Figure. 3A, all kinases can be positively labeled, which 
is consistent with the multiple targets character of staurosphorine. To further 
assess the selectivity of the probe for PKA, we carried out the labeling 
experiments for recombinant PKA in the presense of bacterial proteome. Results 
showed that a stronger fluorescent band was observed for the bacterial lysates of 
bacteria treated with inducer, while almost no labeling was observed for 
un-induced lysates (Figure 3D). These results unambiguously indicate that STS-1 
                                                                         115 
can be used to label and detect the expression levels of PKA from different 
biological samples. 
    
Figure 7.3 Fluorescent labeling of recombinant protein kinases. (A) Three purified 
kinases (30 pmol, lanes 1 to 3 are c-Src, CSK and PKA, respectively) were labeled by 
STS-1. (B) Recombinant PKA (100 nM) was labeled with increasing concentration of 
STS-1 and quantification of fluorescent bands. (C) Dose-dependent labelings of PKA 
with STS-1 (1 µM final concentration) (top) and competitive labeling experiments 
(bottom). (D) Bacterial lysates of induced and un-induced (UI) bacteria expressing 
PKA were labeled by STS-1(1 μM). 
7.3.4 Proteome Profiling of Mammalian Cellular Lysates 
    Next, to study the labeling ability of the probe for endogenous PKA, we 
performed in vitro proteome profiling experiments with HepG2 cell lysates in 
dose-dependent manner together with staurosphorine as competitor. As shown in 
the left panel of Figure.7 4A, a distinct fluorescent band was observed at 40 kDa in 
the fluorescent gel. This band has been confirmed to be endogenous PKA by in 
vitro pull-down and immunoblotting with anti PKA antibody. Additionally, we 
(B) (A) 
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observed that, in addition to PKA, the probe also labeled a number of other 
proteins, and those labeled bands could be competed away by treatment with 
excessive staurosphorine, indicating that most labeled proteins are likely specific 
cellular targets. To further investigate the in situ proteome reactivity profiles of 
STS-1 in HepG2 live cells, we then set out to perform the labeling experiments in 
HepG2 live cells. As shown in the right panel of Figure 7.4, similarly, in addition 
to the expected PKA band confirmed by immunoblotting, we also observed a 
number of staurosphorine-sensitive targets, that is, those labeled bands that were 
competed away by treatments with excessive staurosphorine. Taken together, these 
experiments thus demonstrate the feasibility of our probe for profiling of 
endogenous PKA. 
 
Figure 7.4 Proteome profilings of HepG2 cells and PKA validation. (A) in vitro 
and situ labeling of HepG2 cells by STS-1 (over a concentration range of 1-10 μM 
together with competitive experiments with 100 μM staurosphorine (STS). The red 
asterisks mark the position of endogenous PKA; (B) Silver stain gel for in vitro 
and situ pull down fractions and western blotting analysis (DMSO as negative 
controls; left lanes) with anti PKA antibody. 
7.3.5 Target Identification and Validation 
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large-scale proteomic/mass spectrometric experiments in HepG2 cells. A total of 
43 kinases were identified (35 kinases from in vitro pull-downs, and 21 from in 
situ pull-downs). Out of them, 14 kinases belong to protein kinases: 4 proteins are 
annotated as tyrosine kinases (SRC, YES, CSK and BTK), another 10 proteins are 
serine/threonine kinases (PCTK3, DNA-PKC, STK25, RSK-3, eIf2α, p38, PKA 
C-α, MST4, CDK2 and PKN2). The rest of kinases identified are non-protein 
kinases including lipid kinases, phosphofructokinases, pyruvate kinases, and so on. 
Some of them have been reported as known staurosphorine binding targets 
before.
142 
By comparing the MS results between in vitro and situ pull-downs, 13 
kinases were overlaid as common protein hits. Interestingly, eight unique kinases 
listed in Figure 7.5A were only identified from in situ pull-down experiments. In 
an effort to further validate these seven protein hits, we carried out in vitro and situ 
pull-down experiments followed by immunoblotting with respective antibodies. 
Results confirmed that five of them could be consistantly labeled by STS-1 in live 
cells rather than cell lysates. Additionally, PKA, c-Src and PKN2 could be 
positively labeled both in cell lysates and live cells (Figure 7.5C). Taken together, 
our preliminary results herein thus may provide important information for studying 
the cellular off-targets of staurosphorine in future.  
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Figure 7.5 LCMS results and hit validation. (A) Eight kinases uniquely identified 
from in situ pull-down experiments by LC-MS but not in vitro pull-down. (B) 
Venn diagram illustrating the comparision of the number of kinases identified 
from HepG2 cell lysates and live cells. (C) Western blotting analysis of in situ 
pulled-down fractions of HepG2 live cells treated with STS-1 (or DMSO as 
negative controls; right lanes) with the respective antibodies. 
7.4  Conclusion  
    In summary, we have successfully synthesized a novel “clickable”, cell 
permeable staurosphorine-derived probe which enble to positively label 
endogenous PKA not only in cellular lysates but also live cells. Most notably, the 
preliminary results demonstrated that our permeable probe, not like other probes, 
was very useful for proteomic profiling of the cellular targets of staurosphorine in 
live cells. Therefore, it should provide important implication for studing the 
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8.1  General Information 
8.1.1 Materials 
All chemicals were purchased from commercial vendors and used without 
further purification, unless otherwise noted. Either HPLC grade or distilled solvents 
were used in all the reactions. All moisture-sensitive reactions were performed under 
a positive pressure of nitrogen or argon. Concentration in vacuum was performed on a 
Büchi rotary evaporator. Analytical thin layer chromatography was performed using 
Merck silica gel plates (0.25 mm thickness) with fluorescent indicator UV254. Spots 
were visualized by ultraviolet illumination, iodine staining, KMnO4 staining (for 
alkenes, aldehydes), Nindhydrin staining (for primary amines), or ceric molybdate 
staining. Flash chromatography was performed using Merck silica gel (40 μM particle 
size) and freshly distilled or AR grade solvents. Chemical shifts are reported as δ in 
parts per million (ppm) referenced with respect to residual solvent (CDCl3 = 7.26 ppm, 
methanol-d4 = 3.3 ppm and DMSO-d6 = 2.50 ppm) or from internal standard 
tetramethylsilane (TMS = 0.00 ppm). 
13C NMR spectra are reported as δ in units of 
parts per million (ppm) relative from solvent signal: CDCl3 (δ = 77.0, triplet) and 
methanol-d4 (δ = 49.0, singlet). The following abbreviations were used in reporting 
spectra: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, dd = doublet of 
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doublets. Rink Amide resin, all Fmoc amino acids, O-benzotriazole-N,N,N,N- 
tetramethyl-uronium-hexafluoro-phosphate (HBTU), N-hydroxy-benzotriazole 
(HOBt), triisopropylsilane (TIS) and bromo-tris-pyrrolidino phosphonium 
hexafluorophosphate (PyBrOP) used in peptide synthesis were purchased from GL 
Biochem (China). 4-Formyl-3-methoxyphenoxy Resin (PL-FMP Resin, 0.9 mmol/g, 
75~150 μm, Part no: 1465-799) was purchased from Polymer Laboratories (USA). All 
reactions requiring anhydrous conditions were carried out under an argon or nitrogen 
atmosphere using oven-dried glassware. Solid-phase reactions were performed on an 
IRORI AccuTagTM Combinatorial Chemistry System. Some enzymes were 
purchased from commercial sources. Pepsin and Renin (from Mucor miehei) were 
from Fluka. Enzyme stocks were made fresh using 10 mM HCl (for pepsin) or water 
(for renin). Plasmepsin I (PM-I), Plasmepsin II (PM-II), histoaspartic protease (HAP) 
and HAP mutant H34A, S37A, K78A, E278A were expressed and purified as 
described previously. Anti-PM-I mouse serum mAb1 C6-24, anti-PM-II rabbit serum 
737, anti-PM-IV mouse mAb 13.9.2 were requested from MR4 (USA). The anti-HAP 
mouse mAb was kindly provided by Dr. Daniel E. Goldberg. Some enzymes were 
expressed in E.coli strain BL21-DE3 and purified as described previously. It includes 
Abl (human c-Abl, residues 229-512), c-Src and its mutants (chicken c-Src residues 
251-533 or 83-533). Dasatinib and staurosphorine (98%) were purchased from 
invitrogen. Tris (2-carboxyethyl) phosphine (TCEP), and click chemistry ligand, 
tris[(1-benzyl- 1H-1,2,3-triazol-4-yl)methyl] amine (TBTA) were purchased from 
Sigma-Aldrich. Antibodies against c-Src (SC-8056), cathepsin D, HSPA5, PKA C-α 
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(SC-903), Rsk-4 (JS-31), PRPS2 (L-22), PFK-1 (G-11), Creatine kinase-B (N-20), 
ADK (F-5), PRK2 (C-6), DTYMK (C-17), Pim-3 (C-18), Cdk2 (AN4.3), YSK1 (E-5) 
and PCTAIRE-3 (P-23) were purchased from Santa Cruz Biotechnology, c-Abl, eIf2α, 
phospho-Y416 and phospho-Y527 antibodies were purchased from Cell Signaling 
Technologies (Beverly, MA). Antibody against β-tubulin was purchased from Abcam. 
8.1.2 Instruments 
    Mass spectra were recorded on a Finnigan LCQ mass spectrometer, a Shimadzu 
LC-IT-TOF spectrometer or a Shimadzu LC-ESI spectrometer. Analytical and 
preparative RP-HPLC separations were performed on Phenomex C18 column 
(250×4.60 mm) and Phenomex C18 (250×21.20 mm) coloumns, respectively, using a 
waters 600E HPLC system equipped with a waters 600 controller and a waters 2487 
UV detector. Shimadzu LCMS-IT-TOF system equipped with auto-sampler (cat. No. 
LCMS-2010EV) was used for the analysis of the inhibitor library. Eluents A (0.1% 





C NMR spectra were recorded on a 300 MHz 89 Bruker ACF300 or Bruker 
Avance 500 MHz or DPX-300 NMR. For enzyme inhibition and IC50 measurements, 
Tecan microplate reader (Multimode Reader, Infinite®200) in luminescence mode 
with i-control
TM 
software was used. Fluorescence scanning of the SDS-PAGE gels 
was carried out with Typhoon 9410 Variable Mode Imager scanner (Amersham), and 
where applicable, the bands were quantified with the ImageQuant 3.3 (Molecular 
Dynamics) software installed on the scanner. Microarrays were printed using a contact 
arrayer (Virtek Chipwriter, Ontario, Canada) and scanned on an ArrayWoRxTM 
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microarray scanner (Applied Precision, USA) equipped with the relevant filters for 
coumarin (lex/em: 360/457 nm), fluorescein (lex/em: 490/528 nm), Cy3 (lex/em: 
548/595 nm) and Cy5 (lex/em: 633/685 nm). 
8.2  Solution-phase Synthesis 
8.2.1 General Procedure for Synthesis of Diol-amine Warheads 
General procedure for synthesis of N-benzyloxycarbonyl protection of amino acids 1 
(a-c): 
A solution of the free amino acid (1.0 eq.; 50 mmol) in THF (100 mL) was 
cooled to 0 ºC followed by addition of a solution of Na2CO3 (3.0 eq.; 150 mmol; 
15.90 g) in water (100 mL). Benzyloxycarbonyl chloride (1.1 eq.; 55 mmol; 7.82 mL) 
in THF (30 mL) was then added dropwise to the reaction mixture and the resulting 
mixture was stirred at 0 ºC for 2 h, then warmed up to r.t. and continued overnight. 
Subsequently, the reaction was quenched with water followed by acidification with 
10 % HCl to pH 1-2, and the aqueous layer was extracted with EA (3×100 mL). The 
combined organic layers were washed with brine (2×100 mL) and then dried over 
Na2SO4. Finally the solvent was evaporated under reduced pressure to afford the pure 
Cbz-protected amino acid without further purification. 
(S)-2-[N-(benzyloxycarbonyl)amino]-3-phenyl-propionic acid (1a). White solid. Yield 
= 97 %. 
1
H-NMR (300 MHz, CDCl3), δ 2.80 (d, J = 7.05 Hz, 2H), 4.50 (m, 1H), 4.95 
(s, 2H) , 5.05 (s, 1H) 7.28-7.17 (m, 10H); ESI-MS: m/z [M-H]
-
 = 298.0. 
(S)-2-[N-(benzyloxycarbonyl)amino]-4-methyl-pentanoic acid (1b). Colourless oil. 
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Yield = 96 %. 
1
H-NMR (300 MHz, CDCl3) δ 0.97-0.94 (m, 6H), 1.79-1.50 (m, 3H), 
4.59 (m, 1H), 5.16 (s, 2H), 5.30 (s, 1H), 7.31-7.26 (m, 5H), 8.18 (br s, 1H); ESI-MS: 
m/z [2M + Na]
+
 = 552.9. 
(S)-2-(benzyloxycarbonylamino)propanoic acid (1c). Colourless oil. Yield = 94 %. 
1
H-NMR (300 MHz, CDCl3) δ 1.42 (d, J = 7.32 Hz, 1H), 4.71-4.20 (m, 1H), 5.09 (s, 
2H), 7.40-7.30 (m, 5H), 8.36 (s, 1H); 
13
C-NMR (75 MHz, CDCl3): 175.6, 157.3, 136.5, 
128.4-127.9, 60.4, 50.3, 18.4; ESI-MS: m/z [M-1]
-
 = 222.0. 
General procedure for preparation of Cbz-α-amino alcohols 2(a-c): 
A solution of the Cbz-α-amino acid (1 eq.; 48 mmol) in dry dimethoxyethane 
(DME) (100 mL) was cooled to −15 °C under a nitrogen atmosphere. 
N-methylmorpholine (NMM) (1 eq.; 48 mmol; 6.26 mL) and isobutyl chloroformate 
(ICF) (1 eq.; 48 mmol; 5.28 mL) were added dropwise. After 10 min, the reaction 
mixture was allowed to warm up to r.t. (in ~30 min). The mixture was filtered under 
nitrogen atmosphere to remove the precipitated NMM hydrochloride. The filtrate was 
cooled to −15 °C and a solution of NaBH4 (1.5 eq.; 72 mmol; 2.72 g) in water (10 mL) 
was added. After stirring for 1 h, water (100 mL) was added to quench the reaction. 
DME was then removed under reduced pressure. The aqueous layer was extracted 
with EA (3×50 mL) and the combined organic layers were washed with water and 
saturated NaCl solution and dried with Na2SO4. Finally the solvent was removed 
under reduced pressure. Purification was carried out by column chromatography on 
silica gel (EtOAc/Hexane = 1:1). 
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(S)-(1-benzyl-2-hydroxy-ethyl)-carbamic acid benzyl ester (2a). White solid. Yield = 
75 %. 
1
H-NMR (300 MHz, CDCl3) δ 2.79 (d, J = 7.08 Hz, 1H), 3.53 (m, 2H), 
3.89-3.84 (m, 1H), 4.93 (s, 1H), 5.00 (s, 2H), 7.31-7.11 (m, 10H); 
13
C-NMR (75 MHz, 




(S)-(1-hydroxymethyl-3-methyl-butyl)-carbamic acid benzyl ester (2b). White solid. 
Yield: 77 %. 
1
H-NMR (300 MHz, CDCl3) δ 0.90 (m, 6H), 1.30 (m, 2H), 1.64 (m, 1H), 
3.56 (d, J = 8.01 Hz, 3H), 3.74 (s, 1H), 5.02 (s, 2H), 5.30 (d, 1H), 7.28 (s, 5H);
 
13
C-NMR (75 MHz, CDCl3): 156.6, 136.3, 128.1-126.7, 65.2, 64.7,51.3, 40.2, 25.1, 
22.0; ESI-MS: m/z [2M+ Na]
+
 = 524.9. 
(S)-(1-hydroxypropan)-carbamic acid benzyl ester (2c). White solid. Yield: 70 %. 
1
H-NMR (300 MHz, CDCl3) δ 1.17 (d, J = 6.9 Hz, 3H), 1.66 (s, 1H), 3.56-3.39 (m, 




General procedure for preparation of the Cbz-α-amino aldehydes 3(a-c): 
    A solution of 2 (1.0 eq.; 39.2 mmol) in DCM (100 mL) was added dropwise to a 
solution of DMP (1.3 eq.; 51 mmol; 21.6 g) in DCM (150 mL). The reaction mixture 
was stirred at r.t. for 6 h until TLC indicated complete conversion. Aqueous Na2S2O3 
(150 mL) was then added and stirring was continued for another 30 min. The organic 
layer was separated and the aqueous layer was extracted with DCM (3×50 mL). The 
combined organic layers were then washed with saturated NaHCO3 (2×50 mL), water 
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(2×100 mL) and brine (2×100 mL) and then dried over Na2SO4. The solvent was 
evaporated under reduced pressure. The crude product was purified by flash 
chromatography (EA/hexane, 20-25 % v/v, with 0.1 % pyridine) to afford 3. 
(S)-(1-Benzyl-2-oxo-ethyl)-carbamic acid benzyl ester (3a).Yellow solid. Yield: 70 %. 
1
H-NMR (300 MHz, CDCl3) δ 3.08 (m, 2H), 4.45 (m, 1H), 5.08 (s, 2H), 5.40 (s, 1H), 
7.33-7.21 (m, 10H), 9.57 (s, 1H); 
13
C-NMR (75 MHz, CDCl3): 199.5, 156.5, 136.1, 
129.4-127.7, 67.7, 61.7, 35.9; ESI-MS: m/z [M-H]
-
 = 282.0. 
(S)-(1-Formyl-3-methyl-butyl)-carbamic acid benzyl ester (3b). Colorless oil. Yield: 
65 %. 
1
H-NMR (300 MHz, CDCl3) δ 0.95 (d, 6H), 1.41 (m, 1H), 1.77 (m, 2H), 4.27 
(m, 1H), 5.10 (s, 2H), 5.44 (s, 1H), 7.33 (s, 5H), 9.54 (s, 1H); 
13
C-NMR (75 MHz, 
CDCl3): 199.8, 156.1, 136.1, 128.4-128.0, 66.9, 58.7, 37.8, 24.5, 22.9, 21.7; ESI-MS: 
m/z [M-H]
-
 = 248.1. 
(S)-(1-formylpropan)-carbamic acid benzyl ester (3c). White solid. Yield: 60 %. 
1
H-NMR (300 MHz, CDCl3) δ 1.10 (d, J = 9.6 Hz, 3H), 3.54-3.48 (m, 1H), 5.09 (s, 
2H), 7.35-7.30 (m, 5H). 
General procedure for synthesis of Cbz-protective diols (4a-b) by pinacol 
homocoupling reaction: 
    VCl3 (2 eq.; 60 mmol; 10 g) was refluxed in distilled THF (25 mL) under N2 for 
5 h. The mixture was cooled to r.t., followed by addition of Zn powder (2 eq.; 60 
mmol; 4 g). The resulting mixture was stirred for 30 min, then heated to reflux before 
1,3-dimethylimidazole (36 mL) was added, followed by the dropwise addition of 3 (1 
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eq.; 30 mmol) in distilled THF (20 mL). The reaction mixture was then refluxed for 
further 1 h. The solution was cooled to r.t. and diluted with 10 % aqueous citric acid. 
Extraction with EA was then carried out (3×50 mL) and the combined organic layers 
were washed with water (3×50 mL) and brine (2×50 mL), dried over Na2SO4, filtered 
and concentrated. The crude product was purified by recrystallization with ethanol to 
afford 4. 
(1-Benzyl-4-benzyloxycarbonylamino-2,3-dihydroxy-5-phenyl-pentyl)-carbamic-acid 
benzyl ester (4a). White solid. Yield: 20 %. 
1
H-NMR (300 MHz, CDCl3) δ 2.78-2.58 
(m, 4H), 4.19 (d, J = 4.77 Hz, 2H), 454 (s, 2H), 4.93 (d, J = 8.70 Hz, 4H), 6.82 (d, J = 
9.39 Hz, 2H), 7.36-7.32 (m, 20H); 
13
C-NMR (75 MHz, DMSO-d6): 155.85, 139.3, 





benzyl ester (4b). White solid. Yield: 15 %. 
1
H-NMR (300 MHz, DMSO-d6) δ 0.83 (m, 
12H), 1.12 (m, 2H), 1.44 (m, 4H), 3.17 (s, 2H), 3.91 (m, 2H), 4.34 (m, 2H), 5.02 (m, 
4H), 6.59 (d, J = 8.70 Hz, 4H), 7.33 (s, 10H); 
13
C-NMR (75 MHz, DMSO-d6): 156.0, 




(4-Benzyloxycarbonylamino-2,3-dihydroxy-1-methyl)-carbamic acid benzyl ester (4c). 
White solid. Yield: 10 %. 
1
H-NMR (300 MHz, DMSO-d6) δ 1.00 (d, J = 6.57 Hz, 6H), 
3.20 (s, 2H), 3.77 (s, 2H), 4.36 (d, J = 5.43 Hz, 2H), 5.00 (s, 2H), 6.82 (d, J = 8.55 
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Hz , 2H), 7.35-7.32 (m, 10H); 
13
C-NMR (75 MHz, DMSO-d6): 155.8, 137.4, 128.3, 
127.7, 127.6, 72.9, 65.0, 48.5, 18.0. 
General procedure for protection of Cbz-protected amino diols 4(a-c) to 5(a-c): 
    To a solution of 4 (1 eq.; 2.5 mmol) in acetone (15 mL), 2, 2-dimethoxypropane 
(10 mL) was added at r.t. A catalytic amount of p-TsOH (0.25 mmol) was added and 
the reaction mixture was stirred for 2 h. Upon solvent evaporation, the crude product 
was purified by flash column chromatography (EA/hexane, 20 % v/v) to isolate the 
desired product 5. 
{1-[5-(1-Benzyloxycarbonylamino-2-phenyl-ethyl)-2,2-dimethyl-[1,3]dioxolan-4-yl]-2
-phenyl-ethyl}-carbamic acid benzyl ester (5a). White solid. Yield: 50 %. 
1
H-NMR 
(300 MHz, CDCl3) δ 1.39 (s, 6H), 2.80 (m, 4H), 3.72 (s, 2H), 3.13-3.95 (m, 2H), 
5.02-4.75 (m, 4H), 7.26-7.23 (m, 20H), 7.33 (s, 2H); 
13
C-NMR (75 MHz, CDCl3): 
155.8, 137.4, 136.5, 129.9-127.5, 126.3, 108.5, 80.4, 66.6, 50.2, 39.7, 26.9; LC-MS: 
m/z [M+23]
+
 = 631.3. 
{1-[5-(1-Benzyloxycarbonylamino-3-methyl-butyl)-2,2-dimethyl-[1,3]dioxolan-4-yl]-3
-methyl-butyl}-carbamic acid benzyl ester (5b). White solid. Yield: 50 %. 
1
H-NMR 
(300 MHz, CDCl3) δ 0.99-0.79 (t, J = 6.57 Hz, 2H), 1.35 (s, 6H), 1.61-1.51 (m, 4H), 
3.92-3.65 (m, 2H), 5.29-4.97 (m, 4H), 7.34-7.27 (m, 10H); 
13
C-NMR (75 MHz, 
CDCl3): 156.1, 136.8, 128.5-127.9, 108.6, 81.8, 66.7, 47.6, 42.9, 27.4, 24.7, 24.4, 22.9; 
LC-MS: m/z [M+23]
+
 = 563.3. 
{1-[5-(1-Benzyloxycarbonylamino-3-methyl-butyl)-2,2-dimethyl-[1,3]dioxolan-4-yl]-1
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-methyl)-carbamic acid benzyl ester (5c). White solid. Yield: 60 %. 
1
H-NMR (300 
MHz, CDCl3) δ 1.23-1.19 (m, 6H), 1.34 (s, 6H), 3.61 (s, 2H), 3.92 (s, 2H), 5.09 (s, 
4H), 7.34-7.29 (m, 10H); 
13
C-NMR (75 MHz, CDCl3): 155.8, 136.4, 128.3, 127.9, 
127.8, 108.6, 80.1, 66.5, 60.1, 45.5, 26.8, 19.3, 13.9. 
General procedure for deprotection of the Cbz-protected diols by hydrogenoloysis to 
6(a-c): 
    To a solution of 5 in 1:1 MeOH:EA (50 mL) was added 10% Pd/C under H2 
conditions. The reaction mixture was stirred overnight at r.t. The solid was then 
filtered using celite and the filtrate was concentrated to yield the desired compound 6. 
1-[5-(1-Amino-2-phenyl-ethyl)-2,2-dimethyl-[1,3]dioxolan-4-yl]-2-phenyl-ethylamine 
(6a). Yellow liquid. Yield: 85 %. 
1
H-NMR (300 MHz, CDCl3) δ 1.50 (s, 6H), 2.14 
m(s, 4H), 2.61-2.54 (m, 2H), 2.82-2.76 (dd, J = 4.77 Hz, 2H), 2.96 (d, J = 4.29 Hz, 
2H), 4.02 (s, 2H), 7.24-7.14 (m, 10H); 
13
C-NMR (75 MHz, CDCl3): 134.0, 130.7, 
131.5-128.0, 126.3, 108.8, 79.9, 53.6, 41.8, 27.4; LC-MS: m/z [M+H]
+
 = 341.2. 
1-[5-(1-Amino-3-methyl-butyl)-2,2-dimethyl-[1,3]dioxolan-4-yl]-3-methyl-butylamine 
(6b). Yellow liquid. Yield: 87 %. 
1
H-NMR (300 MHz, CDCl3) δ 0.98-0.55 (m, 12H), 
1.23-1.12 (m, 2H), 1.45-1.28 (m, 2H), 1.77 (s, 4H), 1.94-1.70 (m, 2H), 2.76 (d, J = 
5.58 Hz, 2H), 3.74 (s, 2H); 
13
C-NMR (75 MHz, CDCl3): 108.6, 83.3, 81.8, 50.5, 44.5, 
27.3, 24.3, 23.4, 21.4; LC-MS: m/z [M+H]
+
 = 273.2. 
1-[5-(1-Amino-1-methyl)-2,2-dimethyl-[1,3]dioxolan-4-yl]-1-methylamine(6c). 
Yellow liquid. Yield: 87 %. 
1
H-NMR (300 MHz, CD3OD) δ 3.84 (d, J = 4.62 Hz, 2H), 
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3.23-3.19 (m, 2H), 1.35 (s, 6H), 1.18 (d, J = 6.57 Hz, 6H); 
13
C-NMR (75 MHz, 
CD3OD): 111.9, 81.2, 50.3, 27.6, 17.4. 


































Scheme 8.1 Synthesis of the N-terminal warhead building blocks 4(a-f). 
General procedure for synthesis of bromomethyl ketones 2(a-f): Compound 2 were 
synthesized according to published procedure.
145 
To a solution of Fmoc-protection 
amino acids and N-methylmorpholine (6 mmol) in THF (40 mL) was added isobutyl 
chloro-formate (6 mmol) at -4 
o
C and with stirring. After 15 min, the reaction mixture 
was filtered. Diazomethane in ether (from 1.33 g, 6.2 mmol of 
1-methyl-3-nitrol-nitrosoguanidine and 1.8 mL of 40 wt% aqueous KOH in 10 mL of 
EtOH) was added to the filtrate slowly and warmed up to room temperature slowly. 
After completion of the reaction, the solution was concentrated in vacuo to obtain 
diazo ketone 1 which was dissolved in 30 mL of CH2Cl2. 48% HBr (6 mmol) was 
then added slowly at 0
 o
C and stirred for further 15 min. The reaction mixture was 
finally diluted with EtOAc (40 mL) and washed with saturated sodium bicarbonate, 
and then washed with brine. The organic layer was dried over anhydrous Na2SO4, 
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filtered, and concentrated under reduced pressure to afford bromomethyl ketone 2(a-f) 
in 80-88% yield. 
N-α-Fmoc-phenylalanyldiazomethane (1a). Yield = 85%. 1H-NMR (500 MHz, CDCl3) 
δ 3.05 (d, J = 6.95 Hz, 2H), 4.21 (t, J = 6.00 Hz, 1H), 4.41-4.43 (m, 3H), 5.13 (s, 1H), 
5.29 (s, 1H), 7.17 (d, J = 4.17 Hz, 1H), 7.23-7.32 (m, 6H), 7.40 (t, J = 4.53 Hz, 2H), 




N-α-Fmoc-phenylalanylbromomethylketone (2a). Yield = 86%. 1H-NMR (500 MHz, 
CDCl3) δ 3.09-3.14 (m, 2H), 3.77-3.93 (m, 2 H), 4.17 (d, J = 7.32 Hz, 1H), 4.42 (d, J 
= 6.30 Hz, 2H), 4.78 (d, J = 6.95 Hz, 1H), 5.31 (d, J = 6.95 Hz, 1H), 7.13 (d, J = 6.95 
Hz , 4H), 7.25-7.32 (m, 5H), 7.40 (t, J = 7.55 Hz, 2H), 7.53 (t, J = 7.88 Hz, 2H), 7.76 
(d, J = 7.55 Hz, 2H); 
13
C-NMR (125 MHz, CDCl3) δ 200.3, 158.7, 143.5, 141.3, 




N-α-Fmoc-isobutylalanylbromomethylketone (2b). Yield = 89%. 1H-NMR (300 MHz, 
CDCl3) δ 0.93 (d, J = 10.02 Hz, 6H), 1.43 (t, J = 6.16 Hz, 2 H), 1.61 (t, J = 6.16 Hz, 2 
H), 3.98 (d, J = 4.44 Hz, 2H), 4.18 (t, J = 6.33 Hz, 1H), 4.43 (t, J = 9.05 Hz, 2H), 4.52 
(t, J = 12.66 Hz, 1H), 7.30-7.55 (m, 4H), 7. 65 (t, J = 3.36 Hz, 2H), 7.75 (d, J = 7.56 
Hz, 2H). 
N-α-Fmoc-methylalanylbromomethylketone (2c). Yield = 83%. 1H-NMR (300 MHz, 
CDCl3) δ 1.40 (d, J = 7.42 Hz, 3H), 3.93-4.00 (m, 1H), 4.18-4.25 (m, 2H), 4.38-4.66 
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(m, 3H), 5.39 (s, 2H), 7.29-7.43 (m, 4H), 7.59 (d, J = 5.07 Hz, 2H), 7.77 (d, J = 7.41 
Hz, 2H); 
13
C-NMR (75 MHz, CDCl3) δ 201.5, 143.6, 141.3, 127.7, 127.6, 127.0, 
124.9, 119.9, 66.8, 53.5, 47.1, 45.9, 31.3, 18.7, 17.8, 17.5. 
N-α-Fmoc-4-tert-butoxy-phenylalanylbromomethylketone (2d). Yield = 81%. 
1
H-NMR (300 MHz, CDCl3) δ 1.30 (s, 9H), 3.01 (d, J = 6.75 Hz, 2H), 3.68-3.76 (m, 
2H), 4.18 (t, J = 6.33 Hz, 1H), 4.42 (d, J = 6.57 Hz, 2H), 4.64-4.73 (m, 1H), 5.32 (d, J 
= 7.38 Hz, 1H), 6.92 (d, J = 8.22 Hz, 2H), 7.02 (d, J = 8.22 Hz, 2H), 7.25-7.33 (m, 
2H), 7.40 (t, J = 7.32 Hz, 2H), 7.53-7.56 (m, 2H), 7.76 (d, J = 7.41 Hz, 2H); ESI-MS: 
m/z [M+Na]
+
 = 558.12. 
N-α-Fmoc-4-Boc-butylalanylbromomethylketone (2e). Yield = 85%. 1H-NMR (500 
MHz, CDCl3) δ 1.37 (s, 9H), 1.40 (s, 9H), 1.70 (s, 2H), 1.90 (s, 1H), 3.11 (s, 2H), 
3.95-4.06 (m, 2H), 4.20 (t, J = 6.30 Hz, 1H), 4.39-4.51 (m, 2H), 4.57 (s, 1H), 5.54 (s, 
1H), 7.32 (t, J = 7.55 Hz, 2H), 7.40 (t, J = 7.55 Hz, 2H), 7.59 (d, J = 6.95 Hz, 2H), 
7.76 (d, J = 7.55 Hz, 2H); 
13
C-NMR (125 MHz, CDCl3) δ 200.9, 156.1, 143.7, 141.4, 
127.8, 127.1, 125.1, 120.0, 79.3, 66.93, 57.9, 47.3, 39.7, 32.0, 30.9, 29.7, 28.0, 22.2, 
18.7. 
N-α-Fmoc-isopropylalanylbromomethylketone (2f). Yield = 84%. 1H-NMR (500 
MHz, CDCl3) δ 0.85 (d, J = 6.92 Hz, 3H), 1.01 (d, J = 6.92 Hz, 3H), 2.21-2.25 (m, 1 
H), 3.96-3.4.04 (m, 2H), 4.22 (t, J = 6.95 Hz, 1H), 4.45 (t, J = 7.09 Hz, 2H), 4.56-4.58 
(m, 1H), 5.27 (d, J = 3. 08 Hz, 1H), 7.33 (t, J = 7.55 Hz, 2H), 7.41 (t, J = 7.29 Hz, 
2H), 7.59 (d, J = 3.75 Hz, 2H), 7.77 (d, J = 7.55 Hz, 2H); 
13
C-NMR (125 MHz, 
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CDCl3) δ 200.7, 155.5, 143.7, 141.4, 127.8, 127.1, 125.0, 124.9, 120.0, 67.0, 62.8, 
47.3, 32.7, 30.2, 19.7, 17.0. 
General procedure for synthesis of α-azido ketones 3(a-f): α-azido ketones were 
synthesized according to published procedure with some modifications.
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To a 
solution of α-bromo ketone 2 (5 mmol) and acetic acid (10 mmol) in DMF was added 
NaN3 (7.5 mmol) in water at 0 °C. After stirring for overnight at r.t., the reaction was 
quenched with water and the aqueous layer was extracted with EtOAc. The combined 
organic extracts were washed with brine, dried over anhydrous Na2SO4 and 
concentrated under reduced pressure. Purification of the crude product by silica-gel 
chromatography with hexane/ethyl acetate (80:20) afforded α-azido ketones 3 in 
85-90% yield. 
N-α-Fmoc-phenylalanylazidoketone (3a). Yield = 79%. 1H-NMR (300 MHz, CDCl3) 
δ 3.03 (d, J = 3.39 Hz, 2H), 3.64 (d, J = 11.34 Hz, 1H), 3.90 (d, J = 11.34 Hz, 1H), 
4.18 (t, J = 6.32 Hz, 1H), 4.44 (d, J = 6.42 Hz, 2H), 4.53-4.56 (m, 1H), 5.23 (d, J = 
7.08 Hz, 1H), 7.12 (d, J = 6.90 Hz, 2H), 7.28-7.33 (m, 5H), 7.40 (t, J = 4.17 Hz, 3H), 
7.54 (t, J = 5.10 Hz, 2H), 7.77 (d, J = 7.56 Hz, 2H); 
13
C-NMR (75 MHz, CDCl3) δ 
203.4, 155.8, 143.6, 141.1, 135.2, 129.0, 127.8-127.0(m), 124.9, 120.0, 66.9, 58.7, 
56.6, 47.2, 37.6; ESI-MS: m/z [M+Na]
+
 = 449.166. 
N-α-Fmoc-isobutylalanylalanylazidoketone (3b). Yield = 87%. 1H-NMR (500 MHz, 
CDCl3) δ 0.94 (d, J = 1.90 Hz, 6H), 1.38-1.43 (m, 1H), 1.52-1.56 (m, 2H), 3.96 (d, J 
= 8.30 Hz, 2H), 4.37 (t, J = 8.20 Hz, 1H), 4.38-4.51 (m, 3H), 5.11 (d, J = 7.55 Hz, 
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1H), 7.31-7.34 (m, 2H), 7.41 (t, J = 7.57 Hz, 2H), 7.58 (t, J = 6.95 Hz, 2H), 7.77 (d, J 
= 7.55 Hz, 2H). 
N-α-Fmoc-methylalanylazidoketone (3c). Yield = 75%. 1H-NMR (500 MHz, CDCl3) 
δ 1.35 (d, J = 6.90 Hz, 3H), 4.03 (d, J = 2.50 Hz, 2H), 4.20 (t, J = 6.30 Hz, 1H), 
4.39-4.44 (m, 2H), 4.48-4.52 (m, 1H), 5.34 (d, J = 6.95 Hz, 1H), 7.32 (t, J = 6.95 Hz, 
2H), 7.41 (t, J = 7.55 Hz, 2H), 7.59 (t, J = 6.30 Hz, 2H), 7.77 (d, J = 7.55 Hz, 2H); 
13
C-NMR (125 MHz, CDCl3) δ 201.6, 144.5, 141.3, 126.9, 126.6, 126.0, 124.9, 119.6, 
66.7, 53.1, 47.0, 45.9, 31.2, 18.7, 17.9, 17.7. 
N-α-Fmoc-4-tert-butoxy-phenylalanylazidoketone (3d). Yield = 90%. 1H-NMR (300 
MHz, CDCl3) δ 1.38 (s, 9H), 2.97 (d, J = 6.90 Hz, 2H), 3.58 (d, J = 8.60 Hz, 1H), 
3.86 (d, J = 9.60 Hz, 1H), 4.08-4.19 (m, 1H), 4.42-4.54 (m, 3H), 5.28 (d, J = 7.23 Hz, 
1H), 6.92 (d, J = 8.22 Hz, 2H), 7.01 (d, J = 7.22 Hz, 2H), 7.31 (t, J = 7.31 Hz, 2H), 
7.40 (t, J = 7.40 Hz, 2H), 7.53-7.56 (m, 2H), 7.76 (d, J = 7.41 Hz, 2H)，13C-NMR (75 
MHz, CDCl3) δ 203.6, 155.7, 154.8, 143.5, 141.3, 129.7, 127.7, 124.8, 119.9, 78.7, 
66.9, 58.7, 56.7, 47.2, 37.1, 28.8; ESI-MS: m/z [M+Na]
+
 = 521.217.  
N-α-Fmoc-4-Boc-butylalanylazidoketone (3e). Yield = 85%. 1H-NMR (300 MHz, 
CDCl3) δ 1.23-1.28 (m, 2H), 1.34-1.36 (m, 2H), 1.49 (s, 9H), 1.63-1.71 (m, 2H), 3.09 
(s, 2H), 4.02 (s, 2H), 4.1 (t, J = 6.96 Hz, 1H), 4.19 (t, J = 6.27 Hz, 1H), 4.31-4.43 (m, 
1H), 4.49-4.60 (m, 2H), 7.31 (t, J = 5.87 Hz, 2H), 7.41 (t, J = 7.31 Hz, 2H), 7.59 (d, J 
= 6.96 Hz, 2H), 7.76 (d, J = 7.29 Hz, 2H); 
13
C-NMR (75 MHz, CDCl3) δ 203.7, 156.2, 
143.6, 141.3, 127.8, 127.1, 125.0, 119.9, 79.3, 66.8, 58.0, 55.4, 47.2, 39.5, 30.3, 29.7, 
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28.4, 22.1. 
N-α-Fmoc-isopropylalanylazidoketone (3f). Yield = 72%. 1H-NMR (500 MHz, 
CDCl3) δ 0.86 (d, J = 6.30 Hz, 3H), 1.00 (d, J = 6.30 Hz, 3H), 2.13-2.17 (m, 1H), 4.01 
(d, J = 7.55 Hz, 2H), 4.21 (t, J = 6.30 Hz, 1H), 4.32 (t, J = 4.10 Hz, 1H), 4.39-4.47 (m, 
2H), 5.27 (d, J = 8.20 Hz, 1H), 7.33 (t, J = 7.55 Hz, 2H), 7.41 (t, J = 7.25 Hz, 2H), 
7.58 (d, J = 5.65 Hz, 2H), 7.77 (d, J = 7.55 Hz, 2H); 
13
C-NMR (125 MHz, CDCl3) δ 
203.1, 156.4, 143.6, 141.4, 127.8, 127.1, 125.0, 120.0, 67.0, 62.6, 56.4, 47.3, 30.1, 
19.6, 17.1. 
General procedure for synthesis of α-azido alcohols 4(a-f): 
    α-azido ketones 3 (5 mmol) was dissolved in 20 mL of THF followed by 
addition of sodium borohydride (6 mmol) in 2 mL H2O at 0 
o
C. The reaction mixture 
was then stirred for 1 h and neutralized with aqueous 1 N HCl. After extraction 
washed with brine and dried over anhydrous Na2SO4, and concentrated under reduced 
pressure. Purification by silica-gel chromatography with hexane/EtOAc (85:15) 
afforded bromomethyl alcohol 4 in 50-70%. 
N-α-Fmoc-phenylalanylazidoalcohol (4a). Yield = 55%. 1H-NMR (500 MHz, CDCl3) 
δ 2.84-2.93 (m, 2H), 3.26 (t, J = 6.30 Hz, 1H), 3.35 (s, 1H), 3.69-3.89 (m, 2H), 
4.12-4.17 (m, 1H), 4.40-4.43 (m, 2H), 4.76 (d, J = 6.95 Hz, 1H), 5.07 (d, J = 8.80 Hz, 
1H), 7.14-7.31 (m, 7H), 7.40 (t, J = 7.25 Hz, 2H), 7.46-7.55 (m, 2H), 7.75 (d, J = 6.95 
Hz, 2H); 
13
C-NMR (125 MHz, CDCl3) δ 156.5, 143.7, 141.4, 137.0, 129.3-126.7(m), 
124.9, 119.9, 72.2, 66.5, 54.9, 54.1, 47.3, 38.3; LC-MS: m/z [M+Na]
+
 = 451.175. 
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N-α-Fmoc-isobutylalanylalanylazidoalcohol (4b). Yield =96%. 1H-NMR (500 MHz, 
CDCl3) δ 0.91 (d, J = 3.80 Hz, 6H), 1.24-1.36 (m, 2H), 1.48-1.57 (m, 1H), 3.19-3.31 
(m, 2H), 3.71-3.76 (m, 2H), 4.19 (t, J = 5.97 Hz, 1H), 4.45-4.50 (m, 1H), 4.52-4.56 
(m, 1H), 4.74 (t, J = 8.15 Hz, 1H), 4.86 (t, J = 9.50 Hz, 1H), 7.31 (t, J = 7.25 Hz, 2H), 
7.39 (t, J = 6.95 Hz, 2H), 7.57 (d, J = 6.30 Hz, 2H), 7.75 (d, J = 7.55 Hz, 2H), 
13
C-NMR (125 MHz, CDCl3) δ 156.7, 143.7, 141.4, 127.7, 127.0, 124.8, 119.9, 73.5, 
66.3, 53.7, 52.4, 47.4, 24.6, 23.2, 21.5; LC-MS: m/z [M+Na]
+
 = 417.189. 
N-α-Fmoc-methylalanylazidoalcohol (4c). Yield = 75%. 1H-NMR (300 MHz, CDCl3) 
δ 1.18 (d, J = 5.91 Hz, 3H), 3.25-3.33 (m, 2H), 3.65-3.79 (m, 2H), 4.24 (t, J = 6.24 Hz, 
1H), 4.55 (d, J = 6.72 Hz, 1H), 5.00 (s, 1H), 7.33-7.47 (m, 4H), 7.62 (d, J = 7.41 Hz, 
2H), 7.81 (d, J = 7.56 Hz, 2H); 
13
C-NMR (75 MHz, CDCl3) δ 157.5, 142.6, 139.4, 
137.4, 128.9, 127.3, 121.4, 120.0, 109.6, 72.0, 53.3, 48.9, 16.7. 
N-α-Fmoc-4-tert-butoxy-phenylalanylazidoalcohol (4d): Yield = 90%. 1H-NMR (500 
MHz, CDCl3) δ 1.30 (s, 9H), 2.78-2.84 (m, 2H), 3.25-3.32 (m, 2H), 3.72-3.78 (m, 2H), 
4.11-4.17 (m, 1H), 4.39-4.45 (m, 2H), 4.79 (d, J = 6.95 Hz, 1H), 5.08 (d, J = 8.85 Hz, 
1H), 6.88 (d, J = 7.55 Hz, 2H), 7.02-7.07 (m, 2H), 7.30 (t, J = 7.23 Hz, 2H), 7.39 (t, J 
= 7.25 Hz, 2H), 7.51 (t, J = 7.55 Hz, 2H), 
13
C-NMR (125 MHz, CDCl3) δ 156.4, 
154.2, 143.6, 141.4, 132.2-124.8(m), 124.2, 119.9, 78.4, 72.1, 66.5, 54.9, 54.2, 47.3, 
35.2, 28.8; LC-MS: m/z [M+Na]
+
 = 523.207. 
N-α-Fmoc-4-Boc-butylalanylazidoalcohol (4e). Yield = 88%. 1H-NMR (500 MHz, 
CDCl3) δ 1.23-1.28 (m, 4H), 1.45 (s, 9H), 3.00-3.09 (m, 2H), 3.24-3.28 (m, 2H), 
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3.48-3.75 (m, 2H), 4.19 (t, J = 6.3 Hz, 1H), 4.42-4.61 (m, 2H), 5.01 (s, 1H), 5.13 (d, J 
= 8.85 Hz, 1H), 7.31 (t, J = 7.55 Hz, 2H), 7.40 (t, J = 7.55 Hz, 2H), 7.58 (d, J = 6.95 
Hz, 2H), 7.76 (d, J = 7.55 Hz, 2H); 
13
C-NMR (125 MHz, CDCl3) δ 156.5, 143.7, 
141.3, 127.7, 127.0, 124.9, 119.9, 79.3, 73.1, 66.4, 60.4, 53.9, 47.4, 39.5, 31.3, 29.5, 
22.4, 20.9; LC-MS: m/z [M+H]
+
 = 410.205. 
N-α-Fmoc-isopropylalanylazidoalcohol (4f). Yield = 79%. 1H-NMR (500 MHz, 
CDCl3) δ 0.72 (d, J = 9.55 Hz, 6H), 2.58 (d, J = 5.65 Hz, 1H), 3.19-3.41 (m, 2H), 
3.53-3.58 (m, 1H), 3.67 (s, 1H), 4.49 (t, J = 5.98 Hz, 1H), 4.59-4.64 (m, 2H), 7.33 (t, 
J = 7.57 Hz, 2H), 7.40 (t, J = 3.78 Hz, 2H), 7.59 (t, J = 5.98 Hz, 2H), 7.77 (d, J = 7.55 
Hz, 2H); 
13
C-NMR (125 MHz, CDCl3) δ 157.1, 143.7, 141.5, 127.7, 127.1, 124.9, 
120.0, 71.2, 66.3, 58.6, 54.4, 47.5, 28.0, 20.0; LC-MS: m/z [M+Na]
+
 = 403.154. 








































45-60% yield over 3 steps  
Scheme 8.2 Synthesis of the C-terminal warhead building blocks 8(a-d). 
General procedure for synthesis of α-azido acid 5(a-d): 
    The diazo transfer reaction was performed according to the reported procedure.
111
 
L-Amino acids (10 mmol, 1.0 eqv) was combined with K2CO3 (15 mmol, 1.5 eqv) and 
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CuSO4 pentahydrate (0.1 mmol, 0.01 eqv), distilled H2O (20 mL), and CH3OH (40 
mL). Triflyl azide in CH2Cl2 (20 mmol, 2 equiv.) prepared according to the reported 
procedure was added with stirring, and the resulting mixture was stirred at ambient 
temperature overnight. Subsequently, the organic solvents were removed under 
reduced pressure and the aqueous slurry was diluted with H2O (50 mL). This slurry 
was then acidified to pH 6 with 2N HCl aqueous solution and diluted with 0.25 M, pH 
6.2 phosphate buffer (50 mL) and extracted with EtOAc to remove the sulfonamide 
byproduct. The aqueous phase was then acidified to pH 2 with 2N HCl aqueous 
solution. The product was obtained from another round of EtOAc extractions. The 
EtOAc extracts were combined, dried with anhydrous Na2SO4 and evaporated to 
dryness giving the α-azido acid 5(a-d) in 70-85% yield. 
2-azido-3-phenylpropanoic acid (5a). Yield = 84%. 
1
H-NMR (300 MHz, CDCl3) δ 
3.04 (dd, J = 13.98, 8.88 Hz, 1H), 3.24 (dd, J = 13.98, 4.92 Hz, 1H), 4.13-4.18 (m, 
1H), 7.25-7.33 (m, 5H); 
13
C-NMR (75 MHz, CDCl3) δ 175.6, 135.6, 129.2, 128.7, 
127.4, 63.1, 37.5; LC-MS: m/z [M-H]
--
= 190.1. 
2-azido-4-methylpentanoic acid (5b). Yield = 73%. 
1
H-NMR (300 MHz, CDCl3) δ 
0.99 (d, J = 6.95 Hz, 6H), 1.68-1.78 (m, 2H), 1.80-1.85 (m, 1H), 3.86-3.89 (m, 1H), 
10.77 (br s, 1H); LC-MS: m/z 2[M+H]
+
 = 313.0. 
2-azidopropanoic acid (5c). Yield = 75%. 
1
H-NMR (500 MHz, CDCl3) δ 1.54 (d, J = 
6.95 Hz, 3H), 4.02-4.06 (m, 1H), 10.6 (brs, 1H); 
13
C-NMR (125 MHz, CDCl3) δ 
176.9, 57.0, 16.5. 
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2-azido-3-(4-tert-butoxyphenyl)propanoic acid (5d). Yield = 80%. 
1
H-NMR (300 
MHz, CDCl3) δ 1.34 (s, 9H), 2.99 (dd, J = 13.92, 8.70 Hz, 1H), 3.19 (dd, J = 14.28, 
4.89 Hz, 1H), 4.09-4.14 (m, 1H), 6.74 (d, J = 8.70 Hz, 2H), 7.15 (d, J = 8.37 Hz, 2H), 
8.24 (brs, 1H); 
13
C-NMR (75 MHz, CDCl3) δ 174.8, 154.4, 130.6, 129.7, 124.4, 78.9, 
63.2, 36.9, 28.8. 
General procedure for synthesis of α-azido bromomethyl ketones 7(a-d): 
    Isobutyl chloroformate (9.6 mmol, 1.2 eqv) was added to a solution of α-azido 
acid 5(a-d) (8.0 mmol, 1.0 eqv) and N-methylmorpholine (9.6 mmol, 1.2 eqv) in THF 
(20 mL) at -40 
o
C, and the reaction mixture was stirred for 15 min. The reaction 
mixture was then filtered and diazomethane (4.0 eqv, made from 
1-methyl-3-nitro1-nitrosoguanidine and of 40 wt% aqueous KOH in EtOH) was 
added slowly into the filtrate. The reaction mixture was stirred for 2-3 h at 0
 o
C. After 
completion of reaction, the solvent was evaporated under vacuum and the residue was 
dissolved in DCM followed by the treatment with 48% HBr aq (1.2 eqv) at 0 
o
C. The 
reaction mixture was then stirred for 3 h. After completion of the reaction, it was 
diluted with 15 wt% aqueous citric acid and extracted with DCM. The organic layer 
was washed with saturated sodium bicarbonate and brine. Finally, it was dried over 
anhydrous sodium sulfate, filtered, concentrated and purified by silica-gel 
chromatography with 80:20 hexane/EtOAc afforded α-azido bromomethyl ketones 
7(a-d) in 60-93%. 
3-azido-1-bromo-4-phenylbutan-2-one（7a） Yield = 74%. 1H-NMR (300 MHz, 
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CDCl3) δ 2.99 (d, J = 8.55 Hz, 1H), 3.25 (d, J = 5.58 Hz, 1H), 3.86 (d, J = 4.59 Hz, 
1H), 3.95 (d, J = 6.06 Hz, 1H), 4.35-4.40 (m, 1H), 7.25-7.36 (m, 5H); 
13
C-NMR (75 
MHz, CDCl3) δ 198.3, 135.3, 129.2-128.6(m), 127.5, 66.8, 37.5, 32.3. 
3-azido-1-bromo-5-methylhexan-2-one (7b). Yield = 65%. 
1
H-NMR (300 MHz, 
CDCl3) δ 0.73-1.17 (m, 6H), 1.62 (t, J = 7.48 Hz, 2H), 1.80-1.88 (m, 1H), 3.38 (t, J = 
5.91 Hz, 1H), 4.05 (d, J = 6.27 Hz, 1H), 4.19 (d, J = 7.68 Hz, 1H); 
13
C-NMR (75 
MHz, CDCl3) δ 198.9, 64.7, 40.6, 32.7, 25.4, 23.5, 22.7. 
3-azido-1-bromo-5-methy-2-one (7c). Yield = 60%. 
1
H-NMR (500 MHz, CDCl3) δ 
1.52 (d, J = 6.30 Hz, 3H), 4.08-4.11 (m, 1H), 4.29-4.31 (m, 1H); 
13
C-NMR (125 MHz, 
CDCl3) δ 198.8, 61.0, 31.2, 15.8. 
3-azido-1-bromo-4-(4-tert-butoxyphenyl)butan-2-one (7d). Yield = 93%. 
1
H-NMR 
(300 MHz, CDCl3) δ 1.40 (s, 9H), 2.93-3.01 (m, 1H), 3.09-3.23 (m, 1H), 3.79 (t, J = 
11.26 Hz, 1H), 3.90-4.09 (m, 1H), 4.17-4.34 (m, 1H), 6.96(d, J = 8.22 Hz, 2H), 7.12 
(d, J = 8.40 Hz, 2H); 
13
C-NMR (75 MHz, CDCl3) δ 198.4, 154.8, 129.8, 124.4, 66.9, 
36.9, 28.5, 18.8. 
General procedure for synthesis of α-azido bromomethyl alcohol 8(a-d): 
To the solution of α-azido bromomethyl ketones 7(a-d) (8 mmol, 1 eqv) in 20 
mL of 95:5 THF/H2O, sodium borohydride (12 mmol. 1.5 eqv) was added gradually 
at 0 
o
C. The reaction mixture was stirred for 1 h and then was neutralized with 
aqueous 1N HCl. After extraction with EtOAc, the organic extracts were washed with 
brine, dried with Na2SO4, and concentrated under reduced pressure. Purification by 
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silica-gel chromatography with hexanes/EtOAc (80:20) afforded compound 8(a-d) as 
white solid. 
α-azido bromomethyl-Phe-alcohol (8a). Yield = 75%. 1H-NMR (300 MHz, CDCl3) δ 
2.40 (d, J = 4.44 Hz, 1H), 2.80-3.18 (m, 2H), 3.48-3.52 (m, 1H), 3.65 (d, J = 6.09 Hz, 
1H), 7.29-7.35 (m, 5H); 
13
C-NMR (75 MHz, CDCl3) δ 136.9, 136.6-128.6 (m), 127.0, 
126.9, 72.1, 65.9, 64.8, 37.0, 35.2. LC-MS: m/z [M+Na]
+ 
= 293.990. 
α-azido bromomethyl-Leu-alcohol (8b). Yield = 90%. 1H-NMR (500 MHz, CDCl3) δ 
0.97 (d, J = 2.50 Hz, 6H), 1.38-1.49 (m, 1H), 1.60-1.69 (m, 1H), 1.73-1.84 (m, 1H), 
2.53 (d, J = 5.65 Hz, 1H), 3.31-3.54 (m, 2H), 3.56-3.72 (m, 1H); 
13
C-NMR (125 MHz, 
CDCl3) δ 73.4, 62.9, 39.8, 36.6, 25.3, 23.3, 21.8. LC-MS: m/z 2[M]
+ 
= 388.089. 
α-azido bromomethyl-Ala-alcohol (8c). Yield = 80%. 1H-NMR (500 MHz, CDCl3) δ 
1.36 (d, J = 6.57 Hz, 3H), 2.37 (t, J = 5.43 Hz, 1H), 3.41-3.78 (m, 4H); 
13
C-NMR 




α-azido bromomethyl-Tyr(tBu)-alcohol (8d). Yield = 77%. 1H-NMR (300 MHz, 
CDCl3) δ 1.33 (s, 9H), 2.51 (dd, J = 5.07 Hz, 1H), 2.79 (d, J = 5.66 Hz, 1H), 
2.90-3.14 (m, 2H), 3.52-3.59 (m, 1H), 3.63-3.75 (m, 2H), 6.96 (d, J = 8.40 Hz, 2H), 
7.17 (d, J = 6.60 Hz, 1H); 
13
C-NMR (75 MHz, CDCl3) δ 154.3, 146.9, 
131.8-131.5(m), 129.8, 124.5, 72.2, 71.9, 69.2, 65.0, 37.3, 36.4, 28.8. 
8.2.4 Synthesis of Rhodamine/biotin Bp Alkyne Compounds 




















































































Scheme 8.3 Synthetic scheme of rhodamine and biotin alkyne compounds. 
    Alkyne 6 and 7 were synthesized according to published procedures with some 
modifications. Couplings of 4 with rhodamine derivative 5 or biotin acid afford 
alkyne 6 and 7, respectively. Column purification (5%-10% MeOH/DCM) was 
carried out to isolate the pure product. 
NHS ester (2): To a solution of 6-aminohexanoic acid 1 (6.56 g, 50 mmol) and NaOH 
(2 M, 40 mL) in dioxane/water (2/1; 150 mL) at 0 °C was added (Boc)2O (13.1 g, 60 
mmol). The reaction was allowed to proceed at r.t. overnight. Subsequently, dioxane 
was removed under reduced pressure and the resulting mixture was acidified to pH 2 
with 1 M HCl, followed by extraction with EA (3×50 ml). The combined organic 
layers were dried over Na2SO4, filtered and concentrated to afford colorless oil, which 
was subsequently reacted with NHS (6.72 g, 58 mmol) and EDC (11.2 g, 58 mmol) in 
DMF at r.t. overnight. Upon column purification (20 - 40% EA/hexane), the desired 
product 2 was obtained as colorless oil (11.5 g, 35.0 mmol, 70%). 
1
H-NMR (300 
MHz, CDCl3) δ 4.60 (br s, 1H), 3.16-3.05 (m, 2H), 2.82 (s, 4H), 2.60 (t, J = 7.49 Hz, 
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2H), 1.81-1.70 (m, 2H), 1.51-1.40 (m, 13H); ESI-MS: m/z [M+Na]
+
 = 351.3. 
3-(4-benzoylphenyl)-2-(6-(tert-butoxycarbonyl) hexanamido) propanoic acid (3): 
Compound 2 (1.64 g, 5 mmol) dissolved in 15 mL DMF was added H-p-Bz-Phe-OH 
(1.35 g, 5 mmol) and DIEA (1.05 ml, 6 mmol). The reaction mixture was stirred 
under N2 overnight. After that, DMF was removed in vacuo. The residue was taken 
into EA and washed with 1 M HCl. The EA layer was dried over Na2SO4, filtered and 
concentrated. Upon column chromatography (5-10 % MeOH/DCM), the final product 
3 was obtained as colorless oil (1.98 g, 4.10 mmol, 82%). 
1
H-NMR (300 MHz, CDCl3) 
δ 8.08 (s, 1H), 7.74-7.66 (m, 4H), 7.63-7.56 (m, 1H), 7.49-7.44 (m, 2H), 7.31-7.26 (m, 
2H), 4.83 (br s, 1H), 3.41-2.96 (m, 2H), 2.21-2.05 (m, 2H), 1.61-1.47 (m, 2H), 




de (4): To compound 3 (1.93 g, 4 mmol) dissolved in DMF was added HBTU (1.90 g, 
5 mmol) and DIEA (0.87 ml, 5 mmol) at 0 
o
C. The mixture was stirred for 10 min 
before addition of propylamine (0.28 g, 5 mmol). The mixture was further agitated for 
another 12 h at r.t., after which DMF was removed in vacuo and the residue was taken 
into ethyl acetate (50 mL). The organic layer was washed with saturated NaHCO3 
(2×30 mL), 1 M HCl (2×30 mL), brine (2×30 mL), dried over anhydrous Na2SO4, and 
concentrated under reduced pressure to afford a yellow oily product. Purification of 
this compound by flash chromatography (silica gel, ethyl acetate/hexane = 3:1) 
afforded the intermediate as a white solid (1.65 g, 3 mmol, 75%). 
1
H-NMR (300 MHz, 
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CDCl3) δ 7.77-7.69 (m, 4H), 7.58 (t, J = 7.49 Hz, 1H), 7.46 (t, J = 7.49 Hz, 2H), 7.29 
(t, J = 8.19 Hz, 2H), 6.98 (t, J = 5.1 Hz, 1H), 6.63 (d, J = 7.65 Hz, 1H), 4.86-4.78 (m, 
1H), 3.89-4.05 (m, 2H), 4.05- 3.89 (m, 2H), 3.21-3.02 (m, 4H), 2.20-2.16 (m, 2H), 
1.62-1.52 (m, 2H), 1.30 (s, 12H), 1.27-1.23 (m, 2H). 
13
C-NMR (75 MHz, CDCl3) δ 
196.3, 173.3, 170.6, 141.3, 156.1, 141.5, 137.5, 136.3, 132.4, 130.4, 129.9, 129.3, 
128.3, 79.0, 71.7, 53.8, 40.3, 38.3, 36.1, 29.6, 29.1, 28.4, 26.1, 25.0. 
Deprotection of above intermediate (1.56 g, 3 mmol) with TFA (10 eq) in DCM gave 
4 as yellow oil (1.26 g, 3 mmol, ~100%). 
1
H-NMR (300 MHz, MeOD) δ 7.76-7.69 (m, 
4H), 7.63 (d, J = 7.32 Hz, 1H), 7.52 (t, J = 7.49 Hz, 2H), 7.42 (d, J = 8.01 Hz, 2H), 
4.85- 4.69 (m, 1H), 3.95 (t, J = 2.63 Hz, 2H), 3.31-3.19 (m, 1H), 3.30-2.94 (m, 1H), 
2.91-2.85 (m, 2H), 2.63-2.58 (m, 1H), 2.21-2.16 (m, 2H), 1.55-1.38 (m, 4H); 
13
C-NMR (75 MHz, CDCl3) δ 198.3, 175.9, 172.9, 143.9, 138.9, 137.3, 133.8, 131.2, 
130.9, 130.5, 129.5, 80.3, 72.3, 55.4, 42.0, 39.1, 36.6, 32.6, 31.0, 29.5, 27.9, 27.3, 
26.5, 14.5. 
Alkyne 6: Yield: 50 %. 
1
H-NMR (300 MHz, MeOD) δ 7.62-7.47 (m, 7H), 7.47-7.36 
(m, 1H), 7.34 (d, J = 8.01 Hz, 1H), 7.21 (d, J = 9.39 Hz, 1H), 7.00 (d, J = 8.34 Hz, 
1H), 4.15 (d, J = 5.58 Hz, 4H), 3.88 (s, 1H), 3.63-3.58 (m, 4H), 3.41-3.19 (m, 4H), 
3.31-2.90 (m, 2H), 2.52 (s, 1H), 2.38-2.09 (m, 2H), 1.39-1.21 (m, 8H), 0.91-0.84 (m, 
14H); 
13
C-NMR (75 MHz, CDCl3) δ 172.9, 169.3, 159.3, 157.1, 143.9, 138.9, 136.8, 
133.6, 133.2, 131.5, 130.5, 129.7, 128.9, 115.4, 114.9, 97.4, 80.4, 72.3, 69.1, 55.4, 
46.9, 40.2, 39.0, 36.6, 31.6, 30.7, 30.1, 29.7, 27.3, 26.4, 24.9, 23.9, 14.4, 12.8, 11.4. 




Alkyne 7: Yield: 80 %. 
1
H-NMR (300 MHz, DMSO-d6) δ 9.05 (s, 1H), 8.67-7.34 (m, 
3H), 8.16-8.09 (m, 6H), 8.04 (t, J = 7.44 Hz, 2H), 7.88 (d, J = 8.19 Hz, 2H), 5.82(s, 
2H), 5.15-5.02 (m, 1H), 4.59-4.82 (m, 2H), 4.25-4.58 (m, 2H), 3.88-3.51 (m, 4H), 
3.41-3.24 (m, 7H), 2.08-1.94 (m, 4H), 1.94-1.45 (m, 12H); 
13
C-NMR (75 MHz, 
CDCl3) δ 195.5, 171.9, 170.9, 162.5, 143.3, 137.3, 135.1, 133.3, 132.5, 129.4, 128.5, 
124.5, 119.1, 115.4, 109.7, 80.9, 73.1, 61.1, 59.3, 55.4, 53.3, 40.3, 40.1, 38.9, 37.7, 




































































































Scheme 8.4 Synthesis of two biotin linkers. 
Biotin acid (9). Compound 9 was synthesized according to previous report with some 
modification.
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 To a solution of D-biotin (12 g, 50 mmol) in DMF was added 
N-hydroxysuccinimide (7 g, 60 mmol) and EDC (11.5 g, 60 mmol). The reaction was 
allowed to proceed overnight. The resulting mixture was dried in vacuo to remove 
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DMF. The gel-like residue was recrystallized from EtOH/Acetic acid/H2O (95:1:4) to 
afford biotin-NHS as a white solid (14 g; 80% yield). To a solution of 
6-aminohexanoic acid (1.3 g, 10 mmol) in 30 ml of 1:1 Dioxane/water co-solvent, the 
pH of the solution was adjusted to 8~8.5 by using a 4 M NaOH solution at 0 
o
C. 
Biotin-NHS (3.4 g, 10 mmol) was subsequently added, and the reaction mixture was 
stirred at r.t. overnight. The resulting gelatinous solid formed was added ether, stirred 
for 5 minutes. The supernatant ether was decanted followed by addition of acetone 
and adjusting the pH of the resulting solution to 3 using 2 M HCl at 0 
o
C. Finally, the 
solid was filtered, washed several times with MeOH to afford the pure compound 9 as 
a white solid (2.85 g, 80%). 
1
H-NMR (300 MHz, CDCl3) δ 1.23-1.62 (m, 12H), 2.04 
(t, J = 7.41 Hz, 2H), 2.19 (t, J = 7.23 Hz, 2H), 2.57 (d, J = 12.15 Hz, 1H), 2.82 (dd, J 
= 12.48, 4.92 Hz, 1H), 2.97-3.16 (m, 3H), 4.13 (t, J = 4.29 Hz, 1H), 4.30 (t, J = 7.38 
Hz, 1H), 6.43 (s, 2H), 7.73 (t, J = 5.28 Hz, 1H); 
13
C-NMR (75 MHz, CDCl3) δ 174.8, 




Biotin PEG acid(14). Compound 14 was synthesized according to published 
procedures with some modifications,
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as follows. 
Compound 10. To a stirred solution of diol (1 mmol) in CH2Cl2 (10 mL) was added 
fresh Ag2O (0.35 g, 1.5 mmol), TsCl (0.21 g, 1.1 mmol), and KI (0.033 g, 0.2 mmol). 
The reaction mixture was stirred at r.t. for 8 h, then filtered through a small pad of 
silica gel, and washed with EtOAc. Evaporation of the solvent, followed by column 
chromatography, gave the desired monotosylate product 10 (Yield = 70%). 
1
H-NMR 
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(300 MHz, CDCl3) δ 2.43 (s, 3H), 3.27(s, 1H), 3.57-3.68 (m, 14H), 4.15 (t, J = 4.44 
Hz, 2H), 7.34 (d, J = 8.22 Hz, 2H), 7.78 (d, J = 8.04 Hz, 2H); 
13
C-NMR (75 MHz, 
CDCl3) δ 144.4, 132.4, 129.4, 127.4, 72.0, 70.0-68.9(m), 68.1, 60.9, 21.1. 
Compound 11. To a solution of 10 (10 mmol) in DMF, NaN3 (30 mmol) was added. 
The reaction was then stirred for 8 h at 80 
o
C. After completation of reaction, DMF 
was firstly removed under high vacuum, and the residue was purified by column 
chromatography to afford the desired product in 80% yield. 
1
H-NMR (300 MHz, 
CDCl3) δ 3.39 (t, J = 5.10 Hz, 2H), 3.59 (t, J = 4.92 Hz, 2H), 3.67-3.71 (m, 10H); 
13
C-NMR (75 MHz, CDCl3) δ 72.4, 69.8-70.4(m), 61.3, 50.4. 
Compound 12. To a solution of 11 (10 mmol) in DMF, Pyridinium dichromate (PDC) 
(50 mmol) was added at 0 
o
C. Then the reaction was stirred overnight at r.t. After 
completation of reaction, a lot of brine was added to quench the reaction followed by 
EA extraction. The extrate was dried by Na2SO4, filtrated and evaporated under high 
vacuum. Finally the residue was purified by column chromatography to afford the 
desired product 12 in 55% yield. 
1
H-NMR (300 MHz, CDCl3) δ 3.40 (t, J =4.65 Hz, 
2H), 3.68-3.72 (m, 10H), 4.14 (s, 2H), 8.02 (s, 1H); 
13
C-NMR (75 MHz, CDCl3) δ 
172.1, 69.5-72.1(m), 68.0, 63.5, 50.2. 
Compound 13 & 14. To a solution of 12 (10 mmol) in MeOH, Pd/C (20%w) was 
added at r.t. The reaction was then stirred overnight. After completation of reaction, 
Pd/C was filtrated by celite. The filtrate was evaporated and the residue was purified 
by column chromatography to afford compound 13 in 70% yields. To a solution of 
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above PEG amino acid in 30 mL of 1:1 dioxane/water co-solvent, the pH of the 
solution was adjusted to 8~8.5 by using a 4 M NaOH solution at 0 
o
C. Biotin-NHS 
(3.4 g, 10 mmol) was subsequently added, and the reaction mixture was stirred at r.t. 
overnight. The resulting gelatinous solid formed was added ether, stirred for 5 mins. 
The supernatant ether was decanted followed by addition of acetone and adjusting the 
pH of the resulting solution to 3 using 2 M HCl at 0 
o
C. Finally, the solid was filtered, 
washed several times with MeOH to afford the pure compound 14 as a white solid in 
85% yield. 
1
H-NMR (300 MHz, CDCl3) δ 1.34-1.69 (m, 6H), 2.15 (t, J = 6.99 Hz, 
2H), 2.56-2.61 (m, 1H), 2.77-2.92 (m, 2H), 3.11-3.15 (m, 4H), 3.22-3.66 (m, 8H), 
4.05 (s, 2H), 4.21-4.25 (m, 2H), 4.40-4.79 (m, 2H); 
13
C-NMR (75 MHz, CDCl3) δ 
176.2, 174.23, 167.7, 70.2-71.7(m), 69.2, 63.3, 61.6, 56.9, 41.0, 40.4, 36.7, 36.2, 33.8, 
31.4, 29.5, 26.7, 25.6; LC-MS: m/z [M+H]
+ 
= 434.134. 







    To a solution of 5-(tert-butoxy)-4-((tert-butoxycarbonyl)amino)-5-oxopentanoic 
acid (10.3 g, 33.9 mmol) in DCM, N-methylmorpholine (9.3 mL, 84.8 mmol) and 
isobutyl chloroformate (6.0 mL, 46.2 mmol) were added at 0 °C. After stirring for 0.5 
h at 0 °C, N, O-dimethylhydroxylamine (3.9 g, 40.0 mmol) was added slowly, and the 
reaction was then warmed up to r. t. and stirred for further 4 h. After that, pH of the 
reaction mixture was adjusted to 7 with HCl (1 M) and extracted with DCM (300 
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mL×3). The organic layer was then dried with Na2SO4, concentrated and purified with 
flash chromatography (hexane: EtOAc=10:1/5:1) to give the product 2 (9.17 g, 
78.4%). 
1
H NMR (300 MHz, CDCl3) δ 5.24 (d, J = 8.1 Hz, 1H), 4.12 (d, J = 4.5 Hz, 
1H), 3.61 (s, 3H), 3.10 (s, 3H), 2.44 (m, 2H), 2.05 (m, 1H), 1.90 (m, 1H), 1.40 (s, 9H), 
1.37 (s, 9H); 
13
C NMR (300 MHz, CDCl3) δ 173.4, 171.3, 155.3, 81.6, 79.2, 61.0, 


























































































































































    To a solution of compound 2 (9.17 g, 26.5 mmol) in toluene (200 mL), 
methylmagnesium bromide (40 mL, 3M solution in hexanes) was added at -78 °C. 
The resulting mixture was then stirred for 3 h with the temperature up to -5 °C. 
Subsequently, the reaction was quenched by addition of water (20 mL) at -5 °C 
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followed by extraction with EtOAc (200 mL×3). The separated organic layer was 
washed with brine (200 mL×3) and dried with Na2SO4, concentrated and purified with 
flash chromatography (hexane:EtOAc=10:1/5:1) to give the desired product 3 (5.83 g, 
73.1%). 
1
H NMR (300 MHz, CDCl3) δ 5.10 (s, 1H), 4.09 (s, 1H), 2.42-2.55 (m, 2H), 
2.12 (s, 3H), 2.05-2.07 (m, 1H), 1.78-1.85 (m, 1H), 1.42 (s, 18 H); 
13
C NMR (300 







    Compound 3 (5.83 g, 19.3 mmol) was added to liquid ammonia (20 mL) at 
-78 °C. The reaction mixture was stirred overnight in the sealed tube. Subsequently, 
the reaction was cooled down to -78 °C, and hydroxylamine-O-sulfonic acid (2.60 g, 
23.0 mmol) in methanol (12 mL) was added over 30 min. The reaction mixture was 
then stirred overnight at r.t. while the ammonia was evaporated concurrently. The 
reaction mixture was filtrated and washed with methanol (30 mL×2). The combined 
methanol layer was then concentrated to half of the original volume. 50 mL of 
methanol was added to the residues and cooled down to 0 °C followed by addition of 
TEA (3.1 mL, 23.0 mmol). Subsequently, Iodine was added slowly until the brown 
color of solution formed. The reaction mixture was stirred for further 1 h at r.t, and 
concentrated under vacuum. The aqueous solution was then extracted with EtOAc 
(200 mL) and washed with brine (200 mL). After dried with Na2SO4, the organic layer 
was concentrated and purified with flash chromatography (hexane:EtOAc = 30:1/10:1) 
to give the product 4 (2.2 g, 36.4 %). 
1
H NMR (300 MHz, CDCl3) δ 5.08 (d, J = 7.8 
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Hz, 1H), 4.07 (s, 1H), 1.60-1.65 (m, 1H), 1.28-1.50 (m, 22H), 0.95 (s, 3H); 
13
C NMR 







    To a solution of compound 4 (2.2 g, 7.04 mmol) in THF (15 mL), HCl (4 M, 15 
mL) was added slowly at 0 °C. The resulting solution was stirred for 48 h at r. t. and 
the solvent was evaporated to give product 5 (1.0 g, 74.1%). 
1
H NMR (300 MHz, D2O) 







    To a solution of compound 5 (150 mg, 0.78 mmol) in water (5 mL), sodium 
hydroxide solution (80 mg, 2 mmol) was added at 0 °C followed by addition of 
(Boc)2O (170 mg, 0.78 mmol) in THF (10 mL). The resulting mixture was then stirred 
for 20 h at r.t. in the dark and concentrated under vacuum. The residue was 
re-dissolved in water (10 mL), and pH was adjusted to 6. Subsequently, the aqueous 
solution was extracted with EtOAc (20 mL×3) and the combined organic layer was 
dried with Na2SO4, concentrated, purified with flash chromatography to give the 
product 6b (180 mg, 90.0 %). 
1H NMR (300 MHz, MeOD) δ 4.05 (s, 1H), 1.24-1.71 
(m, 13H), 1.01 (s, 3H). 
2-chloro-N-(2-chloro-6-methylphenyl) thiazole-5-carboxamide (7). To a solution of 
2-chlorothiazole (7.96 g, 66.5 mmol) in THF (100 mL), n-butyllithium (1.6 M) in 
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hexanes (51 mL, 81.6 mmol) was added dropwise at -78
 
°C. Subsequently, 
1-chloro-2-isocyanato-3-methylbenzene (14.0 g, 83.8 mmol) in THF (20 mL) was 
added to the above mixture. After stirring for 2 h at -78 °C, the reaction was quenched 
with saturated aqueous NH4Cl (10 mL) followed by addition of water (300 mL) and 
EtOAc (500 mL). The organic layer was then separated and washed with brine (200 
mL×2), concentrated and purified with flash chromatography (hexane: 
EtOAc=10:1/5:1) to give the desired product 7 (17.0 g, 89.0 %). 
1
H NMR (300 MHz, 
CDCl3) δ 8.08 (s, 1H), 7.65 (br, 1H), 7.26-7.29 (m, 1H), 7.18 (d, J = 3.93 Hz, 2H), 
2.29 (s, 3H).; IT-TOF-MS: m/z [M+1]
+
 calcd: 285.98, Found: 286.98. 
2-chloro-N-(2-chloro-6-methylphenyl)-N-(4-methoxybenzyl)thiazole-5-carboxamide 
(8). To a solution of 7 (153 mg, 0.53 mmol) in acetone, 4-methoxybenzyl chloride 
(124 mg, 0.8 mmol) and cesium carbonate (335 mg, 1.08 mmol) were added. The 
resulting mixture was refluxed. After 10 h, the reaction was concentrated and purified 
with flash chromatography (hexane: EtOAc = 5:1) to give desired product 8 (200mg, 
92.5%). 
1
H NMR (300 MHz, CDCl3) δ 7.32 (s, 2H), 7.28 (d, J = 7.8 Hz, 1H), 7.15 (d, 
J = 8.7 Hz, 2H), 7.10 (d, J = 7.8 Hz, 1H), 6.76 (d, J = 8.4 Hz, 2H), 5.42 (d, J = 13.8 
Hz, 1H), 4.38 (d, J = 13.8 Hz, 1H), 3.77 (s, 3H), 1.57 (s, 3H). IT-TOF-MS: m/z 
[M+1]
+
 calcd: 407.04, Found: 407.03. 
Buchwald-Hartwig coupling reaction for synthesis of compound (9). Sodium hydride 
was added to THF dropwise at 0 °C followed by addition of 
4-amino-6-chloro-2-methylpyrimidine (11.2 g, 77.7 mmol). The mixture was then 
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stirred for 30 min at 0 °C followed by addition of compound 8 in THF (50 mL). The 
resulting mixture was refluxed for 4 h, and was cooled down to r.t. The reaction was 
then quenched with water (50 mL) at 0 °C, and acidified with 1M HCl. The mixture 
was extracted with CHCl3/MeOH (10:1) (200 mL×2). Subsequently, the combined 
organic layer was washed further with HCl (100 mL×2), dried over Na2SO4, 
concentrated to give the product 9 (11.4 g, 80.4%). 
1
H NMR (300 MHz, DMSO-d6) δ 
12.01 (s, 1H), 7.47 (d, J = 8.4 Hz, 1H), 7.42 (m, 2H), 7.30 (d, J = 8.4 Hz, 1H), 7.14 (d, 
J = 8.4 Hz, 2H), 6.81 (m, 3H), 5.21 (d, J = 14.1 Hz, 1H), 4.42 (d, J = 14.1 Hz, 1H), 
3.46 (s, 3H), 2.44 (s, 3H), 1.72 (s, 3H). IT-TOF-MS: m/z [M+1]
+ 
calcd: 514.09; Found: 
514.06. 
Deprotection of the 4-methoxybenzyl group to compound (10). To a solution of 
compound 9 in dichloromethane (80 mL), TFA (70 mL) and triflic acid (10 g, 66.6 
mmol) were added at r.t. After stirring for 9 h, the reaction was poured into ice 
cautiously, and washed with CHCl3 (200 mL×3). The combined organic layer was 
then concentrated and washed with the mixture of hexane and EtOAc (5:1, 200 mL). 
The solid was obtained by filtration, dried, to give the product 10 (8.2 g, 97.6 %). 
1
H 
NMR (300 MHz, DMSO-d6) δ 12.22 (br, 1H), 10.0 (s, 1H), 8.30 (s, 1H), 7.39-7.42 (m, 
1H), 7.25-7.28 (m, 2H), 6.94 (s, 1H), 2.58 (s, 3H), 2.23 (s, 3H). IT-TOF-MS: m/z 
[M+1]
+
 calcd: 394.03; Found: 394.02. 
2-((6-((2-aminoethyl)amino)-2-methylpyrimidin-4-yl)amino)-N-(2-chloro-6-methylph
enyl) thiazole-5-carboxamide (11). Compound 10 (500 mg, 1.26 mmol) was 
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suspended in the dioxane (2 mL) followed by addition of 1, 2-diaminoethane (8 mL). 
The resulting mixture was heated at 90 °C overnight. Subsequently, the solvent was 
evaporated under vacuum and potassium hydroxide aqueous solution (10 M) was 
added to pH 9. The mixture was finally filtrated and the resulting solid was washed 
with ether, dried, to give the yellow solid product 11 (400 mg, 76.2%.) 
1
H NMR (300 
MHz, DMSO-d6) δ 8.20 (s, 1H), 7.38-7.41 (m, 1H), 7.23-7.30 (m, 2H), 5.86 (s, 1H), 
3.37 (s, 2H), 2.85 (s, 2H), 2.36 (s, 3H), 2.24 (s, 3H); 
13
C NMR (300 MHz, DMSO-d6) 
δ 18.69, 25.77, 41.12, 55.26, 83.71, 125.74, 127.34, 128.47, 129.36, 132.84, 133.94, 
139.20, 141.28, 156.27, 160.38, 163.19, 163.60, 165.64. IT-TOF-MS: m/z [M+1]
+
 
calcd: 418.12; Found: 418.11. 
(9H-fluoren-9-yl)methyl(3-(4-benzoylphenyl)-1-((2-((6-((5-((2-chloro-6-methylpheny
l)carbamoyl)thiazol-2-yl)amino)-2-methyl-pyrimi-din-4-yl)amino)ethyl)amino)-1-oxo
propan-2-yl)carbamate (12a). To a solution of 2-((((9H-fluoren-9-yl)methoxy) 
carbonyl)amino)-3-(4-benzoylphenyl) propanoic acid 6a (270 mg, 0.55 mmol), 
coupling reagent HOBt (74 mg, 0.55 mmol), HBTU (208 mg, 0.55 mmol) and DIEA 
(141 mg, 1.1 mmol) were added. Compound 11 (417 mg, 0.5 mmol) was then added 
to the above solution and the reaction was stirred at r.t. overnight. Subsequently, the 
reaction was quenched with water at 0 °C and extracted with the mixture of CHCl3 
and methanol (10:1, 100 mL). The organic layer was washed with water (20 mL), 
sodium bicarbonate solution (20 mL), ammonium chloride solution (20 mL), brine 
(20 mL). The organic layer was concentrated and precipitated with hexane and EtOAc 
(1:1), filtrated, to give the product 12a (400 mg, 88.9%). 
1
H NMR (300 MHz, 
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DMSO-d6) δ 11.41 (s, 1H), 9.88 (s, 1H), 8.22 (s, 2H), 7.84 (d, J = 7.2 Hz, 2H), 
7.58-7.67 (m, 9H), 7.21-7.44 (m, 13H), 5.89 (s, 1H), 4.23-4.28 (m, 2H), 4.10-4.12 (m, 
2H), 3.11-3.32 (m, 1H), 2.72-3.08 (m, 2H), 2.35 (s, 3H), 2.22 (s, 3H). IT-TOF-MS: 
m/z [M+1]
+
 calcd: 891.28; Found: 891.26. 
2-((6-((2-(2-amino-3-(4-benzoylphenyl)propanamido)ethyl)amino)-2-methylpyrimidi
n-4-yl)amino)-N-(2-chloro-6-methylphenyl)thiazole-5-carboxamide (13a). To a 
solution of compound 12a (387 mg, 0.43 mmol) in DMF (10 mL), TBAF (1 M in 
THF, 1 mL) was added and the reaction was stirred for 0.5 h at r.t. The reaction was 
monitored by LC-MS. The product was used for next step without further purification. 
IT-TOF-MS: m/z [M+1]
+
 calcd: 669.22; Found: 669.19. 
DA-1(1a). To a solution of hex-5-ynoic acid (50 mg, 0.44 mmol) in DMF (10 mL), 
coupling reagent HBTU (179 mg, 0.47 mmol), HOBt (67 mg, 0.5 mmol) and DIEA 
(110 mg, 0.92 mmol) were added. The resulting mixture was stirred for 0.5 h at r.t. 
and added to the previous step crude product. The resulting reaction was stirred 
overnight at r.t. followed by quenching with water (20 mL). The reaction was then 
extracted with CHCl3: Methanol (10:1, 20 mL×3) and the combined organic layer was 
concentrated, purified with flash chromatography (DCM:MeOH = 15:1) to give the 
product DA-1 (60 mg, 18.3 % for the two steps). 
1
H NMR (300 MHz, DMSO-d6) δ 
11.37 (s, 1H), 9.82 (s, 1H), 8.12-8.16 (m, 3H), 7.61-7.68 (m, 5H), 7.40-7.52 (m, 2H), 
7.38 (d, J = 8.1 Hz, 2H), 7.26-7.36 (m, 2H), 7.15 (brs, 1H), 5.85 (s, 1H), 3.15 (m, 1H), 
2.70-2.84 (m, 1H), 2.71 (s, 1H), 2.34 (s, 3H), 2.22 (s, 3H), 2.13 (s, 2H), 1.96-1.98 (m, 
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2H), 1.52-1.57 (m, 2H), 1.23 (s, 1H), 0.85 (m, 1H). 
13
C NMR (300 MHz, DMSO-d6) δ 
195.4, 171.4, 171.1, 165.3, 163.0, 162.7, 159.9, 143.4, 140.8, 138.8, 137.2, 135.0, 
133.5, 132.4, 129.5, 129.3, 129.0, 128.5, 127.0, 84.0, 71.3, 53.6, 37.8, 34.0, 25.4, 24.2, 
22.0, 18.3, 17.2, 13.9. IT-TOF-MS: m/z [M+1]
+
 calcd: 763.26; Found: 763.24. 
Tert-butyl(1-((2-((6-((5-((2-chloro-6-methylphenyl)carbamoyl)thiazol-2-yl)amino)-2-
methyl-pyrimidin-4-yl)amino)ethyl)amino)-4-(3-methyl-3H-diazirin-3-yl)-1-oxobutan
-2-yl)carbamate (12b). To a mixture of 2-((tert-butoxycarbonyl)amino)-4-(3-methyl- 
3H-diazirin-3-yl) butanoic acid 6b (180 mg, 0.7 mmol) and compound 11 (200 mg, 
0.48 mmol) in DMF (15 mL), coupling reagent HOBt (105 mg, 0.78 mmol), HBTU 
(300 mg, 0.79 mmol) and DIEA (175 mg, 1.35 mmol) were added. The reaction was 
stirred for 24 h at r.t. in the dark and was then quenched by water (50 mL). 
Subsequently, the mixture was filtrated and the resulting solid was washed with water 
and ether, precipitated in the CHCl3 and methanol (10:1) again to give the product 
12b (190 mg, 57.6%). 
1
H NMR (300 MHz, DMSO-d6) δ 11.39 (s, 1H), 9.83 (s, 1H), 
8.20 (s, 1H), 7.90 (s, 1H), 7.40 (d, J = 2.1 Hz, 1H), 7.22-7.38 (m, 2H), 7.12 (s, 1H), 
6.84 (d, J = 7.5 Hz, 1H), 5.86 (s, 1H), 3.80 (s, 1H), 3.25 (m, 4H), 2.38 (s, 3H), 2.24 (s, 
3H), 1.22-1.48 (m, 13 H), 0.95 (s, 3H). IT-TOF-MS: m/z [M+1]
+
 calcd: 657.25; Found: 
657.30. 
DA-2 (1b). To a solution of compound 12b (188 mg, 0.28 mmol) in DCM (10 mL), 
TFA (10 mL) was added slowly at 0 °C. After stirring overnight at r.t., the solvent was 
removed under vacuum and the residue was suspended to DMF (8 mL) followed by 
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the addition of hex-5-ynoic acid (56 mg, 0.5 mmol), DIEA (240 mg, 1.86 mmol), 
HOBt (60 mg, 0.44 mmol) and HBTU (162 mg, 0.42 mmol). After stirring overnight 
at r.t. in the dark, the reaction was then quenched by water (30 mL) and filtrated. The 
solid was washed with water and ether, precipitated with CHCl3 and methanol (10:1) 
to give the desired product 1b (91 mg, 50 % for two steps). 
1
H NMR (300 MHz, 
DMSO-d6) δ 11.40 (s, 1H), 9.84 (s, 1H), 8.20 (s, 1H), 7.92-7.997 (m, 2H), 7.39 (d, J = 
6.9 Hz, 1H), 7.23-7.28 (m, 2H), 7.13 (br, 1H), 5.87 (s, 1H), 4.18-4.13 (m, 1H), 
3.24-3.31 (m, 4H), 2.76 (s, 1H), 2.38 (s, 3H), 2.12-2.23 (m, 7H), 2.04 (s, 1H), 
1.24-1.67 (m, 7H), 0.95 (s, 3H); 
13
C NMR (300 MHz, DMSO-d6) δ 172.0, 171.8, 
165.63, 163.1, 160.3, 141.1, 139.1, 133.9, 132.8, 129.3, 128.5, 127.3, 125.8, 84.4, 
71.7, 52.3, 39.0, 30.6, 26.8, 26.0, 25.7, 24.5, 19.6, 18.6, 17.7. IT-TOF-MS: m/z 
[M+1]
+
 calcd: 651.24; Found: 651.25. 







    To a solution of diazirine free amino acid (100 mg, 0.7 mmol) and 10% Na2CO3 
(5.2 mL) in dioxane (3.9 mL), Fmoc-Cl (258 mg, 1mmol) was added at r.t. After 20 h 
stirring, pH value of the reaction was adjusted to 2~3 using 1N HCl, and the mixture 
were extracted with ethyl acetate (5 mL × 3). The combined organic layer was dried 
with Na2SO4, concentrated, purified with flash chromatography to give the product 2 
in 85% yield. 








    To a solution of of propargylamine (49 µL) in DMF (5 mL), coupling reagent 
HOBt (104 mg, 0.78 mmol), HBTU (288 mg, 0.78 mmol) and DIEA (200 mg, 1.56 
mmol) were added. Compound 2 (190 mg, 0.5 mmol) was then added to the above 
solution and the reaction was stirred at r.t. overnight. Subsequently, the reaction was 
quenched with water and extracted with EA. The organic layer was washed with 
water (20 mL), sodium bicarbonate solution (20 mL), brine (20 mL). The organic 
layer was concentrated and purified by column chromatography to afford compound 3 
in 93% yield. 
1
H NMR (300 MHz, CDCl3) δ 7.76 (d, J = 7.4 Hz, 2H), 7.56 (d, J = 7.4 
Hz, 2H), 7.41 (t, J = 7.4 Hz, 2H), 7.34-7.29 (m, 2H), 6.41 (s, 1H), 5.37-5.34 (m, 1H), 
4.44-4.42 (m, 2H), 4.22-4.17 (m, 1H), 4.15-4.11 (m, 1H), 4.00 (s, 2H), 2.17 (s, 1H), 
1.49-1.42 (m, 2H), 1.32-1.21 (m, 2H), 1.01 (s, 3H); 
13
C NMR (75 MHz, CDCl3) δ 
170.62, 156.30, 143.54, 141.25, 127.74, 127.05, 124.89, 119.97, 78.80, 71.88, 67.00, 








    Compound 3 was dissolved into 20% piperidine in DMF, and stirred for 10 min 
at r.t. The reaction was concentrated and purified by column chromatography to give 
compound 4 in 98% yield. 
1H NMR (300 MHz, DMSO) δ 8.22 (s, 1H), 3.84 (s, 2H), 
3.09-3.07 (m, 2H), 1.52-1.34 (m, 2H), 1.32-1.06 (m, 2H), 0.97 (s, 3H); 
13
C NMR (75 
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MHz, DMSO) δ 174.9, 81.6, 73.2, 54.2, 40.7, 40.4, 40.1, 39.9, 39.6, 39.3, 39.0, 30.5, 














    To a solution of staurosphorine (STS) (5.0 mg, 10 μmol) in DMSO, succinic 
anhydride (1.5 mg, 15 µmol) and DMAP (61 µg, 20 µmol) were added under dark. 
After 30 h stirring, the mixture was precipitated with 0.1 % TFA in water, and the 
precipitate was triturated twice with 0.1 % TFA in water to afford compound 5 in 92% 
yield.
 1
H NMR (300 MHz, DMSO-d6) δ 12.06 (s, 1H), 9.29 (d, J = 7.9 Hz, 1H), 8.59 (s, 
1H), 8.05 (d, J = 7.7 Hz, 1H), 7.99 (d, J = 8.5 Hz, 1H), 7.67 (d, J = 8.2 Hz, 1H), 7.48 (t, 
J = 7.7 Hz, 2H), 7.35 (t, J = 7.5 Hz, 1H), 7.29 (t, J = 7.5 Hz, 1H), 7.03 (t, J = 7.5 Hz, 1H), 
5.00 (s, 3H), 4.22 (s, 1H), 2.81 (s, 3H), 2.77 (s, 3H), 2.68 (d, J = 5.6 Hz, 1H), 2.60-2.56 
(m, 2H), 2.33 (s, 3H), 2.28-2.17 (m, 1H). LCMS m/z calcd for C32H30N4O6 [M+H]
+ 
= 



















    To a solution of compound 5 in DMSO (1 mL), coupling reagent DMAP (2.4 mg) 
and EDC (15.4 mg) were added, and stirred for 10 min at r.t. Compound 4 was 
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subsequently added into the reaction at 0 
o
C. The mixture was then allowed to warm 
to r.t. After overnight stirring, the mixture was precipitated with 0.1 % TFA in water to 
afford compound STS-1 in 92% yield. 
1H NMR (300 MHz, DMSO) δ 9.29 (d, J = 7.7 
Hz, 1H), 8.61 (s, 1H), 8.33-8.31 (m, 1H), 8.16-8.11 (m, 1H), 8.08-8.03 (m, 1H), 
7.99-7.94 (d, J = 8.2 Hz, 1H), 7.66 (t, J = 7.1 Hz, 1H), 7.49 (t, J = 7.1 Hz, 2H), 7.33 
(dt, J = 18.4 Hz, 2H), 7.04-6.97 (m, 1H), 5.00 (s, 3H), 4.21-4.19 (m, 2H), 3.92-3.86 
(m, 2H), 3.19-3.15 (m, 1H), 2.82-2.74 (m, 6H), 2.69-2.57 (m, 3H), 2.45-2.37 (m, 2H), 
2.36-2.33 (m, 3H), 2.26-2.17 (m, 1H), 1.45-1.38 (m, 3H), 1.22-1.20 (s, 1H), 1.02 (s, 
3H); LCMS m/z calcd for C41H43N8O6 [M+H]
+
 = 743.330, found 743.322; 
C41H42N8O6Na [M+Na]
+
 = 765.3120, found 765.303 (IT-TOF). 
8.3  Solid-phase Synthesis 



































































































Scheme 8.6 Traceless synthesis of symmetric and asymmetric diol inhibitors. 
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    The construction of the inhibitor library was achieved by IRORI® split-and-pool 
directed sorting technology. Final products were released from the solid support by 
our optimized TFA cleavage protocol (below).  
General procedure for reductive amination with (6): 
    PL-FMP resin (75× ~40 mg, 0.9 mmol/g) was taken into 75 MacroKan
TM
 
reactors, with each containing a unique RF tag. The resin was swelled in 1, 
2-dichloroethane (150 mL) for 2 h. Upon decanting of the solvent, the microreactors 
were then distributed into three different 50-mL tubes each containing 2 % acetic acid 
in 1,2-dichloroethane (20 mL). Each of the three diols, 6a-c (5 eq, below) was added 
to each of the three tubes, respectively, followed by incubation for 3 h at r.t. with 
constant shaking. Subsequently sodium triacetoxyborohydride (6 eq) was added, and 
the tubes were shaken for another 8 h before the solutions were decanted. The reactors 
were combined, washed with DCM (3×50 mL), MeOH (3×50 mL) and THF (3×50 
mL) and dried in vacuo to afford resin 7. The success of the reaction was monitored 
by Nynhydrin and Chloranil test. Blue beads indicate the presence of primary or 
secondary amine and the attachment of the diol to the resin. 
General procedure for coupling/synthesis of symmetrical diols (8) (Route I): 
    Selected microreactors containing resin 7 were swelled in DMF for 2 h. The 
solvent was decanted. A solution containing the acid building block (10.0 eq), 
PyBrOP (10.0 eq) and DIPEA (20.0 eq) in DMF was prepared under N2 and mixed 
for 2 min before being added to the resin. The reaction mixture was shaken for 12 h at 
r.t., after which the solution was decanted and the resin was washed with DMF (3×20 
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mL), MeOH (3×20 mL) and (3×20 mL), following by drying in vacuo to afford resin 
8. 
General procedure for coupling/synthesis of asymmetrical diols (11) (Route II): 
    Selected microreactors containing resin 7 were swelled in DMF for 2 h. The 
solvent was decanted. A solution containing the first acid building block (5.0 eq), 
PyBOP (5.0 eq), HOAt (5.0 eq) and DIPEA (10.0 eq) in DMF was prepared under N2 
and mixed for 2 min before being added to the resin. The reaction mixture was shaken 
for 12 h at r.t., after which the solution was decanted and the resin was washed with 
DMF (3×20 mL), MeOH (3×20 mL) and (3×20 mL) followed by drying in vacuo to 
afford the mono-acylated resin 10. Subsequently, the resin was swelled in DMF for 2 
h. The solvent was decanted. A solution containing the desired second acid building 
block (5.0 eq), PyBrOP (5.0 eq) and DIPEA (10.0 eq) in DMF was prepared under N2 
and mixed for 2 min before being added to the resin. The reaction mixture was shaken 
for 12 h at r.t., after which the solution was decanted and the resin was washed with 
DMF (3×20 mL), MeOH (3×20 mL) and (3×20 mL) followed by drying in vacuo to 
afford the asymmetrical diols 11. 
Cleavage of resins (8) and (11) to give the final products (9) and (12): 
    After sorting/decoding, each microreactor was treated with 2.0 mL of a freshly 
prepared cleavage cocktail of TFA/DCM/H2O (5:4:1) for 3.5 h at r.t. The solutions 
were then transferred to an 96-deep well, polypropylene microplate, and concentrated 
with a GeneVac™ HT-4X concentrator to afford the final desired products in 
sufficiently pure form (w/o any purification). LC-MS, NMR characterizations and 
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biological screening were carried out directly with these products. These compounds 
were typically re-dissolved in 0.5 mL of DMSO and kept in -20 
o
C as master stocks. 
Library Characterizations: 
    For LCMS analysis, 40 μL of the samples from the master stocks were 
transferred to a 96-well polypropylene microplate, and LCMS was performed by 
injecting 3 μL using an autosampler. Most products analyzed were shown to be of 
sufficient purity (90-95% for symmetrical diols and 60-95% for asymmetrical diols; 






















H NMR (300 MHz, CDCl3) δ 1.15-1.23 (m, 6H), 2.07 (d, J = 4.71 Hz, 2H), 2.61-2.64 
(m, 4H), 2.72-2.74 (m, 2H), 2.82-2.88 (m, 2H), 3.52-3.72 (m, 4H), 7.12-7.25 (m, 
14H), 7.64 (d, J = 7.65 Hz, 2H), 7.77-7.94 (m, 2H). LCMS found for C36H40N2O4 (M 
+ H)
+














Exact Mass: 612.14  
1
H NMR (500 MHz, DMSO-d6) δ 2.77-2.81 (m, 2H), 2.88-2.93 (m, 2H), 4.64-4.69 (m, 
2H), 4.76 (s, 2H), 7.03-7.06 (t, J = 7.25 Hz, 1H), 7.11-7.15 (t, J = 7.57 Hz, 3H), 7.26 
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(d, J = 6.95 Hz, 3H), 7.31-7.34 (m, 2H), 7.43-7.49 (m, 4H), 8.02 (d, J = 8.85 Hz, 1H). 
13
C-NMR (75 MHz, DMSO-d6): 164.9, 163.4, 160.2, 139.3, 137.0, 130.2, 129.2, 
127.9, 125.7, 123.5, 117.9, 114.6, 72.2, 52.3, 37.4. LCMS found for C32H28Cl2F2N2O4 
(M + Na)
+










Exact Mass: 508.24  
1
H NMR (300 MHz, CDCl3) δ 2.72-2.81 (m, 2H), 2.88-2.90 (m, 2H), 4.05-4.26 (m, 
4H), 4.69 (s, 2H), 7.05-7.28 (m, 11H), 7.40-7.72 (m, 6H), 7.80 (d, J = 6.96 Hz, 14H), 
7.87-7.95 (m, 1H). LCMS found for C32H32N2O4 (M + Na)
+












Exact Mass: 576.16  
1
H NMR (300 MHz, CDCl3) δ 2.72-2.80 (m, 2H), 2.80-2.96 (m, 2H), 4.08-4.29 (m, 
4H), 4.67 (s, 2H), 7.03-7.27 (m, 10H), 7.46 (d, J = 8.70 Hz, 4H), 7.73 (d, J = 8.37 Hz, 
3H), 8.01 (d, J = 9.06 Hz, 1H). LCMS found for C32H30Cl2N2O4 (M + Na)
+











Exact Mass: 608.27  
1
H NMR (300 MHz, CDCl3) δ 2.73-2.60 (m, 2H), 2.82-2.87 (m, 2H), 4.09-4.39 (m, 
4H), 4.80 (s, 2H), 6.98-7.43 (m, 11H), 7.58 (t, J = 3.81 Hz, 4H), 7.81-7.96 (m, 8H), 
8.31 (s, 1H). LCMS found for C40H36N2O4 (M + Na)
+
: m/z = 631.24. 










Exact Mass: 548.36  
1
H NMR (500 MHz, CDCl3) δ 0.67-0.86 (m, 3H), 1.04-1.28 (m, 5H), 1.20-1.28 (m, 
3H), 1.46-1.65 (m, 8H), 1.81-1.86 (m, 3H), 1.90-2.07 (m, 1H), 2.74 (d, J = 8.81 Hz, 
2H), 2.85 (d, J = 6.90 Hz, 2H), 3.97 (d, J = 8.85 Hz, 2H), 4.62 (s, 2H), 4.82-4.91 (m, 
2H), 7.10-7.38 (m, 10H), 7.52 (d, J = 6.81 Hz, 1H), 7.77 (d, J = 6.35, Hz, 18H). 
LCMS found for C34H48N2O4 (M + Na)
+














Exact Mass: 544.17  
1
H NMR (500 MHz, DMSO-d6) δ 0.84-0.86 (m, 12H), 1.23-1.25 (m, 4H), 1.55-1.64 
(m, 2H), 3.25-3.66 (m, 4H), 4.40 (s, 2H), 7.32-7.39 (m, 1H), 7.46-7.51 (m, 2H), 7.63 
(d, J = 9.45 Hz, 1H), 7.68 (d, J = 7.55 Hz, 1H), 7.90 (d, J = 7.55 Hz, 1H). 
13
C-NMR 
(75 MHz, DMSO-d6): 165.7, 163.6, 130.3, 123.6, 117.8, 114.1, 72.7, 49.3, 24.5, 23.4, 
21.9. LCMS found for C32H28Cl2F2N2O4 (M + H)
+












Exact Mass: 500.29  
1
H NMR (500 MHz, DMSO-d6) δ 0.83-0.85 (m, 12H), 1.16-1.19 (m, 4H), 1.64 (d, J = 
7.65Hz, 4H), 1.93-1.99 (m, 2H), 2.04-2.05 (m, 2H), 2.85 (d, J = 6.95 Hz, 1H), 3.12 (s, 
6H), 4.11-4.16 (m, 2H), 7.22 (d, J = 9.55 Hz, 1H), 7.39-7.55 (m, 1H), 7.50-7.55 (m, 
2H), 7.68-7.79 (m, 2H), 8.05 (d, J = 7.59 Hz, 1H), 8.15 (d, J = 8.55 Hz, 1H). LCMS 
found for C28H40N2O6 (M +H)
+
: m/z = 501.00. 












Exact Mass: 500.29  
1
H NMR (500 MHz, DMSO-d6) δ 0.81-0.83 (m, 12H), 1.17-1.21 (m, 4H), 1.62 (d, J = 
7.60Hz, 4H), 1.94-1.99 (m, 2H), 2.06-2.08 (m, 2H), 2.85 (d, J = 6.95 Hz, 1H), 3.12 (s, 
6H), 4.11-4.15 (m, 2H), 7.21 (d, J = 9.45 Hz, 1H), 7.39-7.50 (m, 1H), 7.50-7.56 (m, 
2H), 7.66-7.77 (m, 2H), 7.95 (d, J = 7.55 Hz, 1H), 8.14 (d, J = 8.50 Hz, 1H). LCMS 
found for C28H40N2O6 (M +H)
+












Exact Mass: 508.19  
1
H NMR (300 MHz, CDCl3) δ 0.80-0.90 (m, 12H), 1.40-1.87 (m, 6H), 4.00-4.28 (m, 
4H), 7.42-7.62 (m, 3H), 7.77-7.94 (m, 3H), 8.05-8.30 (m, 2H). LCMS found for 
C26H34Cl2N2O4 (M + Na)
+














Exact Mass: 556.28  
1
H NMR (300 MHz, CDCl3) δ 0.87-0.92 (m, 12H), 1.52-1.78 (m, 6H), 2.72-3.16 (m, 
4H), 4.45-4.52 (m, 8H), 7.57-7.60 (m, 2H), 7.94-7.98 (m, 4H). LCMS found for 
C26H34Cl2N2O4 (M + H)
+










Exact Mass: 480.39  
1
H NMR (500 MHz, CDCl3) δ 0.78-0.87 (m, 12H), 1.08-1.24 (m, 10H), 1.40-1.52 (m, 
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4H), 1.50-1.52 (m, 14H), 1.89-2.08 (m, 4H), 3.04-3.14 (m, 2H), 4.12-4.27 (m, 2H), 
1.40-1.52 (m, 4H), 4.93 (d, J = 12.6 Hz, 2H), 5.07 (d, J = 12.6 Hz, 2H), 7.21 (d, J = 
9.45 Hz, 24H). LCMS found for Chemical Formula: C28H52N2O4 (M + H)
+













Exact Mass: 464.19  
1
H NMR (500 MHz, CDCl3) δ 1.21-1.23 (m, 6H), 1.31-1.34 (m, 4H), 3.55 (d, J = 4.40 
Hz, 1H), 4.17-4.52 (m, 3H), 7.57-7.61 (m, 3H), 7.95-8.01 (m, 6H), 8.46 (s, 1H) 
LCMS found for C26H28N2O6 (M + Na)
+












Exact Mass: 411.18  
1
H NMR (500 MHz, DMSO-d6) δ 1.14-1.19 (m, 6H), 3.75 (s, 3H), 4.26-4.80 (m, 4H), 
5.15-5.30 (m, 2H), 7.77 (d, J = 8.20 Hz, 1H), 7.87-8.10 (m, 7H). LCMS found for 
C22H25N3O5 (M + Na)
+











Exact Mass: 402.20  
1
H NMR (500 MHz, DMSO-d6) δ 1.13-1.26 (m, 9H), 2.62-2.67 (m, 2H), 4.00-4.40 (m, 
4H), 7.28 (d, J = 7.60 Hz, 4H), 7.75-7.81 (m,4H). LCMS found for C22H27FN2O4 (M 
+ Na)
+












Exact Mass: 402.20  
1
H NMR (500 MHz, DMSO-d6) δ 1.13 (d, J = 6.30 Hz, 6H), 2.25 (s, 6H), 4.09-4.38 
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(m, 4H), 7.19 (d, J = 8.20 Hz, 2H), 7.51-7.67 (m, 2H), 7.76 (d, J = 8.80 Hz, 2H). 
LCMS found for C22H27FN2O4 (M + Na)
+













Exact Mass: 402.20  
1
H NMR (500 MHz, DMSO-d6) δ 1.13 (d, J = 6.95 Hz, 6H), 2.35 (s, 6H), 3.77-4.25 
(m, 4H), 7.17-7.29 (m, 3H), 7.89-7.98 (m,3H). LCMS found for C22H27FN2O4 (M + 
H)
+











Exact Mass: 400.20  
1
H NMR (500 MHz, DMSO-d6) δ 1.13 (d, J = 6.95 Hz, 6H), 1.39-1.48 (m, 2H), 
2.16-2.19 (m, 1H), 3.77-4.26 (m, 4H), 7.17-7.28 (m, 3H), 7.89-7.95 (m, 4H). LCMS 
found for C22H28N2O5 (M + H)
+












Exact Mass: 384.15  
1
H NMR (500 MHz, DMSO-d6) δ 1.14 (d, J = 6.95 Hz, 6H), 1.24-1.25 (m, 2H), 
2.16-2.09 (m, 1H), 3.99-4.50 (m, 4H), 7. 85 (d, J = 8.80 Hz, 4H). LCMS found for 
C18H25ClN2O5 (M + Na)
+














Exact Mass: 682.20  
1
H NMR (300 MHz, DMSO-d6) δ 2.72-2.89 (m, 4H), 3.76-3.88 (m, 4H), 6.59-6.63 (m, 
4H), 6.94 (d, J = 5.94 Hz, 2H), 7.12-7.43 (m, 10H), 7.61-8.04 (m, 5H). LCMS found 
                                                                         168 
for C39H33ClF2N2O5 (M + H)
+











Exact Mass: 602.28  
1
H NMR (300 MHz, CDCl3) δ 2.13-2.41 (m, 4H), 2.72-2.88 (m, 4H), 3.31 (s, 1H), 
3.73-3.88 (m, 6H), 6.92-7.36 (m, 15H), 7.43-7.59 (m, 3H), 7.67-7.83 (m, 2H), 
7.90-7.29 (m, 2H). LCMS found for C39H33ClF2N2O5 (M + Na)
+
: m/z = 625.29. 































































Figure 8.1 Structrues of the N-terminal azide warheads (1-8). 






H-NMR (300 MHz, CDCl3) δ 2.83-3.09 (m, 2H), 3.29-3.35 (m, 2H), 
3.76-3.84 (m, 1H), 4.31-4.35 (m, 2H), 6.62 (d, J = 8.22 Hz, 1H), 6.86-7.15 (m, 6H), 
7.21-7.50 (m, 2H); 
13
C-NMR (75 MHz, CDCl3) δ 166.4, 164.7, 161.4, 137.2, 131.9, 
131.7, 131.3, 131.1, 130.9, 129.2, 129.1, 128.6, 126.7, 117.5, 114.2, 72.4, 70.0, 54.9, 





H-NMR (500 MHz, CDCl3) δ 2.14 (s, 3H), 2.27 (s, 3H), 2.74-2.98 (m, 2H), 
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3.23-3.34 (m, 2H), 3.77 (s, 1H), 4.23-4.38 (m, 2H), 6.28 (d, J = 10.0 Hz, 1H), 
6.82-6.93 (m, 6H), 7.09 (d, J = 3.15 Hz, 2H); 
13
C-NMR (125 MHz, CDCl3) δ 171.0, 
153.9, 139.9, 135.7, 127.1, 132.7, 132.4, 132.2, 131.5, 129.5, 129.4, 126.5, 126.1, 






H-NMR (300 MHz, DMSO-d6) δ 0.94 (t, J = 4.20 Hz , 6H), 1.24-1.52 (m, 
2H), 6.52 (d, J = 7.65 Hz, 1H), 6.98-7.10 (m, 1H), 7.12 (d, J = 2.07 Hz, 1H), 
7.54-7.63 (m, 1H); 
13
C-NMR (75 MHz, CDCl3) δ 166.5, 166.0, 164.8, 161.5, 131.6, 







H-NMR (300 MHz, DMSO-d6) δ 0.88 (t, J = 3.90 Hz, 6H), 1.22-1.52 (m, 
4H), 1.72-1.90 (m, 1H), 2.69 (s, 3H), 2.95 (s, 3H), 3.21-3.33 (m, 1H), 3.47-3.53 (m, 
1H), 4.40 (s, 1H), 7.23-7.29 (m, 1H), 7.30-7.50 (m, 2H), 7.94 (s, 1H); 
13
C-NMR (75 
MHz, DMSO-d6) δ 165.4, 163.6, 162.3, 160.3, 158.6, 157.6, 133.9, 130.7, 116.8, 






H-NMR (300 MHz, MeOD) δ 3.17-3.38 (m, 1H), 3.76-3.97 (m, 1H), 
3.76-4.86 (m, 1H), 3.97-4.48 (m, 2H), 4.42-4.48 (m, 1H), 4.86-4.94 (m, 1H), 7.40 (d, 
J = 8.34Hz, 1H), 7.62-7.99 (m, 6H); 
13
C-NMR (75 MHz, CDCl3) δ 168.7, 165.6, 
156.6, 133.8, 133.0, 131.2, 131.1, 130.3, 118.1, 117.8, 116.1, 115.8, 115.3, 114.8, 





H-NMR (300 MHz, MeOD) δ 2.76 (s, 3H), 2.95 (s, 3H), 3.22-3.64 (m, 2H), 
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4.00-4.13 (m, 2H), 4.45-4.51 (m, 1H), 4.93-4.99 (m, 1H), 7.39-7.41 (m, 2H), 
7.62-7.66 (m, 3H), 7.73-7.80 (m, 2H); 
13
C-NMR (75 MHz, CDCl3) δ 172.9, 156.7, 
140.9, 140.7, 136.5, 134.8, 132.2, 132.1, 131.3, 130.4, 130.2, 127.8, 127.0, 126.9, 





H-NMR (300 MHz, CDCl3) δ 0.96-0.99 (m, 6H), 2.07-2.18 (m, 1H), 
3.37-3.46 (m, 2H), 3.83-3.89 (m, 1H), 4.08-4.14 (m, 1H), 6.62 (d, J = 9.42 Hz, 1H), 
6.98-7.04 (m, 1H), 7.09-7.15 (m, 1H), 7.59 (d, J = 6.24 Hz, 1H); 
13
C-NMR (75 MHz, 
CDCl3) δ 166.6, 164.8, 161.4, 131.1-131.7, 129.0, 116.8-117.6, 114.3-114.8, 71.2, 






H-NMR (300 MHz, CDCl3) δ 0.97 (d, J = 4.95 Hz, 6H), 3.76-3.97 (m, 1H), 
1.89-2.19 (m, 1H), 2.32 (d, J = 2.31 Hz, 3H), 2.38 (d, J = 1.98 Hz, 3H), 3.30 (d, J = 
6.42 Hz, 1H), 3.38 (d, J = 3.30 Hz, 1H), 3.69 (t, J = 9.39 Hz, 1H), 3.84 (t, J = 6.06 Hz, 
1H), 3.86-4.07 (m, 1H), 6.08 (d, J = 9.21 Hz, 1H), 6.96-7.02 (m, 2H), 7.22 (d, J = 
7.56 Hz, 1H); 
13
C-NMR (75 MHz, CDCl3) δ 171.4, 170.9, 140.1, 136.0, 133.1, 131.8, 




8.3.3 Traceless Synthesis of Alkyne Building Blocks 
Reductive amination: PL-FMP resin (150 mg) was swelled in DCE (15 ml) for 2 h. 
The solvent was removed, followed by the addition of 2 % glacial acetic acid solution 
in DCE (15 mL) and the propargylamine (10.0 eq). The reaction mixture was shaken 
for 3 h. Then Na(OAc)3BH (10.0 eq) was added and the reaction mixture was shaken 
for further 18 h. The resulting resin was washed with THF (3×20 mL), MeOH (3×20 
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mL) and DCM (3×20 mL) and dried under vacuum to afford 12. The completeness of 
the reaction can be monitored by Chloranil test. Blue beads indicate the presence of 























































































































































Scheme 8.7 Traceless synthesis of alkynes 14(A-S). 
Traceless N-acylation with Acids: The resulting resin firstly was swelled in DMF for 
2 h. The solvent was removed. Then the resin was added a preactived solution of 
acids (5.0 eq), PyBOP (5.0 eq), HOAt (5.0 eq) and DIPEA (10.0 eq) in DMF (or 
solution of sulfonyl chloride (4.0 eq) and DIPEA (6.0 eq) in DCM. The reaction 
mixture was shaken overnight at room temperature and then the resin was washed 
with THF (3×), MeOH (3×) and CH2Cl2 (3×) and dried under vacuum to afford 13. A 
negative chloranil test indicates the completeness of the reaction. 
Cleavage of the product 13(A-S) from solid support: Dried resin was treated with 
cleavage (3 mL) solution consisting of TFA:DCM:H2O (5:4:1) and the mixture was 
shaken for 3 h at r.t. followed by filtration. The solution was concentrated to dryness 
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to afford warhead 14(A-S). 
N-(prop-2-ynyl)-2-naphthamide (14A). 
1
H-NMR (300 MHz, DMSO-d6) δ 3.24 (s, 
1H), 4.12-4.17 (m, 1H), 7.56-7.73 (m, 4H), 8.48 (s, 1H), 9.11 (t, J = 5.40 Hz, 1H); 
13
C-NMR (75 MHz, CDCl3) δ 166.0, 134.2, 132.1, 131.2, 128.9-126.7(m), 124.5, 81.3, 





H-NMR (300 MHz, DMSO-d6) δ 3.17 
(s, 1H), 3.82 (s, 3H), 4.04-4.29 (m, 2H), 7.08-7.11 (m, 1H), 8.92 (t, J = 5.23 Hz, 1H); 
13
C-NMR (75 MHz, DMSO-d6) δ 165.7, 158.6, 135.2, 129.5, 119.9, 117.4, 112.3, 






(300 MHz, DMSO-d6) δ 3.17 (s, 1H), 3.82 (s, 3H), 4.03-4.06 (m, 2H), 4.26-4.29 (m, 
2H), 4.34-4.37 (m, 2H), 6.85-7.00 (m, 2H), 7.27-7.36 (m, 1H), 8.45 (t, J = 5.24 Hz, 
1H); 
13
C-NMR (75 MHz, DMSO-d6) δ 164.2, 143.6, 141.8, 123.1, 122.1, 120.6, 
119.7, 81.3, 72.7, 64.4, 63.6, 28.5; LC-MS: m/z [M+H]
+ 
= 218.077. 
4-Fluoro-N-(prop-2-ynyl) benzamide (14G). 
1
H-NMR (300 MHz, DMSO-d6) δ 3.07 
(s, 1H), 4.04-4.06 (q, 2H), 7.27 (t, J = 5.30 Hz, 1H), 7.93 (q, 2H), 8.95 (s, 1H); 
13
C-NMR (75 MHz, DMSO-d6) δ 165.2, 165.1, 163.2, 159.0-158.1(m), 130.2, 115.3, 
81.4, 72.9, 35.9, 30.8, 28.7; LC-MS: m/z [M+H]
+ 
= 178.058. 
2-(2-fluorophenyl)-N-(prop-2-ynyl) acetamide (14I). 
1
H-NMR (300 MHz, DMSO-d6) 
δ 3.27 (s, 1H), 3.56 (s, 2H), 3.85-3.88 (m, 2H), 7.11-7.16 (m, 2H), 7.27-7.34 (m, 2H), 
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8.52 (s, 1H); 
13
C-NMR (75 MHz, DMSO-d6) δ 168.9, 162.2, 158.9, 131.8, 128.6, 
124.1, 114.9, 81.1, 73.0, 34.9, 28.5; LC-MS: m/z [M+H]
+ 
= 192.076. 
4-Acetyl-N-(prop-2-ynyl) benzenesulfonamide (14N). 
1
H-NMR (300 MHz, DMSO-d
6
) 
δ 2.50 (s, 3H), 3.02 (s, 1H), 7.75 (q, J = 3.48 Hz, 2H), 7.94 (d, J = 8.34 Hz, 2H), 8.12 
(d, J = 8.34 Hz, 1H), 8.36 (t, J = 5.91 Hz, 1H); 
13
C-NMR (75 MHz, CDCl3) δ 197.4, 
144.3, 139.5, 128.9, 127.1, 79.1, 74.9, 31.9, 27.1. 
N-(prop-2-ynyl)naphthalene-2-sulfonamide (14K). 
1
H-NMR (300 MHz, CDCl3) δ 
1.26 (s, 1H), 3.88 (s, 2H), 7.58-7.67 (m, 2H), 7.84-7.98 (m, 4H), 8.48 (s, 1H); 
13




H-NMR (300 MHz, DMSO-d6) δ 
3.06 (t, J = 2.25 Hz, 1H), 3.74 (t, J = 2.79 Hz, 2H), 7.41-7.53 (m, 3H), 7.74 (d, J = 
7.32 Hz, 2H), 7.89 (d, 4H), 8.20 (t, J = 5.75 Hz, 2H); 
13
C-NMR (75 MHz, DMSO-d6) 
δ 144.0, 139.2, 138.5, 132.1, 129.1, 127.4-127.1(m), 79.4, 74.8, 32.0. 
4-nitro-N-(prop-2-ynyl) benzenesulfonamide (14R). 
1
H-NMR (300 MHz, DMSO-d6) 
δ 3.01 (s, 1H), 3.56 (d, J = 6.0 Hz, 2H), 8.06 (d, J = 8.70 Hz, 2H), 8.41 (d, J = 8.70 
Hz, 2H), 8.54 (t, J = 5.75 Hz, 2H); 
13
C-NMR (75 MHz, DMSO-d6) δ 149.6, 146.3, 
128.5, 124.4, 78.8, 75.2, 31.9. 
8.3.4 Procedure for Synthesis of the 198-member N-terminal Library 
Immobilization of 4(a-f) onto DHP resin. According to previously published 
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procedures.
146-148
 HM DHP resin (40 mg) was first swelled in DCE (5 mL) for 2 h. 
The solvent was then removed and 4(a-f)(4.0 eq) and catalytic amount of PPTs 
(Pyridinium p-toluenesulfonate) (1.5 eq) in DCE (10 mL) were added at r.t. The 
reaction was then strirred for 12 h at 60 
o
C. The resulting resin was washed with 




Deprotection of Fmoc group. The resulting resin was suspended in a solution of 
20% piperidine in NMP, shaked for 2 h at r.t. The solvent was then removed by 
filtration and washed with NMP (3×), THF (3×), CH2Cl2 (3×) and Et2O (3×) and 
dried under high vacuum. The completeness of the reaction was monitored by 
ninhydrin test. Blue beads indicate the presence of primary amine and the 
completeness of the reaction. 
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N-a-(1-55):   R1 = a; R2 = 1 to 55
N-b-(1-38)*:  R1 = b; R2 = 1 to 38
N-c-(1-30):   R1 = e; R2 = 1 to 30
N-d-(1-24):   R1 = d; R2 = 1 to 24
N-e-(1-24):   R1 = f;  R2 = 1 to 23
N-f-(1-14):    R1 = c; R2 = 1 to 14







Scheme 8.8 Solid-phase synthesis of the N-terminal library. 
Coupling reactions for acids and sulfonyl chlorides. The resulting resin firstly was 
swelled in dry THF for 2 h, and the solvent was removed. To the resin was added a 
preactived solution containing the corresponding acid (4.0 eq), PyBOP (4.0 eq), 
HOAt (4.0 eq) and DIPEA (8.0 eq) in THF or a solution of the corresponding 
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sulfonyl chloride (4.0 eq) and DIEA (8.0 eq) in dry THF. The reaction mixtures 
were shaken overnight at r.t. and the resin was finally washed with NMP (3×), 
THF (3×), CH2Cl2 (3×) and Et2O (3×) and dried under vacuum. The completeness 
of the reaction was monitored by ninhydrin test. Negative test indicate the absence 
of primary amine and the completeness of the reaction. 
8.3.5 Procedure for Synthesis of the 100-member C-terminal 
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' = a; R2
' = 1-25 
C-b-(1-25):  R1
' = b; R2
' = 1-25    
C-c-(1-25):   R1
' = c; R2
' = 1-25
C-d-(1-25):   R1





Scheme 8.9 Solid-phase synthesis of the C-terminal library. 
Immobilization of 8(a-d) onto DHP resin. HM DHP resin (40 mg) was swelled in 
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DCE (5 mL) for 2 h. The solvent was then removed and 8(a-d) (4.0 eq) and 
catalytic amount of PPTs (Pyridinium p-toluenesulfonate) (1.5 eq) in DCE (10 
mL) were added at r.t. The reaction was then strirred for 12 h at 60 
o
C. The 
resulting resin was washed with NMP (3×), THF (3×), CH2Cl2 (3×) and Et2O (3×) 
and dried in vacuo, then stored at -20 
o
C. 
Amine alkylation and coupling reactions for C-terminal library. Support-bound 
bromomethyl alcohols were added to a vial followed by addition of a solution of 
i-butylamine (10 eqv) in NMP (10 mL). The vial was then sealed and the reaction 
mixture was heated at 80 
o
C for 36 h. The resin was subsequently washed with 
NMP (3×), THF (3×), CH2Cl2 (3×), and ether (3×), and then dried in vacuo. 
Acylation with the sulfonyl chloride (4.0 eqv) and DIEA (8.0 eqv) in dry THF was 
carried out overnight. The resin was then washed with NMP (3×), THF (3×), 
CH2Cl2 (3×), and ether (3×), and then dried under vacuum. 
Reduction of azido group to primary amine. Reduction of the azide was 
accomplished using 0.2 M SnCl2, 0.8 M PhSH, and 1.0 M Et3N in THF (1 mL) for 
4 h. The resin was then washed with 50 vol % aqueous THF solution (3×), THF 
(3×), CH2Cl2 (3×) and ether (3×), and then dried under vacuo. The reaction can be 
monitored by using ninhydrin test. If primary amine presents, the beads will 
become blue color after treatment with ninhydrin reagents. 
Acylation of Primary Amine with Long Chain Biotin Acids . The above resulting 
support-bound amine was then acylated in a preactived solution of biotin acid (4.0 
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eq), PyBOP (4.0 eq), HOAt (4.0 eq) and DIPEA (8.0 eq) in THF. The reaction 
mixture was shaken overnight at r.t., and the resins were washed with NMP (3×), 
THF (3×), CH2Cl2 (3×) and Et2O (3×) and dried under vacuum. The completeness 
of the reaction was monitored by ninhydrin test. If the coupling reaction is 
completed, the beads won‟t have color changes after treatment with ninhydrin 
reagents. 
Cleavage of small molecules from solid support: The compound cleavage, 
microreactors containing of both N- & C-terminal sublibraries were decoded first, 
then cleaved with a 3 mL solution containing TFA (95%) and H2O (5%) for 20 min 
at r.t. Following concentration in vacuo until >90% of cleavage cocktail was 
removed. Cold ether (chilled to -20 °C) was added to the liquid residue to 
precipitate the compounds. The compounds were allowed to precipitate at -20 °C 
for overnight. The ether layer was discarded and the precipitates were dried 
thoroughly in vacuo. The solids were dissolved in 0.5 mL of DMSO and stored at 
-20 °C for future use. LCMS was performed to ensure the compounds were of 
correct mass and sufficient purity. Mass spectra were recorded on a Finnigan LCQ 
mass spectrometer, or a Shimadzu LC-IT-TOF spectrometer. Analytical HPLC was 
carried out on Shimadzu LC-IT-TOF system equipped with an autosampler, using 
reverse-phase Phenomenex Luna 5 μm C18(2) 100 Å 150×3.0 mm (for peptides) 
or 50×3.0 mm (for all other samples) columns. 0.1% TFA/H2O and 0.1% 
TFA/acetonitrile were used as eluents. The flow rate was 0.6 ml/min. Each 
samples were run for 20 min under 10-100% ACN condition. 
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8.4  Click Chemistry Synthesis 
8.4.1 Construction of the 152-member Inhibitor Library against PMs 
    The 152-membered library of aspartic protease inhibitors were assembled in situ 
in a 384-deep well microplate. Both the alkynes and azides were dissolved in a 
minimal amount of DMSO before loading into each well in proportions. The alkynes 
(1.2 eq) were added to the reaction in slight excess so as to ensure that all azides (1.0 
eq) were consumed completely.
 
Subsequently, 1 mL of a mixture of DMSO/H2O (1:1 
volume ratio) was applied to each well. The microplate was shaken for a few minutes, 
followed by sequential addition of catalytic amount of sodium ascorbate (~40%) and 
CuSO4
 
(~10%) into each well to initiate the “Click” chemistry assembly, which was 
continued at r.t. for another 2 d with shaking. The assembled products were used 
directly for subsequent LC-MS analysis and enzymatic assays without any further 
purification. LC-MS analysis of all 152 in situ-assembled products indicated the 
complete consumption of the azides and quantitative formation of the correct triazole 
products in almost every case.  













Hit-1      
White solid. 
1
H-NMR (500 MHz, DMSO-d6) δ 0.83-0.96 (m, 6H), 1.91-1.99 (m, 1H), 
2.33 (s, 3H), 2.31 (s, 3H), 3.80 (s, 2H), 3.91-3.95 (m, 2H), 4.00-4.26 (m, 2H), 4.50 (s, 
3H), 5.27(d, J = 7.55 Hz, 2H), 6.98 (d, J = 7.55 Hz, 2H), 7.05 (d, J = 8.80 Hz, 2H), 
7.29 (dd, J1 = 7.55 Hz, J2 = 7.55 Hz, 1H), 7.85-7.87 (t, J = 4.40 Hz, 3H), 8.05 (s, 1H), 
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8.90 (s, 1H); 
13
C-NMR (125 MHz, d6-DMSO): 169.6, 165.5, 161.6, 145.0, 138.6, 
135.1, 134.9, 134.8, 130.9, 129.1, 127.1, 126.4, 126.3, 125.9, 123.6, 113.5, 69.6, 59.7, 
56.8, 55.6, 55.3, 53.9, 53.7, 34.8, 28.6, 27.4, 20.7, 20.4, 19.7, 19.6, 19.5, 19.48, 15.9, 
14.1; LC-MS: m/z [M+H]
+














OHit-2   
White solid. 
1
H-NMR (500 MHz, DMSO-d6) δ 0.84-0.95 (m, 6H), 2.20-2.29 (m, 1H), 
2.30-2.34 (m, 6H), 2.69 (s, 3H), 3.68-3.79 (m,1H), 3.89-3.94 (m, 1H), 4.09 (s, 2H), 
4.11-4.20 (m, 1H), 4.43(dd, J1 = 1.85 Hz, J2 = 1.90 Hz, 1H), 5.75 (s, 1H), 7.06 (d, J = 
6.30 Hz, 2H), 7.29 (dd, J1 = 7.55 Hz, J2 = 8.20 Hz, 1H), 7.80 (t, J = 9.45 Hz, 1H), 
7.90-7.92 (m, 2H), 8.00 (d, J = 10.10 Hz, 2H); 
13
C-NMR (125 MHz, DMSO-d6): 
197.3, 169.6, 144.3, 143.0, 142.9, 139.3, 138.7, 135.1, 134.8, 134.5, 131.0, 128.9, 
127.1, 126.8, 125.9, 124.0, 69.5, 61.2, 56.8, 55.6, 53.8, 50.5, 38.1, 28.5, 27.4, 27.0, 
22.1, 20.8, 20.3, 19.7, 19.6, 19.5, 15.9; LC-MS: m/z [M+H]
+

















Hit-3   
White solid. 
1
H-NMR (300 MHz, DMSO-d6) δ 0.85 (d, J = 6.39 Hz, 3H), 0.95 (d, J = 
6.57 Hz, 3H), 2.15-2.45 (m, 7H), 3.72-3.78 (m, 2H), 4.03 (d, J = 6.09 Hz, 1H), 
4.11-4.19 (m, 1H), 4.52 (d, J = 12.99 Hz, 1H), 7.29-7.35 (m, 2H), 7.35 (s, 2H), 
7.51-7.55 (m, 2H), 7.80 (s, 1H), 8.03 (t, J = 5.84 Hz, 1H), 8.34 (d, J = 9.39 Hz, 1H); 
13
C-NMR (75 MHz, DMSO-d6): 166.1, 143.3, 140.2, 138.6, 134.2, 130.8, 124.0, 
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H-NMR (300 MHz, DMSO-d6) δ 0.84 (d, J = 6.57 Hz, 3H), 0.95 (d, J = 
6.72 Hz, 3H), 1.22 (d, J = 6.75 Hz, 6H), 2.12-2.30 (m, 1H), 2.93-2.99 (m, 1H), 3.77 (t, 
J = 9.56 Hz, 1H), 4.52 (d, J = 13.80 Hz, 1H), 5.33 (d, J =7.23 Hz, 1H), 7.31 (t, J = 
7.40 Hz, 1H), 7.45 (d, J = 7.38 Hz, 2H), 7.52 (d, J = 8.22 Hz, 2H), 7.72 (d, J = 7.23 
Hz, 2H), 7.83 (s, 1H), 8.06 (s, 1H), 8.34 (d, J = 9.54 Hz, 1H); 
13
C-NMR (75 MHz, 
DMSO-d6): 166.1, 163.6, 160.3, 153.2,143.3,137.9, 134.1, 130.8, 126.8, 124.0, 116.8, 
114.4, 69.6, 56.0, 53.7, 39.5, 33.4,27.4, 23.5, 20.3, 19.7, 15.7, 14.1. LC-MS: m/z 
[M+H]
+



















H-NMR (300 MHz, DMSO-d6) δ 0.84 (d, J = 6.96 Hz, 3H), 0.95 (d, J = 
6.63 Hz, 3H), 2.19 (m, 1H), 3.75 (t, J = 8.01 Hz, 2H), 3.86-3.93 (m, 2H), 4.01-4.06 
(m, 3H), 4.12-4.19 (m, 1H), 4.51 (d, J = 12.54 Hz, 1H), 7.28-7.34 (m, 1H), 7.51-7.56 
(m, 2H), 7.60 (d, J = 8.37 Hz, 2H), 7.76 (d, J = 8.70 Hz, 2H), 8.34 (d, J = 9.39 Hz, 
1H); 
13
C-NMR (75 MHz, DMSO-d6): 166.1, 163.6, 160.3, 143.8,140.3,136.7, 134.1, 
131.0, 130.6, 124.0, 116.7, 114.4, 69.6, 59.8, 55.9, 54.9, 53.7,27.4, 20.5, 15.7, 14.1. 
LC-MS: m/z [M+H]
+
 = 544.0840. 


















H-NMR (300 MHz, CDCl3) δ 0.91 (d, J = 3.12 Hz, 6H), 1.43-1.65 (m, 
2H), 1.76 (s, 1H), 3.73 (d, J = 6.96 Hz, 2H), 3.99-4.18 (m, 2H), 4.25-4.57 (m, 1H), 
4.62 (d, J = 5.58 Hz, 2H), 5.39 (d, J = 6.24 Hz, 1H), 7.28-7.40 (m, 2H), 7.44-7.57 (m, 
4H), 7.75 (d, J = 7.65 Hz, 1H), 7.76-7.79 (m, 2H), 8.05 (d, J = 9.39 Hz, 1H), 8.45 (m, 
1H), 9.03 (m, 1H); 
13
C-NMR (75 MHz, CDCl3): 168.6, 165.8, 165.7, 163.6, 160.3, 
144.5, 134.5, 133.9, 131.3, 131.0, 130.9, 130.6, 130.0, 129.2, 127.2, 125.0, 123.7, 
117.1, 116.7, 114.4, 72.7, 59.8, 53.0, 50.3, 34.6, 24.3, 23.6, 21.4, 20.8, 19.2, 14.1. 
LC-MS: m/z [M+H]
+













Hit-7   
White solid. 
1
H-NMR (300 MHz, CDCl3) δ 0.89 (d, J = 1.74 Hz, 6H), 1.43-1.55 (m, 
2H), 1.71-1.73 (m, 1H), 3.70 (t, J = 7.32 Hz, 2H), 3.91-4.29 (m, 3H), 4.45-4.60 (m, 
3H), 7.29 (t, J = 8.87 Hz, 3H), 7.48-7.52 (m, 2H), 7.92-7.97 (m, 3H), 8.34 (dd, J1 = 
19.17 Hz , J2 = 9.03 Hz, 1H), 9.06 (t, J = 5.57 Hz, 1H); 
13
C-NMR (75 MHz, CDCl3): 
165.7, 165.3, 163.6, 162.3, 160.3, 144.7, 133.9, 131.0, 130.5, 129.9, 123.7, 117.0, 






















H-NMR (300 MHz, CDCl3) δ 0.91 (d, J = 3.84 Hz, 6H), 1.31-1.49 (m, 
2H), 1.52-1.56 (m, 1H), 3.67 (s, 1H), 4.07-4.23 (m, 4H), 4.49 (d, J =11.84 Hz, 1H), 
5.33 (s, 1H), 7.30 (t, J = 9.00 Hz, 1H), 7.48-7.55 (m, 2H), 7.81 (dd, J1 = 6.96 Hz, J2 = 
8.37 Hz, 3H), 8.32 (d, J = 9.06 Hz, 1H); 
13
C-NMR (75 MHz, CDCl3): 165.7, 163.6, 
160.3, 142.9, 139.4, 137.2, 133.9, 131.1, 130.9, 130.6, 130.4, 128.8, 124.0, 117.0, 
116.7, 114.4, 114.1, 72.6, 53.0, 50.3, 38.1, 24.0, 21.4. LC-MS: m/z [M+H]
+ 
= 558.109. 
8.4.2 Synthesis of Affinity-based Probes Targeting Aspartic Proteases 
    Synthesis of all the probes targeting aspartic proteases was followed procedures 
similar to ones previously. In brief, the alkyne (1.2 eq) and the azide (1.0 eq) were 
dissolved in a minimal amount of DMSO. A mixture of DMSO/H2O solution (1:1; 
100 μL) was subsequently added and the reaction was shaken for a few minutes to 
obtain a clear solution. The “click” chemistry was initiated by sequential addition of 
catalytic amounts of sodium ascorbate (0.08 eq) and CuSO4 (0.02 eq). The reaction 
was continued with shaking at r.t. for another 12 hrs. The reaction product was then 
directly injected on LC-MS; results indicated the complete consumption of the azide 
and quantitative formation of the triazole final product in all cases. The final probes 
(A-G) were subsequently characterized by LC-MS. 
Biotin-A3. 
1
H-NMR (300 MHz, DMSO-d6) δ 0.70 (d, J = 5.85 Hz, 6H), 0.78 (d, J = 
5.55 Hz, 2H), 0.90-1.04 (m, 3H), 1.23-1.55 (m, 10H), 1.97-2.03 (m, 64H), 2.27 (s, 
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2H), 2.66-3.00 (m, 10H), 3. 95-4.10 (m, 1H), 4.25-4.27 (m, 2H), 4.55-4.71 (m, 3H), 
5.55 (s, 1H), 6.50 (s, 1H), 6.79 (s, 1H), 7.37 (d, J = 8.19 Hz, 3H), 7.52 (d, J = 6.99 Hz, 






H-NMR (300 MHz, DMSO-d6) δ 0.72 (d, J = 5.85 Hz, 6H), 0.78 (d, J = 
6.15 Hz, 2H), 1.13-1.41(m, 16H), 2.00 (t, J = 6.99 Hz, 4H), 2.66-2.78 (m, 6H), 
2.85-3.15 (m, 24H), 2.29 (s, 2H), 5. 71 (s, 2H), 6.91 (s, 2H), 7.08 (s, 2H), 7.37 (s, 2H), 
7.50-7.65 (m, 3H), 7.66-7.75 (m, 4H), 7.81 (s, 1H); LC-MS: m/z [M+H]
+ 
= 990.150. 
Table 8.1 Summary of LC-MS Characterizations of TER/Biotin Probes. 
Compd MWcalc MWobs Compd MWcalc MWobs 
TER-Bp-alkyne 1012.53 1012.4459 TER-A8 1352.70 1352.7050 
Biotin-Bp-alkyne  645.80  646.2415 Biotin-T1 1081.46 1082.0000 
TER-T1 1448.69 1449.4000 Biotin-T2 1105.48 1106.4935 
TER-T2 1472.71 1472.1000 Biotin-T3 1114.48 1115.1500 
TER-T3 1481.71 1482.2100 Biotin-T4 1108.45 1109.4665 
TER-T4 1475.69 1476.3250 Biotin-A3 1022.45 1045.3755 
TER-T5 1524.70  762.8499 Biotin-A4 1016.42 1039.2927 
TER-A3 1389.69 1390.3000 Biotin-A5 1064.50 1065.4386 
TER-A4 1383.70 1383.6530 Biotin-A6 1007.42 1008.4510 
TER-A5 1431.73 1432.6370 Biotin-A7 1028.30 1028.2812 
TER-A6 1374.70 1374.6310 Biotin-A8  985.46 1008.1500 
TER-A7 1394.74 1394.6470 Biotin-A1  989.43 990.1500 
HPLC conditions: 0-100% B for 10 min, then 100% B for 2 min. (Solvent A: 100% H2O with 0.1 % 
TFA; Solvent B: 100% CH3CN with 0.1 % TFA). 
8.5  Microplate Assay 
8.5.1 Inhibition Activity of Diols Library against Aspartic Proteases 
    The activities of the aspartic proteases were determined by measuring the rate of 
hydrolysis from the commercial available fluorogenic substrates (AnaSpec, USA). 
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The inhibition of all proteins were screened using black polypropylene flat-bottom 
384-well microtiter plates (Greiner, Germany) in a total reaction volume of 20 μl/well, 
monitored with a Tecan Infinite F200 microplate reader at excitation of 390 nm and 
emission of 492 nm prior to the addition of substrate. Different concentrations of 
inhibitors were used in the assay (25 μM~2.5 μM), where necessary. Negative 
controls were performed in the absence of enzyme and positive controls were carried 
out in the presence of enzyme but without inhibitor. Pepsin and HIV-1 protease were 
commercially available. Plasmepsin I and Plasmepsin II were kindly provided by Dr. 
R. Yada (Guelph University, Canada). The assay conditions were given below:  
HIV-1: HIV-1 (5 nM in 2× Assay buffer) = 10 μL.  
HIV Protease Substrate 1 
(Arg-Glu(EDANS)-Ser-Gin-Asn-Tyr-Ile-Val-Gin-Lys(dabcyl-Arg) (5 μM in dd H2O) 
= 5 μL.  
Inhibitor (varied in 10% DMSO/H2O) = 5 μL  
[Assay buffer (1×) = 100 mM Sodium Acetate, 1.0 M NaCl, 1.0 mM EDTA, 1.0 mM 
DTT, 1 mg/mL BSA, pH = 4.7]. 
Plasmepsin I: Plasmepsin I (3 nM in 2× Assay buffer) = 10 μL 
Substrate EDANS-CO-CH2-CH2-CO-ALERMFLSFP-Dap-(DABCYL)-OH (1.5 μM 
in dd H2O) = 5 μL  
Inhibitor (varied in 10% DMSO/H2O) = 5 μL 
[Assay buffer (1×) = 100 mM sodium acetate, 10 % glycerol, pH 5.0].  
Plasmepsin II: Plasmepsin II (3 nM in 2× Assay buffer) = 10 μL 
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Substrate EDANS-CO-CH2-CH2-CO-ALERMFLSFP-Dap-(DABCYL)-OH (1.5 μM 
in dd H2O) = 5 μL  
Inhibitor (varied in 10% DMSO/H2O) = 5 μL  
[Assay buffer (1×) = 100 mM sodium acetate, 10 % glycerol, pH 5.0].  
Pepsin: Pepsin (2 nM in 2× Assay buffer) = 10 μL 
Substrate MOCAc-Ala-Pro-Ala-Lys-Phe-Phe-Arg-Leu-Lys(Dnp)-NH2 (5 μM in dd 
H2O) = 5 μL 
Inhibitor (varied in 10% DMSO/H2O) = 5 μL 
[Assay buffer (1×) =10 mM HCl, pH 2.0].  
The enzymatic reactions were allowed to incubate at r.t. for 15 min before being 
initiated by the addition of substrate, and the reaction was monitored at λex = 340 nm 
and λem = 490 nm, period of 1 or 2 h. Eventually, an inhibitor fingerprint of the library 
against the aspartic proteases was obtained, from which six potential hits (SYM-5, -21, 
-35, -43 and ASM-16, -29) were identified. 
8.5.2 Inhibition Activity of Dasatinib/staurosphorine Probes against Protein  
       Kinases 
    Concentration-dependent experiments were performed to determine the 
inhibition potency and the binding affinity of the probes towards the catalytic domain 
of c-Src, Abl, and Csk. The inhibition assay was performed with Kinase-Glo
®
 Plus 
Luminescent Kinase assay kit from Promega following the manufactures instructions. 
Briefly, recombinant proteins, corresponding peptide substrates (Src substrate 
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subsequence: KVEKIGEGTYGVVYK; Abl substrate sequence: EAIYAAPFAKKK; 
CSK substrate subsequence: KKKKEEIYFFF), ATP and the probe were mixed in the 
HEPES buffer (25 mM HEPES, pH 7.5, 150 mM NaCl, 2 mM MgCl2) at a volume of 
27.5 µL in a flat-bottom solid white 384-well plate. The incubation was allowed to 
continue for 20 min at 37 °C and the reaction was subsequently quenched by the 
addition of an equal volume of the Kinase-Glo reagent. After 5 min of incubation, the 
luminescence readouts from the wells were measured using Tecan microplate reader 
with i-control software. The ATP and substrate peptide concentrations used in the 
assay were 10 µM and 50 µM, respectively. The following control reactions were also 
performed simultaneously. 
1. Enzyme control (No kinase, Buffer+Substrate+ATP), 
2. Inhibitor control (No inhibitor, Buffer+Kinase+Substrate+ATP), 
3. Substrate control (No substrate, Buffer+Kinase+ATP) 
4. Buffer alone. 
    For the inhibition potency of staurosphorine probe, the inhibition assay was 
performed with ProFluor
®
 PKA Assay Kit from Promega following the manufactures 
instructions. Briefly, recombinant PKA, Bisamide Rhodamine 110 peptide substrate 
(PKA R110 Substrate), ATP and probe STS-1 were mixed in the 1× reaction buffer 
provided by kits at a volume of 10 µL in a flat-bottom black 384-well plate. The 
incubation was allowed to continue for 20 min at r.t. and 5 µL protease reagents in 1× 
termination buffer was added into the reaction, mixed and incubated for 30 min at r.t. 
Finally, the reaction was quenched by the addition of 5 µL stabilizer reagent in 1× 
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termination buffer, mixed and the fluorescence readouts from the wells were 
measured at 485/530 nm using Tecan microplate reader with i-control software.  
    The luminescence intensity from each well was measured and the inhibition 
potency was calculated using the following relation, 
Potency = 1 - Remaining activity 
    Dose-dependent inhibition assays were performed by varying the concentration 
of the probe under optimized enzyme concentration of ~50 nM. The IC50 value of the 
probe was calculated from the percentage activity vs. log [concentration of probe] 
curves generated using GraphPad Prism software. 
8.6  Microarray-based Screening 
8.6.1 Preparation of Avidin Slides 
    25×75 mm glass slides (Sigma-Aldrich) were cleaned in piranha solution 
(sulfuric acid/hydrogen peroxide, 7:3). Amine functionality was incorporated onto the 
slides by silanization using a solution of 3% (aminopropyl) triethoxysilane in 2% 
water and 95% ethanol. After 1-2 h incubation, the slides were washed with ethanol 
and cured at 150 ºC for at least 2 h. The resulting amine slides were incubated in a 
solution of 180 mM succinic anhydride in DMF for 30 min before being transferred to 
a boiling water bath for 2 min. The slides were rinsed with ethanol and dried under a 
stream of nitrogen. The carboxylic acid derivatized slide surface was activated with a 
solution of 100 mM of HBTU (O-Benzotriazole-N, N, N‟, N‟-tetramethyl–uronium– 
hexafluoro-phosphate), 200 mM DIEA, and 100 mM N-hydroxysuccinimide in DMF, 
thus generating the NHS-derivatized slides. These surfaces were reacted with a 
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solution of 1 mg/mL avidin in 10 mM NaHCO3 (pH = 9) for 40 min, washed with 
water, air dried. The unreacted NHS groups were quenched with a solution of 2 mM 
aspartic acid in a 0.5 M NaHCO3 buffer, pH 9. These slides were washed with water, 
dried and stored at 4 ºC, ready for printing. 
8.6.2 Microarray Preparation 
    All compounds stocks were prepared in a 1:1 DMSO/PBS spotting solution (to 5 
mM final concentration), and were distributed in 384-well plates. All compounds 
were shown to be completely soluble in this spotting solution. One slide was spotted 
on an ESI SMA arrayer (Ontario, Canada) with the print head installed with 8 Stealth 
SMP8B Microspotting pins (Telechem, USA.). Spots generated were of 
approximately 350 μm diameter and were printed with a spot-spot spacing of 450 μm. 
The pins were rinsed in between samples using two cycles of wash (for 10 s) and 
sonication (for 10 s) in reservoirs containing 70 % ethanol followed by drying under 
reduced pressure (for 10 s). The slides were allowed to stand for 1 h on the printer 
platform and stored at 4 ºC until use. Before incubation with the labeled proteins or 
lysates, the slides were rinsed with PBS (pH 7.4) for 10 min and blocked with 
PBS-containing 1 % BSA for 1 h. For studies with the 284-member library, all 
compounds were spotted on the same slide in duplicate. 
8.6.3 Protein /proteome Labeling and Screening on SMM 
    Cellular lysates were minimally labeled with Cy3 dyes for 1 h on ice 
following the manufacturer‟s protocols. The excessive dye was quenched with a 
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10-fold molar excess of hydroxylamine for a further 1 h. The excess dye was 
removed by buffer exchange with a Microcon centrifugal filter (Millipore, USA) 
or extensive dialysis at 4°C overnight (Amersham, GE Healthcare, USA). The 
labeled lysates was reconstituted in a final buffer volume of 30 μL of HEPES (pH 
5.4) containing 1% bovine serum albumin. In a standard microarray experiment, 
the labeled lysates (4 µg in 30 µL HEPES) was applied under cover slip to the 
array. The samples were then incubated with the array in a humidified chamber for 
1 h at r.t. before repeated rinses with PBST (PBS containing 0.05% of Tween 20), 
typically washes three times (one time/10 min) with gentle shaking. Slides were 
scanned using an ArrayWoRx microarray scanner installed with the relevant filters 
(Cy3, λex/em = 548/595 nm; Cy5, λex/em = 633/685 nm; fluorescein, λex/em = 490/528 
nm). 
8.6.4 Data Extraction and Analysis 
    Microarray data was extracted using the ArrayWoRx software. Values from 
duplicated points were background subtracted and averaged (Duplicated spots with a 
standard deviation > 0.2 were rejected). The data analysis was carried out with 
Microsoft Excel. Venn diagrams were generated to identify the potent binders against 
Aspartic proteases, using the Venn Diagram Generator 
(http://www.pangloss.com/seidel/Protocols/venn.cgi).  
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Figure 8.2 The spotting format of microarrays used in chapter 4 study. (a) The 
arrangement of the 198-member library on microarrary; (b) The spotting format 











Figure 8.3 The spotting format of microarrays used in chapter 5 study, unless 
otherwise specified. 11 selected inhibitor hits were shaded in color. 
8.7  Fluorescent Profiling of Aspartic Proteases and Protein Kinases 
8.7.1 Labeling of Recombinant Aspartic Proteases 
    Detail of the labeling experiment was described below. Pepsin stocks were made 
C-c-14 C-c-16 C-C-18 C-c-23 C-c-25 C-c-15 C-c-17 C-c-19 C-c-24
C-c-4 C-c-6 C-c-8 C-c-10 C-c-12 C-c-5 C-c-7 C-c-9 C-c-11 C-c-13
C-a-20 C-b-21 C-b-23 C-b-25 C-c-2 C-a-21 C-b-22 C-b-24 C-c-1 C-c-3
C-a-10 C-a-12 C-a-14 C-a-16 C-a-18 C-a-11 C-a-13 C-a-15 C-a-17 C-a-19
N-c-44 C-a-2 C-a-4 C-a-6 C-a-8 C-a-1 C-a-3 C-a-5 C-a-7 C-a-9
N-b-50 N-b-52 N-b-31 N-c-2 N-c-42 N-b-51 N-b-53 N-c-1 N-c-3 N-c-43
N-b-37 N-b-40 N-b-42 N-b-44 N-b-47 N-b-38 N-b-55 N-b-43 N-b-46 N-b-49
N-a-45 N-a-47 N-b-20 N-b-22 N-b-33 N-a-46 N-a-48 N-b-21 N-b-32 N-b-34
N-a-35 N-a-37 N-a-39 N-a-41 N-a-43 N-a-36 N-a-38 N-a-40 N-a-42 N-a-44
N-a-25 N-a-27 N-a-29 N-a-31 N-a-33 N-a-26 N-a-28 N-a-30 N-a-32 N-a-34
C-b-15 C-b-17 C-b-19 C-c-20 C-c-22 C-b-16 C-b-18 C-b-20 C-c-21
C-b-5 C-b-7 C-b-9 C-b-11 C-b-13 C-b-6 C-b-8 C-b-10 C-b-12 C-b-14
N-c-40 C-a-22 C-a-24 C-b-1 C-b-3 N-c-55 C-a-23 C-a-25 C-b-2 C-b-4
N-c-18 N-c-18 N-c-22 N-c-33 N-c-37 N-c-19 N-c-21 N-c-32 N-c-34 N-c-38
N-c-6 N-c-10 N-c-12 N-c-14 N-c-16 N-c-8 N-c-11 N-c-13 N-c-15 N-c-17
N-b-12 N-b-14 N-b-16 N-b-16 N-c-4 N-b-13 N-b-15 N-b17 N-b-19 N-c-5
N-a-55 N-b-2 N-b-4 N-b-6 N-b-10 N-b-1 N-b-3 N-b-5 N-b-8 N-b-11
N-a-21 N-a-23 N-a-49 N-a-51 N-a-53 N-a-22 N-a-24 N-a-50 N-a-52 N-a-54
N-a-11 N-a-13 N-a-15 N-a-17 N-a-19 N-a-12 N-a-14 N-a-16 N-a-18 N-a-20





CY22 CY24 Buff Buff CY23 CY25 Buff Buff
CY14 CY16 CY18 CY20 CY15 CY17 CY19 CY21
CY6 CY8 CY10 CY12 CY7 CY9 CY11 CY13
CF1 CF3 CF5 CF7 CF2 CF4 CF6 CF8
NK16 NK18 NK20 NK22 NK17 NK19 NK21 NK23
NK8 NK10 NK12 NK14 NK9 NK11 NK13 NK15
NL34 NL36 NL38 NA2 NL35 NL37 NA11 NA3
NL26 NL28 NL30 NL32 NL27 NL29 NL31 NL32
NL18 NL20 NL22 NL24 NL19 NL21 NL23 NL25
CA23 CA25 CY2 CY4 CA24 CY1 CY3 CY5
CA15 CA17 CA19 CA21 CA16 CA18 CA20 CA20
CA7 CA9 CA11 CA13 CA8 CA10 CA12 CA14
NV30 CK2 CK4 CK6 CK1 CK3 CK5 CK7
NV22 NV24 NV26 NV28 NV23 NV25 NV27 NV29
NV14 NV16 NV18 NV20 NV15 NV17 NV19 NV21
NL10 NL12 NL14 NL16 NL11 NL13 NL15 N-b17
NL2 NL4 NL6 NL8 NL3 NL5 NL7 NL9
NF49 NF51 NF53 NF55 NF50 NF52 NF54 NF56
CL24 CA1 CA3 CA5 CL25 CA2 CA4 CA6
CL16 CL18 CL20 CL22 CL17 CL19 CL21 CL23
CL8 CL10 CL12 CL14 CL9 CL11 CL13 CL15
NV6 NV8 NV10 NV12 NV7 NV9 NV11 NV13
NY22 NY24 NV2 NV4 NY23 NV1 NV3 NV5
NY14 NY16 NY18 NY20 NY15 NY17 NY19 NY21
NF41 NF43 NF45 NF47 NF42 NF44 NF46 NF48
NF33 NF35 NF37 NF39 NF34 NF36 NF38 NF40
NF25 NF27 NF29 NF30 NF26 NF28 NF30 NF32
CF25 CL2 CL4 CL6 CL1 CL3 CL5 CL7
CF17 CF19 CF21 CF23 CF18 CF20 CF22 CF24
CF9 CF11 CF13 CF15 CF10 CF12 CF14 CF16
NY6 NY8 NY10 NY12 NY7 NY9 NY11 NY13
NA12 NA14 NY2 NY4 NA13 NY1 NY3 NY5
NA4 NA6 NA8 NA10 NA5 NA7 NA9 NA11
NF17 NF19 NF21 NF23 NF18 NF19 NF21 NF23
NF9 NF11 NF13 NF15 NF10 NF12 NF14 NF16
NF1 NF3 NF5 NF7 NF2 NF4 NF6 NF8
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fresh using 10 mM HCl. Renin stock was made fresh by using water. Stocks of PM I 
(350 ng/mL in 100 mM NaOAc, 10% glycerol, pH 4.5), PM II (250 ng/mL in 100 
mM NaOAc, 10% glycerol, pH 4.5) and HAP (1.5 mg/mL in 100 mM MES, 10% 
glycerol, pH 6.5) were diluted in appropriate buffer from the in -20 
o
C before use, 
respectively 100 mM NaOAc, 10% glycerol, pH 4.5 for PM I and PM II, 100 mM 
NaOAc, 10% glycerol, pH 6.5 for HAP. Labeling experiments were carried out with 
the following optimized conditions: desired enzyme amount, respectively 100 ng for 
pepsin, 100 ng for renin, 50 ng for PM I, PM II and HAP, were individually incubated 
with each probes (5 µM final concentration) in appropriate buffer for 20 min at r.t. For 
pepsin and renin, reaction buffer condition was as follow: 50 mM Tris Cl pH 2.0. For 
PM I, PM II and HAP, reaction buffer condition was 100 mM NaOAc, 10% glycerol, 
pH 4.5 or 100 mM NaPO4, 10% glycerol pH 7,5. After 20 min incubation at r.t., 
samples were irradiated on ice for 25 min using a B100A lamp (UVP) at a distance of 
5 cm. After irradiation, samples were boiled for 10 min with 4 μL of 6× loading buffer. 
The sample mixture (24 μL) were resolved by 12% SDS-PAGE followed by in-gel 
fluorescence scanning with the Typhoon gel scanner. Labeling bands arising from the 
experiment were spectral quantified by Image J software. Reactivity values were 
imported to cluster analysis software to generate heatmap and treeview for analysis. 
8.7.2 Labeling and Identification of PM I, PM II and HAP 
    Infected RBC lysates were prepared as described previously. The 1.0 mg of total 
protein from infected RBC lysates was pre-incubated in labeling reaction buffer 
containing 100 mM sodium acetate, 10 % glycerol, pH 5.0 and 5 µM photo-affinity 
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probe (P11). After labeling, the reaction samples were desalted and concentrated by 
acetone precipitation overnight at -20 
o
C. Precipitated protein samples were collected 
by centrifugation at 13,000 rpm in a microcentrifuge. Samples were resuspended in 
1× re-swelling buffer (8 M urea, 2% CHAPS and 2% IPG buffer and 0.002% 
bromphenol blue), and briefly sonicated. Just prior to use, DTT was added at a final 
concentration of 3 mg/mL. Rehydration buffer and stock DTT (62.5 mg/mL) were 
stored at -20 °C. Rehydrated IEF strips were isoelectrically focused at r.t. under low 
viscosity oil with a gradient voltage of 0-200 V for 1 min, 200–3,500 V for 1.5 h, and 
a constant voltage of 3,500 V for 1.5 h. After IEF separation, the gel strip was reduced 
and alkylated. The reduction step was performed for 15 min in 10 mL of equilibration 
buffer 1 (0.5% w/v DTT in 50 mM Tris-HCl pH 8.8, 6 M urea, 30% v/v glycerol, 2% 
w/v SDS, and 0.002% w/v bromphenol blue). The alkylation step was performed for 
15 min in 10 mL of equilibration buffer 2 (4.5% w/v iodoacetamide in 50 mM 
Tris-HCl pH 8.8, 6 M urea, 30% v/v glycerol, 2% w/v SDS, and 0.002% w/v 
bromphenol blue). The IEF strip was equilibrated in equilibration buffer stock 
solution (50 mM Tris-HCl pH 8.8, 6 M urea, 30% v/v glycerol, 2% w/v SDS, and 
0.002% w/v bromphenol blue). Next, the equilibrated IEF strips were each placed on 
a preparative well and sealed using 1% agarose plus 0.002% (w/v) bromphenol. After 
electrophoresis the two-dimensional gels were scanned with Typhoon fluorescence 
scanner. Fluorescence spots corresponding to each target were excised directly from 
the gel and saved in -80 
o
C for future MS/MS analysis. Trypsin digestion was 
performed with In-Gel Trypsin Digestion Kit from Pierce. After digestion, digested 
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peptides were then extracted from the gel with 50% ACN and 1% formic acid. 
Extracts were concentrated by speedvec to 10 µL and analyzed by mass spectrometry. 
Spectra were analyzed by Mascot (www.mascot.com) using NCBInr database. 
Parameters used for Mascot searches were as follows: allow up to one missed 
proteolytic cleavage; peptide mass tolerance, 2 Da; production mass tolerance, 0.6 Da. 
8.7.3 Characterization of Known Inhibitors for FV Plasmepsins 
    Further, we evaluated and validated the fidelity of this gel format approach as a 
surrogate assay for inhibitor discovery by testing several well-known plasmespins 
inhibitors against PM I and PM II and HAP. Inhibitor potency against 
well-characterized FV plasmepsins was assessed by incubation of those plasmepsins 
with each inhibitor followed by reaction with the aspartic protease activity–based 
probes. The potency of specific inhibitor scaffolds was measured as a ratio of the 









Figure 8.4 Characterization of two well-known inhibitors against recombinant FV 
plasmepsins in competitive labeling assay.  
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8.7.4 Characterization of AfBPs with γ-30 Cell Lysates 
    Details of the cell lysate labeling experiment are described below: a desired 
lysate amount (15 µg of total proteins as determined by Bradford assay) was 
incubated with the probes (5 μM final concentration; 5 % DMSO) in HEPES buffer 
for 30 min at r.t. After 30 min incubation, samples were irradiated on ice for 25 min 
using a B100A lamp (UVP) at a distance of 5 cm. After irradiation, samples were 
boiled for 10 min with 4 μL of 6× SDS loading buffer, resolved on a 12% SDS-PAGE 
followed by in-gel fluorescence scanning with a Typhoon gel scanner. Western 
blotting was carried out with anti-PS1 (Santa Cruz Biotechnology) 
    To further validate the labeling of PS-NTF by probe, biotin pull-down from 
labeled lysates experiments were carried out as described below: 2 mg of lysates was 
labeled by 5 μM probe A1 in 2 mL reaction using previously described conditions. 
After labeling, the lysates in the reaction were acetone precipitated and resolubilized 
in 0.1% SDS in PBS with brief sonication. This resuspended sample was then 
incubated with avidin-agarose beads (100 μL/1 mg protein) at r.t. for 30 min. After 
centrifugation, supernatant were removed and the beads were washed with 1% SDS in 
PBS for 4 times. After washing, the beads were boiled in elution buffer (200 mM Tris 
pH 6.8, 400 mM DTT, 8% SDS). This pull-down sample from labeled lysates was 
then separated on 12% SDS PAGE gel together with pull-down sample from 
un-labeled lysates. After SDS-PAGE gels separation, proteins were then transferred to 
a PVDF membrane and subsequently blocked with 2.5% (w/v) BSA/PBST. 
Membranes were incubated for 1 h at r.t. with neutravidin conjugated HRP (1:10000) 
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or anti-PS-NTF (1/5000). After wash with PBST for three times, blots were further 
incubated with appropriate secondary antibody for anti-PS-NTF (1:5000) for 1 h at r.t. 
After incubation, blot was washed again with PBST for 3 times and the SuperSignal 
West Pico kit (Pierce) was used to develop the blot. 
8.7.5 Fluorescent Labeling of Mammalian Cell Lysates 
    For individule probe labeling, cellular lysates from mammalian cells 
interested (~50 μg of total proteins as determined by Bradford assay) was 
incubated with individule TER probe (1 μM final concentration; 5 % DMSO) in 
HEPES buffer (50 mM HEPES, pH 5.4, 1 mM EDTA, 100 mM NaCl) for 30 min 
at r.t. After 30 min incubation, samples were irradiated on ice for 25 min using a 
B100A lamp (UVP) at a distance of 5 cm. The reactions were then resuspended in 
50 µL 1× SDS-loading buffer and heated for 10 min at 95 ºC; around 20 µg of 
protein was loaded per gel lane for separation by SDS-PAGE (12% SDS gel), then 
visualized by in-gel fluorescence scanning using a Typhoon 9410 Variable Mode 
Imager scanner. 
    For probe cocktails labeling, cellular lysates from mammalian cells of interest 
(~50 μg of total proteins) were incubated with cocktails of 11 TER probes (0.5 µM 
of each probe, 5 % DMSO) in HEPES buffer (50 mM HEPES, pH 5.4, 1 mM 
EDTA, 100 mM NaCl) for 30 min at r.t. After 30 min incubation, samples were 
irradiated on ice for 25 min using a B100A lamp (UVP) at a distance of 5 cm. 
After irradiation, pre-chilled acetone (0.5 mL) was added to quench the reactions, 
and placed at -20 ºC for 30 min followed by centrifuged at 13,000 rpm for 10 min 
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at 4 ºC to precipitate proteins. The supernatant was discarded and the pellet was 
washed two times with 200 µL of pre-chilled methanol. The protein pellets were 
then resuspended in 50 µL 1× SDS-loading buffer and heated for 10 min at 95 ºC; 
around 20 µg of protein was loaded per gel lane for separation by SDS-PAGE 
(12% SDS gel), then visualized by in-gel fluorescence. 
8.7.6 Proteome Profiling of Protein Kinases 
8.7.6.1 Labeling of Kinases Present in the Bacterial Proteome 
    To evaluate the performance of probe in a complex bacterial proteome, the 
labeling experiments were carried out with kinase probe and bacterial lysates. 
Bacterial lysates were prepared using previous reported procedures with minor 
modification.
 
The culture of LB (100 mL) with a single colony containing PKA gene, 
were grown at 37 ºC with shaking to reach OD600 = 0.8. Subsequently, IPTG (0.2 mM 
final concentration) was added to induce protein expression and incubated for further 
6 h at 37 ºC with shaking (230 rpm). 5 mL LB was taken out before and after inducing, 
respectively, and harvested by centrifugation at 4000 rpm for 10 min at 4 ºC. The 
resulting pellets were resuspended in lysis buffer (25 mM HEPES, pH 7.5, 150 mM 
NaCl, 2 mM MgCl2, 50 µM PMSF) and sonicated (to complete lysis, 10 rounds of 1s 
on and 1s off, at 25 % amplitude), before centrifugation for 10 min (1000 rpm at 4 °C). 
The resulting supernatant was further centrifuged for 15 min (13,000 rpm at 4 °C). 
The total protein concentration of this lysate was then quantified by Bradford‟s Assay 
(Bio-Rad USA), and stored in -20 °C, and used for all subsequent labeling 
experiments. 
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    To different amount of above bacterial lysates, probe (final 1 µM) was added and 
incubated for 30 min at r.t. Subsequently, the reactions were irradiated with UV light 
(~350 nm) for 20 min followed by click-chemistry with rhodamine azide (TER-N3), 
and separated by SDS PAGE gel, and analyzed by in-gel fluorescence scanning. 
Results showed that stronger labeling signal was observed only for the induced lysates, 
and dose-dependent increase of fluorescence band intensity was observed with 
increased amounts of bacterial lysates. 
8.7.6.2 Labeling of Kinases Present in Mammalian Proteome 
For in vitro proteome labeling, kinase probe was added to cell lysates (50 μg) in 
50 μL of HEPEs buffer at a final concentration of 1-50 μM in the presence or absence 
of excess competitor (a final concentration of 100 μM). Unless indicated otherwise, 
samples were incubated for 30 min with varying concentrations of probe at r.t. After 
incubation, the samples were irradiated for 20 min under UV light (~350 nm). 4 μL of 
the freshly premixed click chemistry reaction cocktail in PBS [rhodamine-azide (100 
μM, 1.0 mM stock solution in DMSO), Tris[(1-benzyl-1H-1,2,3-triazol-4-yl) 
methyl]amine (TBTA)(1.0 mM, 24 mM freshly prepared stock solution in deionized 
water), Sodium ascorbate (1 mM, 24 mM freshly prepared stock solution in deionized 
water) and CuSO4 (1 mM, 24 mM freshly prepared stock solution in deionized water)] 
was added and vortexed, then incubated for further 2 h at r.t. with gentle mixing. The 
reactions were terminated by the addition of pre-chilled acetone (0.5 mL), placed at 
-20 
o
C for 30 min and centrifuged at 13,000 rpm for 10 min at 4 oC to precipitate 
proteins. The supernatant was discarded and the pellet was washed two times with 
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200 μL of pre-chilled methanol. The protein pellets were then resuspended in 20 μL 
1× SDS-loading buffer and heated for 10 min at 95 oC; around 20 μg of protein was 
loaded per gel lane for separation by SDS-PAGE (10% SDS gel), then visualized by 
in-gel fluorescence scanning using a Typhoon 9410 Variable Mode Imager scanner.  
For in situ labeling, cells were grown to 80-90% confluence in 24-well plates 
under the conditions described above. The medium was removed, and cells were 
washed twice with cold PBS, treated with 0.5 mL of DMEM-containing probe (1-50 
μM), with or without competitive inhibitor (100 μM). Probes were applied from 
DMSO stocks whereby DMSO never exceeded 1% in the final solution. The same 
volume of DMSO was used as a negative control. After 5 h of incubation at 37 
o
C/5% 
CO2, the medium was aspirated, and cells were washed twice gently with PBS to 
remove the excessive probe followed by UV irradiation (~350 nm) for 20 min on ice. 
The cells were then trypsined and pelleted by centrifugation. Eventually, the cell 
pellets were resuspended in PBS (50 μL), homogenized by sonication, and diluted to 
1 mg/mL with PBS. Probe targets were detected by click chemistry with 
rhodamine-azide, SDS PAGE analysis, and in-gel fluorescence scanning. 
8.8  Pull-down and Mass Spectrometry Identification 
8.8.1 Pull-down Assay with Aspartic Protease Probes 
    Two sets of pull-down assays were carried out. For individule probe 
pull-downs, in brief, biotinylated aspartic protease probes (10 µM final 
concentration) was incubated with fresh T47D cell lysates (~5 mg) for 0.5 h at 4 
o
C in an acidic buffer (50 mM HEPES, pH 5.4, 1 mM EDTA, 100 mM NaCl). In 
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the meanwhile, the same volumn of DMSO was incubated with T47D cell lysates 
as a negative control experiment. Subsequently the samples were irradiated on ice 
for 25 min under UV lamp. The resulting mixtures were incubated with 
NeutrAvidin agarose beads for further 2 h at 4 
o
C. After that, the supernatant was 
removed by centrifugation, and the beads were washed with 0.1% SDS in PBS 
once, and washed with PBS for 4 times. After washing, the beads were boiled in 
the elution buffer (200 mM Tris at pH 6.8 containing 400 mM DTT and 4% SDS) 
for 15 mins. Eluted proteins were separated on 12% SDS-PAGE gel (together with 
negative pull-down control). Following SDS-PAGE separation, protein bands were 
visualized by coomassie blue/silver staining. 
    In order to identify the cell targets of hydroxyethylamine pharmacophore, 
pull-down experiments with cocktails of 11 biotinylated aspartic protease probes 
were also carried out. In brief, fresh T47D cell lysates (~5 mg) were incubated 
with the cocktails of 11 biotinylated probes (5 μM final concentration) for 0.5 h at 
4 
o
C in an acidic buffer (50 mM HEPES, pH 5.4, 1 mM EDTA, 100 mM NaCl). 
Similarly, the same volumn of DMSO was incubated T47D lysates as a negative 
control. Subsequently the reactions were irradiated on ice for 25 min under UV 
lamp and quenched by pre-chilled acetone (10 mL) and placed at -20 ºC for 30 
min. The mixtures were then centrifuged at 13,000 rpm for 10 min at 4 ºC to 
precipitate the proteins. The supernatant was discarded and the pellet was washed 
two times with 10 mL of pre-chilled methanol. The protein pellets were 
resolubilized into 0.1% SDS-PBS buffer. Next, The solutions were incubated with 
                                                                         201 
NeutrAvidin agarose beads for 2 h at 4 
o
C. The supernatant was removed by 
centrifugation, and the beads were washed with 0.1% SDS in PBS once, and 
washed with PBS for 4 times. After washing, the beads were boiled in the elution 
buffer (200 mM Tris at pH 6.8 containing 400 mM DTT and 4% SDS) for 15 mins. 
Eluted proteins were separated on 12% SDS-PAGE gel (together with negative 
pull-down control). The protein bands were visualized by coomassie blue/silver 
staining. 
8.8.2 Pull-down Assay with Kinase Probes 
    To identify in vitro and in situ targets of dasatinib/staurosphorine in cancer cell 
lines, pull-down experiments were carried out followed by immunoblotting and 
MS/MS identification experiments. Fresh cell lysates were prepared as described 
previously. Protein concentrations were determined according to Bradford. In vitro 
pull-down experiment: cellular lysates (5 mg) were supplemented with 200 µL 5× 
HEPEs buffer (125 mM HEPES at pH 7.5, 750 mM NaCl, 10 mM MgCl2), the 
reaction volume will be adjusted to 1 mL with milli-Q water. Subsequently, a solution 
of probes (10 μΜ, 10 μL of a 1 mM stock soloution) was added, and equilibration was 
carried out for 2 h at 4
 o
C. The reaction mixture was then irradiated for 20 min using a 
4W UV lamp. Subsequently, the reaction was reacted with biotin-azide (or biotin 
cleavable azide) by click chemistry under the conditions described before, acetone 
precipitated, and resolubilized in 0.1% SDS in PBS with brief sonication. This 
resuspended sample was then incubated with avidin-agarose beads (100 μL/mg 
protein) overnight at 4 
o
C. After centrifugation, supernatant were removed and the 
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beads were washed with 0.1% SDS once and PBS for 4 times. After washing, the 
beads were boiled in 1× SDS loading buffer (200 mM Tris pH 6.8, 400 mM DTT, 8% 
SDS) for 15 min. If cleavable biotin azide was used, the beads were incubated for 1 h 
at r.t. with elution buffer (25 mM Na2S2O4, 100 mM NH4HCO3, 0.5% SDS).  
    For in situ pull-down, briefly, probes (20 μM) were directly added in live cells 
followed by incubation for 5 h. DMSO should never exceed 1% in the final solution. 
After 5 h of incubation at 37 
o
C/5% CO2, the medium was aspirated, and cells were 
washed twice gently with PBS to remove the excessive probe followed by UV 
irradiation (~350 nm) for 20 min on ice. The cells were then trypsined and pelleted by 
centrifugation. Eventually, the cell pellets were resuspended in PBS (50 μL), 
homogenized by sonication, and diluted to 1 mg/mL with PBS. The labeled lysates 
were then subjected to click reaction with biotin azide, and all the subsequent 
experiments just follow above in vitro pull-down procedure. 
8.8.3 Mass Spectrometric Analysis 
    For MS/MS identification, proteins from pulled-down fractions were separated 
on 10% SDS-PAGE gel followed by silver staining or coomassie staining. Each gel 
lanes were cut into multiple slices. Subsequently, trypsin digestion (using In-Gel 
Trypsin Digestion Kit, Pierce) and peptide extraction (with 50% acetonitrile and 1% 
formic acid) were carried out. The samples were then dried in vacuo and stored at -20 
o
C. LCMS/MS analysis was performed using an LTQ-FT ultra mass spectrometer 
(Thermo Electron, Germany) coupled with an online Shimadzu UFLC system 
utilizing nanospray ionization. Peptides were first enriched with a Zorbax 300SB C18 
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column (5 mm × 0.3 mm, Agilent Technologies), followed by elution into an 
integrated nanopore column (75 μm × 100 mm) packed with C18 material (5 μm 
particle size, 300 Å pore size). Mobile phase A (0.1% formic acid in H2O) and mobile 
phase B (0.1% formic acid in acetonitrile) were used to establish the 90-min gradient, 
comprising 3 min of 0-5% B, then 52 min of 5-30% B, followed by 12 min of 30-60% 
B; maintained at 80% B for 8 min before re-equilibrating at 5% B for 15 min. Sample 
was injected into the MS with an electrospray potential of 1.8 kV without sheath and 
auxiliary gas flow, ion transfer tube temperature of 180 
o
C, and collision gas pressure 
of 0.85 m Torr. A full-survey MS scan (350-2000 m/z range) was acquired in the 7-T 
FT-ICR cell at a resolution of 100,000 and a maximum ion accumulation time of 1000 
ms. Precursor ion charge-state screening was activated. The linear ion trap was used 
to collect peptides where the 10 most intense ions were selected for collision-induced 
dissociation (CID) in MS2, performed concurrently with a maximum ion 
accumulation time of 200 ms. Dynamic exclusion was activated for this process, with 
a repeat count of one and exclusion duration of 30 s. For CID, the activation Q was 
set at 0.25, isolation width (m/z) 2.0, activation time 30 ms, and normalized collision 
energy 35%. The Extract-Msn (version 4.0) program found in Bioworks Browser 3.3 
(Thermo Electron, Germany) was used to extract tandem MS spectra in the data 
format from the raw data of the LTQ-FT ultra. These data files were then converted 
into MASCOT generic file format using an in-house program. Intensity values and 
fragment ion m/z ratios were not manipulated. These data were used to obtain protein 
identities by searching against the corresponding database by means of an in-house 
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MASCOT server (version 2.2.03, Matrix Science, Boston, MA). The search was 
limited to a maximum of two missed trypsin cleavages, #13C of 2, mass tolerances of 
10 ppm for peptide precursors and 0.8 Da for fragment ions. Only proteins with a 
MOWSE score higher than 40, corresponding to p < 0.05, were considered significant. 
The peptide/protein lists obtained were exported to an html file. 
8.9  Cell Culture and Preparation of Lysates 
8.9.1 Parasite Cultures 
    Plasmodium falciparum 3D7 strain was used in this study. Parasites were 
cultured in RPMI medium 1640 (Invitrogen, USA) supplemented with 0.29225 g 
L-glutamine, and 0.05 g hypoxanthine dissolved in 1 mL 1M NaOH. Parasites were 
synchronized twice 16 hrs apart at ring stage using 2.5% sorbitol. Cultures were 
stored at 37 
o
C after gassing with a 5% CO2, 3% O2 and 92% N2 gas mixture and their 
hematocrit maintained at 2.5%. Parasitized red blood cells were treated with 0.1% 
Saponin in PBS for 15 min at r.t. with shake. The parasites were centrifuged and the 
pellet was resuspended in 50 mM Acetate pH 5.5, 1 mM DTT, 0.1% NP-40. Lysates 
were then centrifuged at 15,000 rpm for 5 min and split into a pellet fraction and a 
soluble fraction. 
8.9.2 Mammalian Cell Cultures 
    Cell lines were obtained from the National Cancer Institute Developmental 
Therapeutics Program (NCI60 cell). -30, HEK293T, HepG2, OVCAR-3, T47D, 
MDA-MB-435, HCT116 and MCF7 cells were grown in DMEM (Invitrogen, 
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Carlsbad, CA) containing 10% heat-inactivated fetal bovine serum (FBS; Gibco 
Invitrogen), 100 U/mL penicillin and 100 µg/mL streptomycin (Thermo Scientific, 
Rockford, IL) and maintained in a humidified 37 
o
C incubator with 5% CO2. K562 
cells was grown in RPMI 1640 medium (Invitrogen Corporation) supplemented 
with 10% heat-inactivated fetal bovine serum, 100 U/mL penicillin and 100 µg/mL 
streptomycin and maintained in a humidified 37 
o
C incubator with 5% CO2. 
     Mammalian lysates were prepared as following: fresh cell pellets were 
thawed on ice by suspension in 100 μL of lysis buffer (50 mM HEPES, pH 5.4, 1 
mM EDTA, 100 mM NaCl, 10% Glycerol, 0.1% NP-40), incubated for 15 min on 
ice, and then spun for 20 min at 13,000 rpm at 4 
o
C. The cleared supernatant was 
decanted to an Eppendorf tube and kept at 4 
o
C. Protein concentration was 
quantified by Bradford assay (Bio-Rad, USA), aliquoted and stored in -80 °C, and 
used for subsequent screening on array. 
8.9.2.1 Preparation of Membrane Fractions of γ-30 cells 
    The cellular lysates were centrifuged at 800 rpm for 10 min to remove nuclei and 
cell debris. The postnuclear supernatant was further fractionated by sequential 
centrifugation at 100,000 rpm for 1 h .The collected pellet were resuspended in 
HEPEs buffer with 1% CHAPSO followed by centrifugation at 100,000 rpm for 
further 1 h. The supernant was collected with addition of 20% glycerol and stored at 
-80 
o
C until use. All centrifugation steps were carried out at 4 
o
C. 
8.10 Western Blotting 
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    For immunoblotting experiments, samples were separated on 10% SDS-PAGE 
gel and further transferred to PVDF membranes. Membranes were then blocked with 
3% BSA in TBST (0.1% Tween in TBS) for 1 h at r.t. After blocking, membranes 
were incubated with the respective primary antibody at r.t., or overnight at 4 
o
C. The 
membranes were then washed with TBST (0.1% Tween in TBS) for four times (10 
min/time) and incubated with an appropriate secondary antibody [anti-mouse 
conjugated HRP (1/3000), or anti-rabbit conjugated HRP (1/5000)]. After secondary 
incubation, blots were washed again with TBST for 4 times before the development 
with Dura (Pierce). 
8.11 Cell Proliferation Assay 
Cell viability was determined using the XTT colorimetric cell proliferation kit 
(Roche) following manufacturer‟s guidelines. Briefly, cells were grown to 20-30% 
confluence (since they will reach ∼90% confluence within 48 to 72 h in the absence of 
drugs) in 96-well plates under the conditions described above. The medium was 
aspirated, and then washed with PBS, and treated in duplicate with 0.1 mL of the 
medium containing different concentrations of probes (1-50 μM) or drugs (1-50 μM, 
as a positive control). Probes were applied from DMSO stocks whereby DMSO never 
exceeded 1% in the final solution. The same volume of DMSO was used as a negative 
control. Fresh medium, along with two probes and dasatinib, were added every 24 h. 
However, for K562 cell only one time probes and drug were added. After a total 
treatment time of 72 h, proliferations were assayed using the XTT colorimetric cell 
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proliferation kit (Roche) following manufacturer‟s guidelines (read at 450 nm). Data 
represent the average (s.d. for two trials). 
8.12 Protein Expression and Purification 
All the genes including the chicken c-Src (residues 251-533), c-SrcY416C, 
c-SrcY527C, c-SrcY416C527C and c-SrcT338M genes were cloned into pET-28a 
vector (Novagen) and modified to yield an N-terminal, tobacco etch virus protease 
cleavable (His)6 tag, a plasmid containing tyrosine phosphatase YopH cloned into 
pCDFDuet-1 (Novagen). All the c-Src mutants were generated by site-directed 
mutagenesis and confirmed by sequence analysis. 
All chicken c-Src (residues 251-533) variants were co-expressed in E. Coli and 
purified as previously described.
136 
Firstly, the two plasmids containing the c-Src 
(pET-28a) and the YOPH (pCDFDuet) were co-transformed into Escherichia coli 
BL21DE3 cells and plated on LB agar with kanamycin (50 mg/mL)/streptomycin (50 
mg/mL) and grown overnight at 37 
o
C. The colonies from the plates were then 
resuspended in the expression media (LB, 50 mg/mL/streptomycin, 50 mg/mL 
kanamycin). Cultures were grown to an OD600 of 1.2 at 37 
o
C, cooled for 1 h with 
shaking at 18 
o
C prior to induction for 16 h at 18 
o
C with 0.2 mM IPTG. Cells were 
harvested by 10 min centrifugation at 4000 rpm at 4 
o
C and resuspended in 50 mM 
sodium phosphate (pH 8.0), 300 mM NaCl, 10 mM imidazole for immediate 
purification. Cells were lysed by sonication at 4 
o
C. Insoluble protein and cell debris 
was spinned down through a 30-min centrifugation at 13,000 rpm at 4
 o
C. The 
supernatant was loaded onto a Ni NTA affinity column which was prior washed three 
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times with lysis buffer. The loaded column was incubated 3 h at 4
 o
C followed by 
removing of flow through. The beads were washed ten times with washing buffer (50 
mM NaH2PO4, 300 mM NaCl, 20 mM Imidazole). Finally, protein was eluted with 
elution buffer (50 mM NaH2PO4, 300 mM NaCl, 500 mM Imidazole). The eluted 
fractions were analyzed by SDS-PAGE gel, and buffer was exchanged to PBS by 
dialysis. 
The expression of the full length catalytically inactive Src (srcK295M) was based 
on previous procedure with a little modification.
149
 The coding region for amino acid 
residues 83-533 of chicken c-src gene was subcloned into pRSET vector (Invitrogen) 
with BamHI and HindIII sites on the 5`-and 3`-ends, respectively. The constructed 
plasmid pRSET-dsrc was co-transformed into BL21(DE3) strain of E. coli with 
YOPH(pCDFDuet) in the presence of ampicillin (50 mg/mL) and streptomycin (50 
mg/mL). The cells were grown in LB media at 37 
o
C to reach OD600 = 0.5 on a 1 L 
scale and then induced with 0.2 mM IPTG at 25 
o
C for 14 h. After harvesting and 
lysis, the proteins were purified followed above described procedure. 
8.13 Site-directed Mutagenesis of c-Src to SrcT338M 
Threonine 338 residues of c-Src were mutated to Methionine by using 
QuickChangeTM XL Site-directed Mutagenesis Kit (Strategene) with upstream 




T-3‟. Primers were designed to introduce the desired mutation site. Appropriate 
primer sequences were chosen to ensure that the Tm melting temperature was above 
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78 
o
C. Codon usage of amino acid was calculated to ensure the desired protein would 
be well expressed in E. coli cells. PCR amplification was first carried out to amplify 
the whole sequence of gene with the primer containing desired mutation site. The 
PCR product was confirmed with the desired PCR band with gel analysis. Dpn I 
enzyme was used to digest the template which contains the methylation site. PCR 
product was then transformed into top 10 competent cells and cultured in LB+Kan 
agar plates at 37 
o
C. One of the clonies from the agar plate was picked up and cultured 
in 5 ml LB+ Amp for overnight. Miniprep was used to extract the genes and DNA 
sequencing was carried out to confirm the presence of mutation site and correct frame 
of gene. 
8.14 Transient Transfection 
Briefly, vectors were transfected with Endofectin
TM
 transfection reagents 
(Genecopoeia) at 80% confluence in CHOK1 cell. After 8 h, the medium was 
changed to fresh grown medium. And the cells were incubated further 24 h in 37
 o
C 
/5% CO2 incubator. To generate protein lysates, cells were washed twice with cold 
phosphate buffered saline (PBS), and lysated by lysis buffer (25 mM HEPES at pH 
7.5, 150 mM NaCl, 2 mM MgCl2, 0.1% NP-40) for 30 min on ice. The cells were then 
resuspended and collected by centrifugation. Protein concentration was determined by 
the Bradford assay. 
8.15 Cellular Imaging 
    HepG2 cells were seeded onto 24-well plates containing sterile glass coverslips  
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and grown until 70-80% confluence. Further, cells were treated with 0.5 mL of 
DMEM with 20 µM probes or DMSO. After 5 h, the medium was removed, and cells 
were washed twice with PBS gently followed by UV irradiation (~350 nm) for 10 min. 
The cells were then fixed for 15 min at r.t. with 3.7% formaldehyde in PBS , and 
washed twice with cold PBS again, and permeabilized with 0.1% Triton X-100 in 
PBS for 10 min at r.t. The cells were then blocked with 2% BSA in PBS for 30 min at 
r.t., and then washed twice with PBS. Cells were subsequently treated with a freshly 
premixed click chemistry reaction solution in a 100 µL volume at final concentrations 
of the following reagents: 1 mM of CuSO4, 1 mM of TCEP, 100 µM of TBTA, and 10 
µM of rhodamine-azide in PBS for 2 h at r.t. with vigorous shaking. Cells were 
washed with PBS three times. If the background was still very high, the longer 
washing time was necessary. For colocalizing in situ targets of dasatinib analogues 
with c-Src, cells were further incubated with anti-c-Src primary antibodies (1:50) for 
1 h at r.t. (or overnight at 4
 o
C), and washed twice with PBS. The cells were then 
incubated with FITC conjugated anti-mouse IgG (1:500) for 1 h, washed again. Cells 
were stained with 1 µg/mL Hoechst for 10 min at r.t., washed again before mounting. 
8.16 Molecular Modelling Experiments 
    In order to explore the binding mode of probes with kinases, molecular docking 
studies were carried out using Autodock Vina software.
133
 The Protein structures were 
obtained from the PDB databank (Abl PDB ID 2GQG
132





). Explicit hydrogen atoms were added, all water molecules were 
then deleted. The peptide ligand was removed and the protein structure was processed 
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using AutoDock Tools. All compounds were prepared for docking using AutoDock 
Tools to assign AD4 atom types, calculate Gasteiger charges, and set all rotatable 
bonds as active torsions. The ligand was docked into the protein using AutoDock 
Vina (version 1.11, The Scripps Research Institute). The exhaustiveness parameter 
was set to 100 (default = 8, linear scale); all other default settings were used. The 
macromolecule molecular surface and secondary structure were displayed by PyMol 
(version 0.99, DeLano Scientific LLC. 
8.17 Cell Permeability Assays 
    The assay was carried out as previously described.
151 
MDCK (Madin-Darby 
canine kidney) cells were used for testing the cell permeability. MDCK was seeded 




 per well insert, Millipore® 
#PSHT004R1) and cultured for 3 days before test. When cultures are confluent, 
remove medium and rinse inserts with Hanks‟ Balanced Salt Solution (HBSS, 
Gibco® #14025). Transport assay donor solutions consisted of 100 µM wide type 
drugs, probes and caffeine in transport medium containing 60 µM Lucifer Yellow 
(LY) and 1% DMSO. Transport assays were conducted using 75 µL of apical (AP) 
donor solution and 235 µL of basolateral (BL) acceptor solution (transport medium, 
pH 7.4, following manufacture descriptions of Millipore® #PSHT004R1). Monolayer 
was incubated with donor and acceptor solutions for 60 min at 37 °C, 95% humidity. 
After 60 min, the donor and acceptor solutions of each compound was collected and 
quantified by HPLC. Lucifer Yellow (LY) was quantified using a fluorescence 
96-well plate reader (BioTek® Synergy 4 fluorescence plate reader at Ex = 485 nm 
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and Em = 539 nm). Papp (apparent permeability) values were calculated according to 
the following equation: 
 
 
    where dQ/dt is the permeability rate, C0 is the initial concentration in the donor 
compartment, and A is the surface area of the filter. Permeability rates were calculated 
by plotting the percent of initial AP drug mass (peak area) found in the BL 
compartment versus time and determining the slope of the line. Lucifer yellow (LY) 
results were used as an internal control for each monolayer to verify tight junction 
integrity during the entire assay period. Accordingly, LY Papp values were quantified 
from 60 min basolateral samples after background subtraction. As a quality control, 
results from MDCK monolayer with LY Papp > 30 nm/s were not used. 







Caffeine / 50 µM + - - - 
Lucifer Yellow / 60 µM + + + + 
Compound / 100 µM - - + + 
DMSO 1% 1% 1% 1% 
Papp/nm.s
-1
 762 n.d. 320 142 




























    In summary, we have described a series of technologies that span combinational 
chemistry and microarray-facilitated high-throughput enzyme profiling platform. Two 
classes of proteins which are aspartic proteases and protein kinases have been 
separately studied in this thesis with high throughput technologies. 
    The first objective of this study was to develop a solution-cum-solid phase 
strategy for synthesis of C2-symmetric diols inhibitors targeting HIV-1 protease. It 
was found that both symmetric and asymmetric diol-containing small molecules as 
potential aspartic protease inhibitors could be synthesized and evaluated in a very 
short time. Compared with Wong‟s strategy, ours is more rapid and efficient. This is 
because all compounds including symmetric and asymmetric structures were 
generated by solid-phase synthesis rather than solution-phase synthesis which is quite 
time-consuming. The results have shown that the clear advantage in our strategy lies 
in its feasibility for solid-phase synthesis of asymmetric diols which may be quite 
useful for combating drug resistance of HIV-1 protease in future. Based on the results, 
it appears that the solution-cum-solid phase synthesis is highlighted by its robustness, 
product purity and diversification of a common core in a simple way. Thus, our 
chemical strategy may be readily expanded in future for the construction of much 
bigger compound libraries which may lead to candidate compounds with improved 
biological activities. It should find useful application in high-throughput drug 
discovery for different diseases. 
    The second objective in this thesis was to discover the potent inhibitors and 
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affinity-based probes for functional profiling of plasmepsins (PMs) in 
intraerythrocytic malaria parasites. After subsequent in situ screening of parasites 
with these probes, it was found that compound G16 showed good inhibition against 
all four PMs and parasite growth in infected RBCs. Molecular modelling indicated 
that this inhibitor bound to the active site of the plasmepsins tested, as originally 
designed. Our results indicate the feasibility of using affinity-based probes approaches 
for the identification of inhibitors of less-characterized enzymes (such as HAP) and 
inhibitors of multiple targets. We anticipate that these new chemical tools should 
facilitate the discovery of unknown parasite biology and new anti-malarial drugs. 
    The third and fourth objectives were to identify affinity-based probes for aspartic 
proteases, for example, γ-secretase and cathepsin D, using small molecule microarray 
(SMM) platform. By incubating dye-labled, interest proteins with inhibitor library 
onto a protease-sensitive glass surface, a series of distinct binding profiles between 
inhibitor library and interest proteins or mammalian cell lysates were obtained. Some 
potent and specific affinity-based probes against aspartic proteases were subsequently 
generated from potent inhibitor hits by “click” chemistry. Our results demonstrated 
that SMM platform was able to sensitively report activity-based binding events of 
aspartic proteases towards their small molecule inhibitors. Previous small molecule 
microarray strategies have mainly relied on incubation with a purified protein of 
interest.
 
In our case, since it is notoriously difficult to isolate some aspartic proteases, 
we carried out SMM screening which allows the direct detection of interactions 
between small molecules and target proteins expressed in mammalian cells without 
prior purification. This is because the cellular lysate has the optimum condition for 
proteins living compared with recombinant proteins. It was found that potential 
probes for aspartic proteases could be rapidly identified by using SMM platform. 
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Comparing with the development of traditional probes based on the known inhibitor, 
however, our approach does not require known inhibitors of a protein target and 
minimizes risks involved in the loss of protein-binding property of these inhibitors 
due to linker introduction. The results indicate that our strategy would provide 
comprehensive insight into the behaviors of virtually any cluster of enzymes. The 
functional profile obtained from inhibitor screening contributes towards the 
understanding of the enzymes and proteins and the development of predictive models 
for their functional perturbation. 
    In the fifth and sixth objectives, we have designed and synthesized two cell 
permeable, photo-affinity based probes targeting protein kinases based on well-known 
activity-based protein profiling (ABPP) approach. In order to maximally retain drug‟s 
native activity (Dasatinib
TM
 and Staurosphorine), minimal structure modifications 
have been done in the synthesis of each probe. With the aim to comprehensively study 
the cellular targets of dasatinib/staurosphorine, we performed pull-down/mass 
spectrometric analysis in large scale manners. Consequently, some putative cellular 
off-targets of dasatinib and staurosphorine have been identified using our probes in 
live cells, respectively. The preliminary results demonstated that our probes enabled to 
proteomic profile the cellular on/off-targets of dasatinib/staurosphorine in live cells. 
We predict that our chemical proteomic approach should be broadly useful for 
off-target identification against a number of existing drugs, and it may provide a 
powerful tool for biomarker discovery in future.  
    Considering that research in proteomic area is still at an infant stage, the 
following aspects are recommended for future research. Firstly, due to lack of 
experimental condition, we were unable to detect previously predicted but 
unidentified aspartic proteases from the malaria proteome. Thus, probe G16 might 
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have further targets, other than the four plasmepsins, in the malaria. Identification of 
some other further targets for probe G16 will be an interesting area for future work. In 
addition, it is necessary to develop other chemical probes for profiling of malaria. 
    Secondly, for the microarray work, it should be pointed out that proteins or cell 
lysates may lose activity after they are labeled by dyes. It will cause a lot of 
non-specific bindings between proteins and inhibitors. Thus, it is significant to 
develop other technologies which can be used to proteome profile the interactions 
between inhibitors and the binding proteins in native environment. 
    Thirdly, several aspartic proteases related to human diseases have been 
investigated in this thesis. Studies and explorations of some other aspartic proteases 
which are related to cancers will be our interesting objectives in future. 
    Fourthly, our cell permeable, photo-affinity probes can sucessfully label a wide 
of kinases in live cells. Some of the protein hits, for the first time, were identified as 
putative cellular targets of dasatinib and staurosphorine in our studies. They may be 
considered potential off-targets of dasatinib and staurosphorine in cellular 
environment, which should provide important implication for studing the therapeutic 
functions of dasatinib and staurosphorine. Thus, proper follow-up studies and 
validation experiments will be performed in future. 
    In summary, these high-throughput chemical approaches developed in this thesis 
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11.1 Supplemental Tables 
Table 11.1. Summary of Diol-based Inhibitors Characterizations. 
# ID of Product 
LCMS 1H NMR(Crude 
Product) 
Est % Purity Cal MW Obs MW 
1 SYM-01 >95% 716.29 717.262 - 
2 SYM-02 >95% 568.26 569.233 - 
3 SYM-03 >95% 558.23 559.205 - 
4 SYM-04 ~70% 564.30 587.255 Y 
5 SYM-05 ~60% 612.14 635.197 Y 
6 SYM-06 >95% 564.30 565.274 - 
7 SYM-07 >95% 508.24 531.197 Y 
8 SYM-08 >95% 684.10 707.059 - 
9 SYM-09 >95% 568.24 569.233 - 
10 SYM-10 >95% 634.19 635.18 - 
11 SYM-11 ~90% 568.26 569.236 - 
12 SYM-12 ~50% 576.21 577.192 - 
13 SYM-13 >95% 568.26 569.231 - 
14 SYM-14 ~50% 596.29 597.265 - 
15 SYM-15 ~80% 576.16 599.118 Y 
16 SYM-16 >95% 624.25 625.255 - 
17 SYM-17 ~50% 666.13 689.082 - 
18 SYM-18 - 608.27 - Y 
19 SYM-19 ~70% 496.26 497.231 - 
20 SYM-20 - 538.26 - - 
21 SYM-21 - 548.36 - - 
22 SYM-22 >95% 628.28 629.271 - 
23 SYM-23 ~90% 648.32 649.291 - 
24 SYM-24 ~80% 500.29 523.249 - 
25 SYM-25 >95% 490.26 513.22 - 
26 SYM-26 >95% 496.33 519.287 - 
27 SYM-27 ~90% 544.17 567.192 Y 
28 SYM-28 - 496.33 - - 
29 SYM-29 ~90% 440.27 463.233 - 
                                                                         236 
30 SYM-30 >95% 616.13 617.107 - 
31 SYM-31 ~90% 500.29 523.246 - 
32 SYM-32 70% 551.20 551.280 - 
33 SYM-33 ~80% 500.29 523.249 - 
34 SYM-34 ~90% 508.24 509.174 - 
35 SYM-35 ~90% 487.28 509.174 - 
36 SYM-36 - 513.30 - - 
37 SYM-37 - 508.19 - Y 
38 SYM-38 ~60% 541.25 541.273 Y 
39 SYM-39 - 598.16 - - 
40 SYM-40 - 540.30 - - 
41 SYM-41 - 428.29 - - 
42 SYM-42 ~90% 470.29 471.270 - 
43 SYM-43 - 480.39 - - 
44 SYM-44 - 560.31 - - 
45 ASM-01 ~60% 494.12 495.15 - 
46 ASM-02 >90% 365.20 366.15 - 
47 ASM-03 ~70% 464.19 487.15 Y 
48 ASM-04 ~80% 411.18 434.15 Y 
49 ASM-05 ~70% 402.20 403.15 Y 
50 ASM-06 ~90% 402.20 403.15 Y 
51 ASM-07 ~80% 402.20 403.15 Y 
52 ASM-08 ~80% 466.13 467.20 - 
53 ASM-09 ~80% 400.20 401.15 Y 
54 ASM-10 ~90% 384.15 - Y 
55 ASM-11 ~80% 456.13 457.10 - 
56 ASM-12 - 682.20 683.25 Y 
57 ASM-13 ~60% 612.14 613.205 - 
58 ASM-14 ~80% 602.28 625.29 Y 
59 ASM-15 >95% 646.18 647.1477 - 
60 ASM-16 >95% 517.26 519.2506 - 
61 ASM-17 ~90% 554.20 577.149 - 
62 ASM-18 ~80% 616.26 639.2038 - 
63 ASM-19 ~60% 625.24 624.213 - 
64 ASM-20 ~80% 563.24 564.2102 - 
65 ASM-21 >95% 558.22 559.2800 - 
66 ASM-22 ~60% 554.26 555.2268 - 
67 ASM-23 ~80% 554.26 555.2307 - 
68 ASM-24 ~70% 596.25 619.322 - 
69 ASM-25 ~50% 588.22 587.341 - 
70 ASM-26 - 596.25 - - 
71 ASM-27 - 554.26 - - 
72 ASM-28 - 630.13 - - 
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73 ASM-29 ~80% 618.19 619.145 - 
74 ASM-30 ~60% 552.26 553.207 - 
75 ASM-31 ~70% 560.25 561.207 - 










Cal. MW Obs. MW 
Warhead R1 R2 R3 




>90 571.17 572.168 - 
2 N-B1 B II >90 547.25 548.253 - 
3 N-C1 C 
Leu 
I >95 537.19 538.183 - 
4 N-D1 D II >90 513.27 514.266 - 
5 N-E1 E 
Tyr 
I >90 587.17 588.187 - 
6 N-F1 F II >90 563.25 564.268 - 
7 N-G1 G 
Val 
I >90 523.17 524.191 - 
8 N-H1 H II >95 499.25 500.296 - 




>90 585.19 586.222 - 
10 N-B2 B II >90 561.27 562.275 - 
11 N-C2 C 
Leu 
I >90 551.21 552.222 - 
12 N-D2 D II - 527.29 - - 
13 N-E2 E 
Tyr 
I - 601.19 - - 
14 N-F2 F II - 577.27 - - 
15 N-G2 G 
Val 
I - 537.19 - - 
16 N-H2 H II - 513.27 - - 




>95 551.17 552.187 - 
18 N-B3 B II >90 527.25 528.261 - 
19 N-C3 C 
Leu 
I >95 517.19 518.202 - 
20 N-D3 D II - 493.27 - - 
21 N-E3 E 
Tyr 
I - 567.17 - - 
22 N-F3 F II >90 543.25 544.258 - 
23 N-G3 G 
Val 
I - 503.17 - - 
24 N-H3 H II - 479.25 - ν 




>95 551.17 552.179 - 
26 N-B4 B II >95 527.25 528.261 - 
27 N-C4 C 
Leu 
I >90 517.19 518.198 - 
28 N-D4 D II >90 493.27 494.277 - 
29 N-E4 E 
Tyr 
I - 567.17 - - 
30 N-F4 F II >85 543.25 544.258 - 
31 N-G4 G 
Val 
I - 503.17 - - 
32 N-H4 H II - 479.25 - - 




>90 579.16 580.173 - 
34 N-B5 B II >85 555.24 556.258 - 
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35 N-C5 C 
Leu 
I >95 545.18 546.172 - 
36 N-D5 D II - 521.26 - - 
37 N-E5 E 
Tyr 
I >90 595.16 596.15 - 
38 N-F5 F II >90 571.24 572.236 - 
39 N-G5 G 
Val 
I >85 531.16 532.192 - 
40 N-H5 H II >90 507.24 508.236 - 




>95 555.12 556.111 - 
42 N-B6 B II >95 531.2 532.169 - 
43 N-C6 C 
Leu 
I >95 521.14 522.126 - 
44 N-D6 D II - 497.22 - - 
45 N-E6 E 
Tyr 
I - 571.12 - - 
46 N-F6 F II >85 547.2 548.191 - 
47 N-G6 G 
Val 
I >90 507.12 508.116 - 
48 N-H6 H II - 483.2 - - 




>90 539.15 540.144 - 
50 N-B7 B II >90 515.23 516.226 - 
51 N-C7 C 
Leu 
I >90 505.17 506.163 ν 
52 N-D7 D II >90 481.25 504.221 - 
53 N-E7 E 
Tyr 
I >85 555.15 556.136 - 
54 N-F7 F II >90 531.23 532.215 - 
55 N-G7 G 
Val 
I - 491.15 - - 
56 N-H7 H II >90 467.23 468.226 - 




- 557.14 - - 
58 N-B8 B II - 533.22 - - 
59 N-C8 C 
Leu 
I - 523.16 - - 
60 N-D8 D II - 499.24 - - 
61 N-E8 E 
Tyr 
I - 573.14 - - 
62 N-F8 F II - 549.22 - - 
63 N-G8 G 
Val 
I >90 509.14 510.134 - 
64 N-H8 H II - 485.22 - - 




>95 553.16 554.16 - 
66 N-B9 B II - 529.24 - - 
67 N-C9 C 
Leu 
I >90 519.18 542.177 - 
68 N-D9 D II - 495.26 - - 
69 N-E9 E 
Tyr 
I >85 569.16 570.153 - 
70 N-F9 F II >95 545.24 - - 
71 N-G9 G 
Val 
I >90 505.16 506.16 - 
72 N-H9 H II - 481.24 - - 




>90 546.15 547.147 - 
74 N-B10 B II - 522.23 - - 
75 N-C10 C 
Leu 
I >95 512.17 513.169 - 
76 N-D10 D II >95 488.25 489.242 - 
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77 N-E10 E 
Tyr 
I >90 562.15 563.158 - 
78 N-F10 F II >90 538.23 539.221 - 
79 N-G10 G 
Val 
I >85 498.15 499.167 - 
80 N-H10 H II - 474.23 - - 




>85 607.14 608.1371 - 
82 N-B11 B II >90 583.22 584.2211 - 
83 N-C11 C 
Leu 
I >90 573.16 574.1565 - 
84 N-D11 D II >95 549.24 550.2378 - 
85 N-E11 E 
Tyr 
I >95 623.14 624.132 - 
86 N-F11 F II >95 599.22 600.213 - 
87 N-G11 G 
Val 
I >95 559.14 560.136 - 
88 N-H11 H II >85 535.22 536.222 - 




>90 607.14 608.137 - 
90 N-B12 B II >90 583.22 584.219 - 
91 N-C12 C 
Leu 
I >90 573.16 574.158 ν 
92 N-D12 D II >90 549.24 550.24 - 
93 N-E12 E 
Tyr 
I >95 623.14 624.147 - 
94 N-F12 F II >95 599.22 600.21 - 
95 N-G12 G 
Val 
I >90 559.14 560.149 - 
96 N-H12 H II >90 535.22 536.222 - 




>95 593.11 594.11 - 
98 N-B13 B II >95 569.19 570.191 - 
99 N-C13 C 
Leu 
I >90 559.13 560.129 - 
100 N-D13 D II >95 535.21 536.26 - 
101 N-E13 E 
Tyr 
I >85 609.11 610.105 - 
102 N-F13 F II >85 585.19 586.189 - 
103 N-G13 G 
Val 
I >90 545.11 546.112 - 
104 N-H13 H II >90 521.19 522.191 - 




>90 599.14 600.136 - 
106 N-B14 B II >90 575.22 576.223 - 
107 N-C14 C 
Leu 
I >90 565.16 566.157 - 
108 N-D14 D II >90 541.24 542.232 - 
109 N-E14 E 
Tyr 
I - 615.14 - - 
110 N-F14 F II >85 591.22 592.217 - 
111 N-G14 G 
Val 
I >85 551.14 552.138 - 
112 N-H14 H II >90 527.22 528.218 ν 




>90 585.16 586.159 - 
114 N-B15 B II >85 561.24 562.236 - 
115 N-C15 C 
Leu 
I >90 551.18 552.177 - 
116 N-D15 D II >90 527.26 528.254 - 
117 N-E15 E 
Tyr 
I >95 601.16 602.161 - 
118 N-F15 F II >90 577.24 578.235 - 
                                                                         240 
119 N-G15 G 
Val 
I >90 537.16 538.1544 ν 
120 N-H15 H II >85 513.24 514.248 - 




>90 591.09 592.078 - 
122 N-B16 B II >90 567.17 568.161 - 
123 N-C16 C 
Leu 
I >90 557.11 558.109 ν 
124 N-D16 D II >85 533.19 534.184 - 
125 N-E16 E 
Tyr 
I >95 607.09 608.081 - 
126 N-F16 F II >90 583.17 584.168 - 
127 N-G16 G 
Val 
I >95 543.09 544.084 ν 
128 N-H16 H II >85 519.17 520.161 - 




>90 633.16 634.157 - 
130 N-B17 B II >95 609.24 610.239 - 
131 N-C17 C 
Leu 
I >95 599.18 600.148 - 
132 N-D17 D II >90 575.26 576.239 - 
133 N-E17 E 
Tyr 
I >95 649.16 650.134 - 
134 N-F17 F II >95 625.24 626.209 - 
135 N-G17 G 
Val 
I >95 585.16 586.139 - 
136 N-H17 H II >95 561.24 562.221 - 




>90 602.11 603.094 - 
138 N-B18 B II >90 578.19 579.173 - 
139 N-C18 C 
Leu 
I >90 568.13 569.11 - 
140 N-D18 D II >90 544.21 545.191 - 
141 N-E18 E 
Tyr 
I >90 618.11 619.088 - 
142 N-F18 F II - 594.19 - - 
143 N-G18 G 
Val 
I >90 554.11 555.097 - 
144 N-H18 H II - 530.19 - - 




>90 599.17 600.149 - 
146 N-B19 B II >90 575.25 576.224 - 
147 N-C19 C 
Leu 
I >90 565.19 566.174 - 
148 N-D19 D II >90 541.27 542.245 - 
149 N-E19 E 
Tyr 
I >90 615.17 616.136 - 
150 N-F19 F II >95 591.25 592.226 - 
151 N-G19 G 
Val 
I - 551.17 - ν 
152 N-H19 H II - 527.25 - - 
 
Table 11.3 Summary of LCMS Characterizations of the 284-member Library. 
# ID Compound Warhead 
LCMS 
Est % Purity MWCalc MWObs 




>90 623.31 624.238 
2 A02 N-A2 >90 727.34 728.246 
3 A03 N-A3 ~85 657.28 658.191 
4 A04 N-A4 >90 653.32 654.238 
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~80 675.27 676.179 
6 A06 N-A6 ~85 659.30 660.209 
7 A07 N-A7 ~50 686.29 688.193 
8 A08 N-A8 >90 653.32 654.238 
9 A09 N-A9 ~70 651.36 652.258 
10 A10 N-A10 >90 651.35 652.261 
11 A11 N-A11 ~85 653.32 654.247 
12 A12 N-A12 >90 673.33 674.241 
13 A13 N-A13 >90 648.31 649.226 
14 A14 N-A14 >90 681.32 682.225 
15 A15 N-A15 >90 651.35 652.261 
16 A16 N-A16 ~80 693.26 694.167 
17 A17 N-A17 >90 737.21 740.110 
18 A18 N-A18 ~80 707.30 708.203 
19 A19 N-A19 >90 671.29 672.200 
20 A20 N-A20 ~85 649.33 650.243 
21 A21 N-A21 >90 763.23 764.119 
22 A22 N-A22 ~90 713.27 - 
23 A23 N-A23 ~80 683.34 684.249 
24 A24 N-A24 >90 673.27 674.244 
25 B01 N-A25 ~90 674.33 674.243 
26 B02 N-A26 ~50 638.33 639.244 
27 B03 N-A27 ~80 655.32 656.238 
28 B04 N-A28 ~80 749.21 750.108 
29 B05 N-A29 ~85 687.35 688.259 
30 B06 N-A30 ~70 651.35 652.261 
31 B07 N-A31 ~80 651.35 652.257 
32 B08 N-A32 ~50 681.39 682.299 
33 B09 N-A33 >90 667.34 668.255 
34 B10 N-A34 ~60 643.38 644.291 
35 B11 N-A35 ~50 663.35 664.260 
36 B12 N-A36 ~50 673.35 672.244 
37 B13 N-A37 >90 711.37 712.272 
38 B14 N-A38 ~70 603.35 604.270 
39 B15 N-A39 ~70 671.29 673.223 
40 B16 N-A40 ~80 637.33 - 
41 B17 N-A41 ~85 655.32 656.238 
42 B18 N-A42 ~85 673.30 675.204 
43 B19 N-A43 ~80 709.30 710.203 
44 B20 N-A44 ~80 693.24 694.15 
45 B21 N-A45 ~80 704.27 - 
46 B22 N-A46 ~85 710.29 711.198 
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47 B23 N-A47 ~80 695.26 696.165 
48 B24 N-A48 ~60 691.29 692.196 
49 C01 N-A49 >90 735.31 736.216 
50 C02 N-A50 >90 701.33 702.242 
51 C03 N-A51 >90 665.24 666.150 
52 C04 N-A52 ~70 715.34 716.245 
53 C05 N-A53 >90 701.29 702.199 
54 C06 N-A54 >90 689.29 690.204 
55 C07 N-A55 >90 673.30 674.211 



















  N-Leu 
~80 665.35 666.258 
57 C09 N-B2 ~70 769.37 770.262 
58 C10 N-B3 ~70 699.31 700.208 
59 C11 N-B4 ~80 695.36 696.259 
60 C12 N-B5 ~70 717.30 718.206 
61 C13 N-B6 ~80 701.33 702.231 
62 C14 N-B8 ~70 695.36 696.256 
63 C15 N-B10 ~80 693.38 694.283 
64 C16 N-B11 ~80 695.36 696.259 
65 C17 N-B12 ~70 751.33 - 
66 C18 N-B13 ~80 690.34 691.246 
67 C19 N-B14 ~70 723.35 724.247 
68 C20 N-B15 ~70 693.38 694.282 
69 C21 N-B16 ~70 569.16 570.153 
70 C22 N-B17 ~70 815.20 - 
71 C23 N-B18 ~70 749.33 750.222 
72 C24 N-B19 ~80 713.32 714.227 
73 D01 N-B20 ~80 691.36 692.264 
74 D02 N-B21 ~60 805.26 806.143 
75 D03 N-B22 - 791.27 - 
76 D04 N-B32 ~70 723.42 746.299 
77 D05 N-B33 ~80 709.37 710.278 
78 D06 N-B34 ~70 685.41 686.312 
79 D07 N-B37 ~85 753.40 754.294 
80 D08 N-B38 ~60 645.38 646.292- 
81 D09 N-B40 ~70 679.36 680．265 
82 D10 N-B55 ~70 715.33 716.229 
83 D11 N-B42 ~70 715.33 - 
84 D12 N-B43 ~70 751.33 752.231 
85 D13 N-B44 ~60 735.27 736.172 
86 D14 N-B46 ~60 752.32 753.215 
87 D15 N-B47 - 737.29 - 
88 D16 N-B49 ~60 777.34 778.241 
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89 D17 N-B50 ~60 743.36 744.255 
90 D18 N-B51 ~80 707.27 708.174 
91 D19 N-B52 ~70 757.38 758.269 
92 D20 N-B53 ~70 743.32 744.217 
93 D21 N-B31 ~80 693.38 694.332 
94 D22 N-C1 
  N-Val 
~60 575.31 576.349 
95 D23 N-C2 ~90 679.34 680.353 
96 D24 N-C3 ~80 609.28 610.284 
97 E01 N-C4 ~80 605.32 606.334 
98 E02 N-C5 - 703.28 - 
99 E03 N-C6 ~60 611.30 612.307 
100 E04 N-C8 ~80 605.32 606.336 
101 E05 N-C10 - 679.36 - 
102 E06 N-C11 - 681.34 - 
103 E07 N-C12 ~80 625.33 626.345 
104 E08 N-C13 - 676.33 - 
105 E09 N-C14 ~80 633.32 634.334 
106 E10 N-C15 ~70 603.35 604.355 
107 E11 N-C16 ~40 645.26 646.265 






~40 639.31 640.315 
109 E13 N-D2 >90 743.34 744.349 
110 E14 N-D3 >90 673.27 674.279 
111 E15 N-D4 ~50 669.32 670.328 
112 E16 N-D5 - 691.26 - 
113 E17 N-D6 ~50 675.29 676.304 
114 E18 N-D8 ~60 669.32 670.338 
115 E19 N-D10 ~80 667.34 690.366 
116 E20 N-D11 ~60 669.32 670.336 
117 E21 N-D12 ~70 689.32 690.339 
118 E22 N-D13 - 664.30 - 
119 E23 N-D14 >90 697.31 698.334 
120 E24 N-D15 >90 667.34 668.359 
121 F01 N-D16 ~70 709.25 710.258 
122 F02 N-D17 ~50 753.20 754.177 
123 F03 N-D18 ~80 723.29 724.293 
124 F04 N-D19 ~90 687.29 688.297 
125 F05 N-D20 ~90 665.32 666.345 
126 F06 N-D21 ~50 779.22 780.231 
127 F07 N-D22 >95 729.26 - 
128 F08 N-D55 - 689.29 - 
129 F09 N-D42 - 689.29 - 
130 F10 N-D43 - 725.29 - 
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131 F11 N-D44 ~50 709.24 710.263 
132 F12 N-E1 
  N-Ala 
~70 547.28 548.299 
133 F13 N-E2 ~80 651.31 652.310 
134 F14 N-E3 ~60 581.24 582.284 
135 F15 N-E4 ~80 577.29 578.301 
136 F16 N-E5 ~70 599.23 600.245 
137 F17 N-E6 ~70 583.26 584.279 
138 F18 N-E8 ~80 577.29 578.340 
139 F19 N-E10 ~70 575.31 576.330 
140 F20 N-E11 ~80 577.29 578.301 
141 F21 N-E12 - 597.30 - 
142 F22 N-E13 ~80 572.28 573.288 
143 F23 N-E14 ~70 605.29 606.305 
144 F24 N-E15 ~70 575.31 576.327 
145 G01 N-E16 ~50 617.23 618.247 
146 G02 N-E17 - 661.17 - 
147 G03 N-E18 ~40 631.27 632.251 
148 G04 N-E19 ~50 595.26 596.270 
149 G05 N-E20 ~40 573.30 574.333 
150 G06 N-E21 ~90 687.20 688.212 
151 G07 N-E22 - 637.24 - 
152 G08 N-E32 - 603.35 - 
153 G09 N-E33 ~80 591.31 592.331 
154 G10 N-E34 ~40 567.35 568.328 
155 G11 N-E37 ~60 635.34 636.382 
156 G12 N-E38 ~60 527.31 528.328 
157 G13 N-E40 - 597.27 - 
158 G14 N-E55 - 597.27 - 
159 G15 N-E42 - 633.27 - 
160 G16 N-E43 ~50 617.21 618.272 
161 G17 N-E44 - 634.26 - 









  N-Lys 
 
 
~80 604.34 605.355 
163 G19 N-F2 ~50 708.37 709.379 
164 G20 N-F3 ~70 638.30 639.342 
165 G21 N-F4 ~70 634.35 635.368 
166 G22 N-F5 ~70 656.29 657.296 
167 G23 N-F6 ~70 640.32 641.331 
168 G24 N-F8 ~70 634.35 635.364 
169 H01 N-F10 - 632.37 - 
170 H02 N-F11 ~70 634.35 635.363 
171 H03 N-F12 ~70 654.36 655.368 
172 H04 N-F13 ~80 629.34 630.355 
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173 H05 N-F14 ~70 662.35 663.364 
174 H06 N-F15 ~70 632.37 633.364 
175 H07 N-F16 ~70 674.28 675.293 
176 H08 N-F17 ~70 718.23 721.243 
177 H09 N-F18 ~70 688.32 689.340 
178 H10 N-F19 ~70 652.32 653.333 
179 H11 N-F20 ~60 630.36 631.374 
180 H12 N-F21 ~60 744.25 745.266 
181 H13 N-F22 - 694.29 - 
182 H14 N-F55 ~50 654.32 655.332 
183 H15 N-F42 - 654.32 - 
184 H16 N-F43 - 690.32 - 




- 674.27 - 
186 H18 C-G2 ~70 765.36 766.370 
187 H19 C-G3 >90 749.30 750.318 
188 H20 C-G4 - 760.33 - 
189 H21 C-G5 ~80 766.35 767.375 
190 H22 C-G6 ~60 751.32 752.341 
191 H23 C-G7 ~70 791.38 792.392 
192 H24 C-G8 ~70 757.39 758.410 
193 I01 C-G9 ~50 721.30 722.318 
194 I02 C-G10 ~70 771.41 772.422 
195 I03 C-G11 ~60 757.35 758.362 
196 I04 C-G12 - 745.35 - 
197 I05 C-G13 ~80 729.36 730.369 
198 I06 C-G14 - 841.48 - 
199 I07 C-G15 - 695.38 - 
200 I08 C-G16 >90 772.37 773.381 
201 I09 C-G17 - 760.33 - 
202 I10 C-G18 ~50 757.39 758.409 
203 I11 C-G19 - 785.42 - 
204 I12 C-G20 ~50 808.40 809.415 
205 I13 C-G21 - 817.23 - 
206 I14 C-G22 ~60 765.36 766.372 
207 I15 C-G23 ~80 785.42 786.430 
208 I16 C-G24 ~50 733.33 734.345 
209 I17 C-G25 ~50 751.32 752.333 
210 I18 C-H1 
  C-Leu 
~70 695.38 696.352- 
211 I19 C-H2 ~80 731.38 732.391 
212 I20 C-H3 ~85 715.32 716.335 
213 I21 C-H4 - 726.34 - 
214 I22 C-H5 ~80 732.37 733.380 
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215 I23 C-H6 ~30 717.34 718.354 
216 I24 C-H7 ~80 757.39 758.406 
217 J01 C-H8 - 723.41 - 
218 J02 C-H9 - 687.32 - 
219 J03 C-H10 ~60 737.42 738.438 
220 J04 C-H11 ~70 723.37 724.390 
221 J05 C-H12 ~70 711.37 712.408 
222 J06 C-H13 ~80 695.38 696.383 
223 J07 C-H14 - 807.50 - 
224 J08 C-H15 - 661.39 - 
225 J09 C-H16 ~80 738.38 739.405 
226 J10 C-H17 - 726.34 - 
227 J11 C-H18 ~80 723.41 724.417 
228 J12 C-H19 - 751.44 - 
229 J13 C-H20 - 774.42 - 
230 J14 C-H21 - 783.24 - 
231 J15 C-H22 ~60 731.38 732.389 
232 J16 C-H23 ~80 751.44 752.441 
233 J17 C-H24 ~70 699.35 700.364 
234 J18 C-H25 ~85 717.34 718.357 













- 653.33 - 
236 J20 C-I2 >90 689.33 690.338 
237 J21 C-I3 >90 673.27 674.281 
238 J22 C-I4 - 684.30 - 
239 J23 C-I5 ~70 690.32 691.332 
240 J24 C-I6 ~85 675.29 676.307 
241 K01 C-I7 >90 715.34 716.352 
242 K02 C-I8 ~85 681.36 - 
243 K03 C-I9 ~90 645.27 646.280 
244 K04 C-I10 >95 695.38 696.386 
245 K05 C-I11 >90 681.32 682.339 
246 K06 C-I12 >90 669.32 670.341 
247 K07 C-I13 >95 653.33 654.33 
248 K08 C-I14 - 765.45 - 
249 K09 C-I15 - 619.34 - 
250 K10 C-I16 ~80 696.33 697.343 
251 K11 C-I17 - 684.30 - 
252 K12 C-I18 >90 681.38 682.369 
253 K13 C-I19 ~90 709.39 710.409 
254 K14 C-I20 ~90 732.37 733.389 
255 K15 C-I21 - 741.20 - 
256 K16 C-I22 ~90 689.33 690.335 
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257 K17 C-I23 ~90 709.39 710.397 
258 K18 C-I24 >90 657.30 658.312 
259 K19 C-I25 ~90 675.29 676.309 
260 K20 C-J1 
C-Tyr 
~80 745.35 746.369 
261 K21 C-J2 ~90 781.35 782.365 
262 K22 C-J3 ~90 765.30 766.317 
263 K23 C-J4 - 776.32 - 
264 K24 C-J5 ~90 782.35 783.361 
265 L01 C-J6 ~80 767.32 768.335 
266 L02 C-J7 ~90 807.37 808.383 
267 L03 C-J8 ~90 773.39 - 
268 L04 C-J9 >90 737.30 738.313 
269 L05 C-J10 >90 787.40 788.409 
270 L06 C-J11 ~85 773.35 774.366 
271 L07 C-J12 >90 761.35 762.367 
272 L08 C-J13 ~85 745.35 746.367 
273 L09 C-J14 - 857.48 - 
274 L10 C-J15 - 711.37 - 
275 L11 C-J16 ~90 788.36 789.366 
276 L12 C-J17 - 776.32 - 
277 L13 C-J18 >90 773.39 774.398 
278 L14 C-J19 - 801.42 - 
279 L15 C-J20 ~90 824.40 825.420 
280 L16 C-J21 - 833.22 - 
281 L17 C-J22 ~90 781.35 782.365 
282 L18 C-J23 >90 801.42 802.425 
283 L19 C-J24 ~90 749.33 750.342 
284 L20 C-J25 ~80 767.32 768.339 
 
Table 11.4 Summary of the 75-member, C-terminal Library. 
# ID 




% purity Cal MW OBS MW 
1 C-a-1 Phe 1 - 674.27 - 
2 C-a-2 Phe 2 ~70 765.36 766.370 
3 C-a-3 Phe 3 >90 749.30 750.318 
4 C-a-4 Phe 4 - 760.33 - 
5 C-a-5 Phe 5 ~80 766.35 767.375 
6 C-a-6 Phe 6 ~60 751.32 752.341 
7 C-a-7 Phe 7 ~70 791.38 792.392 
8 C-a-8 Phe 8 ~70 757.39 758.410 
9 C-a-9 Phe 9 ~50 721.30 722.318 
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10 C-a-10 Phe 10 ~70 771.41 772.422 
11 C-a-11 Phe 11 ~60 757.35 758.362 
12 C-a-12 Phe 12 - 745.35 - 
13 C-a-13 Phe 13 ~80 729.36 730.369 
14 C-a-14 Phe 14 - 841.48 - 
15 C-a-15 Phe 15 - 695.38 - 
16 C-a-16 Phe 16 >90 772.37 773.381 
17 C-a-17 Phe 17 - 760.33 - 
18 C-a-18 Phe 18 ~50 757.39 758.409 
19 C-a-19 Phe 19 - 785.42 - 
20 C-a-20 Phe 20 ~50 808.40 809.415 
21 C-a-21 Phe 21 - 817.23 - 
22 C-a-22 Phe 22 ~60 765.36 766.372 
23 C-a-23 Phe 23 ~80 785.42 786.430 
24 C-a-24 Phe 24 ~50 733.33 734.345 
25 C-a-25 Phe 25 ~50 751.32 752.333 
26 C-b-1 Leu 1 ~70 695.38 696.352- 
27 C-b-2 Leu 2 ~80 731.38 732.391 
28 C-b-3 Leu 3 ~85 715.32 716.335 
29 C-b-4 Leu 4 - 726.34 - 
30 C-b-5 Leu 5 ~80 732.37 733.380 
31 C-b-6 Leu 6 ~30 717.34 718.354 
32 C-b-7 Leu 7 ~80 757.39 758.406 
33 C-b-8 Leu 8 - 723.41 - 
34 C-b-9 Leu 9 - 687.32 - 
35 C-b-10 Leu 10 ~60 737.42 738.438 
36 C-b-11 Leu 11 ~70 723.37 724.390 
37 C-b-12 Leu 12 ~70 711.37 712.408 
38 C-b-13 Leu 13 ~80 695.38 696.383 
39 C-b-14 Leu 14 - 807.50 - 
40 C-b-15 Leu 15 - 661.39 - 
41 C-b-16 Leu 16 ~80 738.38 739.405 
42 C-b-17 Leu 17 - 726.34 - 
43 C-b-18 Leu 18 ~80 723.41 724.417 
44 C-b-19 Leu 19 - 751.44 - 
45 C-b-20 Leu 20 - 774.42 - 
46 C-b-21 Leu 21 - 783.24 - 
47 C-b-22 Leu 22 ~60 731.38 732.389 
48 C-b-23 Leu 23 ~80 751.44 752.441 
49 C-b-24 Leu 24 ~70 699.35 700.364 
50 C-b-25 Leu 25 ~85 717.34 718.357 
51 C-c-1 Ala 1 - 653.33 - 
52 C-c-2 Ala 2 >90 689.33 690.338 
                                                                         249 
53 C-c-3 Ala 3 >90 673.27 674.281 
54 C-c-4 Ala 4 - 684.30 - 
55 C-c-5 Ala 5 ~70 690.32 691.332 
56 C-c-6 Ala 6 ~85 675.29 676.307 
57 C-c-7 Ala 7 >90 715.34 716.352 
58 C-c-8 Ala 8 ~85 681.36 - 
59 C-c-9 Ala 9 ~90 645.27 646.280 
60 C-c-10 Ala 10 >95 695.38 696.386 
61 C-c-11 Ala 11 >90 681.32 682.339 
62 C-c-12 Ala 12 >90 669.32 670.341 
63 C-c-13 Ala 13 >95 653.33 654.33 
64 C-c-14 Ala 14 - 765.45 - 
65 C-c-15 Ala 15 - 619.34 - 
66 C-c-16 Ala 16 ~80 696.33 697.343 
67 C-c-17 Ala 17 - 684.30 - 
68 C-c-18 Ala 18 >90 681.38 682.369 
69 C-c-19 Ala 19 ~90 709.39 710.409 
70 C-c-20 Ala 20 ~90 732.37 733.389 
71 C-c-21 Ala 21 - 741.20 - 
72 C-c-22 Ala 22 ~90 689.33 690.335 
73 C-c-23 Ala 23 ~90 709.39 710.397 
74 C-c-24 Ala 24 >90 657.30 658.312 
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Table 11.5 The list of some representative proteins identified from the LCMS experiments. Proteins are sorted by classification. Unique 
peptides are the number of all unique peptides observed for a particular protein. Protein tyrosine kinases, Ser/Thr kinase, o ther kinases and 
nonkinases are labeled in red, blue, pink and black, respectively. -, no data. 
No Kinase Name ID 
MW 
(kDa) 
Unique peptides count  









   
1 Isoform 1 Proto-oncogene tyrosine-protein kinase Src* IPI00641230 61.06 1 - - - - - 
Tyrosine 
kinase 
2 Isoform 2 Proto-oncogene tyrosine-protein kinase Src IPI00328867 61.06 - - 2 - - - 
Tyrosine 
kinase 
3 Proto-oncogene tyrosine-protein kinase Yes* IPI00013981 61.28 1 - 2 - - - 
Tyrosine 
kinase 
4 Isoform Lyn A of tyrosine-protein kinase Lyn* IPI00298625 58.99 1 - 0 - - - 
Tyrosine 
kinase 
5 Isoform 1 Proto-oncogene tyrosine-protein kinase Fyn* IPI00219012 61.23 1 - 0 - - - 
Tyrosine 
kinase 
6 Isoform p59-HCK of Tyrosine-protein kinase HCK* IPI00029769 57.68 1 - 0 - - - 
Tyrosine 
kinase 
7 Tyrosine-protein kinase CSK IPI00013212 51.24 - - 38 - - 36 
Tyrosine 
kinase 
8 Tyrosine-protein kinase BTK IPI00029132 76.92 - - 41 - - 41 
Tyrosine 
kinase 
9 Isoform 1 of Epidermal growth factor receptor (EGFR) IPI00018274 137.6 - - 5 - - - 
Tyrosine 
kinase 
10 Twinfilin-1 (protein tyrosine kinase 9) IPI00183508 44.12 1 - 0 - - - Tyrosine 
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kinase 
11 
Isoform 2 of Serine/threonine-protein kinase PCTAIRE-3 
(PCTK3) 




Isoform 1 of DNA-dependent protein kinase catalytic subunit 
(DNA-PKc) 




Isoform 1 of MAP kinase-activated protein kinase 2 
(MAPKAPK2) 




Isoform CSBP1 of Mitogen-activated protein kinase 14 
(p38α) 
IPI00221141 47.41 - - 41 - - 5 
Serine/threoni
ne kinase 
15 Serine/threonine-protein kinase 25 (STK25) IPI00012093 48.31 2 - 1 2 - - 
Serine/threoni
ne kinase 




Interferon-induced, double-stranded RNA-activated protein 
kinase (eIF-2A) 
IPI00019463 62.51 2 - 2 1 - - 
Serine/threoni
ne kinase 




Isoform 2 of cAMP-dependent protein kinase, alpha-catalytic 
subunit (PKA C-α) 
IPI00217960 39.91 - 2 - 3 - - 
Serine/threoni
ne kinase 
20 Isoform Beta-II of Protein kinase C beta type (PKC-β) IPI00219628 78.16 - - 6 - - - 
Serine/threoni
ne kinase 
21 Serine/threonine-protein kinase 6 (STK6) IPI00298940 46.18 - - 36 - - 3 
Serine/threoni
ne kinase 
22 Cell division protein kinase 2 (CDK2) IPI00031681 34.08 - - 5 - - - 
Serine/threoni
ne kinase 
23 Serine/threonine-protein kinase N2 (PKN2) IPI00002804 130.1 - - 55 - - - Serine/threoni
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9 ne kinase 
24 
Isoform Del-701 of Signal transducer and activator of 
transcription 3(STAT3) 
IPI00306436 88.72 1 3 3 3 - - STAT Family 
25 
Isoform Alpha of Signal transducer and activator of 
transcription 1-alpha/beta (STAT1) 
IPI00030781 87.9 4 - - - - - STAT Family 
26 
Isoform A of Bifunctional 3'-phosphoadenosine 
5'-phosphosulfate 
IPI00030009 70.03 2 - - - - - 
APS kinase 
family 
27 Isoform 1 of Acylglycerol kinase, mitochondrial precursor IPI00019353 47.56 - 1 3 - - - Lipid kinase 
28 Isoform M2 of Pyruvate kinase isozymes M1/M2 IPI00479186 58.54 69 22 37 154 28 14 
Pyruvate 
kinase 
29 Phosphoglycerate kinase 1 IPI00169383 44.98 67 11 17 20 11 4 
Pyruvate 
kinase 
30 Isoform 1 of Pyridoxal kinase IPI00013004 35.31 17 3 2 2 - - 
Pyridoxal 
kinase 
31 Phosphoenolpyruvate carboxykinase [GTP], mitochondrial IPI00294380 71.45 7 2 7 4 - - 
Pyruvate 
kinase 
32 6-phosphofructokinase type C IPI00009790 86.45 5 2 10 4 - - 
phosphofruct
okinase 
33 Isoform 1 of 6-phosphofructokinase, liver type IPI00332371 85.76 8 4 1 5 - - 
phosphofruct
okinase 
34 Isoform 1 of Adenylate kinase 2, mitochondrial IPI00215901 26.69 5 2 1 - - - 
AK2 
subfamily 
35 Ketosamine-3-kinase IPI00099986 34.62 1 - 1 - - - 
Fructosamine 
kinase 
36 Isoform 1 of Nucleoside diphosphate kinase A IPI00012048 17.31 2 - 3 1 - - NDK family 
37 Isoform 3 of Adenylate kinase isoenzyme 2, mitochondrial IPI00172460 22.42 - 2 5 - - - AK2 
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subfamily 
38 CKMT1B Isoform 1 of Creatine kinase U-type, mitochondrial IPI00658109 47.41 - - 5 - - - 
Creatine 
kinase 
39 Ribose-phosphate pyrophosphokinase 1 IPI00219616 35.33 4 - - 11 - - 
pyrophospho
kinase 
40 Isoform 2 of ADP-dependent glucokinase IPI00329593 54.27 1 - 1 - - - 
ADP-depende
nt kinase 
41 Isoform 1 of Ribose-phosphate pyrophosphokinase 2 IPI00219617 35.33 3 - 4 11 - - 
pyrophospho
kinase 
42 Isoform Short of Adenosine kinase IPI00234368 39.08 - 1 3 2 - - AK2 Kinase 
43 Isoform 1 of Inositol-trisphosphate 3-kinase B (IP3K B) IPI00021449 103.1 - 1 - - - - IPK Kinase 
44 Ribose-phosphate pyrophosphokinase 3 IPI00218371 35.39 - 2 - - - - 
pyrophospho
kinase 
45 Creatine kinase B-type IPI00022977 42.90 - 2 16 5 - - 
Creatine 
kinase 
46 Isoform 1 of Hexokinase-1 IPI00018246 103.6 - - 1 - - - Hexokinase 
47 NME1 Nucleoside diphosphate kinase IPI00604590 32.91 - - 3 - - - NDK family 
48 LOC727761 Thymidylate kinase IPI00013862 23.98 - - 1 - - - 
Thymidylate 
kinase 
49 Isoform 2 of SH3-containing GRB2-like protein 3 IPI00216201 39.28 - - 3 - - - SH3 domain 
50 GK Isoform 1 of Glycerol kinase IPI00027424 58.25 - - 3 - - - 
Glycerol 
kinase 
51 Phosphoglycerate kinase 2 IPI00219568 45.17 - - 6 17 - - 
Phosphoglyce
rate kinase 
52 cDNA FLJ56047, highly similar to A kinase anchor protein IPI00022585 102.4 - - 1 - - - - 
53 Serine-threonine kinase receptor-associated protein IPI00294536 40.01 1 - 6 1 - - - 
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54 Isoform 1 of Uridine-cytidine kinase 2 IPI00065671 29.45 1 - 1 - - - 
Uridine-cytidi
ne kinase 
55 Receptor-type tyrosine-protein phosphatase beta IPI00295577 224.3 1 - - - - - PTP family 
56 Protein tyrosine phosphatase-like protein PTPLAD1 IPI00008998 43.36 2 - 4 - - - 
HACD 
family 
57 Tyrosine-protein phosphatase non-receptor type 12 IPI00289082 88.92 - - 1 - - - PTP family 
58 Tyrosine-protein phosphatase non-receptor type 21 IPI00004388 134.1  - 1 59 - - PTP family 
59 
Isoform Gamma-1 of Serine/threonine-protein phosphatase 
PP1-gamma catalytic subunit 
IPI00005705 37.70 4 2 19 2 - - PP-1 family 
60 
Serine/threonine-protein phosphatase 2A 55 kDa regulatory 
subunit B beta isoform 




Serine/threonine-protein phosphatase 2A 65 kDa regulatory 
subunit A alpha isoform 
IPI00554737 66.06 2 - 6 - -- - 
Phosphatase 
2A family 
62 Alkaline phosphatase, placental-like IPI00290380 57.63 5 16 8 - - - 
Alkaline 
phosphatase 
63 Alkaline phosphatase, placental type precursor IPI00007289 59.93 - 16 5 8 - - 
Alkaline 
phosphatase 
64 Protein phosphatase 1F IPI00291412 49.97 - - 2 - - - PP2C family 
65 Isoform 1 of LIM and SH3 domain protein 1 IPI00000861 30.10 - - 5 - - - SH3 domain 
66 Src substrate cortactin IPI00029601 61.72 - 2 2 - - - SH3 domain 
67 DNA damage-binding protein 1 IPI00293464 
128.1
4 
2 7 14 - - - DDB1 family 
68 Proliferation-associated protein 2G4 IPI00299000 44.10 4 - 28 - - - 
Peptidase 
M24 family 
69 Isoform 2 of CDK5 and ABL1 enzyme substrate 1 IPI00178886 42.24 - - 33 - - - Cyclin family 
70 Isoform 1 of Brain acid soluble protein 1 IPI00299024 22.68. 3 - 3 - - - BASP1 
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family 
71 Isoform 2 of Tumor protein D54 IPI00221178 19.95 3 - 2 - - - 
TPD52 
family 
72 Isoform B of Phosphate carrier protein, mitochondrial IPI00215777 40.39 22 1 74 - - - 
Mitochondria
l carrier 
73 Calcium-binding mitochondrial carrier protein Aralar2 IPI00007084 74.53 6 - 30 - - - 
Mitochondria
l carrier 
74 Isoform 1 of ATP-binding cassette sub-family F member 3 IPI00465160 80.09 1 - 1 - - - ABCF family 
75 Lung cancer oncogene 7 IPI00641950 38.38 - - 6 - - - - 
76 Proteasome subunit beta type-4 precursor IPI00555956 29.24 - - 6 - - - 
Peptidase 
T1B family 
77 Isoform 4 of Cancer-associated gene 1 protein IPI00514516 99.42 - - - - - - - 
78 Novel protein similar to Pre-B cell enhancing factor IPI00472879 53.65 - - - 7 - - - 
79 Isoform 1 of Large proline-rich protein BAT3 IPI00465128 
119.7
9 




Serine/threonine protein phosphatase 2A, 55 kDa regulatory 
subunit B, alpha isoform 
IPI00442821 53.55 - - 4 - - - - 




Isoform B of Mannose-6-phosphate receptor-binding protein 
1 




Human immunodeficiency virus type I enhancer-binding 
protein 2 
IPI00144243 27.11 6 - - - - - - 
84 Isoform 1 of SAPK substrate protein 1 IPI00027378 33.42 - - 5 - - - - 
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Table 11.6 The list of kinases identified from the LCMS experiments. Unique peptides are the number of all unique peptides observed for a 
particular protein. Protein kinases are shaded in blue , other kinases are labeled in blue. The unique kinases identified from in situ pulldown were 
shaded yellow. -, no data.  
No Kinase Name ID MW (KDa) 
Unique peptides count 
Family HepG2 
In vitro In situ 
1 Isoform 2 Proto-oncogene tyrosine-protein kinase Src IPI00328867 61.06 2 - Tyrosine kinase 
2 Proto-oncogene tyrosine-protein kinase Yes IPI00013981 61.28 2 - Tyrosine kinase 
3 Tyrosine-protein kinase CSK IPI00013212 51.24 38 - Tyrosine kinase 
4 Tyrosine-protein kinase BTK IPI00029132 76.92 41 - Tyrosine kinase 
5 
Isoform 2 of Serine/threonine-protein kinase PCTAIRE-3 
(PCTK3) 
IPI00394661 54.73 3 - Serine/threonine kinase 
6 
Isoform 1 of DNA-dependent protein kinase catalytic subunit 
(DNA-PKc) 
IPI00296337 47.37 112 129 Serine/threonine kinase 
7 Serine/threonine-protein kinase 25 (STK25) IPI00012093 48.31 1 - Serine/threonine kinase 
8 Ribosomal protein S6 kinase alpha-3 (p90-RSK-3) IPI00020898 84.03 3 1 Serine/threonine kinase 
9 Ribosomal protein S6 kinase alpha-6 IPI00007123 84.39 - 1 Serine/threonine kinase 
10 
Interferon-induced, double-stranded RNA-activated protein 
kinase (eIF-2 α) 
IPI00019463 62.51 2 2 Serine/threonine kinase 
11 
Isoform 2 of cAMP-dependent protein kinase, alpha-catalytic 
subunit (PKA C-α) 
IPI00217960 39.91 - 2 Serine/threonine kinase 
12 serine/threonine protein kinase MST4 isoform IPI00182383 39.86 1 - Serine/threonine kinase 
13 Cell division protein kinase 2 (CDK2) IPI00031681 34.08 5 - Serine/threonine kinase 
14 Serine/threonine-protein kinase N2 (PKN2) IPI00002804 131.9 2 - Serine/threonine kinase 
15 
Isoform 1 of Dephospho-CoA kinase domain-containing 
protein 
IPI00291417 26.65 2 - CoaE family 
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16 Myristoylated alanine-rich C-kinase substrate IPI00219301 31.71 2 - MARCKS family 
17 Isoform 1 of Nucleoside diphosphate kinase B IPI00026260 17.4 3 - NDK family 
18 Isoform 1 of Acylglycerol kinase, mitochondrial precursor IPI00019353 47.56 2 1 Lipid kinase 
19 Isoform M2 of Pyruvate kinase isozymes M1/M2 IPI00479186 58.54 60 1069 Pyruvate kinase 
20 Phosphoglycerate kinase 1 IPI00169383 44.98 15 301 Pyruvate kinase 
21 Isoform 1 of Pyridoxal kinase IPI00013004 35.31 35 41 Pyridoxal kinase 
22 Phosphoenolpyruvate carboxykinase [GTP], mitochondrial IPI00294380 71.45 7 - Pyruvate kinase 
23 6-phosphofructokinase type C IPI00009790 86.45 2 3 phosphofructokinase 
24 Isoform 1 of 6-phosphofructokinase, liver type IPI00332371 85.76 4 9 phosphofructokinase 
25 Isoform 2 of 6-phosphofructokinase, muscle type IPI00219585 82.6 - 3 phosphofructokinase 
26 Phosphofructokinase, platelet IPI00639981 26.4 - 1 phosphofructokinase 
27 Isoform 1 of Adenylate kinase 2, mitochondrial IPI00215901 26.69 12 20 AK2 subfamily 
28 Ketosamine-3-kinase IPI00099986 34.62 1 - Fructosamine kinase 
29 Isoform 1 of Nucleoside diphosphate kinase A IPI00012048 17.31 1 1 NDK family 
30 Creatine kinase B-type IPI00022977 42.90 0 17 Guanido phosphotransferase 
31 Ribose-phosphate pyrophosphokinase 1 IPI00219616 35.33 7 4 pyrophosphokinase 
32 Isoform 2 of ADP-dependent glucokinase IPI00329593 54.27 1 - ADP-dependent kinase 
33 Ribose-phosphate pyrophosphokinase 2 IPI00219617 35.33 - 3 pyrophosphokinase 
34 Isoform Short of Adenosine kinase IPI00234368 39.08 - 1 AK2 Kinase 
35 Isoform 1 of Hexokinase-1 IPI00018246 103.6 20 - Hexokinase 
36 LOC727761 Thymidylate kinase IPI00013862 23.98 - 1 Thymidylate kinase 
37 Isoform 2 of SH3-containing GRB2-like protein 3 IPI00216201 39.28 48 - SH3 domain 
38 Isoform 1 of Uridine-cytidine kinase 2 IPI00065671 29.45 1 - Uridine-cytidine kinase 
39 Isoform 1 of Inhibitor of Bruton tyrosine kinase IPI00792333 15.06 - 2 Tyrosine kinase inhibitor 
40 Isoform R-type of Pyruvate kinase isozymes R/L IPI00027165 62.19 11 - Pyruvate kinase 
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41 FN3KRP Ketosamine-3-kinase IPI00099986 34.6 1 - Fructosamine kinase  
42 Thymidine kinase 1, soluble IPI00299214 30.56 2 - Thymidine kinase 
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*** Acquisition  Parameters ***
DATE_t : 04:38:59
DATE_d : Sep 21 2007
NS :              8
SFO1 :    300.1315000 MHz
SOLVENT : CDCl3
*** Processing Parameters ***
SF :    300.1298215 MHz
XDIM :           8192
*** 1D NMR Plot Parameters ***
Start :           9.00 ppm
Stop :          -0.50 ppm
YScale :         100.00 %
SR :        -178.47 Hz


































































































*** Acquisition  Parameters ***
DATE_t : 04:41:21
DATE_d : Sep 21 2007
NS :             27
SFO1 :     75.4761052 MHz
SOLVENT : CDCl3
*** Processing Parameters ***
SF :     75.4677190 MHz
XDIM :             64
*** 1D NMR Plot Parameters ***
Start :         150.00 ppm
Stop :          -4.99 ppm
YScale :         200.00 %
SR :           0.00 Hz






















































































































































*** Acquisition  Parameters ***
DATE_t : 05:20:34
DATE_d : Feb 13 2008
DS :              2
NS :           2607
O1 :        7924.11 Hz
O2 :        1200.52 Hz
O3 :        7546.30 Hz
SFO1 :     75.4756731 MHz
SFO2 :    300.1312005 MHz
SFO3 :     75.4752953 MHz
SOLVENT : DMSO
*** Processing Parameters ***
AZFW :          0.500 ppm
*** 1D NMR Plot Parameters ***



































































































































































































































*** Acquisition  Parameters ***
DATE_t : 06:27:58
DATE_d : Sep 24 2007
NS :              8
SFO1 :    300.1315000 MHz
SOLVENT : CDCl3
*** Processing Parameters ***
SF :    300.1298215 MHz
XDIM :           8192
*** 1D NMR Plot Parameters ***
Start :           9.00 ppm
Stop :          -0.50 ppm
YScale :          12.50 %
SR :        -178.47 Hz


































































































































































*** Acquisition  Parameters ***
DATE_t : 04:24:32
DATE_d : Sep 08 2007
NS :            258
SFO1 :     75.4760840 MHz
SOLVENT : CDCl3
*** Processing Parameters ***
AQORDER :              0
*** 1D NMR Plot Parameters ***
Start :         200.00 ppm












































































































































































































































































































































































































*** Acquisition  Parameters ***
DATE_t : 05:08:44
DATE_d : Jul 11 2008
NS :              8
SFO1 :    300.1315000 MHz
SOLVENT : DMSO
*** Processing Parameters ***
SF :    300.1300014 MHz
XDIM :           8192
*** 1D NMR Plot Parameters ***
Start :          10.00 ppm
Stop :          -0.50 ppm
YScale :         100.00 %
SR :           1.37 Hz



































































































































































































































































































































*** Acquisition  Parameters ***
DATE_t : 05:10:52
DATE_d : Jul 11 2008
NS :            236
SFO1 :     75.4760840 MHz
SOLVENT : CDCl3
*** 1D NMR Plot Parameters ***
Start :         200.00 ppm
Stop :          -5.00 ppm





















































































































































































































































































































































































































































































































































































*** Acquisition  Parameters ***
DBPOFFS[2]:      0.0000000
DBPOFFS[4]:      0.0000000
SFO1 :    500.1330885 MHz
SFO2 :    500.1330885 MHz
SFO3 :    500.1330885 MHz
SOLVENT : DMSO
*** Processing Parameters ***
AZFW :          0.100 ppm
LB :           0.30 Hz
MAXI :       10000.00 cm
MI :           0.00 cm





































































































































































































































































































































































































































































































































































































































*** Acquisition  Parameters ***
DBPOFFS[2]:      0.0000000
DBPOFFS[4]:      0.0000000
SFO1 :    125.7709936 MHz
SFO2 :    500.1320005 MHz
SFO3 :    125.7703643 MHz
SOLVENT : DMSO
*** Processing Parameters ***
AZFW :          0.500 ppm
LB :           1.00 Hz
MAXI :       10000.00 cm
MI :           0.00 cm


































































































































































































































































































































































































































































































*** Acquisition  Parameters ***
DBPOFFS[2]:      0.0000000
DBPOFFS[4]:      0.0000000
SFO1 :    500.1330885 MHz
SFO2 :    500.1330885 MHz
SFO3 :    500.1330885 MHz
SOLVENT : DMSO
*** Processing Parameters ***
AZFW :          0.100 ppm
LB :           0.30 Hz
MAXI :       10000.00 cm
MI :           0.00 cm

















































































































































































































































































































































*** Acquisition  Parameters ***
DBPOFFS[2]:      0.0000000
DBPOFFS[4]:      0.0000000
SFO1 :    125.7709936 MHz
SFO2 :    500.1320005 MHz
SFO3 :    125.7703643 MHz
SOLVENT : DMSO
*** Processing Parameters ***
AZFW :          0.500 ppm
LB :           1.00 Hz
MAXI :       10000.00 cm
MI :           0.00 cm





































































































































































































































































































































*** Acquisition  Parameters ***
DATE_t : 01:59:53
DATE_d : Jul 09 2008
DBPNAM7 :
DS :              0
NS :              8
O1 :        1853.43 Hz
O2 :        1853.43 Hz
O3 :        1853.43 Hz
SFO1 :    300.1318534 MHz
SFO2 :    300.1318534 MHz
SFO3 :    300.1318534 MHz
SOLVENT : DMSO
*** Processing Parameters ***
AZFW :          0.100 ppm
*** 1D NMR Plot Parameters ***
SR :           0.42 Hz



































































































































































































*** Acquisition  Parameters ***
DATE_t : 02:02:04
DATE_d : Jul 09 2008
DBPNAM7 :
DS :              2
NS :            358
O1 :        7924.11 Hz
O2 :        1200.52 Hz
O3 :        7546.30 Hz
SFO1 :     75.4756731 MHz
SFO2 :    300.1312005 MHz
SFO3 :     75.4752953 MHz
SOLVENT : DMSO
*** Processing Parameters ***
AZFW :          0.500 ppm
*** 1D NMR Plot Parameters ***







































































































































































































































































































































































*** Acquisition  Parameters ***
DBPOFFS[2]:      0.0000000
DBPOFFS[4]:      0.0000000
SFO1 :    300.1318534 MHz
SFO2 :    300.1318534 MHz
SFO3 :    300.1318534 MHz
SOLVENT : DMSO
*** Processing Parameters ***
AZFW :          0.100 ppm
LB :           0.30 Hz
MAXI :       10000.00 cm
MI :           0.00 cm
PC :           1.00
WDW : EM













































































































































































































































































*** Acquisition  Parameters ***
DATE_t : 02:29:44
DATE_d : Jul 09 2008
DBPNAM7 :
DS :              2
NS :            374
O1 :        7924.11 Hz
O2 :        1200.52 Hz
O3 :        7546.30 Hz
SFO1 :     75.4756731 MHz
SFO2 :    300.1312005 MHz
SFO3 :     75.4752953 MHz
SOLVENT : DMSO
*** Processing Parameters ***
AZFW :          0.500 ppm
*** 1D NMR Plot Parameters ***





















































































































































































































































































































































































































































*** Acquisition  Parameters ***
DATE_t : 05:22:27
DATE_d : Jul 11 2008
NS :              1
SFO1 :    300.1315000 MHz
SOLVENT : CDCl3
*** Processing Parameters ***
SF :    300.1300014 MHz
XDIM :           8192
*** 1D NMR Plot Parameters ***
Start :          10.00 ppm
Stop :          -0.50 ppm
YScale :         100.00 %
SR :           1.37 Hz





































































































































































































































































































































































































































































































































































*** Acquisition  Parameters ***
DATE_t : 05:23:37
DATE_d : Jul 11 2008
NS :            245
SFO1 :     75.4760840 MHz
SOLVENT : CDCl3
*** Processing Parameters ***
SF :     75.4677836 MHz
XDIM :             64
*** 1D NMR Plot Parameters ***
Start :         200.00 ppm
Stop :          -5.00 ppm
YScale :         100.00 %
SR :          64.64 Hz


















































































































































































































































































































































































































































































*** Acquisition  Parameters ***
DATE_t : 05:37:23
DATE_d : Jul 11 2008
NS :              8
SFO1 :    300.1315000 MHz
SOLVENT : CDCl3
*** Processing Parameters ***
SF :    300.1300017 MHz
XDIM :           8192
*** 1D NMR Plot Parameters ***
Start :          10.00 ppm
Stop :          -0.50 ppm
YScale :         100.00 %
SR :           1.72 Hz




























































































































































































































































































































































































































































































*** Acquisition  Parameters ***
DATE_t : 05:38:31
DATE_d : Jul 11 2008
NS :            155
SFO1 :     75.4760840 MHz
SOLVENT : CDCl3
*** Processing Parameters ***
SF :     75.4677831 MHz
XDIM :             64
*** 1D NMR Plot Parameters ***
Start :         200.00 ppm
Stop :          -5.00 ppm
YScale :         100.00 %
SR :          64.08 Hz
















































































































































































































































































































































































*** Acquisition  Parameters ***
DATE_t : 05:48:08
DATE_d : Jul 11 2008
NS :              8
SFO1 :    300.1315000 MHz
SOLVENT : CDCl3
*** Processing Parameters ***
SF :    300.1300017 MHz
XDIM :           8192
*** 1D NMR Plot Parameters ***
Start :          10.00 ppm
Stop :          -0.50 ppm
YScale :         100.00 %
SR :           1.72 Hz







































































































































































































































































































































































































































*** Acquisition  Parameters ***
DATE_t : 05:49:05
DATE_d : Jul 11 2008
NS :            151
SFO1 :     75.4760840 MHz
SOLVENT : CDCl3
*** Processing Parameters ***
SF :     75.4677831 MHz
XDIM :             64
*** 1D NMR Plot Parameters ***
Start :         200.00 ppm
Stop :          -5.00 ppm
YScale :         200.00 %
SR :          64.08 Hz


























































































































































































































































































































































































































































































































































*** Acquisition  Parameters ***
DATE_t : 23:59:56
DATE_d : Jul 15 2008
DBPNAM7 :
DS :              0
NS :              8
O1 :        1853.43 Hz
O2 :        1853.43 Hz
O3 :        1853.43 Hz
SFO1 :    300.1318534 MHz
SFO2 :    300.1318534 MHz
SFO3 :    300.1318534 MHz
SOLVENT : DMSO
*** Processing Parameters ***
AZFW :          0.100 ppm
*** 1D NMR Plot Parameters ***
SR :           1.34 Hz




































































































































































































































































































































































































*** Acquisition  Parameters ***
DATE_t : 00:01:22
DATE_d : Jul 16 2008
NS :            391
SFO1 :     75.4756731 MHz
SOLVENT : DMSO
*** Processing Parameters ***
SF :     75.4677831 MHz
XDIM :             64
*** 1D NMR Plot Parameters ***
Start :         190.01 ppm
Stop :          -5.00 ppm
YScale :         100.00 %
SR :          34.08 Hz









































































































































































































































































































*** Acquisition  Parameters ***
DATE_t : 22:47:46
DATE_d : Jun 19 2007
NS :              8
SFO1 :    300.1315000 MHz
SOLVENT : CDCl3
*** 1D NMR Plot Parameters ***
Start :          10.00 ppm

































































































































































































































































*** Acquisition  Parameters ***
DATE_t : 22:49:00
DATE_d : Jun 19 2007
NS :            207
SFO1 :     75.4760840 MHz
SOLVENT : CDCl3
*** 1D NMR Plot Parameters ***
Start :         180.01 ppm





















































































































































































































































































































































































































































































*** Acquisition  Parameters ***
NS :              8
O1 :        3088.51 Hz
O2 :        3088.51 Hz
O3 :        3088.51 Hz
SFO1 :    500.1330885 MHz
SFO2 :    500.1330885 MHz
SFO3 :    500.1330885 MHz
*** 1D NMR Plot Parameters ***










































































































































































































































































































































































































































































*** Acquisition  Parameters ***
NS :             88
O1 :       13204.57 Hz
O2 :        2000.52 Hz
O3 :       12575.30 Hz
SFO1 :    125.7709936 MHz
SFO2 :    500.1320005 MHz
SFO3 :    125.7703643 MHz
*** 1D NMR Plot Parameters ***










































































































































































































































































































*** Acquisition  Parameters ***
NS :              8
O1 :        3088.51 Hz
O2 :        3088.51 Hz
O3 :        3088.51 Hz
SFO1 :    500.1330885 MHz
SFO2 :    500.1330885 MHz
SFO3 :    500.1330885 MHz
*** 1D NMR Plot Parameters ***





















































































































































































































































*** Acquisition  Parameters ***
NS :             38
O1 :       13204.57 Hz
O2 :        2000.52 Hz
O3 :       12575.30 Hz
SFO1 :    125.7709936 MHz
SFO2 :    500.1320005 MHz
SFO3 :    125.7703643 MHz
*** 1D NMR Plot Parameters ***






































































































































































































































































































































*** Acquisition  Parameters ***
BF1 :    300.1300000 MHz
BF2 :    300.1300000 MHz
BF3 :    300.1300000 MHz
DATE_d : Mar 16 2009
*** Processing Parameters ***
SF :    300.1298200 MHz
*** 1D NMR Plot Parameters ***
Start :           9.00 ppm
Stop :          -0.50 ppm











































































































































































































































































*** Acquisition  Parameters ***
BF1 :     75.4677190 MHz
BF2 :    300.1300000 MHz
BF3 :     75.4677190 MHz
DATE_d : Mar 16 2009
*** Processing Parameters ***
SF :     75.4677061 MHz
*** 1D NMR Plot Parameters ***
Start :         207.64 ppm
Stop :         -27.30 ppm





































































































































































































































































































































































































































































































*** Acquisition  Parameters ***
DATE_t : 23:51:11
DATE_d : Mar 17 2009
NS :              8
SFO1 :    300.1312500 MHz
SOLVENT : CDCl3
*** Processing Parameters ***
SF :    300.1298200 MHz
XDIM :           8192
*** 1D NMR Plot Parameters ***
Start :          10.00 ppm
Stop :          -0.50 ppm
YScale :          12.50 %
SR :        -180.04 Hz

















































































































































































































































































































*** Acquisition  Parameters ***
DATE_t : 23:53:02
DATE_d : Mar 17 2009
NS :             74
SFO1 :     75.4745111 MHz
SOLVENT : CDCl3
*** Processing Parameters ***
SF :     75.4677034 MHz
XDIM :             64
*** 1D NMR Plot Parameters ***
Start :         180.00 ppm
Stop :          -4.99 ppm
YScale :         200.00 %
SR :         -15.61 Hz



















































































































































































































































































































































































































































*** Acquisition  Parameters ***
DATE_t : 03:36:14
DATE_d : Oct 12 2007
NS :              8
SFO1 :    300.1315000 MHz
SOLVENT : MeOD
*** Processing Parameters ***
SF :    300.1300227 MHz
XDIM :           8192
*** 1D NMR Plot Parameters ***
Start :           9.00 ppm
Stop :          -0.50 ppm
YScale :          50.00 %
SR :          22.66 Hz














































































































































































































































































































































































































*** Acquisition  Parameters ***
DATE_t : 03:38:58
DATE_d : Oct 12 2007
NS :           5871
SFO1 :     75.4760840 MHz
SOLVENT : CDCl3
*** Processing Parameters ***
SF :     75.4676436 MHz
XDIM :             64
*** 1D NMR Plot Parameters ***
Start :         220.01 ppm
Stop :          -4.99 ppm
YScale :          25.00 %
SR :         -75.36 Hz































































































































































































































































































































































































































































































































































































*** Acquisition  Parameters ***
DATE_t : 04:29:50
DATE_d : Aug 18 2008
DBPNAM7 :
DS :              0
NS :              8
O1 :        1853.43 Hz
O2 :        1853.43 Hz
O3 :        1853.43 Hz
SFO1 :    300.1318534 MHz
SFO2 :    300.1318534 MHz
SFO3 :    300.1318534 MHz
SOLVENT : DMSO
*** Processing Parameters ***
AZFW :          0.100 ppm
*** 1D NMR Plot Parameters ***
SR :           1.00 Hz






















































































































































































































































































































































































*** Acquisition  Parameters ***
DATE_t : 04:32:43
DATE_d : Aug 18 2008
DBPNAM7 :
DS :              2
NS :            605
O1 :        7924.11 Hz
O2 :        1200.52 Hz
O3 :        7546.30 Hz
SFO1 :     75.4756731 MHz
SFO2 :    300.1312005 MHz
SFO3 :     75.4752953 MHz
SOLVENT : DMSO
*** Processing Parameters ***
AZFW :          0.500 ppm
*** 1D NMR Plot Parameters ***
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